Fused heterocyclic compounds as ion channel modulators
Abstract
The present invention relates to compounds that are sodium channel inhibitors and to their use in the treatment of various disease states, including cardiovascular diseases and diabetes. In particular embodiments, the structure of the compounds is given by Formula I: wherein W1. W2, W3 R1, Q, X1, X2 and X3 are as described herein, to methods for the preparation and use of the compounds and to pharmaceutical compositions containing the same.
Term
3.8 yearsto projected expiry
Projected expiry 26 July 2030, counted from filing; an application has no term until it is granted.
- Priority
- Filed
- Published
- Today
- Projected expiry
14 claims: 3 independent, 11 dependent
- 1Patent claims Zastrzeżenia patentowe Compound about Formula III:Związek o Wzorze III: gdzie: where: R1 is aryl or heteroaryl selected from the group consisting of: R1 oznacza aryl lub heteroaryl wybrany z grupy obejmującej: gdzie wspomniany aryl lub heteroaryl są podstawione przez jeden, dwa lub trzy podstawniki niezależnie wybrane z grupy obejmującej hydroksyl, halo, -NO2, CN, -SF5, -Si(CH3)3 -O-CF3, -O-R20, -S15 R20, -C(O)-R20, C(O)OH,-N(R20)(R22), -C(O)-N(R20)(R22), -N(R20)-C(O)-R22, -N(R20)-S(=O)2-R26, -S(=O)2R20, -S(=O)2-N(R20)(R22), C1-C3 alkoksy, C1-4 alkil, C2-4 alkenyl, C2-4 alkinyl, cykloalkil, heteroaryl, i heterocyklil;hydroxy, halo, -NO2, CN, -SF5, -Si (CH3) 3 -O-CF3, -OR, and the substituents on the hydroxy, halo, -NO2, CN, -SF5, -Si (CH3) 3 - O-CF3, -OR.20, -S15 R20, -C (O) -R20, C (O) OH, -N (R20) (R22), -C (O) -N (R20) (R22), -N (R20) -C (O) -R22, -N (R20) -S (= O) 2 -R26, -S (= O) 2 R20, -S (= O) 2 -N (R20) (R22), C 1 -C 3 alkoxy, C 1-4 alkyl, C 2-4 alkenyl, C 2-4 alkynyl, cycloalkyl, heteroaryl, heterocyclyl;alkoxy, alkyl, alkenyl, alkynyl, heteroaryl, cycloalkyl, lubricated heterocyclic substituents, hydroxy, halo;gdzie wspomniany alkoksy, alkil, alkenyl, alkinyl, heteroaryl, cykloalkil, lub heterocyklil są opcjonalnie podstawione przez jeden, dwa lub trzy podstawniki niezależnie wybrane z hydroksylu, halo, - 169 EP 2464645 NO2, -O-CF3, -O-CHF2, fenylu, heterocyklilu, heteroarylu, cykloalkilu, -N(R20)(R22), -C(O)-R20, -C(O)-OR20, -C(O)-N(R20)(R22), -CN, i -O-R20, lub gdzie R1 jest podstawiony przez jeden, dwa lub trzy podstawniki niezależnie wybrane z WOMAN2, -O-CF3, -O-CHF2, phenyl, heterocyclyl, heteroaryl, cycloalkyl, -N (R20) (R22), -C (O) -R20, -C (O) -OR20, -C (O) -N (R20) (R22), -CN, and -OR20, or where R1 is substituted with one, two or three substituents independently selected from EP 2464645 ο EP 2464645 ο - 171 EP 2464645 - 171 EP 2464645 R2 is independently selected from the group consisting of hydrogen, optionally substituted alkoxy, -CF3, -O-CF3, -CN, and -N {R20) C (O) -R22;R2 jest niezależnie wybrany z grupy obejmującej wodór, opcjonalnie podstawiony alkil, amino, opcjonalnie podstawiony alkoksy, -CF3, -O-CF3, -CN, i -N(R20)C(O)-R22;R3 is independently selected from the group consisting of hydrogen, alkyl, - CF3, -halo, and -OR24;R3 jest niezależnie wybrany z grupy obejmującej wodór, alkil, - CF3, -halo, i -O-R24;R4 is independently selected from the group consisting of hydrogen, hydroxyl, halo, C1-4 alkyl, C1-C3 alkoxy, -R25-N (R20) (R22), -R25guar20, -R25-C (O) -OR20, -R25-C (O) -N (R20) (R22), -R25-C (O) -ON (R20) (R22), -R25N (R20) -C (O) -R22, and -R25OC (O) N (R20) (R22), where said alkyl is optionally substituted with one, two or three substituents independently selected from hydroxy and halo, R4 jest niezależnie wybrany z grupy obejmującej wodór, hydroksyl, halo, C1-4 alkil, C1-C3 alkoksy, -R25-N(R20)(R22), -R25-O-R20, -R25-C(O)-O-R20, -R25-C(O)-N(R20)(R22), -R25-C(O)-O-N(R20)(R22), -R25N(R20)-C(O)-R22, i -R25-O-C(O)-N(R20)(R22), gdzie wspomniany alkil jest opcjonalnie podstawiony przez jeden, dwa lub trzy podstawniki niezależnie wybrane z hydroksylu i halo, Q is selected from a covalent bond or C2-4 alkynylene;Q jest wybrany z wiązania kowalencyjnego lub C2-4 alkinylenu;Ra oznacza wodór, C1-15 alkil, C1-4 alkoksy, -C(O)-O-R26, -C(O)-N(R26)(R28), -N(R20)-S(=O)2-R20, cykloalkil, aryl, heteroaryl, i heterocyklil, gdzie wspomniany alkil jest opcjonalnie podstawiony przez jeden, dwa lub trzy podstawniki niezależnie wybrane z hydroksylu, halo, -NO2, -O-CF3, -O-CHF2, cykloalkilu, -CN, i C1-4 alkoksy;oraz wspomniany alkoksy, cykloalkil, aryl, heterocyklil, lub heteroaryl są opcjonalnie podstawione przez jeden, dwa lub trzy podstawniki niezależnie wybrane z hydroksylu, halo, -NO2, -O-CF3, -O-CHF2, fenylu, heterocyklilu, heteroarylu, cykloalkilu, -N(R20)(R22), -C(O)-R20, -C(O)-O-R20, -C(O)-N(R20)(R22), CN, i -O-R20;lub Rthe is hydrogen, C1-15 alkyl, C1-4 alkoxy, -C (O) -OR26, -C (O) -N (R26) (R28), -N (R20) -S (= O) 2 -R20, cycloalkyl, aryl, heteroaryl, heterocyclyl, saturated alkyl ester optionally substituted, hydroxyl, halo, -NO 2, -O-CF 3, -O, -C 1-4 alkoxy;or alkoxy, cycloalkyl, aryl, heterocyclyl, heteroaryl substituent, hydroxy, halo, -NO 2, -O-CF 3, -O-CHF 2, phenyl, phenyl, hydroxy, -N (R20) (R22), -C (O) -R20, -C (O) -OR20, -C (O) -N (R20) (R22), CN, and -OR20;or Ra oznacza -Y-Z-R25-R23-R20, gdzie, Rthe means -YZR25-R23-R20, gee, - 172 EP 2464645 - EP 2464645 C 1 -C 3 alkyl is hydrogen;C 1 -C 3 alkyl is substituted with C 1 -C 3 alkyl;Y oznacza wiązanie kowalencyjne lub jest wybrany z C1-C3 alkilenu opcjonalnie podstawionego przez jedną lub dwie grupy C1-C3 alkil lub fluoro;Z is C2-4 alkynylene, -O-, -S-, -NR ", -NR5'-C (O) -, -NR"-C (O) -NR5'- or -C (O) -NR3- where each R «and R5' is independently hydrogen or lower alkyl;hydroxyl, halo, -NO2, -O-CF3, -O-CHF2, phenyl, heterocyclyl, heteroaryl, cyclo (alkyl) alkyl, hydroxy, halo, -NO2, -O-CF3, -O-CHF2, phenyl, heterocyclyl,20) (R22), -C (O) -R20, -C (O) -OR20, -C (O) -N (R20) (R22), -CN, and -OR20, or • F Z oznacza C2-4 alkinylen, -O-, -S-, -NR", -NR5'-C(O)-, -NR"-C(O)-NR5'- lub -C(O)-NR3-, gdzie każdy R" i R5' oznacza niezależnie wodór lub C1-6 niższy alkil;oraz dalej gdzie wspomniany alkil jest opcjonalnie podstawiony przez jeden, dwa lub trzy podstawniki niezależnie wybrane z hydroksylu, halo, -NO2, -O-CF3, -O-CHF2, fenylu, heterocyklilu, heteroarylu, cykloalkilu, -N(R20)(R22), -C(O)-R20, -C(O)-O-R20, -C(O)-N(R20)(R22), -CN, i -O-R20, lub •F - 173 EP 2464645 - 173 EP 2464645 - 174 EP 2464645 - 174 EP 2464645 - 175 EP 2464645 - EP 2464645 - 177 EP 2464645 - 177 EP 2464645 - 178 EP 2464645 - EP 2464645 - 179 EP 2464645 - 179 EP 2464645 - 180 EP 2464645 - 180 EP 2464645 R20 and R22 C 1 -C 15 alkyl, R20 i R22 są w każdym przypadku niezależnie wybrane z grupy obejmującej wodór, C1-C15 alkil, C2-C15 alkenyl, C2-C15 alkinyl, cykloalkil, heterocyklil, aryl, i heteroaryl, gdzie alkil, alkenyl, alkinyl, heterocyklil, aryl, i heteroaryl są opcjonalnie podstawione przez jeden, dwa lub trzy podstawniki niezależnie wybrane z hydroksylu, halo, alkil, mono- lub dialkiloamino, alkil lub aryl lub heteroaryl amidu, -NO2, -SO2R26, -CN, C1-3 alkoksy, -CF3, -OCF3, arylu, cykloalkilu, i heteroarylu;C2-C15 alkenyl, C2-C15 alkynyl, cycloalkyl, heterocyclyl, aryl, heteroaryl, lower alkyl, alkenyl, alkynyl, heterocyclyl, aryl, heteroaryl moiety, mono-dialkylamino, alkyl-or aryl-or heteroaryl-amide, -NO2, - SO 2 R26, -CN, C 1-3 alkoxy, -CF 3, -OCF 3, aryl, cycloalkyl, heteroaryl;lub gdy R20 i R22 są przyłączone do wspólnego atomu azotu R20 i R22 mogą tworzyć pierścień heterocykliczny, który jest opcjonalnie podstawiony przez jeden, dwa lub trzy podstawniki niezależnie wybrane z hydroksylu, halo, alkilu, mono- lub dialkiloamino, alkil lub aryl lub heteroaryl amidu, -NO2, SO2R26, -CN, C1-3 alkoksy, -CF3, i -OCF3, arylu, i cykloalkilu;or when R20 and R22 A attached to the common atom of nitrogen R20 and R22 may form a heterocyclic ring that is optionally substituted with one, two or three substituents independently selected from hydroxy, halo, alkyl, mono or dialkylamino, alkyl or aryl oreroaryl amide, -N26-CN, C 1-3 alkoxy, -CF 3, -OCF 3, aryl, cycloalkyl;R23 cozaloacyl, heterocyclyl, arylene, alkenyl, substituted, hydroxy, cycloalkylene, heterocyclylene, arylene, heteroarylene, gcycloalkylene, heterocyclylene, arylene, heteroaryl moiety or aryl or heteroaryl amido, -NO2, -SO2R26, -CN, C 1-3 alkoxy, -CF 3, -OCF 3, aryl, cycloalkyl, heteroaryl;R23 oznacza wiązanie kowalencyjne lub jest wybrany z grupy obejmującej cykloalkilen, heterocyklilen, arylen, i heteroarylen, gdzie cykloalkilen, heterocyklilen, arylen, i heteroarylen są opcjonalnie podstawione przez jeden do trzech podstawników niezależnie wybranych z hydroksylu, halo, alkilu, mono- lub dialkiloamino, alkil lub aryl lub heteroaryl amidu, -NO2, -SO2R26, -CN, C1-3 alkoksy, - CF3, -OCF3, arylu, cykloalkilu, i heteroarylu;R24 is in the case independently selected from alkyl or aryl, any of which may be optionally substituted with 1, 2, or 3 alkenyl selected from hydroxyl, -OCF3, halo, C1-C3 alkoxy,20, or alkyl optionally substituted with halo, -NO2, -CF3, -O-CF3, -N (R20) (R22), C (O) -R20, -C (O) -OR20, -C (O) -N (R20) (R22), -CN, or -OR20;R24 jest w każdym przypadku niezależnie wybrany z alkilu lub arylu, z których dowolny może być opcjonalnie podstawiony przez 1, 2, lub 3 grupy niezależnie wybrane z hydroksylu, -OCF3, halo, C1-C3 alkoksy, -O-R20, lub alkilu opcjonalnie podstawionego przez halo, -NO2, -CF3, -O-CF3, -N(R20)(R22), C(O)-R20, -C(O)-O-R20, -C(O)-N(R20)(R22), -CN, lub -O-R20;R25 C 1 -C 3 alkyl;and R25 oznacza w każdym przypadku niezależnie wiązanie kowalencyjne lub jest wybrany z C1-C3 alkilenu opcjonalnie podstawionego przez jedną lub dwie grupy C1-C3 alkil;oraz R26 and R28 halo, C 1-4 alkoxy, hydroxy, C 1-4 alkoxy;R26 i R28 są w każdym przypadku niezależnie wybrane z wodoru, alkilu, lub cykloalkilu, gdzie alkil i cykloalkil mogą być dalej podstawione przez od 1 do 3 podstawników niezależnie wybranych z hydroksylu, halo, C1-4 alkoksy, -CF3, i -OCF3;lub jego farmaceutycznie akceptowalna sól, ester, lub solwat, z zastrzeżeniem, że or a pharmaceutically acceptable salt, ester, or solvate thereof, with the proviso that a. gdy Ra oznacza -Y-Z-R25-R23-R20, Y nie oznacza wiązania kowalencyjnego i Z oznacza -O-, -S-, -C(O)-NR3-, -NR5 -C(O)-, lub NR"-, to R25 nie może oznaczać wiązania;the. when Rthe means -YZR25-R23-R20, Y is not a covalent bond and Z is -O-, -S-, -C (O) -NR3-, -NR5 -C (O) -, or NR "- is R25 cannot mean a bond;b. gdy Ra oznacza -Y-Z-R25-R23-R20,Y oznacza wiązanie kowalencyjne i Z oznacza -O-, -S-, lub NR"-, to R25 oznacza wiązanie kowalencyjne i R23 nie oznacza cykloalkilenu;b. when Rthe means -YZR25-R23-R20, Y is a covalent bond and Z is -O-, -S-, or NR "-, then R25 is a covalent bond and R23 does not mean cycloalkylene;c. gdy Z oznacza -NR5'-C(O)-, to Y nie oznacza wiązania kowalencyjnego;c. when Z is -NR5'-C (O) -, then Y is not a covalent bond;d. R23 and R25 it cannot mean a covalent bond;and d. R23 i R25 nie mogą ona oznaczać wiązania kowalencyjnego;oraz - 181 EP 2464645 - 181 EP 2464645 e. gdy Q oznacza wiązanie, i R1 oznacza heteroaryl, to R1 heteroaryl nie może być dalej podstawiony przez fenyl;oraz e. when Q is a bond, and R1 is heteroaryl, it's R1 heteroaryl cannot be further substituted with phenyl;and f. gdy R2 oznacza podstawiony alkil, to Ra nie oznacza alkilu, cykloalkilu, lub heterocyklilu. f. when R2 means substituted alkyl, it's Rthe does not mean alkyl, cycloalkyl, or heterocyclyl.
- 66- (6-3-cyclopropyl-pyridyl) -3- (trifluoromethyl) [1,2,4] triazolo [4,3-a] pyridine;6-(6-cyklopropylopirydyn-3-ylo)-3-(trifluorometylo)[1,2,4]triazolo[4,3-a]pirydyna;6- (2-cyclopropyl-pyrimidin-5-yl) -3- (trifluoromethyl) [1,2,4] triazolo [4,3-a] pyridine;6-(2-cyklopropylopirymidyn-5-ylo)-3-(trifluorometylo)[1,2,4]triazolo[4,3-a]pirydyna;3- (trifluoromethyl) -6- [6- (trifluoromethyl) pyridin-3-yl] [1,2,4] triazolo [4,3-a] pyridine;3-(trifluorometylo)-6-[6-(trifluorometylo)pirydyn-3-ylo][1,2,4]triazolo[4,3-a]pirydyna;6- [6- (2,2,2-trifluoroethoxy) pyridin-3-yl] -3- (trifluoromethyl) [1,2,4] triazolo [4,3-a] pyridine;6-[6-(2,2,2-trifluoroetoksy)pirydyn-3-ylo]-3-(trifluorometylo)[1,2,4]triazolo[4,3-a]pirydyna;6- (5-cyclopropyl-1,3,4-thiadiazol-2-yl) -3- (trifluoromethyl) [1,2,4] triazolo [4,3-a] pyridine;6-(5-cyklopropylo-1,3,4-tiadiazol-2-ylo)-3-(trifluorometylo)[1,2,4]triazolo[4,3-a]pirydyna;3- (trifluoromethyl) -6- [6- (trifluoromethyl) pyridazin-3-yl] [1,2,4] triazolo [4,3-a] pyridine;3-(trifluorometylo)-6-[6-(trifluorometylo)pirydazyn-3-ylo][1,2,4]triazolo[4,3-a]pirydyna;3- (trifluoromethyl) -6- [2- (trifluoromethyl) pyrimidine-5-a] [1,2,4] triazolo [4,3-a] pyridine;3-(trifluorometylo)-6-[2-(trifluorometylo)pirymidyn-5-ylo][1,2,4]triazolo[4,3-a]pirydyna;3- (1,1-Difluoro-2-methoxyethyl) -6- [6- (2,2,2-trifluoroethoxy) pyridin-3-yl] [1,2,4] triazolo [4,3-a] pyridine ;3-(1,1-difluoro-2-metoksyetylo)-6-[6-(2,2,2-trifluoroetoksy)pirydyn-3-ylo][1,2,4]triazolo[4,3-a]pirydyna;6- [6- (cyclopropyloxy) pyridin-3-yl] -3- (trifluoromethyl) [1,2,4] triazolo [4,3-a] pyridine;6-[6-(cyklopropyloksy)pirydyn-3-ylo]-3-(trifluorometylo)[1,2,4]triazolo[4,3-a]pirydyna;6- [6- (2,2,2-trifluoroethoxy) pyridazin-3-yl] -3- (trifluoromethyl) [1,2,4] triazolo [4,3-a] pyridine;6-[6-(2,2,2-trifluoroetoksy)pirydazyn-3-ylo]-3-(trifluorometylo)[1,2,4]triazolo[4,3-a]pirydyna;3 - [(cyclopropylmethoxy) (difluoro) methylan] -6- [6- (trifluoromethyl) pyridin-3-yl] [1,2,4] triazolo [4,3-a] pyridine;3-[(cyklopropylometoksy)(difluoro)metylo]-6-[6-(trifluorometylo)pirydyn-3-ylo][1,2,4]triazolo[4,3a]pirydyna;3- {Difluoro [(5-glitter-1,2-oxazol-3-yl) methoxy] Methylan} -6- [6- (trifluoromethyl) pyridin-3-yl] [1,2,4] triazolo [4, 3-a] pyridine;and 3-{difluoro[(5-fenylo-1,2-oksazol-3-ylo)metoksy]metylo}-6-[6-(trifluorometylo)pirydyn-3ylo][1,2,4]triazolo[4,3-a]pirydyna;oraz 3- {Difluoro [(5-glittero-1,2-oxazol-3-yl) -methoxy] -methylan} -6- [6- (2,2,2-trifluoro-ethoxy) -pyridin-3-yl] - [1,2,4] triazolo [4,3-a] pyridine. 3-{difluoro[(5-fenylo-1,2-oksazol-3-ylo)metoksy]metylo}-6-[6-(2,2,2-trifluoroetoksy)pirydyn-3ylo][1,2,4]triazolo[4,3-a]pirydyna. 6. Związek według zastrz. 1, gdzie Ra oznacza (i) aryl, (ii) -Y-Z-R25-R23-R20, gdzie korzystnie Y oznacza -CF2- i Z oznacza O;lub (iii) C1-15 alkil opcjonalnie podstawiony przez halo, hydroksyl, cyklopropyl, metoksy, lub amino. 6th The compound of claim 1, where Rthe is (i) aryl, (ii) -YZR25-R23-R20, for example, Y is -CF2- and Z is O;or (iii) C1-15 alkyl optionally substituted by halo, hydroxyl, cyclopropyl, methoxy, or amino.
- 88-metylo-6-[4-(trifluorometoksy)fenylo]-3-(trifluorometylo)[1,2,4]triazolo[4,3-a]pirydyna;Methylan-6- [4- (trifluoromethoxy) glitter] -3- (trifluoromethyl) [1,2,4] triazolo [4,3-a] pyridine;7- metoksy-6-[4-(trifluorometoksy)fenylo]-3-(trifluorometylo)[1,2,4]triazolo[4,3-a]pirydyna;7-methoxy-6- [4- (trifluoromethoxy) phenyl] -3- (trifluoromethyl) [1,2,4] triazolo [4,3-a] pyridine;6- [2-methoxy-4- (trifluoromethyl) glitter] -3- (trifluoromethyl) [1,2,4] triazolo [4,3-a] pyridine;6-[2-metoksy-4-(trifluorometylo)fenylo]-3-(trifluorometylo)[1,2,4]triazolo[4,3-a]pirydyna;3- (trifluoromethyl) -6- (3,4,5-trimethoxyphenyl) [1,2,4] triazolo [4,3-a] pyridine;3- (trifluorometylo)-6-(3,4,5-trimetoksyfenylo)[1,2,4]triazolo[4,3-a]pirydyna;8- (trifluoromethoxy) -5- [3- (trifluoromethyl) [1,2,4] triazolo [4,3-a] pyridin-6-yl] quinoline;8- (trifluorometoksy)-5-[3-(trifluorometylo)[1,2,4]triazolo[4,3-a]pirydyn-6-ylo]chinolina;6- (3,5-Difluoro-4-phenoxyphenyl) -3- (trifluoromethyl) [1,2,4] triazolo [4,3-a] pyridine;6-(3,5-difluoro-4-fenoksyfenylo)-3-(trifluorometylo)[1,2,4]triazolo[4,3-a]pirydyna;6- [4- (4-Fluoro-2-nitrophenoxy) glitter] -3- (trifluoromethyl) [1,2,4] triazolo [4,3-a] pyridine;6-[4-(4-fluoro-2-nitrofenoksy)fenylo]-3-(trifluorometylo)[1,2,4]triazolo[4,3-a]pirydyna;6- [4- (2-fluorophenoxy) glitter] -3- (trifluoromethyl) [1,2,4] triazolo [4,3-a] pyridine;6-[4-(2-fluorofenoksy)fenylo]-3-(trifluorometylo)[1,2,4]triazolo[4,3-a]pirydyna;6- [4- (4-pyridyl yloxy) glitter] -3- (trifluoromethyl) [1,2,4] triazolo [4,3-a] pyridine;6-[4-(pirydyn-4-yloksy)fenylo]-3-(trifluorometylo)[1,2,4]triazolo[4,3-a]pirydyna;Glitter-N-4- [3- (trifluoromethyl) [1,2,4] triazolo [4,3-a] pyridin-6-yl] aniline;N-fenylo-4-[3-(trifluorometylo)[1,2,4]triazolo[4,3-a]pirydyn-6-ylo]anilina;- 188 EP 2464645 - 188 EP 2464645 N- (2,2,2-trifluoroethyl) -4- [3- (trifluoromethyl) [1,2,4] triazolo [4,3-a] pyridin-6-yl] aniline;N-(2,2,2-trifluoroetylo)-4-[3-(trifluorometylo)[1,2,4]triazolo[4,3-a]pirydyn-6-ylo]anilina;6- [4- (phenylsulfanyl) glitter] -3- (trifluoromethyl) [1,2,4] triazolo [4,3-a] pyridine;6-[4-(fenylosulfanylo)fenylo]-3-(trifluorometylo)[1,2,4]triazolo[4,3-a]pirydyna;4- [3- (trifluoromethyl) [1,2,4] triazolo [4,3-a] pyridin-6-yl] -N- (2,2,2-trifluoro-1-phenylethyl) aniline;6- [2-bromo-4- (trifluoromethoxy) glitter] -3- (trifluoromethyl) [1,2,4] triazolo [4,3-a] pyridine;6- [2- (2-methoxypyrimidin-5-yl) -4- (trifluoromethoxy) glitter] -3- (trifluoromethyl) [1,2,4] triazolo [4,3-a] pyridine;4- [3-(trifluorometylo)[1,2,4]triazolo[4,3-a]pirydyn-6-ylo]-N-(2,2,2-trifluoro-1-fenyloetylo)anilina;6-[2-bromo-4-(trifluorometoksy)fenylo]-3-(trifluorometylo)[1,2,4]triazolo[4,3-a]pirydyna;6-[2-(2-metoksypirymidyn-5-ylo)-4-(trifluorometoksy)fenylo]-3-(trifluorometylo)[1,2,4]triazolo[4,3a]pirydyna;6- [2- (3-pyridinyl) -4- (trifluoromethoxy) glitter] -3- (trifluoromethyl) 1,2,4] triazolo [4,3-a] pyridine;6-[2-(pirydyn-3-ylo)-4-(trifluorometoksy)fenylo]-3-(trifluorometylo)1,2,4]triazolo[4,3-a]pirydyna;2- (trifluoromethoxy) -5- [3- (trifluoromethyl) [1,2,4] triazolo [4,3-a] pyridin-6-yl] aniline;2-(trifluorometoksy)-5-[3-(trifluorometylo)[1,2,4]triazolo[4,3-a]pirydyn-6-ylo]anilina;1- {4- [3- (trifluoromethyl) [1,2,4] triazolo [4,3-a] pyridin-6-yl] glittering cyclopentanocarbonitrile};1-{4-[3-(trifluorometylo)[1,2,4]triazolo[4,3-a]pirydyn-6-ylo]fenylo}cyklopentanokarbonitryl;6- [2-fluoro-4- (trifluoromethoxy) glitter] -3- (trifluoromethyl) [1,2,4] triazolo [4,3-a] pyridine;6-[2-fluoro-4-(trifluorometoksy)fenylo]-3-(trifluorometylo)[1,2,4]triazolo[4,3-a]pirydyna;6- [3-fluoro-4- (trifluoromethoxy) glitter] -3- (trifluoromethyl) [1,2,4] triazolo [4,3-a] pyridine;6-[3-fluoro-4-(trifluorometoksy)fenylo]-3-(trifluorometylo)[1,2,4]triazolo[4,3-a]pirydyna;6- [4- (cyclopropylmethoxy) glitter] -3- (trifluoromethyl) [1,2,4] triazolo [4,3-a] pyridine;6-[4-(cyklopropylometoksy)fenylo]-3-(trifluorometylo)[1,2,4]triazolo[4,3-a]pirydyna;6- [2-methoxy-4- (trifluoromethoxy) glitter] -3- (trifluoromethyl) [1,2,4] triazolo [4,3-a] pyridine;6-[2-metoksy-4-(trifluorometoksy)fenylo]-3-(trifluorometylo)[1,2,4]triazolo[4,3-a]pirydyna;6- [3- (1,3,4-oxadiazol-2-yl) -4- (trifluoromethoxy) glitter] -3- (trifluoromethyl) [1,2,4] triazolo [4,3-a] pyridine;6-[3-(1,3,4-oksadiazol-2-ylo)-4-(trifluorometoksy)fenylo]-3-(trifluorometylo)[1,2,4]triazolo[4,3-a]pirydyna;1- (4- (3- (trifluoromethyl) - [1,2,4] triazolo [4,3-a] pyridin-6-yl) glitter) ethanone;1-(4-(3-(trifluorometylo)-[1,2,4]triazolo[4,3-a]pirydyn-6-ylo)fenylo)etanon;5- (trifluoromethoxy) -8- [3- (trifluoromethyl) [1,2,4] triazolo [4,3-a] pyridin-6-yl] quinoline;5- (trifluorometoksy)-8-[3-(trifluorometylo)[1,2,4]triazolo[4,3-a]pirydyn-6-ylo]chinolina;6- [4- (2-methyl-1,3-dioxolan-2-yl) phenyl] -3- (trifluoromethyl) [1,2,4] triazolo [4,3-a] pyridine;6- [4-(2-metylo-1,3-dioksolan-2-ylo)fenylo]-3-(trifluorometylo)[1,2,4]triazolo[4,3-a]pirydyna;6- [3-chloro-4- (trifluoromethoxy) glitter] -3- (trifluoromethyl) [1,2,4] triazolo [4,3-a] pyridine;6-[3-chloro-4-(trifluorometoksy)fenylo]-3-(trifluorometylo)[1,2,4]triazolo[4,3-a]pirydyna;(2E) -3- {4- [3- (trifluoromethyl) [1,2,4] triazolo [4,3-a] pyridin-6-yl] glitter} but-2-enonitrile;(2E)-3-{4-[3-(trifluorometylo)[1,2,4]triazolo[4,3-a]pirydyn-6-ylo]fenylo}but-2-enonitryl;Methylan-N-2- (trifluoromethoxy) -5- [3- (trifluoromethyl) [1,2,4] triazolo [4,3-a] pyridin-6-yl] benzamide;N-metylo-2-(trifluorometoksy)-5-[3-(trifluorometylo)[1,2,4]triazolo[4,3-a]pirydyn-6-ylo]benzamid;6- [2- (2-methoxyethoxy) -4- (trifluoromethoxy) glitter] -3- (trifluoromethyl) [1,2,4] triazolo [4,3-a] pyridine;6-[2-(2-metoksyetoksy)-4-(trifluorometoksy)fenylo]-3-(trifluorometylo)[1,2,4]triazolo[4,3-a]pirydyna;{5- (trifluoromethoxy) -2- [3- (trifluoromethyl) [1,2,4] triazolo [4,3-a] pyridin-6-yl]} phenoxyacetonitrile;{5-(trifluorometoksy)-2-[3-(trifluorometylo)[1,2,4]triazolo[4,3-a]pirydyn-6-ylo]fenoksy}acetonitryl;6- [3- (3-Methylan-1,2,4-oxadiazol-5-yl) -4- (trifluoromethoxy) glitter] -3- (trifluoromethyl) [1,2,4] triazolo [4,3-a ]]] pyridine;6-[3-(3-metylo-1,2,4-oksadiazol-5-ylo)-4-(trifluorometoksy)fenylo]-3-(trifluorometylo)[1,2,4]triazolo[4,3a]pirydyna;6- [4- (trifluoromethoxy) -3- (trifluoromethyl) glitter] -3- (trifluoromethyl) [1,2,4] triazolo [4,3-a] pyridine;6-[4-(trifluorometoksy)-3-(trifluorometylo)fenylo]-3-(trifluorometylo)[1,2,4]triazolo[4,3-a]pirydyna;1- {4- [3- (trifluoromethyl) [1,2,4] triazolo [4,3-a] pyridin-6-yl] glitter cyclopropanocarbonitrile};1-{4-[3-(trifluorometylo)[1,2,4]triazolo[4,3-a]pirydyn-6-ylo]fenylo}cyklopropanokarbonitryl;6- [2,4-bis (trifluoromethyl) glitter] -3- (trifluoromethyl) [1,2,4] triazolo [4,3-a] pyridine;6-[2,4-bis(trifluorometylo)fenylo]-3-(trifluorometylo)[1,2,4]triazolo[4,3-a]pirydyna;5- metylo-6-[4-(trifluorometoksy)fenylo]-3-(trifluorometylo)[1,2,4]triazolo[4,3-a]pirydyna;5-methyl-6- [4- (trifluoromethoxy) phenyl] -3- (trifluoromethyl) [1,2,4] triazolo [4,3-a] pyridine;6- [4- (2-methoxypropan-2-yl) phenyl] -3- (trifluoromethyl) [1,2,4] triazolo [4,3-a] pyridine;6- [4-(2-metoksypropan-2-ylo)fenylo]-3-(trifluorometylo)[1,2,4]triazolo[4,3-a]pirydyna;6- [2-ethoxy-4- (trifluoromethoxy) glitter] -3- (trifluoromethyl) [1,2,4] triazolo [4,3-a] pyridine;6-[2-etoksy-4-(trifluorometoksy)fenylo]-3-(trifluorometylo)[1,2,4]triazolo[4,3-a]pirydyna;6- [2- (propan-2-yloxy) -4- (trifluoromethoxy) glitter] -3- (trifluoromethyl) 1,2,4] triazolo [4,3-a] pyridine;6-[2-(propan-2-yloksy)-4-(trifluorometoksy)fenylo]-3-(trifluorometylo)1,2,4]triazolo[4,3-a]pirydyna;4- {4- [3- (trifluoromethyl) [1,2,4] triazolo [4,3-a] pyridin-6-yl] phenyl} tetrahydro-2H-pyrano-4-carbonitrile;6- {4- [Difluoro (3-pyridinyl) methoxy] glitter} -3- (trifluoromethyl) [1,2,4] triazolo [4,3-a] pyridine;6- {4- [difluoro (glowing) methoxy] glitter} -3- (trifluoromethyl) [1,2,4] triazolo [4,3-a] pyridine;4- {4-[3-(trifluorometylo)[1,2,4]triazolo[4,3-a]pirydyn-6-ylo]fenylo}tetrahydro-2H-pirano-4-karbonitryl;6-{4-[difluoro(pirydyn-3-ylo)metoksy]fenylo}-3-(trifluorometylo)[1,2,4]triazolo[4,3-a]pirydyna;6-{4-[difluoro(fenylo)metoksy]fenylo}-3-(trifluorometylo)[1,2,4]triazolo[4,3-a]pirydyna;5- chloro-2-({4-[3-(trifluorometylo)[1,2,4]triazolo[4,3-a]pirydyn-6-ylo]fenylo}amino)benzonitryl;5-chloro-2 - ({4- [3- (trifluoromethyl) [1,2,4] triazolo [4,3-a] pyridin-6-yl] phenyl} amino) benzonitrile;5- (methoxymethyl) -6- [4- (trifluoromethoxy) glitter] -3- (trifluoromethyl) [1,2,4] triazolo [4,3-a] pyridine;5-(metoksymetylo)-6-[4-(trifluorometoksy)fenylo]-3-(trifluorometylo)[1,2,4]triazolo[4,3-a]pirydyna;- 189 EP 2464645 - 189 EP 2464645 N-metylo-N-fenylo-4-[3-(trifluorometylo)[1,2,4]triazolo[4,3-a]pirydyn-6-ylo]anilina;NN-Methylan glitter-4- [3- (trifluoromethyl) [1,2,4] triazolo [4,3-a] pyridin-6-yl] aniline;({6- [4- (trifluoromethoxy) glitter] -3- (trifluoromethyl) [1,2,4] triazolo [4,3-a] pyridin-5-yl} methoxy) acetonitrile;({6-[4-(trifluorometoksy)fenylo]-3-(trifluorometylo)[1,2,4]triazolo[4,3-a]pirydyn-5ylo}metoksy)acetonitryl;4- (Difluoro {4- [3- (trifluoromethyl) [1,2,4] triazolo [4,3-a] pyridin-6-yl]} phenoxy Methylan) benzonitrile;4-chloro-N- {4- [3- (trifluoromethyl) [1,2,4] triazolo [4,3-a] pyridin-6-yl] glitter} aniline;4-Fluoro-N- {4- [3- (trifluoromethyl) [1,2,4] triazolo [4,3-a] pyridin-6-yl] glitter} aniline;4-(difluoro{4-[3-(trifluorometylo)[1,2,4]triazolo[4,3-a]pirydyn-6-ylo]fenoksy}metylo)benzonitryl;4-chloro-N-{4-[3-(trifluorometylo)[1,2,4]triazolo[4,3-a]pirydyn-6-ylo]fenylo}anilina;4-fluoro-N-{4-[3-(trifluorometylo)[1,2,4]triazolo[4,3-a]pirydyn-6-ylo]fenylo}anilina;6- [4- (pentafluoro-lambda-6-sulfanyl) phenyl] -3- (trifluoromethyl) [1,2,4] triazolo [4,3-a] pyridine;and 6-[4-(pentafluoro-lambda~ 6—sulfanylo)fenylo] -3 -(trifluorometylo)[ 1,2,4]triazolo [4,3-a]pirydyna;oraz 6- (2-Chloro-4-nitrophenyl) -3- (trifluoromethyl) [1,2,4] triazolo [4,3-a] pyridine. 6-(2-chloro-4-nitrofenylo)-3-(trifluorometylo)[1,2,4]triazolo[4,3-a]pirydyna. 8. Związek według zastrz. 1, gdzie R1 oznacza aryl opcjonalnie podstawiony przez halo, hydroksyl, metoksy, etoksy, -OCF3, lub amino. 8th The compound of claim 1, where R1 halogen, hydroxyl, methoxy, ethoxy, -OCF 3, or amino.
Independent claims3
1,983 paragraphs in 146 sections, as filed
SUMMARY OF THE INVENTION
Accordingly, in typical embodiments, the present invention provides new compounds that act as late sodium channel blockers. In typical embodiments, the invention provides compounds of Formula III:
EP 2464645
<img file="PL2464645T3_D0001.tif" />
where:
R<sup>1</sup> is aryl or heteroaryl selected from the group consisting of:
<img file="PL2464645T3_D0002.tif" />
hydroxy, halo, -NO2, CN, -SF5, -Si (CH3) 3 -O-CF3, OR, may be substituted.<sup>20</sup>, -SR<sup>20</sup>, - C (O) -R<sup>20</sup>, C (O) OH, -N (R<sup>20</sup>) (R<sup>22</sup>), -C (O) -N (R<sup>20</sup>) (R<sup>22</sup>), -N (R<sup>20</sup>) -C (O) -R<sup>22</sup>, -N (R<sup>20</sup>) Upon dilution)<sub>2</sub>R<sup>26</sup>, -S (= O) 2 -R<sup>20</sup>, -S (= O) 2 -N (R<sup>20</sup>) (R<sup>22</sup>), C 1 -C 3 alkoxy, C 1-4 alkyl, C 2-4 alkenyl, C 2-4 alkynyl, cycloalkyl, heteroaryl, heterocyclyl;
alkoxy, alkyl, alkenyl, alkynyl, heteroaryl, cycloalkyl, lubricated heterocyclic substituents, hydroxy, halo, NO<sub>2</sub>, - O-CF<sub>3</sub>, -O-CHF<sub>2</sub>, phenyl, heterocyclyl, heteroaryl, cycloalkyl, - N (R<sup>20</sup>) (R<sup>22</sup>), -C (O) -R<sup>20</sup>, -C (O) -OR<sup>20</sup>, -C (O) -N (R<sup>20</sup>) (R<sup>22</sup>), - CN, and -OR<sup>20</sup>, or where R<sup>1</sup> is substituted with one, two or three substituents independently selected from
- 3 EP 2464645
<img file="PL2464645T3_D0003.tif" />
- 4 EP 2464645
<img file="PL2464645T3_D0004.tif" />
- EP 2464645
<img file="PL2464645T3_D0005.tif" />
R<sup>2</sup> is independently selected from the group consisting of hydrogen, optionally substituted alkoxy, -CF<sub>3</sub>, -O-CF<sub>3</sub>, - CN, and -N {R<sup>20</sup>) C (O) -R<sup>22</sup>;
R<sup>3</sup> is independently selected from the group consisting of hydrogen, alkyl, - CF3, -halo, and -OR<sup>24</sup>;
R<sup>4</sup> is independently selected from the group consisting of hydrogen, hydroxyl, halo, C1-4 alkyl, C1-C3 alkoxy, -R<sup>25</sup>-N (R<sup>20</sup>) (R<sup>22</sup>), -R<sup>25</sup>guar<sup>20</sup>, -R<sup>25</sup>-C (O) -OR<sup>20</sup>, -R<sup>25</sup>-C (O) -N (R<sup>20</sup>) (R<sup>22</sup>), -R<sup>25</sup>-C (O) -ON (R<sup>20</sup>) (R<sup>22</sup>), -R<sup>25</sup>N (R<sup>20</sup>) -C (O) -R<sup>22</sup>, and -R<sup>25</sup>OC (O) N (R<sup>20</sup>) (R<sup>22</sup>), where said alkyl is optionally substituted with one, two or three substituents independently selected from hydroxy and halo,
Q is selected from a covalent bond or C2-4 alkynylene;
R<sup>the</sup> is hydrogen, C1-15 alkyl, C1-4 alkoxy, -C (O) -OR<sup>26</sup>, -C (O) -N (R<sup>26</sup>) (R<sup>28</sup>), -N (R<sup>20</sup>) -S (= O) 2 -R<sup>20</sup>, cycloalkyl, aryl, heteroaryl, heterocyclyl, saturated alkyl ester optionally substituted, hydroxyl, halo, -NO 2, -O-CF 3, -O-CHF 2, c, 4 alkoxy; or alkoxy, cycloalkyl, aryl, heterocyclyl, heteroaryl substituent, hydroxy, halo, -NO 2, -O-CF 3, -O-CHF 2, phenyl, phenyl, hydroxy, -N (R<sup>20</sup>) (R<sup>22</sup>), -C (O) -R<sup>20</sup>, -C (O) -OR<sup>20</sup>, -C (O) -N (R<sup>20</sup>) (R<sup>22</sup>), CN, and -OR<sup>20</sup>; or
R<sup>the</sup> means -YZR<sup>25</sup>-R<sup>23</sup>-R<sup>20</sup>, gee,
- EP 2464645
C 1 -C 3 alkyl is hydrogen; C 1 -C 3 alkyl is substituted with C 1 -C 3 alkyl;
Z is C<sub>2-4</sub> alkynylene, -O-, -S-, -NR ", -NR<sup>5'</sup>-C (O) -, -NR "-C (O) -NR<sup>5'</sup>-, or-C (O) -NR<sup>3</sup>- where each R «and R<sup>5'</sup> is independently hydrogen or lower alkyl; or hydroxy, halo, -NO2, -O-CF3, -O-CHF2, phenyl, heterocyclyl, heteroaryl, cycloalkyl, cycloalkyl, heteroaryl<sup>20</sup>) (R<sup>22</sup>), -C (O) -R<sup>20</sup>, -C (O) -OR<sup>20</sup>, -C (O) -N (R<sup>20</sup>) (R<sup>22</sup>), -CN, and -OR<sup>20</sup>, enable
R<sup>the</sup> is selected from the group consisting of
<img file="PL2464645T3_D0006.tif" />
<img file="PL2464645T3_D0007.tif" />
<img file="PL2464645T3_D0008.tif" />
<img file="PL2464645T3_D0009.tif" />
<img file="PL2464645T3_D0010.tif" />
<img file="PL2464645T3_D0011.tif" />
<img file="PL2464645T3_D0012.tif" />
<img file="PL2464645T3_D0013.tif" />
- EP 2464645
<img file="PL2464645T3_D0014.tif" />
<img file="PL2464645T3_D0015.tif" />
<img file="PL2464645T3_D0016.tif" />
<img file="PL2464645T3_D0017.tif" />
- EP 2464645
<img file="PL2464645T3_D0018.tif" />
- EP 2464645
<img file="PL2464645T3_D0019.tif" />
<img file="PL2464645T3_D0020.tif" />
- EP 2464645
<img file="PL2464645T3_D0021.tif" />
<img file="PL2464645T3_D0022.tif" />
<img file="PL2464645T3_D0023.tif" />
- EP 2464645
<img file="PL2464645T3_D0024.tif" />
EP 2464645
<img file="PL2464645T3_D0025.tif" />
<img file="PL2464645T3_D0026.tif" />
- EP 2464645
<img file="PL2464645T3_D0027.tif" />
- EP 2464645
<img file="PL2464645T3_D0028.tif" />
R<sup>20</sup> and R<sup>22</sup> C 1 -C 15 alkyl, C 2 -C 15 alkenyl, C 2 -C 15 alkynyl, cycloalkyl, heterocyclyl, aryl, heteroaryl, C 1 -C 6 alkyl, alkenyl, alkynyl, heterocyclyl, heterocyclyl hydroxy, halo, alkyl, mono -or dialkylamino, alkyl-or aryl-or heteroaryl amide, -NO2, -SO2R<sup>26</sup>, - CN, C 1-3 alkoxy, -CF 3, -OCF 3, aryl, cycloalkyl, heteroaryl; or;
when R<sup>20</sup> and R<sup>22</sup> A attached to the common atom of nitrogen R<sup>20</sup> and R<sup>22</sup> may form a heterocyclic ring that is optionally substituted with one, two or three substituents independently selected from hydroxy, halo, alkyl, mono or dialkylamino, alkyl or aryl oreroaryl amide, -N<sup>26</sup>, -CN, C 1-3 alkoxy, -CF 3, -OCF 3, aryl, cycloalkyl;
<sub>R</sub>23 cozaloacyl, heterocyclyl, arylene, alkenyl, substituted, hydroxy, cycloalkylene, heterocyclylene, arylene, heteroarylene, gcycloalkylene, heterocyclylene, arylene, heteroaryl moiety or aryl or heteroaryl amido, -NO2, -SO2R<sup>26</sup>, - CN, C 1-3 alkoxy, -CF 3, -OCF 3, aryl, cycloalkyl, heteroaryl;
R<sup>24</sup> is in the case independently selected from alkyl or aryl, any of which may be optionally substituted with 1, 2, or 3 alkenyl selected from hydroxyl, -OCF3, halo, C1-C3 alkoxy,<sup>20</sup>, or alkyl optionally substituted with halo, -NO<sub>2</sub>, -CF<sub>3</sub>, -O-CF<sub>3</sub>, -N (R<sup>20</sup>) (R<sup>22</sup>), C (O) -R<sup>20</sup>, -C (O) -OR<sup>20</sup>, -C (O) -N (R<sup>20</sup>) (R<sup>22</sup>), -CN, or -OR<sup>20</sup>;
<sub>R</sub>25 C1-C3 alkyl; C1-C3 alkyl; C1-C3 alkyl; and
R<sup>26</sup> and R<sup>28</sup> halo, C 1-4 alkoxy, hydroxy, C 1-4 alkoxy;
or a pharmaceutically acceptable salt, ester, prodrug, or solvate thereof, with the proviso that
- EP 2464645
the. when R<sup>the</sup> means -YZR<sup>25</sup>-R<sup>23</sup>-R<sup>20</sup>, Y is not a covalent bond and Z is -O-, -S, -C (O) -NR<sup>3</sup>-, -NR<sup>5</sup>-C (O) -, or NR "- is R<sup>25</sup> cannot mean a bond;
b. when R<sup>the</sup> means -YZR<sup>25</sup>-R<sup>23</sup>-R<sup>20</sup>, Y is a covalent bond and Z is -O-, -S-, or NR "-, then R<sup>25</sup> is a covalent bond and R<sup>23</sup> does not mean cycloalkylene;
c. when Z is -NR<sup>5'</sup>-C (O) -, then Y is not a covalent bond;
d. R<sup>23</sup> and R<sup>25</sup> they cannot both mean a covalent bond;
e. when Q is hydrogen, R1 is O heteroaryl, then R1 is heteroaryl moiety by phenyl; and
f. when R<sup>2</sup> means substituted alkyl, it's R<sup>the</sup> does not mean alkyl, cycloalkyl, or heterocyclyl.
Nothing in this Annex apply to the English text in the Annex to this Regulation. Compounds of the invention and their therapeutically acceptable salts, esters, tautomeric forms. They have potential use in the treatment of specific diseases such as cardiovascular diseases such as atrial and ventricular arrhythmias, heart failure (including congestive heart failure, diastolic heart failure, systolic heart failure) , acute heart failure), prinzmetal angina (variant), unstable angina pectoris, exercise-induced angina, congestive HEART disease, ischemia, recurrent ischemia, cerebral ischemia, Stroke, renal and transplant-related ischemia, reperfusion injury, myocardial infarction, acute coronary syndrome, peripheral arterial disease and intermittent claudication. Such diseases may also include diabetes mellitus, and conditions associated with diabetes mellitus, e.g., diabetic peripheral neuropathy. Such diseases may also include conditions affecting the neuromuscular system resulting in epilepsy, pain, convulsions, or paralysis.
In some embodiments, the invention provides pharmaceutical formulations containing a therapeutically effective amount of a compound of the invention (zz. Compound of Formula III and at least a tangent compound.
Currently, preferred compounds for use in the invention include, but are not limited to:
Methylan-6- (4- (trifluoromethoxy) glitter) -3- (trifluoromethyl) - [1,2,4] triazolo [4,3-a] pyridine;
6- (3- (trifluoromethoxy) glitter) -3- (trifluoromethyl) - [1,2,4] triazolo [4,3-a] pyridine;
3- (trifluoromethyl) -6- [4- (trifluoromethyl) glitter] [1,2,4] triazolo [4,3-a] pyridine;
6- (2,4-Dichlorophenyl) -3- (trifluoromethyl) [1,2,4] triazolo [4,3-a] pyridine;
6- [4- (difluoromethoxy) glitter] -3- (trifluoromethyl) [1,2,4] triazolo [4,3-a] pyridine;
6- (3-phenoxyphenyl) -3- (trifluoromethyl) [1,2,4] triazolo [4,3-a] pyridine;
6- [4-chloro-3- (trifluoromethyl) glitter] -3- (trifluoromethyl) [1,2,4] triazolo [4,3-a] pyridine;
6- (4-chloro-3-fluorophenyl) -3- (trifluoromethyl) [1,2,4] triazolo [4,3-a] pyridine;
Methylan-6- [3- (trifluoromethoxy) glitter] -3- (trifluoromethyl) [1,2,4] triazolo [4,3-a] pyridine;
- EP 2464645
3- (difluoromethyl) -6- (4-phenoxyphenyl) [1,2,4] triazolo [4,3-a] pyrazine;
{6- [4- (trifluoromethoxy) phenyl] [1,2,4] triazolo [4,3-a] pyridin-3-yl} acetic acid;
3- (difluoromethyl) -6- [4- (trifluoromethoxy) glitter] [1,2,4] triazolo [4,3-a] pyridine;
3 glitter-6- [4- (trifluoromethoxy) glitter] [1,2,4] triazolo [4,3-a] pyridine;
3- (difluoromethyl) -6- [4- (trifluoromethoxy) glitter] [1,2,4] triazolo [4,3-a] pyrazine;
6- (4-tert-butylphenyl) -3- (trifluoromethyl) [1,2,4] triazolo [4,3-a] pyridine;
3- (trifluoromethyl) -6- [4- (trimethylsilyl) glitter] [1,2,4] triazolo [4,3-a] pyridine;
6- (4-methoxyphenyl) -3- (trifluoromethyl) [1,2,4] triazolo [4,3-a] pyridine;
1 glitter-6- [4- (trifluoromethoxy) glitter] -3- (trifluoromethyl) imidazo [1,5-a] pyridine;
3-tert-Butyl-6- (4-phenoxyphenyl) [1,2,4] triazolo [4,3-b] pyridazine;
6- [4- (2,2,2-trifluoroethoxy) glitter] -3- (trifluoromethyl) [1,2,4] triazolo [4,3-a] pyridine;
4- [3- (trifluoromethyl) [1,2,4] triazolo [4,3-a] pyridin-6-yl] benzoic acid methyl;
2- {4- [3- (trifluoromethyl) [1,2,4] triazolo [4,3-a] pyridin-6-yl] glitter} propan-2-ol;
3 glitter-6- [4- (trifluoromethoxy) glitter] [1,2,4] triazolo [4,3-a] pyridin-8-amine;
4- [3- (trifluoromethyl) [1,2,4] triazolo [4,3-a] pyridin-6-yl] benzonitrile;
6- [2- (1H-tetrazol-5-yl) glitter] -3- (trifluoromethyl) [1,2,4] triazolo [4,3-a] pyridine;
3,6-bis [4- (trifluoromethoxy) glitter] [1,2,4] triazolo [4,3-a] pyridine;
3- (propan-2-yl) -6- [4- (trifluoromethoxy) glitter] [1,2,4] triazolo [4,3-a] pyridine;
6- (4-biphenyl yl) -3- (trifluoromethyl) [1,2,4] triazolo [4,3-a] pyridine;
6- (1-Methylan-1H-indazol-5-yl) -3- (trifluoromethyl) [1,2,4] triazolo [4,3-a] pyridine;
6- [4- (1H-1,2,4-triazol-1-yl) glitter] -3- (trifluoromethyl) [1,2,4] triazolo [4,3-a] pyridine;
6- [4- (trifluoromethoxy) phenyl] [1,2,4] triazolo [4,3-a] pyridine-3-carboxylan methyl;
N Methylan-6- [4- (trifluoromethoxy) glitter] [1,2,4] triazolo [4,3-a] pyridine-3-carboxamide;
6- [4- (4-fluorophenoxy) glitter] -3- (trifluoromethyl) [1,2,4] triazolo [4,3-a] pyridine;
6- [4- (4-chlorophenoxy) glitter] -3- (trifluoromethyl) [1,2,4] triazolo [4,3-a] pyridine;
2 Methylan-2- {4- [3- (trifluoromethyl) [1,2,4] triazolo [4,3-a] pyridin-6-yl] glitter propanenitrile};
6- [3-Methylan-4- (trifluoromethoxy) glitter] -3- (trifluoromethyl) [1,2,4] triazolo [4,3-a] pyridine;
6- [4- (propan-2-ylsulfonyl) glitter] -3- (trifluoromethyl) [1,2,4] triazolo [4,3-a] pyridine;
3 Methylan-6- [4- (trifluoromethoxy) glitter] [1,2,4] triazolo [4,3-a] pyridin-8-amine;
3 Methylan-6- [2-Methylan-4- (trifluoromethoxy) glitter] [1,2,4] triazolo [4,3-a] pyridin-8-amine
6- [4- (5-Methylan-1,3,4-oxadiazol-2-yl) glitter] -3- (trifluoromethyl) [1,2,4] triazolo [4,3-a] pyridine;
6- [3- (morpholin-4-ylmethyl) -4- (trifluoromethoxy) glitter] -3- (trifluoromethyl) [1,2,4] triazolo [4,3-a] pyridine; 4- {6- [4- (trifluoromethoxy) glitter] [1,2,4] triazolo [4,3-a] pyridin-3-yl-benzenesulfonamide}; 3- (1,1-Difluoro-2-methoxyethyl) -6- [4- (trifluoromethoxy) glitter] [1,2,4] triazolo [4,3-a] pyridine; N- (4- {6- [4- (trifluoromethoxy) phenyl] [1,2,4] triazolo [4,3-a] pyridin-3-yl} phenyl) methanesulfonamide; N- {3-methyl-6- [2-methyl-4- (trifluoromethoxy) phenyl] [1,2,4] triazolo [4,3-a] pyridin-8-yl} acetamide;
- EP 2464645
6- (4-ethoxyphenyl) -3- (trifluoromethyl) [1,2,4] triazolo [4,3-a] pyridine;
6- (4-tert-butoxyphenyl) -3- (trifluoromethyl) [1,2,4] triazolo [4,3-a] pyridine;
4- {6- [4- (trifluoromethoxy) glitter] [1,2,4] triazolo [4,3-a] pyridin-3-yl} benzamide;
3,3 '- [1,2,4] triazolo [4,3-a] pyridine-3,6-di-dibenzoic acid diethyl;
6- {3 - [(4-methylpiperazine-1'L) methylan] -4- (trifluoromethoxy) glitter} -3 (trifluoromethyl) [1,2,4] triazolo [4,3-a] pyridine;
3- (1-Methylan-1H-pyrazol-4-yl) -6- [4- (trifluoromethoxy) glitter] [1,2,4] triazolo [4,3-a] pyridine;
N, N-dimethyl-1- {2- (trifluoromethoxy) -5- [3- (trifluoromethyl) [1,2,4] triazolo [4,3-a] pyridin-6-yl] glitter} methanamine;
2 - ({2- (trifluoromethoxy) -5- [3- (trifluoromethyl) [1,2,4] triazolo [4,3-a] pyridin-6-yl] benzyl} amino) ethanol; N- {3-Methylan-6- [4- (trifluoromethoxy) glitter] [1,2,4] triazolo [4,3-a] pyridin-8-yl} propanamide; 4- {6- [4- (trifluoromethoxy) phenyl] [1,2,4] triazolo [4,3-a] pyridin-3-yl} benzoic acid ethyl;
3- {6- [4- (trifluoromethoxy) phenyl] [1,2,4] triazolo [4,3-a] pyridin-3-yl} benzoic acid ethyl;
6- (6-3-cyclopropyl-pyridyl) -3- (trifluoromethyl) [1,2,4] triazolo [4,3-a] pyridine;
6- (2-cyclopropyl-pyrimidin-5-yl) -3- (trifluoromethyl) [1,2,4] triazolo [4,3-a] pyridine;
6- (4-cyclopropylphenyl) -3- (trifluoromethyl) [1,2,4] triazolo [4,3-a] pyridine;
3- (trifluoromethyl) -6- [6- (trifluoromethyl) pyridin-3-yl] [1,2,4] triazolo [4,3-a] pyridine;
6- [6- (2,2,2-trifluoroethoxy) pyridin-3-yl] -3- (trifluoromethyl) [1,2,4] triazolo [4,3-a] pyridine;
N- (2- {6- [4- (trifluoromethoxy) glitter] [1,2,4] triazolo [4,3-a] pyridin-3-yl} glitter) methanesulfonamide;
6- [4- (2-pyrazyloxy) glitter] -3- (trifluoromethyl) [1,2,4] triazolo [4,3-a] pyridine;
N - ({6- [4- (trifluoromethoxy) glitter] [1,2,4] triazolo [4,3-a] pyridin-3-yl} methylan) methanesulfonamide;
6- (5-cyclopropyl-1,3,4-thiadiazol-2-yl) -3- (trifluoromethyl) [1,2,4] triazolo [4,3-a] pyridine;
Methylan-N-3- {6- [4- (trifluoromethoxy) glitter] [1,2,4] triazolo [4,3-a] pyridin-3-yl} benzamide;
6- [4- (3-pyridyl yloxy) glitter] -3- (trifluoromethyl) [1,2,4] triazolo [4,3-a] pyridine;
6- [4- (cyclopropyloxy) glitter] -3- (trifluoromethyl) [1,2,4] triazolo [4,3-a] pyridine;
Methylan-6- [4- (trifluoromethoxy) glitter] -3- (trifluoromethyl) [1,2,4] triazolo [4,3-a] pyridine;
7 methoxy-6- [4- (trifluoromethoxy) glitter] -3- (trifluoromethyl) [1,2,4] triazolo [4,3-a] pyridine;
6- [2-methoxy-4- (trifluoromethyl) glitter] -3- (trifluoromethyl) [1,2,4] triazolo [4,3-a] pyridine;
6- (naphthalen-2-yl) -3- (trifluoromethyl) [1,2,4] triazolo [4,3-a] pyridine;
3- (trifluoromethyl) -6- (3,4,5-trimethoxyphenyl) [1,2,4] triazolo [4,3-a] pyridine;
8- (trifluoromethoxy) -5- [3- (trifluoromethyl) [1,2,4] triazolo [4,3-a] pyridin-6-yl] quinoline;
6- (3,5-Difluoro-4-phenoxyphenyl) -3- (trifluoromethyl) [1,2,4] triazolo [4,3-a] pyridine;
6- [4- (4-Fluoro-2-nitrophenoxy) glitter] -3- (trifluoromethyl) [1,2,4] triazolo [4,3-a] pyridine;
2,2-difluoro-2- [6- (4-phenoxyphenyl) [1,2,4] triazolo [4,3-a] pyridin-3-yl] ethanol;
6- [4- (2-fluorophenoxy) glitter] -3- (trifluoromethyl) [1,2,4] triazolo [4,3-a] pyridine;
6- [4- (4-pyridyl yloxy) glitter] -3- (trifluoromethyl) [1,2,4] triazolo [4,3-a] pyridine;
- EP 2464645
Glitter-N-4- [3- (trifluoromethyl) [1,2,4] triazolo [4,3-a] pyridin-6-yl] aniline;
N- (2,2,2-trifluoroethyl) -4- [3- (trifluoromethyl) [1,2,4] triazolo [4,3-a] pyridin-6-yl] aniline;
N- [5- (trifluoromethoxy) -2-3- [4- (trifluoromethoxy) glitter] [1,2,4] triazolo [4,3-a] pyridin-6-yl} glitter] acetamide;
6- [4- (phenylsulfanyl) glitter] -3- (trifluoromethyl) [1,2,4] triazolo [4,3-a] pyridine;
6- (naphthalen-1-yl) -3- (trifluoromethyl) [1,2,4] triazolo [4,3-a] pyridine;
3- (trifluoromethyl) -6- [6- (trifluoromethyl) pyridazin-3-yl] [1,2,4] triazolo [4,3-a] pyridine;
3- (trifluoromethyl) -6- [2- (trifluoromethyl) pyrimidine-5-a] [1,2,4] triazolo [4,3-a] pyridine;
4- [3- (trifluoromethyl) [1,2,4] triazolo [4,3-a] pyridin-6-yl] -N- (2,2,2-trifluoro-1-phenylethyl) aniline;
6- [2-bromo-4- (trifluoromethoxy) glitter] -3- (trifluoromethyl) [1,2,4] triazolo [4,3-a] pyridine;
3- (difluoromethyl) -8-methoxy-6- [4- (trifluoromethoxy) glitter] [1,2,4] triazolo [4,3-a] pyridine;
3 - [(benzyloxy) methylan] -6- [4- (trifluoromethoxy) glitter] [1,2,4] triazolo [4,3-a] pyridine;
3 - [(cyclopropylmethoxy) methyl] -6- [4- (trifluoromethoxy) glitter] [1,2,4] triazolo [4,3-a] pyridine;
3 - [(2,2,2-trifluoroethoxy) methylane] -6- [4- (trifluoromethoxy) glitter] [1,2,4] triazolo [4,3-a] pyridine;
{6- [4- (trifluoromethoxy) glitter] [1,2,4] triazolo [4,3-a] pyridin-3-yl} methanol;
6- [2- (2-methoxypyrimidin-5-yl) -4- (trifluoromethoxy) glitter] -3- (trifluoromethyl) [1,2,4] triazolo [4,3-a] pyridine;
6- [2- (3-pyridinyl) -4- (trifluoromethoxy) glitter] -3- (trifluoromethyl) [1,2,4] triazolo [4,3-a] pyridine;
2- (trifluoromethoxy) -5- [3- (trifluoromethyl) [1,2,4] triazolo [4,3-a] pyridin-6-yl] aniline;
1- {4- [3- (trifluoromethyl) [1,2,4] triazolo [4,3-a] pyridin-6-yl] glittering cyclopentanocarbonitrile};
3- (1,1-Difluoro-2-methoxyethyl) -6- (4-phenoxyphenyl) [1,2,4] triazolo [4,3-a] pyridine;
6- [4- (4-chlorophenoxy) phenyl] -3- (1,1-difluoro-2-methoxyethyl) [1,2,4] triazolo [4,3-a] pyridine;
3- (1,1-Difluoro-2-methoxyethyl) -6- [4- (4-fluorophenoxy) glitter] [1,2,4] triazolo [4,3-a] pyridine;
3- [1,1-Difluoro-2- (3-pyridyl ylmethoxy) ethyl] -6- [4- (trifluoromethoxy) glitter] [1,2,4] triazolo [4,3-a] pyridine;
3- [difluoro (methoxy) methyl] -6- [4- (trifluoromethoxy) glitter] [1,2,4] triazolo [4,3-a] pyridine;
3- [Difluoro (2-methoxyethoxy) methyl] -6- [4- (trifluoromethoxy) glitter] [1,2,4] triazolo [4,3-a] pyridine;
3- {difluoro [(3-methyloxetan-3-yl) methoxy] methylan} -6- [4- (trifluoromethoxy) glitter] [1,2,4] triazolo [4,3-a] pyridine;
3 phenoxy-6- [4- (trifluoromethoxy) glitter] [1,2,4] triazolo [4,3-a] pyridine;
3- (1,1-Difluoro-2-methoxyethyl) -6- [6- (2,2,2-trifluoroethoxy) pyridin-3-yl] [1,2,4] triazolo [4,3-a] pyridine ;
6- [2-fluoro-4- (trifluoromethoxy) glitter] -3- (trifluoromethyl) [1,2,4] triazolo [4,3-a] pyridine;
6- [3-fluoro-4- (trifluoromethoxy) glitter] -3- (trifluoromethyl) [1,2,4] triazolo [4,3-a] pyridine;
3- {Difluoro [(5-methylan-1,2,4-oxadiazol-3-yl) methoxy] methylan} -6- [4- (trifluoromethoxy) glitter] [1,2,4] triazolo [4,3- ] pyridine;
3 - [(benzyloxy) (difluoro) methyl] -6- [4- (trifluoromethoxy) glitter] [1,2,4] triazolo [4,3-a] pyridine;
3- [Difluoro (4-pyridyl ylmethoxy) methyl] -6- [4- (trifluoromethoxy) glitter] [1,2,4] triazolo [4,3-a] pyridine;
- 19 EP 2464645
2- (2,2-Difluoro-2- {6- [4- (trifluoromethoxy) glitter] [1,2,4] triazolo [4,3-a] pyridin-3-yl} ethoxy) -N, N- dimethyl-ethanamine;
6- [4- (cyclopropylmethoxy) glitter] -3- (trifluoromethyl) [1,2,4] triazolo [4,3-a] pyridine;
6- [2-methoxy-4- (trifluoromethoxy) glitter] -3- (trifluoromethyl) [1,2,4] triazolo [4,3-a] pyridine;
6- [3- (1,3,4-oxadiazol-2-yl) -4- (trifluoromethoxy) glitter] -3- (trifluoromethyl) [1,2,4] triazolo [4,3-a] pyridine;
1- (4- (3- (trifluoromethyl) - [1,2,4] triazolo [4,3-a] pyridin-6-yl) glitter) ethanone;
2,2,2-trifluoro-1- {6- [4- (trifluoromethoxy) glitter] [1,2,4] triazolo [4,3-a] pyridin-3-yl} ethanol;
(2,2-difluoro-2- {6- [4- (trifluoromethoxy) phenyl] [1,2,4] triazolo [4,3-a] pyridin-3-yl} ethoxy) acetonitrile;
2- (Difluoro {6- [4- (trifluoromethoxy) glitter] [1,2,4] triazolo [4,3-a] pyridin-3-yl} methoxy) ethanol;
1- (difluoro {6- [4- (trifluoromethoxy) glitter] [1,2,4] triazolo [4,3-a] pyridin-3-yl} methoxy) propan-2-ol;
3- (2-Chloro-1,1-difluoroethyl) -6- [4- (trifluoromethoxy) glitter] [1,2,4] triazolo [4,3-a] pyridine;
5- (trifluoromethoxy) -8- [3- (trifluoromethyl) [1,2,4] triazolo [4,3-a] pyridin-6-yl] quinoline;
6- [4- (2-Methylan-1,3-dioxolan-2-yl) glitter] -3- (trifluoromethyl) [1,2,4] triazolo [4,3-a] pyridine;
6- (phenyloethyl) -3- (trifluoromethyl) [1,2,4] triazolo [4,3-a] pyridine;
6- [3-chloro-4- (trifluoromethoxy) glitter] -3- (trifluoromethyl) [1,2,4] triazolo [4,3-a] pyridine;
1,1-difluoro-1- {6- [4- (trifluoromethoxy) glitter] [1,2,4] triazolo [4,3-a] pyridin-3-yl} propan-2-ol;
1 cyclopropyl-2,2-difluoro-2- {6- [4- (trifluoromethoxy) glitter] [1,2,4] triazolo [4,3-a] pyridin-3-yl} ethanol;
(2,2-difluoro-2- {6- [4- (trifluoromethoxy) phenyl] [1,2,4] triazolo [4,3-a] pyridin-3-yl} ethoxy) ethyl acetate;
N, N-dimethyl-6- [4- (trifluoromethoxy) glitter] [1,2,4] triazolo [4,3-a] pyridin-3-amine;
(2E) -3- {4- [3- (trifluoromethyl) [1,2,4] triazolo [4,3-a] pyridin-6-yl] glitter} but-2-enonitrile;
3- (Phenylsulfanyl) -6- [4- (trifluoromethoxy) glitter] [1,2,4] triazolo [4,3-a] pyridine;
3- (cyclopropyloxyethyl) -6- [4- (trifluoromethoxy) glitter] [1,2,4] triazolo [4,3-a] pyridine;
3- [1,1-Difluoro-2- (2-pyridine ylmethoxy) ethyl] -6- [4- (trifluoromethoxy) glitter] [1,2,4] triazolo [4,3-a] pyridine;
2 Methylan-4- {6- [4- (trifluoromethoxy) glitter] [1,2,4] triazolo [4,3-a]} pyridine-3-but-3-yn-2-ol;
Methylan-N-2- (trifluoromethoxy) -5- [3- (trifluoromethyl) [1,2,4] triazolo [4,3-a] pyridin-6-yl] benzamide;
N- (2,2-Difluoro-2- {6- [4- (trifluoromethoxy) glitter] [1,2,4] triazolo [4,3-a] pyridin-3-yl} ethyl) methanesulfonamide;
1,1-Difluoro-2-methylan-1- {6- [4- (trifluoromethoxy) glitter] [1,2,4] triazolo [4,3-a] pyridin-3-yl} propan-2-ol;
3- (trifluoromethyl) -6 - {[4- (trifluoromethyl) glitter] ethynyl} [1,2,4] triazolo [4,3-a] pyridine;
6- [2- (2-methoxyethoxy) -4- (trifluoromethoxy) glitter] -3- (trifluoromethyl) [1,2,4] triazolo [4,3-a] pyridine;
6- [6- (cyclopropyloxy) pyridin-3-yl] -3- (trifluoromethyl) [1,2,4] triazolo [4,3-a] pyridine;
{5- (trifluoromethoxy) -2- [3- (trifluoromethyl) [1,2,4] triazolo [4,3-a] pyridin-6-yl] phenoxy} acetonitrile;
6- [3- (3-Methylan-1,2,4-oxadiazol-5-yl) -4- (trifluoromethoxy) glitter] -3- (trifluoromethyl) [1,2,4] triazolo [4,3-a ]]] pyridine;
N- (2,2-Difluoro-2- {6- [4- (trifluoromethoxy) phenyl] [1,2,4] triazolo [4,3-a] pyridin-3-yl} ethyl) pyridine-2-carboxamide ;
- EP 2464645
3 methoxy-6- [4- (trifluoromethoxy) glitter] [1,2,4] triazolo [4,3-a] pyridine;
3- (2,2,2-trifluoroethoxy) -6- [4- (trifluoromethoxy) glitter] [1,2,4] triazolo [4,3-a] pyridine;
6- [6- (2,2,2-trifluoroethoxy) pyridazin-3-yl] -3- (trifluoromethyl) [1,2,4] triazolo [4,3-a] pyridine;
3- (1,1-Difluoro-2-methoxyethyl) -6- [3-methylan-4- (trifluoromethoxy) glitter] [1,2,4] triazolo [4,3-a] pyridine;
6- [4- (trifluoromethoxy) -3- (trifluoromethyl) glitter] -3- (trifluoromethyl) [1,2,4] triazolo [4,3-a] pyridine;
3- {2 - [(3,4-difluorobenzyl) oxy] -1,1-difluoroethyl} -6- [4- (trifluoromethoxy) glitter] [1,2,4] triazolo [4,3-a] pyridine;
3- (1,1-Difluoro-2-methoxyethyl) -6- (phenyloethyl) [1,2,4] triazolo [4,3-a] pyridine;
3- {Difluoro [(5-methylan-1,2-oxazol-3-yl) methoxy] Methylan} -6- [4- (trifluoromethoxy) glitter] [1,2,4] triazolo [4,3-a] pyridynia;
1- {4- [3- (trifluoromethyl) [1,2,4] triazolo [4,3-a] pyridin-6-yl] glitter cyclopropanocarbonitrile};
3- (difluoromethoxy {6- [4- (trifluoromethoxy) glitter] [1,2,4] triazolo [4,3-a] pyridin-3-yl} methylan) pentan-3-ol;
2,2-Difluoro-2- (6 - {[4- (trifluoromethyl) glitter] ethynyl} [1,2,4] triazolo [4,3-a] pyridin-3-yl) ethanol;
6- [2,4-bis (trifluoromethyl) glitter] -3- (trifluoromethyl) [1,2,4] triazolo [4,3-a] pyridine;
3- (1,1-Difluoro-2-methoxyethyl) -6- [2-methylan-4- (trifluoromethoxy) glitter] [1,2,4] triazolo [4,3-a] pyridine;
Methylan-6- [4- (trifluoromethoxy) glitter] -3- (trifluoromethyl) [1,2,4] triazolo [4,3-a] pyridine;
3- [Difluoro (3-pyridylylmethoxy) methylan] -6- [4- (trifluoromethoxy) glitter] [1,2,4] triazolo [4,3-a] pyridine;
1- (2,2-Difluoro-2- {6- [4- (trifluoromethoxy) glitter] [1,2,4] triazolo [4,3-a] pyridin-3-yl} ethoxy) -2-methylpropane- 2-ol;
3 - {[(5-cyclopropyl-1,2,4-oxadiazol-3-yl) methoxy] (difluoromethoxy) methylan} -6- [4- (trifluoromethoxy) glitter] [1,2,4] triazolo [4, 3 -a] pyridine;
3- (Difluoromethoxy {[5- (2-methylpropyl) -1,2,4-oxadiazol-3-yl]} methoxy Methylan) -6- [4- (trifluoromethoxy) glitter] [1,2,4] triazolo [ 4,3-a] pyridine;
3- (Difluoromethoxy {[5- (propan-2-yl) -1,2,4-oxadiazol-3-yl]} methoxy Methylan) -6- [4- (trifluoromethoxy) glitter] [1,2,4] triazolo [4,3-a] pyridine;
3- [Difluoro (2-pyridylylmethoxy) methylan] -6- [4- (trifluoromethoxy) glitter] [1,2,4] triazolo [4,3-a] pyridine;
4 - [(difluoro {6- [4- (trifluoromethoxy) glitter] [1,2,4] triazolo [4,3-a] pyridin-3-yl} methoxy) methylan] quinoline;
3 - [(cyclopropylmethoxy) (difluoro) methyl] -6- [4- (trifluoromethoxy) glitter] [1,2,4] triazolo [4,3-a] pyridine;
3- {Difluoro [(1-glittero-1H-1,2,3-triazol-4-yl) methoxy] Methylan} -6- [4- (trifluoromethoxy) glitter] [1,2,4] triazolo [4, 3 -a] pyridine;
3- [Difluoro (3-pyridazine-ylmethoxy) methyl] -6- [4- (trifluoromethoxy) glitter] [1,2,4] triazolo [4,3-a] pyridine;
3- {Difluoro [1- (4-fluorophenyl) ethoxy] methylan} -6- [4- (trifluoromethoxy) glitter] [1,2,4] triazolo [4,3-a] pyridine;
6- [4- (2-methoxypropan-2-yl) glitter] -3- (trifluoromethyl) [1,2,4] triazolo [4,3-a] pyridine;
6- [2-ethoxy-4- (trifluoromethoxy) glitter] -3- (trifluoromethyl) [1,2,4] triazolo [4,3-a] pyridine;
6- [2- (propan-2-yloxy) -4- (trifluoromethoxy) glitter] -3- (trifluoromethyl) [1,2,4] triazolo [4,3-a] pyridine;
3- {Difluoro [(1-methyl-5-phenyl-1H-pyrazol-3-yl) methoxy] methyl} -6- [4- (trifluoromethoxy) phenyl] [1,2,4] triazolo [4,3- a]] pyridine;
- 21 EP 2464645
3 - {[(2,2-difluoro-1,3-benzodioxol-5-yl) methoxy] (difluoromethoxy) methylan} -6- [4- (trifluoromethoxy) glitter] [1,2,4] triazoles [4, 3 -a] pyridine;
6- [4- (trifluoromethoxy) glitter] -3 - ({[4- (trifluoromethyl) benzyl]} oxy Methylan) [1,2,4] triazolo [4,3-a] pyridine;
3 - {[(4-fluorobenzyl) oxy] methylan} -6- [4- (trifluoromethoxy) glitter] [1,2,4] triazolo [4,3-a] pyridine;
3 - {[(2,5-dimethyl-1,3-oxazol-4-yl) methoxy] (difluoromethoxy) methylan} -6- [4- (trifluoromethoxy) glitter] [1,2,4] triazolo [4, 3 -a] pyridine;
3- {Difluoro [(5-methylan-2-glitter-1,3-oxazol-4-yl) methoxy] methylan} -6- [4- (trifluoromethoxy) glitter] [1,2,4] triazolo [4, 3 -a] pyridine;
3- {difluoro [1- (2-pyridyl) ethoxy] methylan} -6- [4- (trifluoromethoxy) glitter] [1,2,4] triazolo [4,3-a] pyridine;
3 - {[1- (4-chlorophenyl) ethoxy] (difluoromethoxy) methylan} -6- [4- (trifluoromethoxy) glitter] [1,2,4] triazolo [4,3-a] pyridine;
3- (1,1-Difluoro-2-methoxyethyl) -6- [3-fluoro-4- (trifluoromethoxy) glitter] [1,2,4] triazolo [4,3-a] pyridine;
3- (1,1-Difluoro-2-methoxyethyl) -6- (3,5-difluoro-4-phenoxyphenyl) [1,2,4] triazolo [4,3-a] pyridine;
3- (1,1-Difluoro-2-methoxyethyl) -6 - {[4- (trifluoromethyl) glitter] ethynyl} [1,2,4] triazolo [4,3-a] pyridine;
3- (2 - {[3- (4-chlorophenyl) -1,2-oxazol-5-yl] methoxy} -1,1-difluoroethyl) -6- [4- (trifluoromethoxy) glitter] [1,2, 4] triazolo [4,3-a] pyridine;
3 - {[(2-fluorobenzyl) oxy] methylan} -6- [4- (trifluoromethoxy) glitter] [1,2,4] triazolo [4,3-a] pyridine;
6- [4- (trifluoromethoxy) glitter] -3 - ({[2- (trifluoromethyl) benzyl]} oxy Methylan) [1,2,4] triazolo [4,3-a] pyridine;
3 - {[(2,4-difluorobenzyl) oxy] methylan} -6- [4- (trifluoromethoxy) glitter] [1,2,4] triazolo [4,3-a] pyridine;
3 - {[(4-chlorobenzyl) oxy] methylan} -6- [4- (trifluoromethoxy) glitter] [1,2,4] triazolo [4,3-a] pyridine;
3 - ({[4- (trifluoromethoxy) benzyl]} oxy Methylan) -6- [4- (trifluoromethoxy) glitter] [1,2,4] triazolo [4,3-a] pyridine;
N- (2,2-difluoro-2- {6- [4- (trifluoromethoxy) glitter] [1,2,4] triazolo [4,3-a] pyridin-3-yl} ethyl) benzamide;
3 - [(2-pyridyl ylmethoxy) methylane] -6- [4- (trifluoromethoxy) glitter] [1,2,4] triazolo [4,3-a] pyridine;
3- [Difluoro (2-pyrimidinylmethyl) methyl] -6- [4- (trifluoromethoxy) glitter] [1,2,4] triazolo [4,3-a] pyridine;
3 - [(1-phenyloethoxy) methylan] -6- [4- (trifluoromethoxy) glitter] [1,2,4] triazolo [4,3-a] pyridine;
3 - {[1- (2,4-dichlorophenyl) ethoxy] (difluoromethoxy) methylan} -6- [4- (trifluoromethoxy) glitter] [1,2,4] triazolo [4,3-a] pyridine;
1 - [(difluoro {6- [4- (trifluoromethoxy) glitter] [1,2,4] triazolo [4,3-a] pyridin-3-yl} methoxy) methylan] cyclobutanol;
3- {1- [Difluoro (3-pyridyl) methoxy] ethyl} -6- [4- (trifluoromethoxy) glitter] [1,2,4] triazolo [4,3-a] pyridine;
3 - {[(2,4-dichlorobenzyl) oxy] methylan} -6- [4- (trifluoromethoxy) glitter] [1,2,4] triazolo [4,3-a] pyridine;
3 - {[(2,4-dimethylobenzyl) oxy] methylan} -6- [4- (trifluoromethoxy) glitter] [1,2,4] triazolo [4,3-a] pyridine;
3 - {[(5-methylpyridin-2-yl) methoxy] methylan} -6- [4- (trifluoromethoxy) glitter] [1,2,4] triazolo [4,3-a] pyridine;
4- {4- [3- (trifluoromethyl) [1,2,4] triazolo [4,3-a] pyridin-6-yl] glitter} tetrahydro-2H-pyran-4-carbonitrile;
- EP 2464645
3- [1- (2-pyridyl ylmethoxy) ethyl] -6- [4- (trifluoromethoxy) glitter] [1,2,4] triazolo [4,3-a] pyridine;
(2S) -2 - [(Difluoro {6- [4- (trifluoromethoxy) phenyl] [1,2,4] triazolo [4,3-a] pyridin-3-yl} methoxy) methyl] pyrrolidine-1-carboxylic acid tert-butyl;
3 - {[difluoro (3-pyridyl) methoxy] methylan} -6- [4- (trifluoromethoxy) glitter] [1,2,4] triazolo [4,3-a] pyridine;
6- [4- (trifluoromethoxy) glitter] -3- [3- (trifluoromethyl) phenoxy] [1,2,4] triazolo [4,3-a] pyridine;
3 - {[(5-cyclobutyl-1,2,4-oxadiazol-3-yl) methoxy] (difluoromethoxy) methylan} -6- [4- (trifluoromethoxy) glitter] [1,2,4] triazolo [4, 3 -a] pyridine;
3- (4,4-Difluoro-piperidin-1'-yl) -6- [4- (trifluoromethoxy) -glitter] [1,2,4] triazolo [4,3-a] pyridine;
3 - [(difluoro {6- [4- (trifluoromethoxy) glitter] [1,2,4] triazolo [4,3-a] pyridin-3-yl} methoxy) methylan] benzonitrile;
3- (difluoromethoxy {3 - [(2-methoxyphenyl) sulfanyl] -2-methylpropoxy} methylan) -6- [4- (trifluoromethoxy) glitter] [1,2,4] triazolo [4,3-a] pyridine;
3- [Difluoro (1- {3- [4- (trifluoromethyl) glitter] -1,2-oxazol-5-yl} ethoxy) methylan] -6- [4- (trifluoromethoxy) glitter] [1,2,4 ] triazolo [4,3-a] pyridine;
1- (2,2-Difluoro-2- {6- [4- (trifluoromethoxy) glitter] [1,2,4] triazolo [4,3-a] pyridin-3-yl} ethyl) -3-phenyl- mono;
3- (Difluoromethoxy {2- [4- (4-methoxyphenyl) piperazinyl] -1]} ethoxy Methylan) -6- [4- (trifluoromethoxy) glitter] [1,2,4] triazolo [4,3-a] pyridine;
6- [4- (trifluoromethoxy) glitter] [1,2,4] triazolo [4,3-a] pyridine-3-carboxamide;
3 - {[(3-cyclopropylmethylan-1H-pyrazol-5'-yl) methoxy] (difluoromethoxy) methylan} -6- [4- (trifluoromethoxy) glitter] [1,2,4] triazolo [4,3- - a] a bathhouse;
1- (2-Chlorophenoxy) -3- (2,2-difluoro-2- {6- [4- (trifluoromethoxy) glitter] [1,2,4] triazolo [4,3-a] pyridin-3-yl ]} ethoxy) -propan-2-ol;
6- {4- [Difluoro (3-pyridinyl) methoxy] glitter} -3- (trifluoromethyl) [1,2,4] triazolo [4,3-a] pyridine;
6- {4- [difluoro (glowing) methoxy] glitter} -3- (trifluoromethyl) [1,2,4] triazolo [4,3-a] pyridine;
3- (2-methylphenoxy) -6- [4- (trifluoromethoxy) glitter] [1,2,4] triazolo [4,3-a] pyridine;
1- (2,2-Difluoro-2- {6- [4- (trifluoromethoxy) glitter] [1,2,4] triazolo [4,3-a] pyridin-3-yl} ethoxy) -3- (2 , 5-dimethylophenoxy) propan-2-ol;
3 - [(cyclopropylmethoxy) (difluoro) methylan] -6- [6- (trifluoromethyl) pyridin-3-yl] [1,2,4] triazolo [4,3-a] pyridine;
5-chloro-2 - ({4- [3- (trifluoromethyl) [1,2,4] triazolo [4,3-a] pyridin-6-yl] glitter} amino) benzonitrile;
5- (methoxymethyl) -6- [4- (trifluoromethoxy) glitter] -3- (trifluoromethyl) [1,2,4] triazolo [4,3-a] pyridine;
NN-Methylan glitter-4- [3- (trifluoromethyl) [1,2,4] triazolo [4,3-a] pyridin-6-yl] aniline;
({6- [4- (trifluoromethoxy) glitter] -3- (trifluoromethyl) [1,2,4] triazolo [4,3-a] pyridin-5-yl} methoxy) acetonitrile;
4- (Difluoro {4- [3- (trifluoromethyl) [1,2,4] triazolo [4,3-a] pyridin-6-yl]} phenoxy Methylan) benzonitrile;
5 - [(difluoro {6- [4- (trifluoromethoxy) glitter] [1,2,4] triazolo [4,3-a] pyridin-3-yl} methoxy) methylan] quinoline;
3- [1- (Difluoro {6- [4- (trifluoromethoxy) glitter] [1,2,4] triazolo [4,3-a] pyridin-3-yl} methoxy) ethyl] quinoline;
- EP 2464645
4-chloro-N- {4- [3- (trifluoromethyl) [1,2,4] triazolo [4,3-a] pyridin-6-yl] glitter} aniline;
4-Fluoro-N- {4- [3- (trifluoromethyl) [1,2,4] triazolo [4,3-a] pyridin-6-yl] glitter} aniline;
3 - {[2- (2,6-dimethylophenoxy) ethoxy] (difluoromethoxy) methylan} -6- [4- (trifluoromethoxy) glitter] [1,2,4] triazolo [4,3-a] pyridine;
6- [4- (pentafluoro-lambda-6-sulfanyl) phenyl] -3- (trifluoromethyl) [1,2,4] triazolo [4,3-a] pyridine;
3- {difluoro [(1-glittero-1H-pyrazol-4-yl) methoxy] methylan} -6- [4- (trifluoromethoxy) glitter] [1,2,4] triazolo [4,3-a] pyridine;
3- [Difluoro ({2- [4- (trifluoromethyl) phenyl] -1,3-oxazol-4-yl} methoxy) methyl] -6- [4- (trifluoromethoxy) phenyl] [1,2,4] triazoles [4,3-a] pyridine;
4 - [(Difluoro {6- [4- (trifluoromethoxy) phenyl] [1,2,4] triazolo [4,3-a] pyridin-3-yl} methoxy) methyl] -2-methylquinoline;
4 - [(Difluoro {6- [4- (trifluoromethoxy) glitter] [1,2,4] triazolo [4,3-a] pyridin-3-yl} methoxy) Methylan] -2 (trifluoromethyl) quinoline;
6 - [(difluoro {6- [4- (trifluoromethoxy) glitter] [1,2,4] triazolo [4,3-a] pyridin-3-yl} methoxy) methylan] quinoxaline;
6- (2-chloro-4-nitrophenyl) -3- (trifluoromethyl) [1,2,4] triazolo [4,3-a] pyridine;
3 - [(but-2-yn-1-yloxy) (difluoro) methylan] -6- [4- (trifluoromethoxy) glitter] [1,2,4] triazolo [4,3-a] pyridine;
3 - {[(2,2-difluorocyclopropyl) methoxy] (difluoromethoxy) methylan} -6- [4- (trifluoromethoxy) glitter] [1,2,4] triazolo [4,3-a] pyridine;
3- {Difluoro [(3-phenyloprop-2-yn-1-yl) oxy] methylan} -6- [4- (trifluoromethoxy) glitter] [1,2,4] triazolo [4,3-a] pyridine;
3- {Difluoro [(1-Methylan-1H-benzoimidazol-2-yl) methoxy] Methylan} -6- [4- (trifluoromethoxy) glitter] [1,2,4] triazolo [4,3-a] pyridine;
3 - {[(1-Benzyl-1H-1,2,3-triazol-4-yl) methoxy] (difluoromethoxy) methylan} -6- [4- (trifluoromethoxy) glitter] [1,2,4] triazolo [ 4,3-a] pyridine;
3- {Difluoro [(5-glittero-1,2-oxazol-3-yl) methoxy] Methylan} -6- [4- (trifluoromethoxy) glitter] [1,2,4] triazolo [4,3-a] pyridynia;
3- {Difluoro [(2-glitter-1,3-oxazol-4-yl) methoxy] methylan} -6- [4- (trifluoromethoxy) glitter] [1,2,4] triazolo [4,3-a] pyridynia;
3- {Difluoro [(5-Methylan-2-glitter-2H-1,2,3-triazol-4-yl) methoxy] Methylan} -6- [4- (trifluoromethoxy) glitter] [1,2,4] triazolo [4,3-a] pyridine;
3- {difluoro [(1-methylan-1H-pyrazol-3-yl) methoxy] methylan} -6- [4- (trifluoromethoxy) glitter] [1,2,4] triazolo [4,3-a] pyridine;
3 - [{[1- (4-chlorophenyl) -5-methylan-1H-pyrazol-3-yl] methoxy} (difluoro) methylan] -6- [4- (trifluoromethoxy) glitter] [1,2,4] triazolo [4,3-a] pyridine;
3 - [(3,3-diphenylopropoxy) (difluoro) methylan] -6- [4- (trifluoromethoxy) glitter] [1,2,4] triazolo [4,3-a] pyridine;
3-phenoxy-6 - {[4- (trifluoromethyl) phenyl] ethynyl} [1,2,4] triazolo [4,3-a] pyridine;
- 24 EP 2464645
3- (Difluoromethoxy {[3- (2-pyrimidinyl) benzyl]} oxy Methylan) -6- [4- (trifluoromethoxy) glitter] [1,2,4] triazolo [4,3-a] pyridine;
3- (Difluoromethoxy {[3- (3-pyridinyl) benzyl]} oxy Methylan) -6- [4- (trifluoromethoxy) glitter] [1,2,4] triazolo [4,3-a] pyridine;
3- {Difluoro [(1-methylan-1H-indazol-3-yl) methoxy] methylan} -6- [4- (trifluoromethoxy) glitter] [1,2,4] triazolo [4,3-a] pyridine;
3- [chloro (difluoro) methylan] -6- [4- (trifluoromethoxy) glitter] [1,2,4] triazolo [4,3-a] pyridine;
3- (1,1-Difluoro-2-methoxyethyl) -6 - {[4- (trifluoromethoxy) glitter] ethynyl} [1,2,4] triazolo [4,3-a] pyridine;
3- (1,1-Difluoro-2-methoxyethyl) -6 - [(4-fluorophenyl) ethynyl] [1,2,4] triazolo [4,3-a] pyridine;
3- (Difluoromethoxy {[2- (1H-1,2,4-triazol-1-yl) benzyl]} oxy Methylan) -6- [4- (trifluoromethoxy) glitter] [1,2,4] triazolo [4 , 3-a] pyridine;
3- (Difluoromethoxy {[2- (2-Methylan-1H-imidazol-1-yl) benzyl]} oxy Methylan) -6- [4- (trifluoromethoxy) glitter] [1,2,4] triazolo [4.3 - a] pyridine;
3- (Difluoromethoxy {[2-glitter-5- (trifluoromethyl) -1,3-oxazol-4-yl]} methoxy Methylan) -6- [4- (trifluoromethoxy) glitter] [1,2,4] triazolo [ 4,3-a] pyridine;
3- (Difluoromethoxy {[1-glitter-3- (trifluoromethyl) -1H-pyrazol-4-yl]} methoxy Methylan) -6- [4- (trifluoromethoxy) glitter] [1,2,4] triazolo [4, 3 -a] pyridine;
3- (Difluoro {[6- (1H-pyrazol-1-yl) pyridin-3-yl] methoxy} methyl) -6- [4- (trifluoromethoxy) phenyl] [1,2,4] triazolo [4.3 - a] pyridine;
6 cyclopropyl-2 '- [(difluoro {6- [4- (trifluoromethoxy) glitter] [1,2,4] triazolo [4,3-a] pyridin-3-yl} methoxy) methylane] -3,4' -bipyridine;
3 - [{[3- (4-Cyclopropyl-1H-imidazol-1-yl) benzyl] oxy} (difluoro) methylan] -6- [4- (trifluoromethoxy) glitter] [1,2,4] triazolo [4 , 3-a] pyridine;
3- (Difluoromethoxy {[5- (4-fluorophenyl) -1,2-oxazol-3-yl]} methoxy Methylan) -6- [4- (trifluoromethoxy) glitter] [1,2,4] triazolo [4, 3 -a] pyridine;
3- {Difluoro [(5-glitter-1,2-oxazol-3-yl) methoxy] Methylan} -6- [6- (trifluoromethyl) pyridin-3-yl] [1,2,4] triazolo [4, 3-a] pyridine;
3- (Difluoromethoxy {[2- (1-piperidinyl) pyridine-4-yl]} methoxy Methylan) -6- [4- (trifluoromethoxy) glitter] [1,2,4] triazolo [4,3-a] pyridine ;
3 - {[(2,2-dimethyl-2,3-dihydroquinazoline-1-benzofuran-7-yl) methoxy] (difluoromethoxy) methylan} -6- [4- (trifluoromethoxy) glitter] [1,2,4] triazolo [4,3-a] pyridine;
3 - {[2- (2,6-difluorophenyl) ethoxy] (difluoromethoxy) methylan} -6- [4- (trifluoromethoxy) glitter] [1,2,4] triazolo [4,3-a] pyridine;
3- {Difluoro [(5-glittero-1,2,4-oxadiazol-3-yl) methoxy] Methylan} -6- [4- (trifluoromethoxy) glitter] [1,2,4] triazolo [4,3- ] pyridine;
3- {Difluoro [(5-glittero-1,2-oxazol-3-yl) -methoxy] -methylan} -6- [6- (2,2,2-trifluoro-ethoxy) -pyridin-3-yl] - [1,2,4] triazolo [4,3-a] pyridine;
- EP 2464645
3 - [{[2- (6-3-Cyclopropylpyridyl) benzyl] oxy} (difluoro) methylan] -6- [4- (trifluoromethoxy) glitter] [1,2,4] triazolo [4,3- a] pyridine ;
3 - [{[5- (2-chlorophenyl) -1,2-oxazol-3-yl] methoxy} (difluoro) methylan] -6- [4- (trifluoromethoxy) glitter] [1,2,4] triazolo [ 4,3-a] pyridine;
3- (Difluoromethoxy {[2- (3-pyridinyl) benzyl]} oxy Methylan) -6- [4- (trifluoromethoxy) glitter] [1,2,4] triazolo [4,3-a] pyridine; and
3- (Difluoromethoxy {[2- (1H-pyrazol-1-yl) benzyl]} oxy Methylan) -6- [4- (trifluoromethoxy) glitter] [1,2,4] triazolo [4,3-a] pyridine .
DETAILED DESCRIPTION OF THE INVENTION
Definitions and general parameters
Yak is used in this description, the following words and phrases are to have the meanings given below, except where their context indicates otherwise.
The term "alkyl" shall mean 1 to 20 atoms in weg. Therein, the term grouping includes methyl, ethyl, n-propyl, iso-propyl, n-butyl, iso-butyl, t-butyl, n-hexyl, n-decyl, tetradecyl, and thymic.
The term "pod alkyl" applies to:
1) alkyl, alkoxy, alkylloxy, acyl, acyloxy, alkyl, alkylloxy, acyl, acyloxy, amino, aminocarbonyl, alkoxycarbonylamino, azido, cyano, halogen, hydroxy, keto, thiocarbonyl, carboxy, carboxyalkyl, arylthio, heteroarylthio, heterocyclyl, alkyl aryl, aryloxy, heteroaryl, aminosulfonyl, aminocarbonyl, heteroaryl, amino heterocyclooxy, hydroxyamino, alkoxyamino, nitro, -SO-alkyl, -SO-aryl, -SO-heteroaryl, -SO 2 -alkyl, SO 2 -aryl, -SO 2 -heteroaryl. If alkyl is added, alkyl, carboxy, carboxylalkyl, aminocarbonyl, hydroxy, alkoxy, halogen, CF 3, halogen, CF 3, O) n R, alkyl of aryl, aryl, heteroaryl in is 0, 1 or 2; or
2) a group of alkyl radicals having from 1 to 10 atoms (about 1, 2, 3, 4, or 5 atoms), unbranched alkyl, cycloalkyl, alkenyl, and aryl; cycloalkenyl, alkynyl, aryl, heteroaryl and heterocyclyl. Alkyl, alkoxy, halogen, CF 3, amino, sub-amino, cyano, or -S (O) n R, aryl, luberoaryl and n is 0, 1 or 2; or 3) group alkyl yak as defined above which has both 1, 2, 3, 4 or 5 yak substituents as defined above and is also interrupted by 1-10 atoms (pp 1, 2, 3, 4, or 5 atoms) yak as defined higher.
The, "term groups include methyl, ethyl, n-propyl, iso-propyl, n-butyl, iso -butyl, t-butyl, n-hexyl, and thymic.
- EP 2464645
The term & quot; podcasting alkyl & quot; 3, 4, or 5 atoms yak are defined for substituted alkyl, or the lower lower alkyl yak group is defined above, the disease has both 1, 2, 3, 4 or 5 yow substituents as defined above by 1, 2, 2 ,. or 5 atoms as defined above.
The term & quot; alkylene & quot; refers to a diradical with a branched or unbranched saturated hydrocarbon chain, typically having from 1 to 20 carbon atoms (pp 1-10 carbon atoms, or 1, 2, 3, 4, or 5). Therein, the terms are grouped by yak methylene (-CH 2 -), ethylene (-CH 2 CH 2 -), propylene isomers (e.g., - CH 2 CH 2 CH 2 - and -CH (CH 3) CH 2 - ). ). ), the like.
The term "nickel alkylene" is intended to be used as a base for 1, 2, 3, 4, 5, or 6 atoms.
The term "substituted alkylene" applies to:
(1) alkyl, alkenyl, alkenyl, cycloalkenyl, acyl, alkyl, alkenyl, alkynyl, alkenyl, alkenyl, alkenyl, alkenyl, alkenyl, alkylloxy, acyloxy, amino, aminocarbonyl, alkoxycarbonylamino, azido, cyano, halogen, hydroxy, keto, thiocarbon , carboxes, carboxyalkyl, arylthio, heteroarylothio, heterocyclylothio, thiol, alkylthio, aryl, aryloxy, heteroaryl, aminosulfonyl, heterocyclyl, heterocycloxy, hydroxyamino, alkoxyamino, nitro, -SO-alkyl, -SO-aryl, -SO-heteroaryl, SO 2 -alkyl, SO 2 -aryl, -SO 2 -heteroaryl. If alkyl is added, alkyl, carboxy, carboxylalkyl, aminocarbonyl, hydroxy, alkoxy, halo, halo, alkyl, carboxyl, amino, cyano, amino, halo, alkyl, carboxy, amino, halo, (O) n R, alkyl of aryl , aryl, luberoaryl and n are 0, 1 or 2; or (2) groups alkylene yak as defined above, which is interrupted by 1-10 groups (e.g. 1, 2, 3, 4, or 5) independently selected from -O-, -S-, sulfonyl, - C (O) -, -C (O) O-, -C (O) N-, and - NR a, alkyl group, alkyl, cycloalkyl, cycloalkenyl, aryl, heteroaryl and heterocyclyl; or (3) group alkylene yak as defined above which has both 1, 2, 3, 4 or 5 yak substituents as defined above, yak and is interrupted by 1-10 groups of yak as defined above. Prodruged alkyls to chloromethylene (-CH (Cl) -), aminoethylene (-CH (NH 2) CH 2 -), methylaminoethylene (-CH (NHMe) CH 2 -), isomeryl 2-carboxypropylene (-CH 2 CH (CO 2 )). )). H) CH2 -), ethoxyethyl (-CH2CH2OCH2CH2-), ethylmethylloaminoethyl (-CH2CH2-N (CH3) -CH2CH2-), 1-ethoxy-2- (2-ethoxyethoxy) ethane (CH2CH2O-CH2CH2-OCH2CH2-OCH2CH2-). , thym similar.
The term "aralkyl" refers to a group of aryl groups which may be alkylated, aryl or alkylenically defined. "Polycarbonate aralkyl" "Polycarbonate polycarbonate aralkyl" is the alkylene of the aryl covalently linked to an optionally substituted alkylene group. Contains aralkyl groups which are prodrugs of benzyl, phenyloethyl, 3- (4-methoxyphenyl) propyl, and thymic similar.
- EP 2464645
The term & quot; alkoxy & quot; lubricated cycloalkenyl, alkoxy, alkenyl, alkynyl, cycloalkyl and cycloalkenyl. Typical groups include alkoxy to alkyl-O-moiety, for example, methoxy, ethoxy, n-propoxy, iso-propoxy, n-butoxy, tert-butoxy, sec-butoxy, n-pentoxy, n-hexyloxy, 1,2-dimethylbutoxy , and the like.
The term "lower alkoxy" refers to the group RO-, wherein R is an optionally substituted lower alkyl yak as defined above. Therein, the term "grouping" includes methoxy, ethoxy, n-propoxy, isopropoxy, n-butoxy, iso-butoxy, t-butoxy, n-hexyloxy, thymic similar.
The term "alkylthio" refers to a group of radicals RS-, alkoxy, and alkoxy.
The term & quot; alkenyl & quot; , e.g. 1, 2, or 3 carbon-carbon double bonds. Types of groups include alkenyl obenyl ethenyl (or vinyl, t-CH = CH 2), 1-propylene (or allyl, -CH 2 CH = CH 2), isopropylene (-C (CH 3) = CH 2), bicyclo [2.2 .1] heptene, the like. In the case where alkenyl is attached to nitrogen, the double bond cannot be alpha to nitrogen.
The term "nickel alkenyl" shall be substituted with 2 atoms (s) 6 atoms.
The term & quot; lower alkenyl & quot; , acylamino, acyloxy, amino, aminocarbonyl, alkoxycarbonylamino, azido, cyano, halogen, hydroxy, keto, thiocarbonyl, carboxy, carboxyalkyl, arylthio, heteroarylothio, heterocyclylthio, thiol, alkylthio, aryl, aryloxy, heteroaryl, aminocarbonylamino, heteroaryloxy, heterocyclyl, heterocycloxy, hydroxyamino, alkoxyamino, nitro, -SO-alkyl, -SO-aryl, -SO-heteroaryl, -SO2-alkyl, SO2-aryl-SO2-heteroaryl. If alkyl is added, alkyl, carboxy, carboxylalkyl, aminocarbonyl, hydroxy, alkoxy, halo, halo, alkyl, carboxyl, amino, cyano, amino, halo, alkyl, carboxes, amino, halo, (O) n R, g R means alkyl, aryl, or heteroaryl in is 0, 1 or 2.
The term "alkynyl" refers to monocyclic or monocyclic derivativ es which may, however, be added to the 2-membered group. 1, 2, or 3 carbon-carbon triple bonds.
Typical groups include alkynyl-lower ethynyl (-C = C.'H). propargyl (or propynyl, -C = C.'C.'H3). and the like. In the case where alkynyl is attached to nitrogen, the triple bond cannot be alpha to nitrogen.
The term & quot; lower alkynyl & quot; , acylamino, acyloxy, amino, aminocarbonyl, alkoxycarbonylamino, azido, cyano, halogen, hydroxy, keto, thiocarbonyl, carboxy, carboxyalkyl, arylthio, heteroarylothio, heterocyclylthio, thiol, alkylthio, aryl, aryloxy, heteroaryl,
- aminocarbonylamino, heteroaryloxy, heterocyclyl, heterocycloxy, hydroxyamino, alkoxyamino, nitro, -SO-alkyl, -SO-aryl, -SO-heteroaryl, -SO2-alkyl, SO2-aryl-SO2-heteroaryl. If alkyl is added, alkyl, carboxy, carboxylalkyl, aminocarbonyl, hydroxy, alkoxy, halo, halo, alkyl, carboxyl, amino, cyano, amino, halo, alkyl, carboxes, amino, halo, (O) n R, g R g and s is alkyl, aryl, or heteroaryl and n is 0, 1 or 2.
The term "aminocarbonyl" refers to a -C (O) NRR moiety containing a radical, alkyl, cycloalkyl, aryl, heteroaryl, heterocyclyl, or heterocyclic ring (e.g.), Morpholino. If alkyl is added, alkyl, carboxy, carboxylalkyl, aminocarbonyl, hydroxy, alkoxy, halo, halo, alkyl, carboxyl, amino, cyano, amino, halo, alkyl, carboxes, amino, halo, (O) n R, g R g and s is alkyl, aryl, or heteroaryl and n is 0, 1 or 2.
The term & quot; ester & quot;, lubricated carboxyl ester dot-C (O) OR, alkyl radicals, cycloalkyl, aryl, heteroaryl, lubricated heterocyclyl, optionally substituted alkyl, alkoxy, halogen, CF 3, amino, pod. , cyano, or - S (O) n R a, w is a moiety Ra is alkyl, aryl, or heteroaryl and n is 0, 1 or 2.
The term "acyloamino" is a dot-like group -NRC (O) R d -cycloalkyl, alkyl, aryl, heteroaryl, or heterocyclyl. The substituents are alkyl, alkoxy, halogen, CF 3, amino, sub-amino, cyano, or -S (O) n R, aryl, or heteroaryl in is 0, 1 or 2.
The term "acyloxy" refers to a -C (O) -alkyl, -OC (O) -cycloalkyl, -OC (O) -aryl, -OC (O) -heteroaryl, -OC (O) -heterocyclyl group. If alkyl is added, alkyl, carboxy, carboxylalkyl, aminocarbonyl, hydroxy, alkoxy, halo, halo, alkyl, carboxyl, amino, cyano, amino, halo, alkyl, carboxes, amino, halo, (O) n R, g R means alkyl, aryl, or heteroaryl in is 0, 1 or 2.
The term "aryl" refers to an aromatic, aromatic, carboxy-cyclic moiety of 6 to 20 atoms which may be added to the residue (e.g., Phenyl), or to the biphenyl), to the skondensic acid, or to the fluorine . . . Typical aryls are obeyed by phenyl, fluorenyl, naphthyl, anthryl, iodim alike.
If you are using an aryl, a group of aryl moles are optionally substituted by 1, 2, 3, 4 or 5 substituents (typically 1, 2, or 3 substituents) selected from cyanyl, acylamino, acyloxy, amino, aminocarbonyl selected from , alkoxycarbonylamino, azido, cyano, halogen, hydroxy, keto, thiocarbonyl, carboxes, carboxyalkyl, arylthio, heteroarylothio, heterocyclylthio, thiol, aryl, thiol, heteroaryl, aminosulfonyl, aminocarbonylamino, heteroaryloxy, heterocyclyl, heterocycloxy, hydroxyamino, alkoxyamino, nitro, -SO-alkyl, -SO-aryl, -SO-heteroaryl, -SO 2 -alkyl, SO 2 -aryl, -SO 2 -heteroaryl. If alkyl is added, alkyl, carboxy, carboxylalkyl, aminocarbonyl, hydroxy, alkoxy, halo, halo, alkyl, carboxyl, amino, cyano, amino, halo, alkyl, carboxes, amino, halo, (O) n R, g R means alkyl, aryl, or heteroaryl in is 0, 1 or 2.
- EP 2464645
The term "aryloxy" refers to groups aryl-O- where group aryl is as defined above, and includes optionally substituted aryl groups as defined above. The term "arylothio" refers to a group of radicals RS-, gjie R is yak defined for aryl.
The term "amino" dotic group is -NH2.
The term & quot; podstic amino & quot; lower alkylene and Z is alkenyl, cycloalkenyl, lubricated alkynyl. If alkyl is added, alkyl, carboxy, carboxylalkyl, aminocarbonyl, hydroxy, alkoxy, halo, halo, alkyl, carboxyl, amino, cyano, amino, halo, alkyl, carboxes, amino, halo, (O) n R, g R means alkyl, aryl, or heteroaryl in is 0, 1 or 2.
The term "carboxylalkyl" refers to the group -C (O) O-alkyl, -C (O) O-cycloalkyl, lower alkyl cycloalkyl group defined by the term "alkyl, alkenyl, alkynyl, alkoxy, halogen, CF 3". , amino, substituted amino, cyano, or -S (O) n R, alkyl, aryl, or heteroaryl and n is 0, 1 or 2.
The term "cycloalkyl" is intended to denote a cyclic alkyl group which may contain 3 atoms. Cycloalkyl heavy, cyclic, cyclic, cyclic, alkyl, cyclic, alkyl, cycloalkyl, cycloalkyl, cycloalkyl, cycloalkyl, cycloalkyl, cycloalkyl, cycloalkyl, cycloalkyl, cycloalkyl, cycloalkyl, cycloalkyl, cycloalkyl, cycloalkyl, cycloalkyl, cycloalkyl. , and the like.
The term "substituted cycloalkyl" refers to cycloalkyl groups having 1, 2, 3, 4 or 5 substituents (typically 1, 2, or 3 substituents) selected from the group consisting of alkyl, alkenyl, alkynyl, alkoxy, cycloalkyl, cycloalkenyl, acyl , acylamino, acyloxy, amino, aminocarbonyl, alkoxycarbonylamino, azido, cyano, halogen, hydroxy, keto, thiocarbonyl, carboxes, carboxyalkyl, arylthio, heteroarylthio, heterocyclylthio, thiol, alkylthio, aryl, aryloxy, heteroaryl, amino heteroaryloxy, heterocyclyl, heterocyclooxy, hydroxyamino, alkoxyamino, nitro, -SO-alkyl, -SO-aryl, SO-heteroaryl, -SO2-alkyl, SO2-aryl and -SO2-heteroary. The term "substituted cycloalkyl" also includes cycloalkyl groups where one or more carbon atoms in the ring of the cycloalkyl group is a carbonyl group (ie, the oxygen atom is oxo to the ring). Unless otherwise limited by definition, all substituents may optionally be further substituted with 1, 2, or 3 substituents selected from alkyl, carboxy, carboxyalkyl, aminocarbonyl, hydroxy, alkoxy, halogen, CF 3, amino, substituted amino, cyano, and -S (O) n R where R is alkyl, aryl, or heteroaryl and n is 0, 1 or 2.
The term "halogen" or "halo" refers to fluorine, bromine, chlorine, and iodine.
The term "acyl" means a -C (O) R group consisting of hydrogen, optionally substituted alkyl, optionally substituted cycloalkyl, optionally substituted heterocyclyl, optionally substituted aryl, and optionally substituted heteroaryl.
The term "heteroaryl" refers to a group containing 1 to 15 carbon atoms and 1 to 4 heteroatoms selected from oxygen, nitrogen, and sulfur in at least one ring. The term "heteroaryl" is generic to "aromatic heteroaryl" and "partially saturated heteroaryl". The term "aromatic heteroaryl" refers to a heteroaryl in which at least one ring is aromatic. examples
Aromatic heteroaryls include pyrrole, thiophene, pyridine, quinoline, pteridine. The term "partially saturated heteroaryl" refers to a heteroaryl having an equivalent structure to the parent aromatic heteroaryl that has one or more double bonds in the aromatic ring. Examples of partially saturated heteroaryls include dihydropyrrole, dihydropyridine, 1,2,3,4-tetrahydronaphthalene.
The heteroaryl substituent may be optionally substituted with 1 to 5 substituents (typically 1, 2, or 3 substituents) selected from the group consisting of alkyl, alkenyl, alkynyl, alkoxy, cycloalkyl, cycloalkenyl, acyl, acylamino, acyloxy, amino, aminocarbonyl, alkoxycarbonylamino, azido, cyano, halogen, hydroxy, keto, thiocarbonyl, carboxes, carboxyalkyl (alkyl ester), arylthio, heteroaryl, heteroarylthio, heterocyclylthio, thiol, alkylthio, aryl, aryloxy, aralkyl, heteroaryl, aminosulfonyl, aminocarbonylamino, heteroaryloxy, heterocyclyl, heterocycloxy, hydroxyamino, alkoxyamino, nitro, -SO-alkyl, -SO-aryl, -SO-heteroaryl, SO2 and -SO2-heteroaryl. Unless otherwise limited by definition, all substituents may optionally be further substituted with 1, 2, or 3 substituents selected from alkyl, carboxy, carboxyalkyl, aminocarbonyl, hydroxy, alkoxy, halogen, CF 3, amino, substituted amino, cyano, and - S (O) n R where R is alkyl, aryl, or heteroaryl and n is 0, 1 or 2. Such heteroaryl groups may have one ring (eg, pyridyl or furyl) or multiple fused rings (eg, indolizinyl, benzothiazole, or benzothienyl). Examples of nitrogenous heterocyclyls and heteroaryls include, but are not limited to, pyrrole, imidazole, pyrazole, pyridine, pyrazine, pyrimidine, pyridazine, indolizine, isoindole, indole, indazole, purine, quinolizine, isoquinoline, quinoline, phthalazine, carbazole , carboline, phenanthridine, acridine, phenanthroline, isothiazole, phenazine, isoxazole, phenoxazine, phenothiazine, imidazolidine, imidazoline, and the like as well as N-alkoxy-nitrogen containing heteroaryl compounds.
The term "heteroaryloxy" refers to the heteroaryl-O- group.
The term "heterocyclyl" refers to a monoradical saturated group having from one to 40 carbon atoms and from 1 to 10 heteroatoms, preferably 1 to 4 heteroatoms selected from nitrogen, sulfur, phosphorus, and / or ring oxygen.
The heterocyclic substituent may be optionally substituted with one to five substituents (typically 1, 2, or 3 substituents) selected from the group consisting of alkyl, alkenyl, alkynyl, alkoxy, cycloalkyl, cycloalkenyl, acyl, acylamino, acyloxy, amino, aminocarbonyl, alkoxycarbonylamino, azido, cyano, halogen, hydroxy, keto, thiocarbonyl, carboxes, carboxyalkyl, arylthio, heteroarylthio, heterocyclylthio, thiol, alkylthio, aryl, aryloxy, heteroaryl, aminosulfonyl, aminocarbonylamino, heteroaryloxy, heterocyclyl, heterocycloxy, hydroxyamino, alkoxyamino, nitro, -SO-alkyl, -SO-aryl, -SO-heteroaryl, -SO2-alkyl, SO2aryl and -SO2-heteroaryl . Unless otherwise limited by definition, all substituents may optionally be further substituted with 1, 2, or 3 substituents selected from alkyl, carboxy, carboxyalkyl, aminocarbonyl, hydroxy, alkoxy, halogen, CF 3, amino, substituted amino, cyano, and - S (O) n R where R is alkyl, aryl, or heteroaryl and n is 0, 1 or 2. Heterocyclic groups can have one ring or multiple fused rings. Preferred heterocyclic groups include tetrahydrofuranyl, morpholino, piperidinyl, and the like.
EP 2464645
The term "thiol" refers to the group -SH.
The term "substituted alkylthio" refers to a group -S-substituted alkyl.
The term "heteroarylthiol" refers to a group -S-heteroaryl where the heteroaryl group is as defined above includes optionally substituted heteroaryl groups as also defined above.
The term "sulfoxide" refers to a group -S (O) R where R is alkyl, aryl, or heteroaryl. "Substituted sulfoxide" refers to a group -S (O) R where R is substituted alkyl, substituted aryl, or substituted heteroaryl, as defined.
The term "sulfone" refers to a group -S (O) 2 R where R is alkyl, aryl, or heteroaryl. "Substituted sulfone" refers to a group -S (O) 2 R where R is substituted alkyl, substituted aryl, or substituted heteroaryl, as defined above.
The term "keto" refers to the group -C (O) -. The term "thiocarbonyl" refers to the group -C (S) -. The term "carboxy" refers to the group -C (O) -OH.
"Optional" or "optional" means that the event or circumstance described below may or may not occur, and that description includes cases where the event or circumstance occurs and cases where it does not occur.
The "substituted" group includes the requirements in which the monoradical substituent is bonded to one atom of the substituted group (eg, forming a chain), and also includes included in which the substituent may be attached to two adjacent atoms of the substituted group. a fused ring on the substituted group.
A compound of a given Formula (eg, "a compound of Formula III") is intended to include compounds of the invention as the results, and acceptable salts, acceptable esters, hydrates, polymorphs, and prodrugs of such compounds. In addition, the compounds of the invention may have one or more asymmetric centers, and may be prepared as racemic mixtures or as individual enantiomers or diastereomers. The number of stereoisomers present in any given compound The formula depends on the number of asymmetric centers present (2n stereoisomers are possible where the number of asymmetric centers is). Individual stereoisomers can be obtained by dissolving a racemic or non-racemic intermediate at the appropriate stage of synthesis, or by separating the compound by conventional methods. Individual stereoisomers (including individual enantiomers and diastereomers) are well within the scope of the present invention unless specifically indicated otherwise.
Isomers are different compounds that have the same molecular formula.
Stereoisomers are isomers that differ only in how they are arranged in space.
Enantiomers are a pair of stereoisomers that are non-superimposable by their mirror images. The 1: 1 mixture of a pair of enantiomers is a "racemic" mixture. The term "(±)" is used to indicate a racemic mixture where appropriate.
Diastereomers are stereoisomers that have at least two asymmetric atoms, but which are not mirror images of each other.
Absolute stereochemistry is determined according to the Cahn Ingold Prelog RS system. When the compound is a pure enantiomer, the stereochemistry at each chiral carbon can be determined by R or S. Separated compounds whose absolute configuration is (+) or (-) in the direction (right or left-handedness). ) in which they rotate the plane of polarized light at the wavelength of the sodium line D.
Any formula or structure provided, including compounds of Formula III, is also intended to represent unlabelled forms as well as isotopically labeled forms of the compounds. Isotopically labeled compounds have the structures represented by the formula given except that one or more atoms are replaced by an atom having a selected atomic mass or mass number. Examples of isotopes that can be included in the invention include isotopes of hydrogen, carbon, nitrogen, oxygen, phosphorus, fluorine, and chlorine, but not limited to 2H (deuterium, D), 3H (tritium), 11C, 13C, 14C, 15N, 18F, 31P, 32P, 35S, 36Cl, and 125I. Various isotopically labeled compounds of the present invention, for example those into which radioactive isotopes such as 3H, 13C, and 14C have been incorporated. Such isotopically labeled compounds may be useful in metabolic studies, reaction kinetics studies, detection or imaging techniques such as positron emission topography (PET) or single photon emission tomography (SPECT) including drug or substrate tissue distribution studies, or in radiological treatment. Patients.
Deuterium-labeled or substituted therapeutic compounds of the invention may have improved DMPK (drug metabolism and pharmacokinetics) properties in distribution, metabolism and excretion (ADME). Substitution with heavier isotopes such as deuterium may provide some therapeutic benefits resulting from increased metabolic stability, for example increased in vivo half-life or reduced dosage requirements. The 18F labeled compound may be useful for PET or SPECT testing. The isotope-labeled compounds of the present invention and their prodrugs can generally be prepared by performing the procedures in the schemes or the examples and preparations described below by replacing with a readily available isotope-labeled reagent. Further, substitution with heavier isotopes, particularly deuterium (ie, 2H or D) may provide some therapeutic benefits resulting from increased metabolic stability, for example increased in vivo half life or reduced dosage requirements or improved therapeutic index. It is understood that deuterium in this context is seen as a substituent in the compound of formula (I).
The concentration of such a heavier isotope, especially deuterium, can be defined by the isotopic enrichment factor. In the compounds of the present invention, any atom is not specifically designated as a particular isotope is intended to represent any stable isotope of that atom. Unless otherwise specified, when the position is specifically designated "H" or "hydrogen", it is understood that the position has hydrogen in its natural isotope occurrence. Accordingly, in the compounds of the present invention, any atom specifically designated as deuterium (D) is intended to represent deuterium.
The term "therapeutically effective amount" refers to an amount that is sufficient for treatment, as defined below, when administered to a mammal in need of an amount. A therapeutically effective amount will be
Vary depending on the subject being treated and the disease state, the weight and age of the subject, the severity of the disease condition, the method of administration and the like which can be easily determined by one of ordinary skill in art.
The term "treatment" or "treatment" means any treatment for a disease in a mammal, including:
(i) preventing the disease, ie, causing the clinical symptoms not to appear;
(ii) inhibiting the disease, ie arresting the development of clinical symptoms; and / or (iii) relieving the disease, ie, causing regression of clinical symptoms.
In many cases, the compounds of the present invention may form acid and / or basic salts due to the presence of amino and / or carboxy groups or groups similar thereto.
The term "acceptable salt" refers to a salt that retains biological effectiveness and properties of a given compound that are not biologically or otherwise undesirable. Pharmaceutically acceptable base addition salts can be prepared from inorganic and organic bases. Salts derived from inorganic bases include, by way of example only, sodium, potassium, lithium, ammonium, calcium and magnesium salts. Salts derived from organic bases include, without limitation, salts of primary, secondary and tertiary amines, such as alkylamines, dialkylamines, trialkylamines, substituted alkylamines, di (substituted alkyl) amines, tri (substituted alkyl) amines, alkenylamines, dialkenylamines, trialkenylamines, substituted alkenylamines, di (substituted alkenyl) amines, tri (substituted alkenyl) amines, cycloalkylamines, di (cycloalkyl) amines, tri (cycloalkyl) amines, substituted cycloalkylamines, disubstituted cycloalkylamines, tri-substituted cycloalkylamines, cycloalkenylamines, di (cycloalkenyl) amines, substituted cycloalkenylamines, disubstituted cycloalkenylamines, tri-substituted cycloalkenylamines, diarylamines, diarylamines, triarylamines mixed di- and tri-amines wherein at least two of the substituents are different and selected from alkyl, substituted alkyl, alkenyl, substituted alkenyl, cycloalkyl, substituted cycloalkyl, cycloalkenyl, substituted cycloalkenyl, aryl, heteroaryl, heterocyclic group, and the like. Also included are amines where two or three substituents, together with amino nitrogen, form a heterocyclic or heteroaryl group.
Specific examples of suitable amines include, by way of example only, isopropylamine, trimethylamine, diethylamine, tri (isopropyl) amine, tri (n-propyl) amine, ethanolamine, 2-dimethylaminoethanol, tromethamine, lysine, arginine, histidine, caffeine, procaine , choline hydrabamine, betaine, ethylenediamine, glucosamine, N-alkylglucamines, theobromine, purines, piperazine, piperidine, morpholine, N-ethylpiperidine, and the like.
Pharmaceutically acceptable acid addition salts can be prepared from inorganic and organic acids. Salts derived from inorganic acids include hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, phosphoric acid, and the like. Salts derived from organic acids include acetic acid, propionic acid, glycolic acid, pyruvic acid, oxalic acid, malic acid, malonic acid, succinic acid, maleic acid, fumaric acid,
Tartaric acid, citric acid, benzoic acid, cinnamic acid, mandelic acid, methanesulfonic acid, ethanesulfonic acid, p-toluene sulfonic acid, salicylic acid, and the like.
As used herein, "acceptable acceptable carrier" includes any and all solvents, dispersion media, coatings, antibacterial and antifungal agents, isotonic and absorption delaying agents, and the like. The use of such media and agents for active substances is known in the art. Unless any conventional medium or agent is incompatible with the active ingredient, its use in pharmaceutical compositions is contemplated. Additional active ingredients may also be included in the composition.
Coronary artery disease or cardiovascular disease refers to one or more of, for example, heart failure (including congestive heart disease, diastolic heart failure and systolic heart failure), acute heart failure, ischemia, and recurrent ischemia, myocardial infarction, arrhythmias, angina pectoris (including exercise-induced angina, variant angina, stable angina, unstable angina), acute coronary syndrome, diabetes mellitus, and intermittent claudication.
Intermittent claudication means pain associated with peripheral arterial disease. Peripheral Artery Disease or PAD is a type of occlusive peripheral vascular disease (PVD). PAD affects arteries outside the heart and brain. The most common symptom of PAD is painful cramps in hips, thighs, or calves when walking, climbing stairs, or straining. This pain is called intermittent claudication. When listing intermittent claudication, it is intended to cover both PAD and PVD
Arrhythmia refers to any abnormal heart rate. Bradycardia refers to an abnormally slow heart rate while tachycardia refers to an abnormally fast heart rate. As used herein, the treatment of arrhythmias is intended to include treatment of supraventricular tachycardia such as atrial fibrillation, atrial flutter, atrial tachycardia, atrial tachycardia, and ventricular tachycardia (VT), including idiopathic ventricular tachycardia, ventricular fibrillation, and
When a group (moiety) is described as attached to the second group and the attachment site is not indicated exactly, the given group may be attached at any available location to the given group to any available space in the second group. For example, "lower alkyl-substituted phenyl", where the attachment points are not given, may have any lower alkyl group site attached to any available phenyl group site. In this regard, "available space" is the place of the group where the hydrogen of the group can be replaced by a substituent.
Nomenclature
The names of the compounds of the present invention are given using ACD / Name for Chemical Compounding Software (Advanced Chemistry Development, Inc., Toronto). Other compounds or radicals may be called common names, or systematic or non-systematic names. The naming and numbering of the compounds is illustrated by a representative compound:
EP 2464645
<img file="PL2464645T3_D0029.tif" />
called 6- (3- (trifluoromethoxy) phenyl) -3- (trifluoromethyl) - [1,2,4] triazolo [4,3-a] pyridine.
Compounds of Formula III
Essentially, in typical requirements, the present invention provides compounds that act as sodium channel blockers. The invention relates to compounds of Formula III:
<img file="PL2464645T3_D0030.tif" />
where:
R<sup>1</sup> is aryl or heteroaryl selected from:
<img file="PL2464645T3_D0031.tif" />
- optionally substituted with aryl or heteroaryl being optionally substituted with one, two or three substituents independently selected from the group consisting of hydroxyl, halo, -NO 2, CN, -SF 5, -Si (CH 3) 3 -O-CF 3 , OR<sup>20</sup>, -SR<sup>20</sup>, -C (O) -R<sup>20</sup>, C (O) OH, -N (R<sup>20</sup>) (R<sup>22</sup>), -C (O) -N (R<sup>20</sup>) (R<sup>22</sup>), -N (R<sup>20</sup>) -C (O) -R<sup>22</sup>, -N (R<sup>20</sup>) -S (= O)<sub>2</sub>-R<sup>26</sup>, -S (= O) 2 -R<sup>20</sup>, -S (-O) 2 -N (R<sup>20</sup>) (R<sup>22</sup>), C 1 -C 3 alkoxy, C 1-4 alkyl, C 2-4 alkenyl, C 2-4 alkynyl, cycloalkyl, heteroaryl, and heterocyclyl;
alkoxy, alkyl, alkenyl, alkynyl, heteroaryl, cycloalkyl, or heterocyclyl are optionally substituted with one, two or three substituents independently selected from hydroxyl, halo, NO<sub>2</sub>, -O-CF<sub>3</sub>, -O-CHF<sub>2</sub>, phenyl, heterocyclyl, heteroaryl, cycloalkyl, -N (R<sup>20</sup>) (R<sup>22</sup>) - C (O) -R<sup>20</sup>, -C (O) -OR<sup>20</sup>, -C (O) -N (R<sup>20</sup>) (R<sup>22</sup>), -CN, and -OR<sup>20</sup>, or where R<sup>1</sup> is substituted with one, two or three substituents independently selected from
<img file="PL2464645T3_D0032.tif" />
<img file="PL2464645T3_D0033.tif" />
<img file="PL2464645T3_D0034.tif" />
<img file="PL2464645T3_D0035.tif" />
<img file="PL2464645T3_D0036.tif" />
<img file="PL2464645T3_D0037.tif" />
<img file="PL2464645T3_D0038.tif" />
EP 2464645
<img file="PL2464645T3_D0039.tif" />
EP 2464645
<img file="PL2464645T3_D0040.tif" />
<img file="PL2464645T3_D0041.tif" />
<img file="PL2464645T3_D0042.tif" />
<img file="PL2464645T3_D0043.tif" />
R<sup>2</sup> is independently selected from the group consisting of hydrogen, optionally substituted alkyl, amino, optionally substituted alkoxy, -CF<sub>3</sub>, -O-CF<sub>3</sub>, -CN, and -N (R<sup>20</sup>) C (O) -R<sup>22</sup>;
R<sup>3</sup> is independently selected from the group consisting of hydrogen, alkyl, -CF 3, -halo, and -OR<sup>24</sup>;
R<sup>4</sup> is independently selected from the group consisting of hydrogen, hydroxyl, halo, C1-4 alkyl, C1-C3 alkoxy, -R<sup>25</sup>-N (R<sup>20</sup>) (R<sup>22</sup>), -R<sup>25</sup>-GUARD<sup>20</sup>, -R<sup>25</sup>-C (O) -OR<sup>20</sup>, -R<sup>25</sup>-C (O) -N (R<sup>20</sup>) (R<sup>22</sup>), -R<sup>25</sup>-C (O) -ON (R<sup>20</sup>) (R<sup>22</sup>), -R<sup>25</sup>N (R<sup>20</sup>) -C (O) -R<sup>22</sup>, and -R<sup>25</sup>-OC (O) -N (R<sup>20</sup>) (R<sup>22</sup>), said alkyl is optionally substituted with one, two or three substituents independently selected from hydroxyl and halo,
Q is selected from a covalent bond or C 2-4 alkynylene;
R<sup>and</sup> is hydrogen, C1-15 alkyl, C1-4 alkoxy, -C (O) -OR<sup>26</sup>, -C (O) -N (R<sup>26</sup>) (R<sup>28</sup>), - N (R<sup>20</sup>) -S (= O) 2 -R<sup>20</sup>, cycloalkyl, aryl, heteroaryl, heterocyclyl,
Wherein said alkyl is optionally substituted with one, two or three substituents independently selected from hydroxyl, halo, -NO 2, -O-CF 3, -O-CHF 2, cycloalkyl, -CN, and C 1-4 alkoxy; and said alkoxy, cycloalkyl, aryl, heterocyclyl, or heteroaryl are optionally substituted with one, two or three substituents independently selected from hydroxy, halo, -NO 2, -O-CF 3, -O-CHF 2, phenyl, heterocyclyl, heteroaryl , cycloalkyl, -N (R<sup>20</sup>) (R<sup>22</sup>), -C (O) -R<sup>20</sup>, -C (O) -OR<sup>20</sup>, -C (O) -N (R<sup>20</sup>) (R<sup>22</sup>), CN, and -OR<sup>20</sup>; guard
R<sup>and</sup> means -YZR<sup>25</sup>-R<sup>23</sup>-R<sup>20</sup>WHERE
Y is a covalent bond or is selected from C 1 -C 3 alkylene optionally substituted with one or two C 1 -C 3 alkyl or fluoro groups;
Z is C<sub>2-4</sub> alkynylene, -O-, -S -, -NR ", -NR<sup>5'</sup>-C (O) -, -NR<sup>"</sup>-C (O) -NR<sup>5'</sup>-, or -C (O) -NR<sup>3</sup>- where each R "and R<sup>5'</sup> is independently hydrogen or lower alkyl; and furthermore the alkyl is optionally substituted with one, two or three substituents independently selected from hydroxyl, halo, -NO 2, -O-CF 3, -O-CHF 2, phenyl, heterocyclyl, heteroaryl, cycloalkyl, -N (R<sup>20</sup>) (R<sup>22</sup>), -C (O) -R<sup>20</sup>, -C (O) -OR<sup>20</sup>, -C (O) -N (R<sup>20</sup>) (R<sup>22</sup>), -CN, and -OR<sup>20</sup>, or
R<sup>and</sup> is selected from the group consisting of
<img file="PL2464645T3_D0044.tif" />
<img file="PL2464645T3_D0045.tif" />
<img file="PL2464645T3_D0046.tif" />
<img file="PL2464645T3_D0047.tif" />
<img file="PL2464645T3_D0048.tif" />
EP 2464645
<img file="PL2464645T3_D0049.tif" />
EP 2464645
<img file="PL2464645T3_D0050.tif" />
EP 2464645
<img file="PL2464645T3_D0051.tif" />
EP 2464645
<img file="PL2464645T3_D0052.tif" />
EP 2464645
<img file="PL2464645T3_D0053.tif" />
<img file="PL2464645T3_D0054.tif" />
<img file="PL2464645T3_D0055.tif" />
<img file="PL2464645T3_D0056.tif" />
<img file="PL2464645T3_D0057.tif" />
<img file="PL2464645T3_D0058.tif" />
EP 2464645
<img file="PL2464645T3_D0059.tif" />
<img file="PL2464645T3_D0060.tif" />
EP 2464645
<img file="PL2464645T3_D0061.tif" />
<img file="PL2464645T3_D0062.tif" />
<img file="PL2464645T3_D0063.tif" />
<img file="PL2464645T3_D0064.tif" />
<img file="PL2464645T3_D0065.tif" />
<img file="PL2464645T3_D0066.tif" />
<img file="PL2464645T3_D0067.tif" />
EP 2464645
<img file="PL2464645T3_D0068.tif" />
R<sup>20</sup> and R<sup>22</sup> are in each case independently selected from the group consisting of hydrogen, C 1 -C 15 alkyl, C 2 -C 15 alkenyl, C 2 -C 15 alkynyl, cycloalkyl, heterocyclyl, aryl, and heteroaryl, where alkyl, alkenyl, alkynyl, heterocyclyl, aryl, and heteroaryl are optionally substituted with one, two or three substituents independently selected from hydroxy, halo, alkyl, mono- or dialkylamino, alkyl or aryl or heteroaryl amide, -NO 2, -SO 2 R<sup>26</sup>-CN, C 1-3 alkoxy, -CF 3, -OCF 3, aryl, cycloalkyl, and heteroaryl; guard;
when R<sup>20</sup> and R<sup>22</sup> are attached to the common nitrogen atom R<sup>20</sup> and R<sup>22</sup> may form a heterocyclic ring. which is optionally substituted by one. two or three substituents independently selected from hydroxyl, halo, alkyl, mono- or dialkylamino, alkyl or aryl or heteroaryl amide, -NO2, SO2R<sup>26</sup>-CN, C 1-3 alkoxy, -CF 3, and -OCF 3, aryl, cycloalkyl;
<sub>R</sub>23 is a covalent bond or is selected from the group consisting of cycloalkylene, heterocyclylene, arylene, and heteroarylene, where cycloalkylene, heterocyclylene, arylene, and heteroarylene are optionally substituted with one to three substituents independently selected from hydroxyl, halo, alkyl, mono- or dialkylamino, alkyl or aryl or heteroaryl amide, -NO2, -SO2R<sup>26</sup>-CN, C 1-3 alkoxy, -CF 3, -OCF 3, aryl, cycloalkyl, and heteroaryl;
R<sup>24</sup> is in each case independently selected from alkyl or aryl. any of which may be optionally substituted with 1, 2, or 3 groups independently selected from hydroxyl, -OCF 3, halo, C 1 -C 3 alkoxy, -OR<sup>20</sup>, or alkyl optionally substituted with halo, -NO<sub>2</sub>, -CF<sub>3</sub>, -O-CF<sub>3</sub>, -N (R<sup>20</sup>) (R<sup>22</sup>) - C (O) R<sup>20</sup>, -C (O) -OR<sup>20</sup>, -C (O) -N (R<sup>20</sup>) (R<sup>22</sup>), -CN, or -OR<sup>20</sup>;
R<sup>25</sup> each case independently represents a covalent bond or is selected from C1-C3 alkylene optionally substituted by one or two C1-C3 alkyl groups; and
EP 2464645
R<sup>26</sup> and R<sup>28</sup> are in each case independently selected from hydrogen, alkyl, or cycloalkyl, wherein alkyl and cycloalkyl may be further substituted with from 1 to 3 substituents independently selected from hydroxyl, halo, C 1-4 alkoxy, -CF 3, and -OCF 3;
or a acc Acceptable salt, ester, prodrug, or solvate number, with proviso that
the. when R<sup>and</sup> means -YZR<sup>25</sup>-R<sup>23</sup>-R<sup>20</sup>, Y is not a covalent bond and Z is -O-, -S, -C (O) -NR<sup>3</sup>-, -NR<sup>5'</sup>-C (O) -, or NR "- is R<sup>25</sup> cannot mean a bond;
b. when R<sup>and</sup> means -YZR<sup>25</sup>-R<sup>23</sup>-R<sup>20</sup>, Y is a covalent bond and Z is -O-, -S-, or NR "-, then R<sup>25</sup> is a covalent bond and R<sup>23</sup> is not cycloalkylene;
c. when Z is -NR<sup>5'</sup>-C (O) -, then Y is not a covalent bond; d. R<sup>23</sup> and R<sup>25</sup> they cannot both mean a covalent bond; and e. when Q is absent and R<sup>1</sup> is heteroaryl, it's R<sup>1</sup> heteroaryl cannot be further substituted with phenyl; and
f. when R<sup>2</sup> is substituted alkyl, then R<sup>and</sup> is not alkyl, cycloalkyl, or heterocyclyl;
Typically, R substituents<sup>1</sup> aryl and heteroaryl are a mono or bicyclic ring of 1 to 3 heteroatoms selected from O, N, and S. R moieties<sup>1</sup> include the following:
<img file="PL2464645T3_D0069.tif" />
- 49 EP 2464645
R grouping<sup>1</sup> is further substituted with 1 to 3 substituents as defined above.
For example, when R<sup>1</sup> is substituted aryl, such as substituted phenyl, common substituents such as
32 34 30 32 34
R<sup>30</sup>, R<sup>32</sup>, and R<sup>34</sup> where R<sup>30</sup>, R<sup>32</sup>, and R<sup>34</sup> are independently selected from the group consisting of hydrogen, hydroxyl, -OCF<sub>3</sub>, halo, C 1 -C 3 alkoxy, -OR<sup>20</sup>, or C 1-4 alkyl optionally substituted with one, two or three substituents selected from halo, -NO 2, -CF 3, -O-CF 3, -N (R<sup>20</sup>) (R<sup>22</sup>), -C (O) -R<sup>20</sup>, -C (O) -OR<sup>20</sup>, -C (O) -N (R<sup>20</sup>) (R<sup>22</sup>), -CN, or OR<sup>20</sup>, with the proviso that at least one of Rs<sup>30</sup>, R<sup>32</sup>, and R<sup>34</sup> does not mean hydrogen. Common substituents are R-ring structures<sup>1</sup> include, but are not limited to, hydrogen; methyl, ethyl, propyl, isopropyl, tert-butyl, halo; amino, alkylamino such as methylamino, dialkylamino such as dimethylamino, aminoalkyl, alkaminoalkyl, dialkylaminoalkyl, aryloxy such as phenoxy; halo substituted alkyl such as CF3 and CHF2; methoxy, ethoxy, propoxy, isopropoxy, tert-butoxy, methylthio, ethylthio, propylthio, and halo substituted alkoxy such as trifluoromethoxy and difluoromethoxy. Other typical substituents include, but are not limited to the following:
<img file="PL2464645T3_D0070.tif" />
<img file="PL2464645T3_D0071.tif" />
<img file="PL2464645T3_D0072.tif" />
<img file="PL2464645T3_D0073.tif" />
<img file="PL2464645T3_D0074.tif" />
<img file="PL2464645T3_D0075.tif" />
EP 2464645
<img file="PL2464645T3_D0076.tif" />
EP 2464645
<img file="PL2464645T3_D0077.tif" />
Normal R groups<sup>2</sup> include, but are not limited to, hydrogen, methyl, methoxy, hydroxymethyl,
CF3, cyano, amino, acetamide, alkylamide, and cycloalkylcarboxamide.
Typical R groups<sup>3</sup> include, but are not limited to, hydrogen, methoxy, and methyl.
Normal R groups<sup>4</sup> include, without limitation, hydrogen, halo, methyl, methoxy, hydroxymethyl, (morpholine-4-carbonyloxy) methyl, (dimethylcarbamoyloxy) methyl, (cyanomethoxy) methyl, methoxymethyl, amino, dimethylamino, and cycloalkylcarboxamide.
Ordinary R groups<sup>and</sup> include, but are not limited to hydrogen, methyl, dimethylamino, CF 3, -OCF 3, -OCH 3, - OCH 2 COOH, NHCH 2 CH 3, CONHCH 3, -CH 2 CONHCH 3, -CH 2 CON (CH 3) 2, 15
EP 2464645
CH 2 CONH (CH 2) 2 OH, -COOCH 2 CH 3, -CH 2 OH, -COOH, carboxyphenyl, methoxycarbonylphenyl. Very ordinary R groups<sup>and</sup> is hydrogen, -CF 3, -OCF 3. Examples of R groups<sup>and</sup> include, without limitation, the following:
<img file="PL2464645T3_D0078.tif" />
EP 2464645
<img file="PL2464645T3_D0079.tif" />
<img file="PL2464645T3_D0080.tif" />
<img file="PL2464645T3_D0081.tif" />
EP 2464645
<img file="PL2464645T3_D0082.tif" />
EP 2464645
<img file="PL2464645T3_D0083.tif" />
EP 2464645
<img file="PL2464645T3_D0084.tif" />
<img file="PL2464645T3_D0085.tif" />
<img file="PL2464645T3_D0086.tif" />
EP 2464645
<img file="PL2464645T3_D0087.tif" />
<img file="PL2464645T3_D0088.tif" />
<img file="PL2464645T3_D0089.tif" />
<img file="PL2464645T3_D0090.tif" />
EP 2464645
<img file="PL2464645T3_D0091.tif" />
EP 2464645
<img file="PL2464645T3_D0092.tif" />
Further embodiments
In typical embodiments, the compounds provided by the present invention are effective in treating conditions known to respond to administration of late sodium channel blockers.
- including but not limited to cardiovascular diseases such as atrial and ventricular arrhythmias, including atrial fibrillation, Prinzmetal angina pectoris (variant), stable angina pectoris, unstable angina pectoris, ischemia and traumatic reperfusion in the heart, kidney, liver and brain, exercise-induced angina, pulmonary hypertension, congestive heart disease including diastolic and systolic heart failure, and myocardial infarction. In some embodiments, compounds of the present invention that act as late sodium channel blockers can be used to treat diseases affecting the neuromuscular system resulting in pain, itching, seizures, or paralysis, or to treat diabetes or reduced insulin sensitivity, and conditions with diabetes such as diabetic peripheral neuropathy.
Some compounds of the invention may also have sufficient activity in modulating neural sodium channels, ie, Nav 1.1, 1.2, 1.7, and / or 1.8, and may have appropriate pharmacokinetic properties such that they may be active on the central and / or peripheral system nervous. As a result, some compounds of the invention may also be of use in the treatment of epilepsy or pain or itching of neuropathic origin.
In typical embodiments, the present invention is intended to include the disclosed compounds, and their acceptable salts, acceptable esters, tautomeric forms, polymorphs, and prodrugs of such compounds. In some embodiments, the present invention includes a pharmaceutically acceptable salt, an acceptable salt, a hydrate, a tautomeric form, a polymorph, an enantiomer, a mixture of enantiomers, a stereoisomer or a mixture of stereoisomers (pure or as a racemic or non-racemic mixture). of a compound described herein, eg a compound of Formula (I); such as the compound of Formula (I) named stated.
Pharmaceutical compositions and administration
The compounds of the present invention are usually administered in the form of pharmaceutical compositions. The present invention therefore provides pharmaceutical compositions containing as active ingredient one or more of the compounds described, and one or more acceptable excipients, carriers, including inert solid diluents and fillers, diluents including sterile aqueous. solution and various organic solvents, transmission enhancers, solubilizers and adjuvants. The pharmaceutical compositions may be administered alone or in combination with other therapeutic agents. Such compositions are prepared in the art known in the art of pharmaceuticals (see, eg, Remington's Pharmaceutical Sciences, Mace Publishing Co., Philadelphia, PA 17te Ed. (1985); and Modern Pharmaceutics, Marcel Dekker, Inc. 3rd Edition (GS Banker). & CT Rhodes, Eds.)
The pharmaceutical compositions may be administered in single or multiple doses by the administration of agents having similar utility, for example as described in these patents and patent applications incorporated by reference, including rectal, buccal, intranasal and dermal, intraarterial, intravenous, intraperitoneal injection, parenterally, intramuscularly, subcutaneously, orally, topically, as an inhalation agent, or by impregnated or coated devices such as a stent, for example, or a cylindrical polymer inserted into an artery.
EP 2464645
One mode of administration is parenteral administration, in particular by injection. Forms in which new compositions of the present invention may be included for administration by injection include free or oily suspensions or emulsions, with sesame oil, corn oil, cottonseed oil, or peanut oil, as well as elixirs, mannitol, dextrose, or a sterile aqueous solution, and similar pharmaceutical media. Aqueous solutions in brine are also conventionally used for injection, but less preferred in the context of the present invention. Ethanol, glycerol, propylene glycol, liquid polyethylene glycol, and the like (and their respective mixtures), cyclodextrin derivatives, and vegetable oils can also be used. Proper fluidity can be maintained, for example, by the use of a coating such as lecithin, by the maintenance of the required particle size in the case of dispersions, and by the use of surfactants. Prevention of the action of microorganisms can be achieved by various antibacterial and antifungal agents, for example, parabens, chlorobutanol, phenol, sorbic acid, thimerosal, and the like.
Sterile injectable solutions are prepared by incorporating a compound of the present invention in the required amount into a suitable solvent with various other ingredients as required, and sterilizing by filtration. Generally, the dispersions are prepared by incorporating various sterilized active ingredients into a sterile medium that contains the base dispersion medium and the other ingredients required from those given above. For sterile powders for the preparation of sterile injectable solutions, preferred production methods are vacuum drying and freeze drying techniques that provide the active ingredient powder plus any additional desired ingredient from its previously sterile filtered solution.
Oral administration is another route for administering compounds of the invention. Administration can be via enteric coated capsules or tablets, or the like. In the preparation of pharmaceutical compositions containing at least one compound described, the active ingredient is usually diluted by an excipient and / or encapsulated in a carrier that will be in the form of a capsule, sachet, paper or other container. When the excipient serves as a diluent, it may be in solid, semi-solid or liquid form (as above), which material acts as a support, carrier or medium for the active ingredient. Thus, the compositions may be in the form of tablets, pills, powders, lozenges, sachets, cachets, elixirs, suspensions, emulsions, solutions, syrups, aerosols (as solid or in a liquid medium), for example, up to 10% wt. active compound, soft and hard gelatin capsules, sterile injectable solutions, and sterile packaged powders.
Some examples of suitable excipients include lactose, dextrose, sucrose, sorbitol, mannitol, starches, acacia, calcium phosphate, alginates, tragacanth, gelatin, calcium silicate, microcrystalline cellulose, polyvinylpyrrolidone, cellulose, sterile water, syrup, and methyloc. The formulations may optionally contain: lubricants such as talc, magnesium stearate, and mineral oil; wetting agents; emulsifying and suspending agents; preservatives such as methyl benzoates and propyl hydroxybenzoates; sweeteners; and flavors.
The compositions of the invention may be formulated to provide rapid, sustained or delayed release of the active ingredient upon administration to the patient using procedures known in the art. Controlled drug delivery systems for oral administration include osmotic pump systems and dissolution systems containing polymer-coated reservoirs or drug matrix formulations. Examples of controlled release systems are given in U.S. Patent Nos. PS 3,845,770; 4,326,525; 4.902514; and 5,616,345. Another formulation for use in the present invention uses transdermal delivery devices ("patches"). Such transdermal patches may be used to provide continuous or discontinuous infusion of the present invention in controlled amounts. The construction and use of transdermal patches for delivery of pharmaceutical agents is known in the art. See, eg, U.S. Patent Nos. 5,023,252, 4,992,445 and 5,001,139. Such patches can be constructed for continuous, pulsed or demanded delivery of pharmaceuticals.
The compositions are preferably formulated in unit dosage form. The term "unit dosage forms" refers to physically discrete units suitable as unitary dosages for human subjects and other mammals, each unit containing a predetermined amount of active material calculated to provide the desired therapeutic effect, in conjunction with a suitable pharmaceutical excipient (eg, tablet, capsule, ampoule). The compounds are generally administered in an effective amount. Preferably, for oral administration, each unit dose contains from 1 mg to 2 g of the compound described herein, and for parenteral administration, preferably from 0.1 to 700 mg of the compound described above. It will be understood, however, that the amount of the compound actually administered will usually be determined by the physician, in the light of the relevant circumstances, including the condition being treated, the route of administration chosen, the compound actually administered and its relative activity , age, weight, and response of the individual patient, severity of the patient's symptoms, and the like.
For the preparation of solid compositions such as tablets, the main active ingredient is mixed with a pharmaceutical excipient to form a solid pre-formulation composition containing a homogenous mixture of the present invention. When referring to these preformulation compositions as homogeneous, it is understood that the active ingredient is dispersed evenly throughout the composition so that the composition can be readily divided into equally effective unit dosage forms such as tablets, pills and capsules.
The tablets or pills of the present invention may be coated or otherwise formulated to provide a dosage form providing a prolonged effect or protection against acidic conditions in the stomach. For example, a tablet or pill may contain an internal dose component and an external dose component, the latter in the form of an envelope over the former. These two components can be separated by an enteric layer that serves to withstand disintegration in the stomach and allows the intact internal component to pass into the duodenum or to delay its release. Many materials can be used for such enteric layers or coatings, such materials include many polymeric acids and mixtures of polymeric acids with such materials as shellac, cetyl alcohol, and cellulose acetate.
Inhalable or insufflated compositions include solutions and suspensions in acceptable solvents, aqueous or organic solvents, or mixtures of solvents, and powders. Liquid or solid compositions may contain suitable acceptable excipients as described above. Preferably, the compositions are administered orally or nasally for local or systemic effect. Compositions in particularly acceptable solvents may be nebulized using inert gases. Nebulized solutions can be inhaled directly from the device
The nebulizing device or nebulizing device may be attached to a face tent or breathing device with intermittent hypertension. The composition as a solution, suspension, or powder can be administered, preferably orally or nasally, from devices that deliver the formulation in an appropriate manner.
Combination therapy
Patients treated with the administration of late sodium channel blockers of the invention often show diseases or conditions that benefit from treatment with other therapeutic agents. These diseases or conditions may be of cardiovascular nature or may be associated with pulmonary disorders, metabolic disorders, gastrointestinal disorders, and the like. In addition, some coronary patients are treated by the administration of late sodium channel blockers of the invention exhibit conditions that may benefit from treatment with other therapeutic agents, which include antibiotics, analgesics, and / or antidepressants and anti-anxiety agents.
Combination therapy with a cardiovascular agent
Diseases or conditions associated with cardiovascular system that may benefit from combination therapy of late sodium channel blockers with other therapeutic agents include, without limitation, angina including stable angina, unstable angina (UA), angina stress-induced pain, variant angina, arrhythmias, intermittent claudication, myocardial infarction including non-STE myocardial infarction (NSTEMI), pulmonary hypertension including pulmonary hypertension, heart failure including congestive (or chronic) heart failure and diastolic heart failure and preserved ejection fraction (diastolic dysfunction), acute heart failure, or recurrent ischemia.
Therapeutic agents for treating diseases or conditions associated with the cardiovascular system include anti-angina agents, anti-heart failure agents, anti-coagulants, anti-arrhythmics, anti-hypertensive agents, and lipid lowering agents.
Co-administration of late sodium channel blockers of invention with therapeutic agents suitable for treatment of cardiovascular related conditions allows for improvement in the standard of treatment the patient receives.
Agents against angina pectoris
Anti-angina agents include beta-blockers, calcium channel blockers, and nitrates. Beta blockers reduce the heart's need for oxygen by reducing its load resulting in reduced heart rate and less vigorous heart contractions. Examples of beta blockers include acebutolol (Sectral), atenolol (Tenormin), betaxolol (Kerlone), bisoprolol / hydrochlorothiazide (Ziac), bisoprolol (Zebeta), carteolol (Cartrol), esmolol (Brevibloc), labetalol (Normodyneop, Trandolate) , Toprol XL), nadolol (Corgard), propranolol (Inderal), sotalol (Betapace), and timolol (Blocadren).
EP 2464645
Nitrates dilate the arteries and veins, thereby increasing coronary blood flow and reducing blood pressure. Examples of nitrates include nitroglycerin, nitrate patches, isosorbide dinitrate, and isosorbide-5-mononitrate.
Calcium channel blockers prevent the normal flow of calcium to the heart cells and blood vessels, causing the vessels to relax, thereby increasing the flow of blood and oxygen to the heart. Examples of calcium channel blockers include amlodipine (Norvasc, Lotrel), bepridil (Vascor), diltiazem (Cardizem, Tiazac), felodipine (Plendil), nifedipine (Adalat, Procardia), nimodipine (Nimotop), nisoldine (Sular), calanapamil Isoptin, Verelan), and nicardipine.
Agents against heart failure
Agents used to treat heart failure include diuretics, ACE inhibitors, vasodilators, and cardiac glycosides. Diuretics eliminate excess fluid in tissues and circulation, thus alleviating many symptoms of heart failure. Examples of diuretics include hydrochlorothiazide, metolazone (Zaroxolyn), furosemide (Lasix), bumetanide (Bumex), spironolactone (Aldactone), and eplerenone (Inspra).
Angiotensin converting enzyme (ACE) inhibitors reduce load on the heart by dilating blood vessels and reducing resistance to blood flow. Examples of ACE inhibitors include benazepril (Lotensin), captopril (Capoten), enalapril (Vasotec), fosinopril (Monopril), lisinopril (Prinivil, Zestril), moexypril (Univasc), perindopril (Aceon), quinapril (Accupril), ramipril (Altace) ), and trandolapril (Mavik).
Vasodilators reduce the pressure on the blood vessels by relaxing and dilating them. Examples of vasodilators include hydralazine, diazoxide, prazosin, clonidine, and methyldopa. ACE inhibitors, nitrates, potassium channel activators, and calcium channel blockers also act as vasodilators.
Cardiac glycosides are compounds that increase the strength of heart contractions. These compounds increase the ability to pump the heart and improve the abnormal heartbeat. Examples of cardiac glycosides include digital, digoxin, and digitoxin.
Anticoagulants
Anticoagulants inhibit the ability to form blood clots. There are three main types of anticoagulants - platelet inhibitors, anticoagulants, and thrombolytic agents.
Platelet inhibitors inhibit platelet-forming thrombus activity, thereby reducing coagulation in the arteries. Examples of platelet inhibitors include acetylsalicylic acid (aspirin), ticlopidine, clopidogrel (plavix), dipyridamole, cilostazol, persant sulfinopyrazone, dipyridamole, indomethacin, and IIIb / IIla glycoprotein inhibitors such as abciximab, and tirofiblate. Beta blockers and calcium channel blockers also have a plaque-inhibiting effect.
Anticoagulants prevent clot enlargement and prevent formation of new clots. Examples of anticoagulants include bivalirudin (Angiomax), warfarin (Coumadin), unfractionated heparin, low molecular weight heparin, danaparoid, lepirudin, and argatroban.
EP 2464645
Thrombolytic agents break down an existing blood clot. Examples of thrombolytic agents include streptokinase, urokinase, and tenecteplase (TNK), and tissue plasminogen activator (t-PA).
Anti-arrhythmic agents
Anti-arrhythmic agents are used to treat heart rate and arrhythmias. Examples of anti-arrhythmic agents include amiodarone, dronedarone, quinidine, procainamide, lidocaine, and propafenone. Cardiac glycosides and beta blockers are also used as anti-arrhythmic agents.
Combinations with amiodarone and dronedarone are of particular interest given to the recently discovered synergistic effect of the late sodium channel blocker ranolazine and amiodarone and dronedarone. See. U.S. Patent Application No. 20100056536 and Provisional U.S. Patent Application No. 61 / 288,739, incorporated herein by reference in their entirety.
Antihypertensive agents
Antihypertensive agents are used to treat hypertension, a condition in which blood pressure is higher than normal. Hypertension is associated with many aspects of cardiovascular disease, including congestive heart failure, atherosclerosis, and clot formation. Examples of antihypertensive agents include alpha-1-adrenoceptor antagonists such as prazosin (Minipress), doxazosin mesylate (Cardura), prazosin hydrochloride (Minipress), prazosin, polythiazide (Minizide), and terazosin hydrochloride (Hytrin); beta-adrenergic antagonists such as propranolol (Inderal), nadolol (Corgard), timolol (Blocadren), metoprolol (Lopressor), and pindolol (Visken); central alpha-adrenoceptor agonists such as clonidine hydrochloride (Catapres), clonidine hydrochloride and chlortalidone (Clorpres, Combipres), guanabenz acetate (Wytensin), guanfacine hydrochloride (Tenex), methyldopa (Aldomet), methyldopa and chlorothiazide (Aldoclor) ; combined alpha / beta-adrenergic antagonists such as labetalol (Normodyne, Trandate), Carvedilol (Coreg); adrenergic neuron blocking agents such as guanethidine (Ismelin), reserpine (Serpasil); antihypertensive agents acting on the central nervous system such as clonidine (Catapres), methyldopa (Aldomet), guanabenz (Wytensin); anti-angiotensin II agents; ACE inhibitors such as perindopril (Aceon) captopril (Capoten), enalapril (Vasotec), lisinopril (Prinivil, Zestril); angiotensin-II receptor antagonists such as Candesartan (Atacand), Eprosartan (Teveten), Irbesartan (Avapro), Losartan (Cozaar), Telmisartan (Micardis), Valsartan (Diovan); calcium channel blockers such as verapamil (Calan, Isoptin), diltiazem (Cardizem), nifedipine (Adalat, Procardia); diuretics; direct vasodilators such as nitropruside (Nipride), diazoxide (Hyperstat IV), hydralazine (Apresoline), minoxidil (Loniten), verapamil; and potassium channel activators such as aprykalim, bimakalim, cromakalim, uterus, nicorandil, and pinacidil.
Lipid lowering agents
Lipid lowering agents are used to lower the amount of cholesterol or fatty sugars present in the blood. Examples of lipid lowering agents include bezafibrate (Bezalip), ciprofibrate
EP 2464645 (Modalim), and statins such as atorvastatin (Lipitor), fluvastatin (Lescol), lovastatin (Mevacor, Altocor), mvastatin, pitavastatin (Livalo, Pitava), pravastatin (Lipostat), rosuvastatin (Crestor), and simvastatin (Zocor). ).
In the present invention. a patient with acute coronary artery disease often suffers from secondary medical conditions such as one or more of a metabolic disorder. pulmonary disorder. peripheral vascular disorder. or digestive tract disorder. Such patients may benefit from a combination therapy comprising administering ranolazine to the patient in combination with at least one therapeutic agent.
Combination therapy with pulmonary disorders
Pulmonary disorder refers to any disease or condition associated with the lungs. Examples of pulmonary disorders include. without limiting it. asthma, chronic obstructive pulmonary disease (COPD), bronchitis, and emphysema.
Examples of therapeutic agents used to treat pulmonary disorders include bronchodilators including beta2 agonists and anticholinergics, corticosteroids, and electrolyte supplements. Specific examples of therapeutic agents used to treat pulmonary disorders include epinephrine, terbutaline (Brethaire, Bricanyl), albuterol (Proventil), salmeterol (Serevent, Serevent Diskus), theophylline, ipratropium bromide (Atrovent), tiotropium (Spiriva), methylprednisrolone, Medrol. , magnesium, and potassium.
Combination therapy with metabolic disorders
Examples of metabolic disorders include. without limiting it. diabetes, including type I and II. metabolic syndrome. dyslipidemia, obesity. glucose intolerance. hypertension. elevated serum cholesterol. and elevated triglycerides.
Examples of therapeutic agents used to treat metabolic disorders include antihypertensive agents and lipid lowering agents. as described in the section "Combination therapy with a cardiovascular agent" above. Additional therapeutic agents used to treat metabolic disorders include insulin, sulfonylureas, biguanides, alpha-glucosidase inhibitors, and incretin mimetics.
Combination therapy with peripheral vascular disorders
Peripheral vascular disorders are disorders associated with blood vessels (arteries and veins) that lie outside the heart and brain. Including. for example, peripheral arterial disease (PAD), a condition that occurs when the arteries supply blood to internal organs. shoulders. and legs become completely or partially blocked as a result of atherosclerosis.
Combination therapy with gastrointestinal disorders
Gastrointestinal disorders concern diseases and conditions related to the gastrointestinal tract. Examples of gastrointestinal disorders include gastrointestinal reflux disease (GERD),
Inflammatory bowel disease (IBD), gastroenteritis, gastritis and peptic ulcer, and pancreatitis.
Examples of therapeutic agents used to treat gastrointestinal disorders include proton pump inhibitors such as pantoprazole (Protonix), lansoprazole (Prevacid), esomeprazole (Nexium), omeprazole (Prilosec), rabeprazole; H2 blocker such as cimetidine (Tagamet), ranitidine (Zantac), famotidine (Pepcid), nizatidine (Axid); prostaglandins such as misoprostol (Cytotec); sucralfate; and antacids.
Combination therapy with antibiotics, painkillers, antidepressants and anxiolytics
Patients with acute coronary artery disease may have conditions that benefit from administration of therapeutic agents or agents that are antibiotics, analgesics, antidepressants and anxiolytics in combination with ranolazine.
antibiotics
Antibiotics are therapeutic agents that kill or stop the growth of microorganisms, including bacteria and fungi. Examples of antibiotics include β-lactam antibiotics including penicillins (amoxicillin), cephalosporins, such as cefazolin, cefuroxime, cefadroxil (Duricef), cefalexin (Keflex), cefradine (Velosef), cefaclor (Ceflorin), cefprozil (Cefzil), Lorabid), cefixime (Suprax), cefpodoxime proxetil (Vantin), ceftybuten (Cedax), cefdynir (Omnicef), ceftriaxone (Rocephin), carbapenems, and monobactams; tetracyclines such as tetracycline; macrolide antibiotics such as erythromycin; aminoglycosides such as gentamicin, tobramycin, amikacin; quinolones such as ciprofloxacin; cyclic peptides such as vancomycin, streptogramins, polymyxins; lincosamides such as clindamycin; oxazolidinones such as linezolid; and sulfa-antibiotics such as sulfisoxazole.
Painkillers
Painkillers are therapeutic agents that are used to relieve pain. Examples of analgesics include opiates and morphinomimetics such as fentanyl and morphine; acetaminophen; NSAIDs, and COX-2 inhibitors. Given the ability of late sodium channel blockers of the invention to treat neuropathic pain by inhibiting NaV 1.7 and 1.8 sodium pathways, combinations with analgesics are of particular interest. See. Publication of US Patent Application No. 20090203707.
Antidepressants and anxiolytics
Antidepressants and anxiolytics include those used to treat anxiety disorders, depression, and those used as sedatives. Examples of antidepressants and anxiolytics include benzodiazepines such as diazepam, lorazepam, and midazolam; benzodiazepines; barbiturates; glutethimide; chloral hydrate; meprobamate; sertraline (Zoloft, Lustral, Apo-Sertral, Asentra,
EP 2464645
Gladem, Serlift, Stimuloton); escitalopram (Lexapro, Cipralex); fluoxetine (Prozac, Sarafem, Fluctin, Fontex, Prodep, Fludep, Lovan); venlafaxine (Effexor XR, Efexor); citalopram (Celexa, Cipramil, Talohexane); paroxetine (Paxil, Seroxat, Aropax); trazodone (Desyrel); amitriptyline (Elavil); and bupropion (Wellbutrin, Zyban).
Accordingly, one aspect of the invention provides a composition comprising the late sodium channel blockers of the invention and at least one therapeutic agent. In an alternative embodiment, the composition comprises the late sodium channel blockers of the invention and at least two therapeutic agents. In further alternative embodiments, the composition comprises the late sodium channel blockers of the invention and at least three therapeutic agents, the late sodium channel blockers of the invention and at least four therapeutic agents, or the late sodium channel blockers of the invention and at least five therapeutic agents.
The methods of combination therapy include co-administration of one formulation comprising the late sodium channel blockers of the invention and the therapeutic agent or agents, substantially simultaneous administration of more than one formulation comprising the late sodium channel blocker of the invention and the therapeutic agent or agents, and subsequent administration of the late sodium channel blocker of the present invention. invention and therapeutic agent or agents in any order, preferably, there is a period of time where the sodium channel blocker of the invention and the therapeutic agent or agents simultaneously exert their therapeutic effect.
Synthesis of example compounds
The compounds of the invention can be prepared using the disclosed methods and their routine modifications, which will be apparent in the present disclosure and methods known in the art. Conventional and known methods of synthesis may be used in addition to this description. The synthesis of typical compounds described herein, eg, compounds with structures described by one or more of Formula I can be obtained as described in the following examples. If available, reagents can be purchased commercially, eg from Sigma Aldrich or other chemical suppliers.
General syntheses:
Typical embodiments of the present compounds can be synthesized using the general synthetic schemes described below. It will be apparent that the general schemes can be altered by substituting starting materials for other materials with similar structure to obtain products that are correspondingly different. The following are descriptions of the synthesis to provide many examples of how starting materials can vary to give the corresponding products. When substituent groups are defined for the desired product, the necessary starting materials can generally be determined by inspection. Starting materials are typically obtained from commercial sources or synthesized using published methods. To synthesize compounds that are embodiments of the present invention, inspection of the structure of the synthesized compound will provide the identity of each substituent group. The identity of the final product will generally reveal the identity of the necessary starting materials by a simple inspection process, considering the examples given here.
EP 2464645
Synthesis reaction parameters
The terms "solvent," "inert organic solvent" or "inert solvent" refer to an inert solvent described in combination with it (including, for example, benzene, toluene, acetonitrile, tetrahydrofuran ("THF") , dimethylformamide ("DMF"), chloroform, methylene chloride (or dichloromethane), diethyl ether, methanol, pyridine and the like). Unless otherwise specified, the solvents used in the present invention are an inert organic solvent, and the reactions are carried out under an inert gas, preferably nitrogen.
The term "qs" means the addition of an amount sufficient to achieve the specified function, eg, to bring the solution to the desired volume (ie, 100%).
Synthesis of compounds
The compounds are typically produced by first providing the molecular core (1); 6-bromo [1,2,4] triazolo [4,3-a] pyridine, 6-bromo-3-methyl [1,2,4] triazolo [4,3-a] ] pyridine, 6-bromo-N-ethyl- [1,2,4] triazolo [4,3-a] pyridin-3-amine, and the like, or de novo synthesized, and the desired R substituents<sup>1</sup>Q using conditions known as Suzuki coupling. This process is shown below in Scheme Reaction I for a compound of Formula IA.
REACTION SCHEME
<img file="PL2464645T3_D0093.tif" />
(1)
<img file="PL2464645T3_D0094.tif" />
(And)
Pd-cat., Base, solvent, heat or microwave radiation
<img file="PL2464645T3_D0095.tif" />
about
Generally, the halogenated compound of Formula (1), in this case a brominated compound, is reacted with an appropriately substituted boronic acid derivative of Formula R<sup>1</sup>-QB (OH) 2 in an inert solvent, for example aqueous N, N-dimethylformamide, in the presence of a weak base, for example sodium bicarbonate. The reaction is typically carried out in the presence of a metal catalyst with a suitable ligand, for example dichlorobis (triphenylphosphine) palladium (II), at a temperature of about
120-170 ° C, for about 10 minutes to about 1 hour. When the reaction is essentially complete, the product o
Pattern I is isolated by conventional means.
It will be appreciated that various R substituents can be modified or added before or after the addition of R moiety<sup>1</sup>Q. For example, in some embodiments, the R moiety<sup>and</sup> can be coupled to the core before adding R substituents<sup>1</sup>Q. Also, in the case where the substituent R<sup>and </sup>contains a heteroaryl ring, the ring can be synthesized and cyclized before or after the R portion is added<sup>1</sup>Q.
It will also appreciate the addition of any substituent may result in a number of isomeric products, any or all of which can be isolated and purified by conventional techniques.
Optional core synthesis
EP 2464645
When a compound of Formula (1) is synthesized de novo, the various components W and X are typically formed by selecting the appropriate reagents for the core synthesis. Additional modification to obtain the desired R substituent<sup>1</sup>, R<sup>2</sup>, R<sup>3</sup>, R<sup>4</sup>, R<sup>and</sup>, or R<sup>b</sup>, can be sequentially performed using conventional techniques.
Table 1 below shows methods for the synthesis of typical compounds of Formula (1) (structures marked with * included as reference only).
Table 1. Methods for the compound core Formula (1)
<td>Intended PATTERN STRUCTURE (1)</td><td>Reagents</td><td>CONDITIONS</td>
<td>R<sup>+</sup>77 ¼ R<sup>2</sup> (*)</td><td>R<sup>2</sup><sup>r</sup>V "<sup>n</sup><sub>3</sub>A \ 7 \ R<sup>3</sup> cl R<sup>4</sup>NaN<sub>3</sub>, PTTS, DMF</td><td>Pyridine, sodium azide, and pyridine 4-methylbenzenesulfonate in anhydrous DMF were sealed in a microwave tube and exposed to radiation at 160 ° C for 30 min, cooled, and opened. Additional sodium azide and pyridine 4-methylbenzenesulfonate were added, sealed, and exposed to radiation at 200 ° C for 30 min. After cooling, the mixture was concentrated in vacuo, diluted with DMF and MeOH, filtered, and subjected to preparative gradient HPLC.</td>
<td>γ <ą N R<sup>2</sup> (*)</td><td>R <-N. Y R<sup>4</sup>NaN<sub>3</sub>, PTTS, DMF</td><td>Pyridazine, sodium azide, and pyridine 4-methylbenzenesulfonate in anhydrous DMF were encapsulated in a microwave tube and irradiated at 160 ° C for 30 min, cooled, and opened. Additional sodium azide and pyridine 4-methylbenzenesulfonate were added, sealed, and exposed to radiation at 200 ° C for 30 min. After cooling, the mixture was concentrated in vacuo, diluted with DMF and MeOH, filtered and subjected to preparative gradient HPLC.</td>
<td>R<sup>4</sup> R<sup>and</sup><sup>br</sup>75 R<sup>2</sup></td><td>Ύ1 N NHNH<sub>2</sub>(R<sup>and</sup>CCO) 2 O</td><td>The anhydride was slowly added to the hydrazinyl pyridine and the reaction mixture was heated to reflux for 3 days, concentrated, and dried azeotropically with toluene and purified by gradient chromatography.</td>
<td>R<sup>4</sup> R<sup>and</sup><sup>β</sup>ύΜ " R<sup>2</sup> (*)</td><td><sup>&</sup>an kA ^ NH<sub>2</sub>(R<sup>and</sup>CCO) 2 O</td><td>Dissolved pyridine in a solvent such as CH2Cl2 at RT. Base and anhydride added at RT. Stir at RT for about 1 hour. POCl added<sub>3</sub>. Stirred at RT for 12 to 24 hours, then at 160 ° C for 0.5 to 2 hours and then at 180 ° C for 4-6 hours. Quenched with aqueous NaHCO3 in an ice bath and extracted with EtOAc. The product can be collected by further washing and then purified by conventional techniques such as silica gel chromatography.</td>
EP 2464645
<td>R<sup>and</sup>Ύ; 5 R<sup>2</sup> (*)</td><td>Ύ "<sup>ν</sup>k ^ NHNHj (R<sup>and</sup>CCO) 2 O</td><td rowspan="2">Pyridazine or pyrazine and anhydride were placed in a solvent such as toluene and heated from 100 ° C to 120 ° C for 1 to 4 hours. The reaction mixture was concentrated and the product was extracted by dissolving in Cl2CH2 and washing with NaHCO3.</td>
<td>R<sup>4</sup> R<sup>and</sup><sup>These</sup>cent, J, 1 <sup>N</sup>R<sup>2</sup> (*)</td><td><sup>cl</sup>v ^<sup>n</sup>'^<sup>x</sup>NHNH<sub>2</sub>(R<sup>and</sup>CCO)<sub>2</sub>ABOUT</td>
<td>R<sup>4</sup> R '<sup>Βγ</sup>> Λν4 3 ^ · - ^ N r3 <sup>n</sup> (*)</td><td><sup>b</sup>Va N NHNH<sub>2</sub>R<sup>and</sup>COOH</td><td>Aldehyde and acetic acid were added to a solution of hydrazinopyrimidine in a solvent, eg, dichloromethane. The reaction mixture was stirred at rt for 1-4 hours before adding iodobenzene diacetate. The resulting reaction mixture was stirred at RT for another 1-4 hours. The mixture was evaporated in vacuo and purified by preparative TLC.</td>
The following examples show preferred embodiments of the invention. It will be appreciated by those skilled in the art that the techniques disclosed in the examples below represent those techniques discovered by the author as well as in the practice of invention, and should be considered as the preferred fashion of practice. However, those of ordinary skill in the art should appreciate that many changes may be made to the specific embodiments disclosed and still obtain the same or similar result without departing from the spirit and claims of the invention.
Example 1
Preparation of the compound of Formula I where W<sup>1</sup>, In<sup>2</sup>, and in<sup>3</sup> are CH, X<sup>1</sup> means CR<sup>and</sup>, and X<sup>2</sup> means N
A. Preparation of a compound of Formula I in which R<sup>1</sup> is 4-trifluoromethoxyphenyl, Q is a covalent bond, W<sup>1</sup>, In<sup>2</sup>, and in<sup>3</sup> are CH, X<sup>1</sup> means CCF<sub>3</sub>, and X<sup>2</sup> means N
<img file="PL2464645T3_D0096.tif" />
Step 1. Preparation of 6-bromo-3- (trifluoromethyl) - [1,2,4] triazolo [4,3- b] pyridine, a compound of Formula
<img file="PL2464645T3_D0097.tif" />
(1.
- 72 EP 2464645
5-Bromo-2-hydrazinylpyridine (Frontier Scientific, Salt Lake City, UT) (2.092 g) was placed in a 100 mL round-bottom flask equipped with a reflux condenser. Trifluoroacetic anhydride (50 mL) was added slowly and the reaction mixture was heated to reflux for 3 days. Concentrated. and dried azeotropically with toluene. Gradient chromatography (ethyl acetate / hexanes) gave a brown solid.
<sup>1</sup>1 H NMR (400 MHz, CDCl 3): δ 8.39 (br p. 1H); 7.83 (dd. J = 9.8, 1.0 Hz, 1H); 7.54 (dd, J = 9.8, 1.6 Hz, 1H).
Alternate Step 1. Preparation of 6-bromo-3- (trifluoromethyl) - [1,2,4] triazolo [4,3-a] pyridine, a compound of Formula (1).
<img file="PL2464645T3_D0098.tif" />
To a suspension of hydrazide (35.0 g, 0.186 mol) in butyronitrile at 0 ° C was added trifluoroacetic anhydride (79 mL, 0.558 mol) by syringe at such a rate. that the internal temperature was below 35 ° C. The flask was closed and heated to 135 ° C overnight. The reaction was cooled, and concentrated under reduced pressure. H2O (100 mL) was added to the residue and the mixture was neutralized with NaHCO3 (water). CH2Cl2 (200ml) was added, the layers were separated, and the organic layer was washed with brine (100ml). The organic phases were dried over MgSO4, filtered, and concentrated to a brown solid. The solids were suspended in hexanes / ether (2: 1, 100ml), sonicated to homogeneity. and filtered. The solids were washed with cold hexanes / ether (10: 1.2x50 mL) and dried to give the product.
Alternate Stage 1.
compound of Formula (1).
Preparation of 6-bromo-3- (trifluoromethyl) - [1,2,4] triazolo [4,3- b] pyridine,
<img file="PL2464645T3_D0099.tif" />
A suspension of 5-bromo-3-nitro-2-hydrazinopyridine (2.0 g, 8.58 mmol) in trimethylorthoacetate (20 mL) was heated at 80 ° C for 20 h. After cooling, the solvent was distilled off, the residue was dissolved in ethyl acetate (200 mL), washed with water. Brine. dried over sodium sulfate and concentrated to give the product 6-bromo-3-methyl-8-nitro- [1,2,4] triazolo [4,3-a] pyridine.
Step 2. Preparation of 6- (4- (trifluoromethoxy) phenyl) -3- (trifluoromethyl) - [1,2,4] triazolo [4,3u] [pyridine
<img file="PL2464645T3_D0100.tif" />
- 73 EP 2464645
In a 100 mL round-bottomed flask 6-bromo-3- (trifluoromethyl) - [1,2,4] triazolo [4,3-a] pyridine (2.124 g), 4-trifluoromethoxyphenylboronic acid (2.466 g), and sodium carbonate (0.635 g) was suspended in a mixture of DMF (81 mL) and deionized water (9 mL) nitrogen-degassed. Tetrakis (triphenylphosphine) palladium (0.462 g) was added and the reaction mixture was stirred at 90 ° C overnight, concentrated, the residue was dissolved in ethyl acetate, and washed with water (2 *) and concentrated NaHCO<sub>3</sub>. The combined organic phase was dried over MgSO 4 and concentrated, then subjected to gradient chromatography (ethyl acetate / hexane) to give a dark gray solid. The material was recrystallized from ethyl acetate / hexanes to give a white material.
<sup>1</sup>1 H NMR (400 MHz, CDCl 3): δ 8.32 (s, 1H); 8.03 (d, J = 9.7 Hz, 1H); 7.69 (d, J = 9.7, 1H); 7.62 (d, J = 7.7 Hz, 2H); 7.41 (d, J = 7.7, 2H).<sup>19</sup>F NMR (377 MHz, CDCl 3): δ -57.81 (s, 1F); -62.99 (s, 1F). MS (ES +, m / z) 348.0 (base peak, M + H)<sup>+</sup>); 370.0 (M + Na<sup>+</sup>); 717.0 (2M + Na<sup>+</sup>).
Alternate Step 2. 6- (4- (Trifluoromethoxy) phenyl) - [1,2,4] triazolo [4,3-a] pyridine.
<img file="PL2464645T3_D0101.tif" />
In a 5 mL tube, 6-bromo- [1,2,4] triazolo [4,3-a] pyridine (93 mg), 4-trifluoromethoxyphenylboronic acid (115 mg), and potassium carbonate (187 mg) were suspended in. DMF (2 mL) previously degassed with nitrogen. Tetrakis (triphenylphosphine) palladium (20 mg) was added and the reaction mixture was heated in a microwave reactor at 150 ° C for 30 min, filtered and concentrated. The residue was subjected to gradient chromatography (MeOH / dichloromethane) to give a white powder, 56.4 mg (43% yield).
<sup>1</sup>1 H NMR (400 MHz, CDCl 3): δ 8.89 (s, 1H), 8.27 (br s, 1H); 7.89 (d, J = 9.2 Hz, 1H); 7.59 (d, J = 8.4, 2H); 7.52 (d, J = 9.6 Hz, 1H); 7.36 (d, J = 7.6, 2H).
MS (ES +, m / z) 280.0 (base peak, M + H)<sup>+</sup>); 581.0 (2M + Na<sup>+</sup>).
Alternate Step 2. Preparation of 6- (4-cyclopropylphenyl) -3- (trifluoromethyl) - [1,2,4] triazolo [4,3a] pyridine
<img file="PL2464645T3_D0102.tif" />
4-cyclopropylphenylboronic acid dppf (Pd) CI<sub>2</sub>
K<sub>2</sub>WHAT<sub>3</sub>
Toluene / EtOH / H<sub>2</sub>0
<img file="PL2464645T3_D0103.tif" />
Suspension of 6-bromo-3- (trifluoromethyl) - [1,2,4] triazolo [4,3-a] pyridine (50 mg, 0.19 mmol), acid
4-cyclopropylphenylboronic (34 mg, 0.21 mmol), dppf (Pd) Cl 2 (6.9 mg, 0.094 mmol), potassium carbonate (52 mg, 0.62 mmol) in degassed toluene (1 mL), degassed water (0.5 mL) and degassed ethanol (0.5 mL) was heated at 90 ° C for 1 h. The layers were separated, the organic layer was concentrated and the residue was purified by column chromatography to give 6- (4-cyclopropylphenyl) -3 (trifluoromethyl) - [1,2,4] triazolo [4,3-a] pyridine as a white powder.
- 74 EP 2464645
304.2 (M + 1).
<sup>1</sup>1 H NMR (DMSO) δ 8.29 (s, 1H), 8.01 (d, J = 9.6 Hz, 1H), 7.74 (dd, J = 1.2, 9.6 Hz, 1H), 7.46 (d, J = 8 Hz, 2H) , 7.26 (s, 1H), 7.22 (d, J = 8.4 Hz, 1H), 1.94-1.97 (m, 1H), 1.05-1.09 (m, 2H), 0.75-0.79 (m, 1H).
Optional Step 3. Preparation of N-methyl-3- (6- (4- (trifluoromethoxy) phenyl) - [1,2,4] triazolo [4,3a] pyridin-3-yl) benzamide
<img file="PL2464645T3_D0104.tif" />
Ethyl 3- (6- (4- (trifluoromethoxy) phenyl) - [1,2,4] triazolo [4,3-a] pyridin-3-yl) benzoate, prepared as described above, was mixed in 40% CH 3 NH 2 H2O (2.5 mL) and EtOH (1.5 mL) at 60 ° C in a closed tube overnight. The reaction mixture was concentrated and purified by HPLC and further purified by prep-TLC (5% MeOH / CH 2 Cl 2) to give N-methyl-3- (6- (4- (trifluoromethoxy) phenyl) - [1,2,4] triazolo [4,3-a] pyridin-3-yl) benzamide.
MS m / z 413.0 (M + H) @ +
B. Preparation of compounds of Formula I by changing R<sup>1</sup> and X<sup>1</sup>
Similarly, following the procedure of Example 1A, but optionally substituting other boronic acids or pinacolate esters for 4-trifluoromethoxyphenylboronic acid and / or substituting other precursors of formula (1) or prepared as disclosed in In various Examples or acquired commercially and / or other anhydrides, the following compounds of Formula I were prepared (are only incorporated by reference):
3-methyl-6- [4- (trifluoromethoxy) phenyl] [1,2,4] triazolo [4,3-a] pyridine;
N-ethyl-6- [4- (trifluoromethoxy) phenyl] [1,2,4] triazolo [4,3-a] pyridin-3-amine;
6- (4-phenoxyphenyl) -3- (trifluoromethyl) [1,2,4] triazolo [4,3-a] pyridine;
3-methyl-6- (4-phenoxyphenyl) [1,2,4] triazolo [4,3-a] pyridine;
6- [2-methoxy-5- (trifluoromethyl) phenyl] -3-methyl- [1,2,4] triazolo [4,3-a] pyridine;
N-ethyl-6- (4-phenoxyphenyl) [1,2,4] triazolo [4,3-a] pyridine-3-amine 331.1 (base peak, M + H<sup>+</sup>); 683.3 (2M + Na<sup>+</sup>);
N- (4- {6- [4- (trifluoromethoxy) phenyl] [1,2,4] triazolo [4,3-a] pyridin-3-yl} phenyl) methanesulfonamide MS m / z 449.0 (M + H)
4- {6- [4- (trifluoromethoxy) phenyl] [1,2,4] triazolo [4,3-a] pyridin-3-yl} benzamide
MS m / z 399.0 (M + H) @ +
3,3 '- [1,2,4] Triazolo [4,3-a] pyridine-3,6-dildibenzoate diethyl
MS m / z 416.1 (M + H)
Ethyl 3- {6- [4- (trifluoromethoxy) phenyl] [1,2,4] triazolo [4,3-a] pyridin-3-yl} benzoate
EP 2464645
MS m / z 428.0 (M + H) @ +
N- (2- {6- [4- (trifluoromethoxy) phenyl] [1,2,4] triazolo [4,3-a] pyridin-3-yl} phenyl) methanesulfonamide
MS m / z 449.0 (M + H) @ +
4- {6- [4- (trifluoromethoxy) phenyl] [1,2,4] triazolo [4,3-a] pyridin-3-yl} benzenesulfonamide
MS m / z 435.0 (M + H) @ +
N-ethyl-6- (3-phenoxyphenyl) [1,2,4] triazolo [4,3-a] pyridin-3-amine, 331.1 (base peak, M + H<sup>+</sup>); 684.3 (2M + Na<sup>+</sup>);
7-methyl-6- [4- (trifluoromethoxy) phenyl] -3- (trifluoromethyl) [1,2,4] triazolo [4,3-a] pyridine;
6- [3- (trifluoromethoxy) phenyl] -3- (trifluoromethyl) [1,2,4] triazolo [4,3-a] pyridine;
3- (trifluoromethyl) -6- [4- (trifluoromethyl) phenyl] [1,2,4] triazolo [4,3-a] pyridine;
6- (2,4-dichlorophenyl) -3- (trifluoromethyl) [1,2,4] triazolo [4,3-a] pyridine;
6- [4- (difluoromethoxy) phenyl] -3- (trifluoromethyl) [1,2,4] triazolo [4,3-a] pyridine;
6- (3-phenoxyphenyl) -3- (trifluoromethyl) [1,2,4] triazolo [4,3-a] pyridine;
6- [4-chloro-3- (trifluoromethyl) phenyl] -3- (trifluoromethyl) [1,2,4] triazolo [4,3-a] pyridine;
6- (4-chloro-3-fluorophenyl) -3- (trifluoromethyl) [1,2,4] triazolo [4,3-a] pyridine; and
6- [4- (trifluoromethoxy) phenyl] [1,2,4] triazolo [1,5-a] pyridine (*);
6- (3-phenoxyphenyl) [1,2,4] triazolo [1,5-a] pyridine (*);
Ethyl 4- {6- [4- (trifluoromethoxy) phenyl] [1,2,4] triazolo [4,3-a] pyridin-3-yl} benzoate <sup>1</sup>1 H-NMR (DMSO-d 6) δ 8.74 (s, 1H), 8.17 (s, 4H), 8.01 (dd, 1H), 7.91 (dd, 2H), 7.82 (dd, 1H), 7.49 (d, 2H) , 4.36 (q, 2H), 1.35 (t, 3H);
MS m / z 428.0 (M + H) @ +
3-phenyl-6- [4- (trifluoromethoxy) phenyl] [1,2,4] triazolo [4,3-a] pyridine,
MS (ESI +) 356.14 (base peak, M + H)<sup>+</sup>);
3- (trifluoromethyl) -6- [4- (trifluoromethyl) phenyl] [1,2,4] triazolo [4,3-a] pyridine <sup>1</sup>1 H NMR: 8.18 (s, 1H); 7.98 (d, 1H); 7.42 (d, 1H); 7.50 (d, 2H); 7.21 (s, 1H); 7.18 (d, 1H),<sup>19</sup>F NMR: -58.24 (s, 1F); -63.57 (s, 1F);
6- (4-phenoxyphenyl) -3- (trifluoromethyl) imidazo [1,5-a] pyridine (*),
MS (ESI +) 329.9 (base peak, M + H)<sup>+</sup>); 680.9 (2M + Na<sup>+</sup>);
6- (2,4-dichlorophenyl) -3- (trifluoromethyl) [1,2,4] triazolo [4,3-a] pyridine,
MS (ESI +) 331.9 [base peak, M (<sup>35</sup>Cl2) + H<sup>+</sup>]; 333.9 [M (<sup>35</sup>cl<sup>37</sup>Cl) + H<sup>+</sup>]; 335.9 [M (<sup>37</sup>Cl2) + H<sup>+</sup>]; 353.9; 686.8.
6- (3- (trifluoromethoxy) phenyl) -3- (trifluoromethyl) - [1,2,4] triazolo [4,3-a] pyridine
MS (ESI +) 347.9 (base peak, M + H)<sup>+</sup>); 369.9 (M + Na<sup>+</sup>); 716.9 (2M + Na<sup>+</sup>);
7-Methyl-6- (4- (trifluoromethoxy) phenyl) -3- (trifluoromethyl) - [1,2,4] triazolo [4,3-a] pyridine, <sup>1</sup>1 H NMR: 8.45 (s, 1H); 7.95 (s, 1H); 7.70 (d, 2H); 7.54 (d, 2H); 2.39 (d, 3H),<sup>19</sup>F NMR: -58.50 (s, 1F); -63.44 (s, 1F);
6- [4- (Pentafluoro-lambda-6-sulfanyl) phenyl] -3- (trifluoromethyl) [1,2,4] triazolo [4,3-a] pyridine
EP 2464645
MS (ESI +) 389.9 (base peak, M + H)<sup>+</sup>).
1- (4- (3- (trifluoromethyl) - [1,2,4] triazolo [4,3-a] pyridin-6-yl) phenyl) ethanone
MS (ESI +) 306.0 (base peak, M + H)<sup>+</sup>); 328.0 (M + Na<sup>+</sup>); 633.1 (2M + Na<sup>+</sup>).
6- (4-tert-Butoxy-phenyl) -3- (trifluoromethyl) [1,2,4] triazolo [4,3-a] pyridine
MS (ESI +) 336.0 (base peak, M + H)<sup>+</sup>); 693.1 (2M + Na<sup>+</sup>).;
6- [4- (5-methyl-1,3,4-oxadiazol-2-yl) phenyl] -3- (trifluoromethyl) [1,2,4] triazolo [4,3-a] pyridine, MS (ESI) +) 346.0 (base peak, M + H<sup>+</sup>); 368.0 (M + Na<sup>+</sup>); 713.1 (2M + Na<sup>+</sup>); 6- [4- (propan-2-ylsulfonyl) phenyl] -3- (trifluoromethyl) [1,2,4] triazolo [4,3-a] pyridine MS (ESI +) 370.0 (base peak, M + H)<sup>+</sup>); 392.0 (M + Na<sup>+</sup>); 761.0 (2M + Na<sup>+</sup>); 6- [3-methyl-4- (trifluoromethoxy) phenyl] -3- (trifluoromethyl) [1,2,4] triazolo [4,3-a] pyridine,
MS (ESI +) 362.0 (base peak, M + H)<sup>+</sup>); 384.0 (M + Na<sup>+</sup>); 745.1 (2M + Na<sup>+</sup>);
2-methyl-2- {4- [3- (trifluoromethyl) [1,2,4] triazolo [4,3-a] pyridin-6-yl] phenyl} propanenitrile,
MS (ESI +) 331.0 (base peak, M + H)<sup>+</sup>); 353.0 (M + Na<sup>+</sup>); 683.1 (2M + Na<sup>+</sup>); 6- (1-methyl-1H-indazol-5-yl) -3- (trifluoromethyl) [1,2,4] triazolo [4,3-a] pyridine,
MS (ESI +) 318.0 (base peak, M + H)<sup>+</sup>); 340.0 (M + Na<sup>+</sup>); 657.1 (2M + Na<sup>+</sup>);
6- (biphenyl-4-yl) -3- (trifluoromethyl) [1,2,4] triazolo [4,3-a] pyridine,
MS (ESI +) 340.1 (base peak, M + H)<sup>+</sup>); 701.1 (2M + Na<sup>+</sup>).;
Methyl 4- [3- (trifluoromethyl) [1,2,4] triazolo [4,3-a] pyridin-6-yl] benzoate;
3- (trifluoromethyl) -6- [4- (trimethylsilyl) phenyl] [1,2,4] triazolo [4,3-a] pyridine,
MS (ESI +) 336.0 (base peak, M + H)<sup>+</sup>); 358.0 (M + Na<sup>+</sup>); 693.1 (2M + Na<sup>+</sup>); 6- (4-tert-butylphenyl) -3- (trifluoromethyl) [1,2,4] triazolo [4,3-a] pyridine,
MS (ESI +) 320.2 (base peak, M + H)<sup>+</sup>);
3- (difluoromethyl) -6- [4- (trifluoromethoxy) phenyl] [1,2,4] triazolo [4,3-a] pyridine,
MS (ESI +) 330.2 (base peak, M + H)<sup>+</sup>);
6- (4-chloro-3-fluorophenyl) -3- (trifluoromethyl) [1,2,4] triazolo [4,3-a] pyridine,
MS (ESI +) 315.9 (base peak, M + H)<sup>+</sup>).;
6- [4-chloro-3- (trifluoromethyl) phenyl] -3- (trifluoromethyl) [1,2,4] triazolo [4,3-a] pyridine,
MS (ESI +) 365.9 (base peak, M + H)<sup>+</sup>).;
6- (3-phenoxyphenyl) -3- (trifluoromethyl) [1,2,4] triazolo [4,3-a] pyridine,
MS (ESI +) 356.0 (base peak, M + H)<sup>+</sup>); 377.9 (M + Na<sup>+</sup>); 733.0 (2M + Na<sup>+</sup>);
7-methyl-6- [3- (trifluoromethoxy) phenyl] -3- (trifluoromethyl) [1,2,4] triazolo [4,3-a] pyridine,
MS (ESI +) 361.9 (base peak, M + H)<sup>+</sup>); 383.9 (M + Na<sup>+</sup>); 744.9 (2M + Na<sup>+</sup>); 7-methoxy-6- [4- (trifluoromethoxy) phenyl] -3- (trifluoromethyl) [1,2,4] triazolo [4,3-a] pyridine,
MS (ESI +) 378.0 (base peak, M + H)<sup>+</sup>); 400.0 (M + Na<sup>+</sup>); 777.1 (2M + Na<sup>+</sup>); 6- (4-methoxyphenyl) -3- (trifluoromethyl) [1,2,4] triazolo [4,3-a] pyridine,<sup>1</sup>1 H NMR: 8.22 (s, 1H); 7.92 (d, 1H); 7.63 (d, 1H); 7.44 (d, 2H); 7.00 (d, 2H); 3.85 (s, 3H);
- 77 EP 2464645
6- [4- (2,2,2-trifluoroethoxy) phenyl] -3- (trifluoromethyl) [1,2,4] triazolo [4,3-a] pyridine,
MS (ESI +) 362.0 (base peak, M + H)<sup>+</sup>); 384.0 (M + Na<sup>+</sup>); 745.0 (2M + Na<sup>+</sup>);
6- (2-methyl-4- (trifluoromethoxy) phenyl) -3- (trifluoromethyl) - [1,2,4] triazolo [4,3-a] pyridine,
MS (ESI +) 361.9 (base peak, M + H)<sup>+</sup>); 383.9 (M + Na<sup>+</sup>).;
2-methyl-6- (3-phenoxyphenyl) [1,2,4] triazolo [1,5-a] pyridine (*);
8-methyl-6- (4-phenoxyphenyl) [1,2,4] triazolo [1,5-a] pyridine (*);
5-methyl-6- [4- (trifluoromethyl) phenyl] [1,2,4] triazolo [1,5-a] pyridine (*);
4- (3- (trifluoromethyl) - [1,2,4] triazolo [4,3-a] pyridin-6-yl) phenol;
4- (3- (trifluoromethyl) - [1,2,4] triazolo [4,3-a] pyridin-6-yl) aniline;
3- (propan-2-yl) -6- [4- (trifluoromethoxy) phenyl] [1,2,4] triazolo [4,3-a] pyridine,
MS (ESI +) 322.0 (base peak, M + H)<sup>+</sup>);
6- (4-methoxyphenyl) -3- (trifluoromethyl) imidazo [1,5-a] pyridine (*),
LCMS (EI: 70eV) 293 (M + H) +<sup>+</sup>+1);
6- (6- (2,2,2-trifluoroethoxy) pyridin-3-yl) -3- (trifluoromethyl) imidazo [1,5-a] pyridine (*),
LCMS (EI: 70eV) 362 (M + H) +<sup>+</sup>+1);
6-phenyl-3- (trifluoromethyl) imidazo [1,5-a] pyridine (*),
LCMS (EI: 70eV) 263 (M + H) +<sup>+</sup>+1);
6- (4- (2,2,2-trifluoroethoxy) phenyl) -3- (trifluoromethyl) imidazo [1,5-a] pyridine (*),
LCMS (EI: 70eV) 293 (M + H) +<sup>+</sup>+1);
6- (6- (methylthio) pyridin-3-yl) -3- (trifluoromethyl) imidazo [1,5-a] pyridine (*),
LCMS (EI: 70eV) 310 (M + H) +<sup>+</sup>+1);
3- (trifluoromethyl) -6- [6- (trifluoromethyl) pyridin-3-yl] [1,2,4] triazolo [4,3-a] pyridine
MS (ESI +) 333.1 (M + 1);
6- [6- (2,2,2-trifluoroethoxy) pyridin-3-yl] -3- (trifluoromethyl) [1,2,4] triazolo [4,3-a] pyridine,
MS (ESI +) 363.1 (M + 1);
6- [2-methoxy-4- (trifluoromethyl) phenyl] -3- (trifluoromethyl) [1,2,4] triazolo [4,3-a] pyridine,
MS (ESI +) 362.1 (M + 1);
8- (trifluoromethoxy) -5- [3- (trifluoromethyl) [1,2,4] triazolo [4,3-a] pyridin-6-yl] quinoline,
MS (ESI +) 399.1 (M + 1);
N-phenyl-4- [3- (trifluoromethyl) [1,2,4] triazolo [4,3-a] pyridin-6-yl] aniline,
MS (ESI +) 355.3 (M + 1);
6- [4- (phenylsulfanyl) phenyl] -3- (trifluoromethyl) [1,2,4] triazolo [4,3-a] pyridine,
MS (ESI +) 372.1 (M + 1), <sup>1</sup>1 H NMR (CDCl 3) δ 8.33 (p. 1H). 08.08-8.19 (m, 1H), 7.83 (d, J = 6.8 Hz, 1H), 7.66-7.72 (m, 2H), 7.43-7.53 (m, 4H), 7.37-7.45 (m, 3H);
6- [4- (cyclopropylmethoxy) phenyl] -3- (trifluoromethyl) [1,2,4] triazolo [4,3-a] pyridine,
EP 2464645
MS (ESI +) 334.2 (M + 1); and
5-methyl-6- [4- (trifluoromethoxy) phenyl] -3- (trifluoromethyl) [1,2,4] triazolo [4,3-a] pyridine,
MS (ESI +) 362.2 (M + 1), <sup>1</sup>1 H NMR (CDCl 3) δ 7.87 (d, J = 9.2 Hz, 1H), 7.32-7.42 (m, 5H), 2.68 (s, 3H).
C. Preparation of compounds of Formula I by changing R<sup>1</sup>, R<sup>2</sup>, and R<sup>3</sup>
Similarly, according to the procedure of Example 1A, but optionally substituting other boronic acids or pinacolate esters for 4-trifluoromethoxyphenylboronic acid and / or substituting other compounds of Formula (1), obtained commercially or prepared using other precursors of formula (1) or other anhydrides, other compounds of Formula I may be prepared.
Preparation of the compound of Formula I where W<sup>1</sup>
Example 2 and W<sup>2</sup> mean CH, W<sup>3</sup> is N and X<sup>1</sup> means CR<sup>and</sup>, and X is N
A. Preparation of a compound of Formula I in which R<sup>1</sup> is 4-trifluoromethoxyphenyl, Q is a covalent bond, W<sup>1</sup> and W.<sup>2</sup> mean CH, W<sup>3</sup> is N and X<sup>1</sup> is CCF3, and X<sup>2</sup> means N (included as a reference only)
<img file="PL2464645T3_D0105.tif" />
Step 1. Preparation of 6-chloro-3- (trifluoromethyl) - [1,2,4] triazolo [4,3-b] pyridazine, a compound o
Pattern (1).
CF<sub>3</sub>
Ck .N
<img file="PL2464645T3_D0106.tif" />
NHNH,
OO
F<sub>3</sub>C ^ O ^ CF<sub>3</sub> TOLUENE
110 C
Ck ^ N 7
<img file="PL2464645T3_D0107.tif" />
N
In a thick-walled pressure tube, a suspension of 3-chloro-6-hydrazinopyridazine (6.90 mmol) and trifluoroacetic anhydride (7.59 mmol) in toluene (10mL) was heated at 110 C for 2 h. The reaction mixture was concentrated. The residue was dissolved in dichloromethane and washed with sat. NaHCO3. The organic extract was dried over Na2SO4 and evaporated in vacuo to give a brown compound 6-chloro-3- (trifluoromethyl) - [1,2,4] triazolo [4,3-b] pyridazine.
Step 2. Preparation of 6- (4- (trifluoromethoxy) phenyl) -3- (trifluoromethyl) - [1,2,4] triazolo [4.3b] pyridazine
- 79 EP 2464645
<img file="PL2464645T3_D0108.tif" />
6-chloro-3- (trifluoromethyl) - [1,2,4] triazolo [4.3b] pyridazine (0.982 mmol), 4- (trifluoromethoxy) phenylboronic acid (1.18 mmol), tetrakis (triphenylphosphine) were added to the round-bottomed flask. ) palladium (0.0491 mmol), 2M Na2CO3 (2mL), and 1,2-dimethoxyethane (3mL). The resulting reaction mixture was heated at 85 C for 2 h. The reaction mixture was diluted with ethyl acetate and filtered through celite. The filtrate was washed with water. The organic extract was dried over Na2SO4 and evaporated in vacuo. The crude residue was purified by preparative HPLC to give 6- (4- (trifluoromethoxy) phenyl) -3- (trifluoromethyl) - [1,2,4] triazolo [4,3-b] pyridazine.
<sup>1</sup>H-NMR (DMSO) 7.65 (d, 2H, J = 8.0 Hz), 8.25 (d, 1H, J = 8.0 Hz), 8.26 (d, 2H, J = 8.0 Hz), 8.74 (d, 1H, J, = 8.0 Hz), MS m / z 348.9 (M<sup>+</sup>).
Alternate Step 2. Preparation of 3-isopropyl-6- (2-methyl-4- (trifluoromethoxy) phenyl) [1,2,4] triazolo [4,3-b] pyridazine (only incorporated by reference).
<img file="PL2464645T3_D0109.tif" />
microwave, 10 min
6-chloro-3-isopropyl- [1,2,4] triazolo [4,3-b] pyridazine prepared as described in Step 1 above (1.28 mmol), 2-methyl-4 (trifluoromethoxy) phenylboronic acid was added to the microwave tube. (1.40 mmol), tetrakis (triphenylphosphine) palladium (0.064 mmol), 2M Na2CO3 (1mL), and DMF (3mL). The resulting reaction mixture was heated in the microwave at 130 C for 10min. The reaction mixture was diluted with ethyl acetate and filtered through celite. The filtrate was washed with water. The organic extract was dried over Na2SO4 and evaporated in vacuo. The crude residue was purified by preparative HPLC to give 3-isopropyl-6- (2-methyl-4- (trifluoromethoxy) phenyl) [1,2,4] triazolo [4,3-b] pyridazine.
MS m / z 337 (M<sup>+</sup>).
<sup>1</sup>H-NMR (DMSO) 8.375-8.408 (d, 1H), 7.667-7.695 (d, 1H), 7.525-7.557 (d, 1H), 7.405-7.441 (m, 2H), 3.460-3.645 (m, 1H) , 1.420-1.444 (m, 6H).
B. Preparation of compounds of Formula I by changing R<sup>1</sup>, X1, and X
Similarly, following the procedure of Reference Example 2A above, but optionally substituting other boronic acids or pinacolate esters for 4-trifluoromethoxyphenylboronic acid and / or substituting other compounds of Formula (1), obtained commercially or prepared by conventional methods known in the art or disclosed herein, the following compounds of Formula I were prepared (compounds marked * included only as a reference):
6- (4-phenoxyphenyl) -3- (trifluoromethyl) [1,2,4] triazolo [4,3-b] pyridazine (*);
- 80 EP 2464645
3- (difluoromethyl) -6- [4- (trifluoromethoxy) phenyl] [1,2,4] triazolo [4,3-b] pyridazine (*);
3- (difluoromethyl) -6- (4-phenoxyphenyl) [1,2,4] triazolo [4,3-b] pyridazine (*);
6- (4-phenoxyphenyl) [1,2,4] triazolo [4,3-b] pyridazine (*),
MS m / z 405.0 (M<sup>+</sup>);
6- [4- (trifluoromethoxy) phenyl] [1,2,4] triazolo [4,3-b] pyridazine (*),
MS m / z 281.0 (M<sup>+</sup>);
3- (1-methyl-1H-pyrazol-4-yl) -6- (4- (trifluoromethoxy) phenyl) - [1,2,4] triazolo [4,3-a] pyridine,
MS m / z 360.1 (M<sup>+</sup>);
N- [5- (trifluoromethoxy) -2- {3- [4- (trifluoromethoxy) phenyl] [1,2,4] triazolo [4,3-a] pyridin-6-yl} phenyl] acetamide '
MS m / z 497.1 (M<sup>+</sup>):
3,6-bis [4- (trifluoromethoxy) phenyl] [1,2,4] triazolo [4,3-b] pyridazine (*) '
MS m / z 441.1 (M<sup>+</sup>);
6- [2-methyl-4- (trifluoromethoxy) phenyl] -3- (trifluoromethyl) [1,2,4] triazolo [4,3-b] pyridazine (*),
MS m / z 363 (M<sup>+</sup>), <sup>1</sup>H-NMR (DMSO) 8.671-8.703 (s, 1H), 7.847-7.880 (s, 1H), 7.691-7.719 (s, 1H), 7.400-7.459 (m, 2H), 2.442-2.494 (m, 3H) ;
6- (4-phenoxyphenyl) -3- (propan-2-yl) [1,2,4] triazolo [4,3-b] pyridazine (*),
MS m / z 331 (M<sup>+</sup>), <sup>1</sup>H-NMR (DMSO) 8.361-8.393 (d, 1H), 8.126-8.154 (d, 2H), 7.875-7.907 (d, 1H), 7.429-7.454 (t, 2H), 7.113-7.222 (m, 5H) , 3.600-3.645 (m, 1H), 1.155-1.477 (m, 6H);
2- (trifluoromethoxy) -5- [3- (trifluoromethyl) [1,2,4] triazolo [4,3-a] pyridin-6-yl] aniline,
MS m / z 363.1 (M<sup>+</sup>);
6- (3,5-difluoro-4-phenoxyphenyl) -3- (propan-2-yl) [1,2,4] triazolo [4,3-b] pyridazine (*),
MS m / z 367.1 (M<sup>+</sup>);
3- (propan-2-yl) -6- [6- (2,2,2-trifluoroethoxy) pyridin-3-yl] [1,2,4] triazolo [4,3-b] pyridazine (*),
MS m / z 338.1 (M<sup>+</sup>);
6- [3-fluoro-4- (trifluoromethoxy) phenyl] -3- (trifluoromethyl) [1,2,4] triazolo [4,3-b] pyridazine (*),
MS m / z 367.1 (M<sup>+</sup>), <sup>1</sup>H-NMR (DMSO) 8.749-8.782 (d, 1H), 8.248-8.281 (d, 2H), 8.072-8.100 (d, 1H), 7.800-7.825 (t, 1H);
6- (3,5-difluoro-4-phenoxyphenyl) -3- (trifluoromethyl) [1,2,4] triazolo [4,3-b] pyridazine (*),
MS m / z 393.1 (M<sup>+</sup>);
6- [4- (4-chlorophenoxy) phenyl] -3- (trifluoromethyl) [1,2,4] triazolo [4,3-b] pyridazine (*),
MS m / z 392.1 (M<sup>+</sup>);
3- (difluoromethyl) -6- [6- (2,2,2-trifluoroethoxy) pyridin-3-yl] [1,2,4] triazolo [4,3-b] pyridazine (*),
MS m / z 346.1 (M<sup>+</sup>);
3- (difluoromethyl) -6- [3-fluoro-4- (trifluoromethoxy) phenyl] [1,2,4] triazolo [4,3-b] pyridazine (*),
- 81 EP 2464645
MS m / z 349.1 (M<sup>+</sup>);
3-tert-butyl-6- (4-phenoxyphenyl) [1,2,4] triazolo [4,3-b] pyridazine (*),
MS m / z 345.1 (M<sup>+</sup>);
3-tert-butyl-6- [4- (2,2,2-trifluoroethoxy) phenyl] [1,2,4] triazolo [4,3-b] pyridazine (*),
MS m / z 351.1 (M<sup>+</sup>);
6- [6- (2,2,2-trifluoroethoxy) pyridin-3-yl] -3- (trifluoromethyl) [1,2,4] triazolo [4,3-b] pyridazine (*) '
MS m / z 364.1 (M<sup>+</sup>).
<sup>1</sup>H-NMR (DMSO) 8.992 (s, 1H), 8.703-8.734 (d, 1H), 8.483-8.514 (d, 1H), 8.256-8.288 (d, 1H), 7.2457.273 (d, 1H), 5.105 -5.135 (q, 2H);
3-ethyl-6- (4-phenoxyphenyl) [1,2,4] triazolo [4,3-b] pyridazine (*), and
MS m / z 317.1 (M +), <sup>1</sup>H-NMR (DMSO) 8.358-8.390 (d, 1H), 8.127-8.155 (d, 2H), 7.871-7.903 (d, 1H), 7.426-7.479 (m, 2H), 7.110-7.245 (m, 5H) , 3.138-3.163 (m, 2H), 1.392-1.442 (t, 3H).
C. Preparation of compounds of Formula I by changing R<sup>1</sup>, X and X2
Similarly, following the procedure of Reference Example 2A above, but optionally substituting other boronic acids or pinacolate esters for 4-trifluoromethoxyphenylboronic acid and / or substituting other compounds of Formula (1), obtained commercially or made using other precursors of formula (1) or other anhydrides, other compounds of Formula I can be prepared.
Reference example 3
Preparation of the compound of Formula I where W<sup>1</sup> and W.<sup>2</sup> means CH, W<sup>3</sup> is N and X<sup>1</sup> means CR<sup>and</sup>, and X is N (included only as a reference)
<img file="PL2464645T3_D0110.tif" />
A. Preparation of a compound of Formula I in which R<sup>1</sup> is 4-methylsulfonylphenyl, Q is a covalent bond, W<sup>1</sup> and W.<sup>2</sup> mean CH, W<sup>3</sup> is N and X<sup>1</sup> means CR<sup>and</sup>, R<sup>and</sup> is 4-chlorobenzyl, and X<sup>2</sup> means N
Step 1. Preparation of 6 N- (4- (6-chloropyridazin-3-yl) phenyl) methanesulfonamide, a precursor of formula (1).
<img file="PL2464645T3_D0111.tif" />
- 82 EP 2464645
3,6-dichloropyridazine (20.1 mmol), 4 (methylsulfonylamino) phenylboronic acid (20.1 mmol), tetrakis (triphenylphosphine) palladium (1.00 mmol), 2M Na2CO3 (30 mL), and 1,2-dimethoxyethane were added to the round-bottomed flask. (120 mL). The resulting reaction mixture was heated at 85 C for 22 h. The reaction mixture was diluted with ethyl acetate and filtered through celite. The filtrate was washed with water. The organic extract was dried over Na2SO4 and evaporated in vacuo. The crude residue was purified by biotage column chromatography eluting with 4: 1 ethyl acetate-hexane to give N- (4- (6-chloropyridazin-3-yl) phenyl) methanesulfonamide.
Step 2. Preparation of N- (4- (6-hydrazinylpyridazin-3-yl) phenyl) methanesulfonamide.
<img file="PL2464645T3_D0112.tif" />
A suspension of N- (4- (6-chloropyridazin-3-yl) phenyl) methanesulfonamide (2.82 mmol) in hydrazine monohydrate (6 mL) was heated at 120 C for 1 h and evaporated in vacuo. The residue was dissolved in dichloromethane, washed with water, dried over Na2SO4, and evaporated in vacuo to give N- (4- (6-hydrazinylpyridazin-3-yl) phenyl) methanesulfonamide.
Etap_3._Wytwarzanie_N- (4- (6- (2- (2- (4-chlorophenyl) acetyl) hydrazinyl) pyridazin-3-
<img file="PL2464645T3_D0113.tif" />
To a suspension of 2- (4-chlorophenyl) acetic acid (1.07 mmol), HOBT (1.07 mmol), and EDCI hydrochloride (1.61 mmol) in DMF (7 mL) was added N- (4- (6-hydrazinyl-pyridazin-3-yl) phenyl) methanesulfonamide (1.07 mmol) in 10 mL DMF and diisopropylethylamine (3.77 mmol). The resulting mixture was stirred at rt for 22 h and evaporated in vacuo. The desired product N- (4- (6- (2- (2- (4-chlorophenyl) acetyl) hydrazinyl) pyridazin-3-yl) phenyl) methanesulfonamide precipitated from water.
Step_4._ Preparation of N- (4- (6- (2- (2- (4-chlorophenyl) acetyl) hydrazinyl) pyridazin-3-yl) phenyl) methanesulfonamide, a compound of Formula I (incorporated by reference only).
- 83 EP 2464645
<img file="PL2464645T3_D0114.tif" />
N- (4- (6- (2- (2- (4-chlorophenyl) acetyl) hydrazinyl) pyridazin-3-yl) phenyl) methanesulfonamide (0.928 mmol), triphenylphosphine (3.25 mmol), azidotrimethylsilane (3.25) were added to the round-bottomed flask. mmol), diethyl azodicarboxylate (4.18 mmol), and THF (13 mL). The resulting mixture was stirred at rt for 22 h. The reaction mixture was diluted with dichloromethane and washed with sat. NaHCO3 and brine. The organic extract was dried over Na2SO4 and evaporated in vacuo. The crude product was washed with dichloromethane and methanol. The yellow solid was further purified by recrystallization of DMF and water to obtain N- (4- (3- (4-chlorobenzyl) [1,2,4] triazolo [4,3-b] pyridazin-6-yl) phenyl) methanesulfonamide.
<sup>1</sup>H-NMR (DMSO) 3.10 (s, 3H), 4.58 (s, 2H), 7.36-7.44 (m, 6H), 7.90-7.93 (d, 1H, J, 12 Hz), 8.08-8.11 (d, 2H , J, = 12 Hz), 8.39-8.42 (d, 1H, J, = 12 Hz), 10.24 (s, 1H), MS m / z 413.9 (M<sup>+</sup>).
B. Preparation of the compound of Formula I by changing R<sup>1</sup>
Similarly, following the procedures of Reference Example 3A above, but substituting other boronic acids or pinacolate esters for 4- (methylsulfonylamino) phenylboronic acid, the following compounds of Formula I were prepared (compounds marked with * are included only as a reference): N- (4- {3- [4- (trifluoromethyl) benzyl] [1,2,4] triazolo [4,3-b] pyridazin-6-yl} phenyl) methanesulfonamide (*); and
3- (difluoromethyl) -6- [4- (trifluoromethoxy) phenyl] [1,2,4] triazolo [4,3-a] pyrazine (*),
MS m / z 331 (M<sup>+</sup>), <sup>1</sup>H-NMR (DMSO) 9.683 (s, 1H), 9.227 (s, 1H), 8.236-8.265 (d, 2H), 8.013-7.669 (t, 1H).
C. Preparation of compounds of Formula I by changing R<sup>1</sup> and R<sup>and</sup>
Similarly, following the procedure of Reference Example 3A above, but optionally substituting other boronic acids or pinacolate esters for 4- (methylsulfonylamino) phenylboronic acid and / or substituting other CR compounds<sup>and</sup> acid derivatives for diethyl azodicarboxylate, other compounds of Formula I can be prepared.
Reference example 4
Preparation of the compound of Formula I where W<sup>1</sup> and W.<sup>2</sup> mean CH, W<sup>3</sup> is N and X<sup>1</sup> means CR<sup>and</sup>, and X<sup>2</sup> means N
- 84 EP 2464645
A. Preparation of compounds of Formula I in which R<sup>1</sup> is 4-trifluoromethoxyphenyl, Q is a covalent bond, W<sup>1</sup> and W.<sup>2</sup> means CH, W<sup>3</sup> is N and X<sup>1</sup> is CCH7CF3, and X<sup>2</sup> means N (included only as a reference)
<img file="PL2464645T3_D0115.tif" />
Step 1. Preparation of 3,3,3-trifluoro-N '- (6- (4-phenoxyphenyl) pyridazin-3-yl) propanhydrazide.
<img file="PL2464645T3_D0116.tif" />
To a solution of 3,3,3-trifluoropropionic acid (2.07 mmol) in DCM (10mL), EDCI HCl (3.02 mmol) and HOBt (2.07 mmol) were added. The solution was stirred at RT for 0.5 h and 3-hydrazinyl-6- (4-phenoxyphenyl) pyridazine A, prepared as disclosed in Example 3, (2.07 mmol) in 30 mL DCM and EDIPA ((7.24 mmol) was added. The coupling reaction will also work with , 3-dicyclohexylcarbodiimide and DCM as solvent or EDCI HCl and methanol as solvent. The resulting reaction mixture was stirred at RT overnight. The mixture was diluted with sat. aqueous NaHCO3. The organic extract was washed with H2O and dried over Na2SO4 and evaporated in vacuo. The crude product was purified by prep TLC eluting with a mixture of 5% methanol and dichloromethane to afford B.
Step 2. Preparation of 6- (4-phenoxyphenyl) -3- (2,2,2-trifluorethyl) - [1,2,4] triazolo [4,3-b] pyridazine, a compound of Formula I.
<img file="PL2464645T3_D0117.tif" />
To solution B (0.67 mmol) in acetonitrile, triphenylphosphine dichloride (4.02 mmol) was added. The reaction mixture was heated at 85 C overnight. The reaction mixture was evaporated in vacuo. The residue was diluted with DCM, washed with water and purified by prep HPLC to give 6- (4-phenoxyphenyl) -3- (2,2,2-trifluoroethyl) - [1,2,4] triazolo [4,3-b] pyridazine.
MS m / z 371 (M<sup>+</sup>).
<sup>1</sup>H-NMR (DMSO) 8.477-8.509 (d, 1H), 8.185-8.214 (d, 2H), 7.997-8.030 (d, 1H), 7.431-7.483 (t, 2H), 7.118-7.229 (m, 5H) , 4.400-4.588 (m, 2H).
EP 2464645
Optional Stage 3. Addition of the R grouping<sup>1</sup> by Suzuki coupling (only incorporated as a reference)
<img file="PL2464645T3_D0118.tif" />
Compound 3- (6- (2-methyl-4- (trifluoromethoxy) phenyl) - [1,2,4] triazolo [4,3-b] pyridazin-3-yl) benzonitrile was prepared by reacting 3- (6-chloro [ 1,2,4] triazolo [4,3-b] pyridazin-3-yl) benzonitrile, using the methods disclosed in Example 3, from 2-methyl-4- (trifluoromethoxy) phenylboronic acid according to the method disclosed in Example 2, Alternative Step 2.
B. Preparation of the compound of Formula I by changing R<sup>1</sup>
Similarly, following the procedures of Reference Example 4A above, but substituting other hydrazinopyridazine for 3-hydrazinyl-6- (4-phenoxyphenyl) pyridazine or other acids for 3,3,3-trofluoropropionic acid, the following compounds of Formula I were prepared (compounds marked with * are included only as a reference):
3-cyclopropyl-6- (4-phenoxyphenyl) [1,2,4] triazolo [4,3-b] pyridazine (*),
MS m / z 329.1 (M +);
3- (1-methyl-1H-pyrazol-4-yl) -6- (4-phenoxyphenyl) [1,2,4] triazolo [4,3-b] pyridazine (*),
MS m / z 369.1 (M +);
3- [4- (methylsulfonyl) phenyl] -6- (4-phenoxyphenyl) [1,2,4] triazolo [4,3-b] pyridazine (*),
MS m / z 443.1 (M +);
6-bromo-3- (1-methyl-1H-pyrazol-4-yl) - [1,2,4] triazolo [4,3-a] pyridine (*);
3- [6- (4-fluorophenyl) [1,2,4] triazolo [4,3-b] pyridazin-3-yl] benzonitrile (*),
MS m / z 316 (M +);
3- [6- (4-methoxyphenyl) [1,2,4] triazolo [4,3-b] pyridazin-3-yl] benzonitrile (*),
MS m / z328.1 (M +);
4- [6- (4-methoxyphenyl) [1,2,4] triazolo [4,3-b] pyridazin-3-yl] benzonitrile (*),
MS m / z 328.1 (M +);
4- {6- [4- (trifluoromethoxy) phenyl] [1,2,4] triazolo [4,3-b] pyridazin-3-yl} benzonitrile (*),
MS m / z 382.0 (M +);
4- {6- [2-methyl-4- (trifluoromethoxy) phenyl] [1,2,4] triazolo [4,3-b] pyridazin-3-yl} benzonitrile (*),
MS m / z 396.1 (M +);
4- [6- (4-phenoxyphenyl) [1,2,4] triazolo [4,3-b] pyridazin-3-yl] benzonitrile (*),
MS m / z 390 (M +);
6-bromo-3- (4- (trifluoromethoxy) phenyl) - [1,2,4] triazolo [4,3-a] pyridine (*);
6-bromo-3- (4- (trifluoromethoxy) phenyl) - [1,2,4] triazolo [4,3-b] pyridazine (*); and
2- [6- (4-phenoxyphenyl) [1,2,4] triazolo [4,3-b] pyridazin-3-yl] propan-2-ol (*),
- 86 EP 2464645
MS m / z 347.1 (M +).
C. Preparation of compounds of Formula I by changing R<sup>1</sup> and R<sup>and</sup>
Similarly, following the procedure of Reference Example 4A above, but by substituting other hydrazinopyridazine for 3-hydrazinyl-6- (4-phenoxyphenyl) pyridazine or other acids for 3,3,3-trofluoropropionic acid, other compounds of Formula I can be prepared.
Example 5
Preparation of a compound of Formula I where R<sup>1</sup> is substituted phenyl, W<sup>1</sup> and W.<sup>2</sup> mean CH, W<sup>3 </sup>is N and X<sup>1</sup> means CR<sup>and</sup>, and X<sup>2</sup> means N
A. Preparation of a compound of Formula I in which R<sup>1</sup> means 4- (pyridin-3-yloxy) phenyl) -3 (trifluoromethyl), Q is a covalent bond, W<sup>1</sup>, In<sup>2</sup>, and in<sup>3</sup> are CH, and X<sup>1</sup> means
CCH2CF3, and X<sup>2</sup> means N
<img file="PL2464645T3_D0119.tif" />
Step 1 - Preparation of the triazolopyridine boronic acid intermediate
Br bis (pinakolato) dibor Pd (dppf) CI<sub>2</sub>, KOAc Dioxane
HO '
OH and
, B
To the mixture of aryl bromide prepared as disclosed in Example 1 (10g, 38 mmol), bis (pinacolato) diborium (14.3g, 56 mmol), Pd (dppf) Cl2 (1.1g, 1.5 mmol), and KOAc (6.6g, 68 mmol) degassed dioxane (90 mL) was added. The reaction was heated to 75 ° C for 4 h and AcOH (684 mg, 114 mmol) and H2O (30 mL) were added, stirred 10 minutes and cooled. The residue was partitioned between 2N NaOH and Et2O, the layers were separated and the aqueous layer was washed further with Et2O. The aqueous layer was acidified with 1N HCl to pH = ~ 2, and a precipitate formed. The aqueous layer was filtered, and the solids were washed successively with CH3CN / H2O (1: 1), CH3CN, and Et2O. The solids were dried and collected to give boronic acid.
Step 2 - Preparation of the compound of Formula I
<img file="PL2464645T3_D0120.tif" />
- EP 2464645
3- (Trifluoromethyl) - [1,2,4] triazolo [4,3-a] pyridin-6-ylboronic acid suspension (80 mg, 0.35 mmol), 2- (4-bromophenoxy) pyridine (79 mg, 0.32 mmol ), dppf (Pd) Cl2 (12 mg, 0.016 mmol), potassium carbonate (87 mg, 0.63 mmol) in degassed toluene (1 mL), degassed water (0.5 mL) and degassed ethanol (0.5 mL) was heated at 90 ° C for 1 h. Solvent was removed and the residue was purified by RP-HPLC to give the product as a white powder.
357.1 (M + 1).
Alternate Step 2 - Preparation of the compound of Formula I
<img file="PL2464645T3_D0121.tif" />
Boronic acid suspension (360 mg, 1.6 mmol), 2-bromo-1-iodo-4- (trifluoromethoxy) benzene (575 mg, 1.6 mmol), dppf (Pd) Cl2 (57 mg, 0.078 mmol), potassium carbonate (433 mg, 3.1 mmol) in degassed toluene (4 mL), degassed water (2 mL) and degassed ethanol (2 mL) was heated at 45 ° C for 3 h. The layers were separated and the organics were concentrated and purified by column chromatography to give the desired product .
426.0 (M + 1).
<sup>1</sup>H NMR (CDCl3) δ 8.23 (s, 1H), 7.99 (s, 1H), 7.64 (s, 1H), 7.30-7.53 (m, 3H).
Alternate Step 2 - Preparation of the compound of Formula I
<img file="PL2464645T3_D0122.tif" />
3- (Trifluoromethyl) - [1,2,4] triazolo [4,3-a] pyridin-6-ylboronic acid (56.2 mg, 0.217 mmol), 4-bromo-2-fluoro-1- (trifluoromethoxy) benzene (50.0mg , 0.217 mmol, 1.0 equivalent) and Pd (PPh<sub>3</sub>)<sub>4</sub> (12.6 mg, 0.0109 mmol, 0.05 equiv.) Was placed in a 50 mL round-bottomed flask under nitrogen. 2M-Na2CO3 (1.0 mL, 2.0 mmol) and DMF (4 mL) were added to the flask at ambient temperature. The mixture was heated at 110 ° C for 1 h. The mixture was filtered through Celite (3 g) and Celite was washed with EtOAc (70 mL). The organic layer was washed with brine (30mL) and dried with Na2SO4. The solvent was removed under reduced pressure. The resulting crude mixture was purified by column chromatography (SiO2 = 25 g, EtOAc / hexane = 1: 3 to 1: 1, Rf = 0.3 with EtOAc / hexane = 1: 1) to give 6- (3-fluoro-4 (trifluoromethoxy) phenyl) -3- (trifluoromethyl) - [1,2,4] triazolo [4,3-a] pyridine as colorless crystals. LCMS (EI: 70 eV) 366 (M ++ 1)
- 88 EP 2464645 <sup>1</sup>H-NMR (300 MHz, CDCl<sub>3</sub>): 7.43-7.66 (3H, m), 7.76 (1H, d, J = 9.6 Hz), 8.13 (1H, d, J = 9.6 Hz), 8.42 (1H, s).
B. Optional secondary modification of the bromo R group<sup>1</sup>
<img file="PL2464645T3_D0123.tif" />
Compound 6- (2- (pyridin-3-yl) -4- (trifluoromethoxy) phenyl) -3- (trifluoromethyl) - [1,2,4] triazolo [4,3a] pyridine, prepared using the methods disclosed in Example 1.
MS m / z 425.1 (M + 1).
C. Preparation of the compound of Formula I by changing R<sup>1</sup>
Similarly, according to the procedures of Example 5A or 5B above, but substituting other aryl bromides or other brominated R moieties<sup>1</sup>, the following compounds of Formula I were prepared: 6- (2- (2-methoxypyrimidin-5-yl) -4- (trifluoromethoxy) phenyl) -3- (trifluoromethyl) - [1,2,4] triazolo [4.3 a ] pyridine
MS m / z 456.2 (M + 1);
6- (3-chloro-4- (trifluoromethoxy) phenyl) -3- (trifluoromethyl) - [1,2,4] triazolo [4,3-a] pyridine,
LCMS (EI: 70 eV) 382 (M<sup>+</sup>+1), <sup>1</sup>H-NMR (300 MHz, CDCl3): 7.51 (1H, br s), 7.64-7.76 (2H, m), 8.12 (1H, d, J = 9.6 Hz), 8.33 (1H, s);
5- (trifluoromethoxy) -8- (3- (trifluoromethyl) - [1,2,4] triazolo [4,3-a] pyridin-6-yl) quinoline, <sup>1</sup>H-NMR (300 MHz, CDCl3): 7.59 (1H, d, J = 9.6 Hz), 7.63 (1H, dd, J = 8.4, 4.3 Hz), 7.83 (1H, d, J = 8.4 Hz), 7.84 ( 1H, dd, J = 8.4, 1.7 Hz), 8.00 (1H, d, J = 9.6 Hz), 8.54 (1H, s), 8.59 (1H, d, J = 8.4 Hz), 9.01 (1H, dd, J = 4.3, 1.7 Hz);
6- (2-fluoro-4- (trifluoromethoxy) phenyl) -3- (trifluoromethyl) - [1,2,4] triazolo [4,3-a] pyridine,
LCMS (EI: 70 eV) 366 (M<sup>+</sup>+1), <sup>1</sup>H-NMR (300 MHz, CDCl3): 7.17 (1H, d, J = 10.8 Hz), 7.22 (1H, d, J = 8.4 Hz), 7.55 (1H, t, J = 8.4 Hz), 7.62 (1H, d, J = 9.6 Hz), 8.01 (1H, d, J = 9.6 Hz), 8.36 (1H, s);
6- [4- (pyridin-4-yloxy) phenyl] -3- (trifluoromethyl) [1,2,4] triazolo [4,3-a] pyridine,
MS m / z 357.1 (M + 1); and
6- [4- (cyclopropyloxy) phenyl] -3- (trifluoromethyl) [1,2,4] triazolo [4,3-a] pyridine,
MS m / z 320.1 (M + 1).
D. Preparation of compounds of Formula I by changing R<sup>1</sup>
- 89 EP 2464645
Similarly, following the procedure of Example 5A or 5B above, but substituting other aryl bromides or other brominated R moieties<sup>1</sup>, other compounds of Formula I may be prepared.
Reference example 6
Alternative preparation of a compound of Formula I where W<sup>1</sup> and W.<sup>2</sup> mean CH, W<sup>3</sup> is N and X<sup>1 </sup>means CR<sup>and</sup>, and X<sup>2</sup> means N
A. Preparation of a compound of Formula I in which R<sup>1</sup>is 4-trifluoromethoxyphenyl, Q is a covalent bond, W<sup>1</sup> and W.<sup>2</sup> mean CH, W<sup>3</sup> is N and X<sup>1</sup> mean CCIĄ and X<sup>2</sup> means N (included only as a reference)
<img file="PL2464645T3_D0124.tif" />
Step 1. Preparation of 6-chloro-3- (trifluoromethyl) - [1,2,4] triazolo [4,3-b] pyridazine, a compound o
Pattern (1).
<img file="PL2464645T3_D0125.tif" />
To a solution of 2,5-dichloropyrazine (2.91 mmol) in 1,2-dimethoxyethane (9mL), 4 (phenoxyphenyl) boronic acid (3.49 mmol) and tetrakis (triphenylphosphine) palladium (0.145 mmol) and 2M Na<sub>2</sub>WHAT<sub>3</sub> (3 mL). The resulting mixture was heated at 85 C for 2 h. The reaction mixture was diluted with ethyl acetate and filtered through celite. The organic extract was dried over Na2SO4 and evaporated in vacuo. The crude product was purified by biotage chromatography and then prep TLC eluting with a mixture of 5% ethyl acetate and hexane to give 2-chloro-5- (4-phenoxyphenyl) pyrazine.
Step 2. Preparation of 2-hydrazinyl-5- (4-phenoxyphenyl) pyrazine.
<img file="PL2464645T3_D0126.tif" />
Hydrazine monohydrate (2mL) was added to a solution of 2-chloro-5- (4-phenoxyphenyl) pyrazine in 2 mL of ethanol. The reaction mixture was heated at 110 C for 2 h and evaporated in vacuo. The residue was dissolved in dichloromethane, washed with water, dried over Na2SO4, and evaporated in vacuo to give 2-hydrazinyl-5- (4-phenoxyphenyl) pyrazine.
Step 3. Preparation of 6- (4-phenoxyphenyl) -3- (trifluoromethyl) - [1,2,4] triazolo [4,3-a] pyrazine.
- 90 EP 2464645
<img file="PL2464645T3_D0127.tif" />
In a thick-walled pressure tube, a suspension of 2-hydrazinyl-5- (4-phenoxyphenyl) pyrazine (0.827 mmol) and trifluoroacetic anhydride (0.993 mmol) in toluene (10mL) was heated at 110 C for 2 h. The reaction mixture was evaporated in vacuo and purified by preparative HPLC to give 6- (4-phenoxyphenyl) -3- (trifluoromethyl) - [1,2,4] triazolo [4,3-a] pyrazine.
<sup>1</sup>H-NMR (DMSO) 7.12 (t, 2H, J = 8.0 Hz), 7.15 (d, 2H, J = 8.0 Hz), 7.21 (t, 1H, J, = 8.0 Hz), 7.45 (t, 2H, J = 8.0 Hz), 8.20 (d, 2H, J = 8.0 Hz), 8.95 (s, 1H), 9.75 (s, 1H), (MS m / z 357.0 (M<sup>+</sup>).
B. Preparation of the compound of Formula I by changing R<sup>1</sup>
Similarly, following the procedure of Example 6A above, but substituting another 4- (phenoxyphenyl) boronic acid for 4-trifluoromethoxyphenylboronic acid, the following compound of Formula I was prepared and included only as a reference:
6- (4- (trifluoromethoxy) phenyl) -3- (trifluoromethyl) - [1,2,4] triazolo [4,3-a] pyrazine (*).
C. Preparation of compounds of Formula I by changing R<sup>1</sup> and X<sup>1</sup>
Similarly, following the procedure of Example 6A above, but optionally substituting other boronic acids or pinacolate esters for 4- (phenoxyphenyl) boronic acid and / or substituting other compounds of Formula (1), commercially obtained or prepared using other formula precursors (1 ) or other anhydrides, other compounds of Formula I may be prepared.
Reference example 7
Preparation of the compound of Formula I where W<sup>1</sup>, In<sup>2</sup>, and in<sup>3</sup> are CH, X<sup>1</sup> means CR<sup>and</sup>, and X<sup>2</sup> means
CR<sup>b</sup>
A. Preparation of a compound of Formula I in which R<sup>1</sup> is 4-triflouromethylphenyl, Q is a covalent bond, W<sup>1</sup>, In<sup>2</sup>, and in<sup>3</sup> means CH, X<sup>1</sup> is CCF3, and X<sup>2</sup> means CH (only included as a reference)
<img file="PL2464645T3_D0128.tif" />
Step 1. Preparation of 6-bromo-3- (trifluoromethyl) imidazo [1,5-a] pyridine, a compound of Formula (1).
- 91 EP 2464645
<img file="PL2464645T3_D0129.tif" />
In a 50 mL round-bottomed flask, 5-bromo-2-aminomethylpyridine (113.8 mg, 0.608 mmol) was dissolved in CH2Cl2 (2 mL) at rt. Triethylamine (0.5 mL) and trifluoroacetic anhydride (TFAA, 300.0 mg, 1.428 mmol, 2.35 eq.) Were added sequentially. After stirring for 1 h at the same temperature, POCl3 (1 mL) was added to the reaction mixture. The mixture was stirred at rt for 18 h, 160 ° C for 1 h and then 180 ° C for 5 h. The reaction mixture was poured into aqueous sat. NaHCO3 solution (50 mL) under cooling with a water bath. The mixture was extracted with EtOAc (30 mL × 3). Combined organic layers with brine (30 mL x 2) and dried over Na2SO4. The solvent was removed under reduced pressure to give the crude material (brown oil, 141.4 mg). The crude product was purified by silica gel column chromatography (SiO2 = 25 g, EtOAc / hexane = 1: 3, Rf = 0.4) to give the desired product, 6-bromo-3- (trifluoromethyl) imidazo [1,5-a] pyridine , compound of Formula (1).
Preparation of 3-ethyl-5 - ((6- (4-phenoxyphenyl) imidazo [1,2-a] pyridin-2 Stage 2. R<sup>1</sup> Coupling of yl) methyl) -1,2,4-oxadiazole, a compound of Formula I.
<img file="PL2464645T3_D0130.tif" />
Pd (PPh<sub>3</sub>)<sub>4</sub>
N32CO3
DMF / H<sub>2</sub>At 110 ° C, 1 hour
<img file="PL2464645T3_D0131.tif" />
6-bromo-3- (trifluoromethyl) imidazo [1,5-a] pyridine, 4-trifluoromethylphenylboronic acid (127.7 mg, 0.620 mmol, 1.5 equiv) and Pd (PPh3) 4 (24.3 mg, 0.021 mmol, 0.05 equiv. ) was placed in a 50 mL round-bottomed flask under nitrogen. 2M-Na was added to the flask<sub>2</sub>WHAT<sub>3</sub> (1.0 mL, 2.0 mmol, 4.8 equiv) and DMF (4 mL) at ambient temperature. The mixture was heated at 110 ° C for 2 h. The mixture was filtered through Celite (3 g) and Celite was washed with EtOAc (70 mL). The solvent was removed under reduced pressure. The resulting crude mixture was purified by column chromatography (SiO2 = 25 g, EtOAc / hexane = 1: 3, Rf = 0.35). Fractions containing the desired product were concentrated by rotary evaporation to afford impure material. The impure material was dissolved in CH2Cl2 (50 mL) and the solution was washed with aqueous 2N-NaOH (30 mL) to give the desired product as colorless crystals 6- (4- (trifluoromethoxy) phenyl) -3- (trifluoromethyl) imidazo [1,5-a ] pyridine.
TLC: Rf 0.35 (SiO2, EtOAc / hexane = 1: 3),
LCMS (EI: 70 eV) 347 (M<sup>+</sup>), <sup>1</sup>H-NMR (400 MHz, CDCl3): 7.18 (1H, d, J = 9.6 Hz), 7.36 (2H, d, J = 8.0 Hz), 7.58 (1H, s), 7.60 (2H, d, J = 8.0 Hz), 7.67 (1H, d, J = 9.6 Hz), 8.25 (1H, s).
B. Alternative preparation of a compound of Formula I wherein R<sup>1</sup> means Heteroaryl
6-bromo-3- (trifluoromethyl) imidazo [1,5-a] pyridine, prepared as disclosed in Example 1, (46.7 mg, 0.176 mmol), 4-trifluoromethylphenylboronic acid (107.8 mg, 0.264 mmol, 1.5 equivalent) and Pd (PPh<sub>3</sub>)<sub>4</sub> (10.2 mg, 0.0088 mmol, 0.05 equivalent) was placed in a 50 mL round-bottomed flask underneath
With nitrogen. DMF (4 mL) was added to the flask at ambient temperature. The mixture was heated at 110 ° C for 1 h. The mixture was filtered through Celite (3 g) and Celite was washed with EtOAc (70 mL). The filtrate was washed with brine (30 mL) and dried with Na2SO4. The solvent was removed under reduced pressure. The resulting crude mixture was purified by column chromatography (SiO2 = 25 g, EtOAc / hexane = 1: 3, Rf = 0.37). Fractions containing the desired product were concentrated by rotary evaporation to afford material contaminated with an organo-tin residue. The impure material was suspended in hexane (5 mL) and the suspension was filtered to give the desired product, 2- (3- (trifluoromethyl) imidazo [1,5a] pyridin-6-yl) benzo [d] oxazole (only incorporated by reference), as colorless crystal.
C. Preparation of the compound of Formula I by changing R<sup>1</sup>
Similarly, following the procedures of Example 7A or 7B above, but substituting other boronic acids or pinacolate esters for 4-trifluoromethylphenylboronic acid, the following compound of Formula I was prepared (compounds marked with * are only incorporated by reference):
6- (4-phenoxyphenyl) -3- (trifluoromethyl) imidazo [1,5-a] pyridine (*);
2- (3- (trifluoromethyl) imidazo [1,5-a] pyridin-6-yl) benzo [d] thiazole (*), LCMS (EI: 70 eV) 320 (M ++ 1); 2- (3- (trifluoromethyl) imidazo [1,5-a] pyridin-6-yl) benzo [d] oxazole (*),<sup>1</sup>H-NMR (300 MHz, CDCl<sub>3</sub>): 7.36-7.50 (2H, m), 7.58-7.84 (5H, m), 7.58 (1H, s), 9.04 (1H, s); 2- (3- (trifluoromethyl) imidazo [1,5-a] pyridin-6-yl) thiazole (*),
LCMS (EI: 70 eV) 270 (M ++ 1); and
2- (3- (trifluoromethyl) imidazo [1,5-a] pyridin-6-yl) oxazole (*),
LCMS (EI: 70 eV) 254 (M ++ 1).
C. Preparation of compounds of Formula I by changing R<sup>1</sup>, R<sup>2</sup>, and R<sup>3</sup>
Similarly, following the procedure of Reference Example 7A above, but optionally substituting other boronic acids or pinacolate esters for 4-trifluoromethoxyphenylboronic acid and / or substituting other compounds of Formula (1), obtained commercially or made using other precursors of formula (1), other compounds of Formula I may be prepared.
Reference example 8
Preparation of the compound of Formula I where W<sup>1</sup> means CR<sup>2</sup>, R<sup>2</sup> means Methyl, W<sup>2</sup> and W.<sup>3</sup> are CH, and X<sup>1</sup> and X<sup>2</sup> mean N (included only as a reference)
<img file="PL2464645T3_D0132.tif" />
- 93 EP 2464645
A. Preparation of a compound of Formula I in which W<sup>1</sup> means CR<sup>2</sup>, R<sup>2</sup> means Methyl, W<sup>2</sup> and W.<sup>3 </sup>are CH, and X<sup>1</sup> and X<sup>2</sup> mean N
Step 1. Preparation of 2-chloro-3-methyl-5- (4- (trifluoromethoxy) phenyl) pyridine, precursor of formula (1).
<img file="PL2464645T3_D0133.tif" />
To a solution of 1-iodo-4- (trifluoromethoxy) benzene (288 mg, 1.0 mmol) and 6-chloro-5-methylpyridin-3-ylboronic acid (223 mg, 1.3 mmol) in DMF (2 mL) was added K2CO3 (552 mg, 4.0 mmol) and H2O (0.5 mL). The reaction mixture was stirred for 5 min under an atmosphere of dry N2. Pd (PPh3) 4 (10 mg, 0.009 mmol) was added, and the resulting mixture was irradiated at 120 ° C for 10 min. Cooled, diluted with EtOAc (20 mL), filtered through a pad of celite, washed with 10% DMF in EtOAc (50 mL), transferred to a separatory funnel, the organic phase washed with 2N Na2CO3 (20 mL, 4.00 mmol), H2O (20 mL), % aqueous NH4Cl (50 mL) and brine (50 mL), and dried and concentrated. The crude mixture was subjected to preparative HPLC with a MeCN / H2O gradient (5% to 98%) containing 0.1% TFA to give 2-chloro-3-methyl-5- (4- (trifluoromethoxy) phenyl) pyridine,
MS m / z 288.0 (M + H), HPLC purity> 97%.
Step 2. Preparation of 8-methyl-6- (4- (trifluoromethoxy) phenyl) tetrazolo [1,5-a] pyridine, a compound o
Model I.
<img file="PL2464645T3_D0134.tif" />
A mixture of 2-chloro-3-methyl-5- (4- (trifluoromethoxy) phenyl) pyridine prepared as described above (58 mg, 0.20 mmol), sodium azide (21 mg, 0.30 mmol), and pyridine 4-methylbenzenesulfonate (5 mg , 0.02 mmol) in anhydrous DMF (2.0 mL) was sealed in a Biotage microwave tube and irradiated at 160 ° C for 30 min. Cooled, pressure released by opening the cap, additional sodium azide (65 mg, 1.00 mmol) and pyridine 4-methylbenzenesulfonate (52 mg, 0.20 mmol) were added, sealed, and irradiated at 200 ° C for 30 min. After cooling, the mixture was concentrated in vacuo, diluted with DMF (1.0 mL) and MeOH (2.0 mL), filtered, and subjected to preparative HPLC with a MeCN / H2O gradient (5% to 98 containing 0.1% TFA) to give 8-methyl-6- (4- (trifluoromethoxy) phenyl) tetrazolo [1,5-a] pyridine
MS m / z 295.0 (M + H), HPLC purity> 97%.
<sup>1</sup>1 H NMR (400 MHz; acetone-d 6) δ9.27 (d, J = 0.8 Hz, 1H), 7.98 (m, 3H); 7.52 (d, J = 8.2 Hz, 2H); 2.77 (s, 3H).
- 94 EP 2464645
B. Preparation of the compound of Formula I by changing R<sup>1</sup>, In<sup>1</sup>, and in<sup>2</sup>
Similarly, following the procedures of Reference Example 8A above, but substituting other precursors for 1-iodo-4- (trifluoromethoxy) benzene or other boronic acids for 6-chloro-5-methylpyridin-3-ylboronic acid, the following compounds of Formula I (compounds marked with * are included only as a reference):
6- (4-phenoxyphenyl) tetrazolo [1,5-a] pyridine (*);
6- (4- (trifluoromethoxy) phenyl) tetrazolo [1,5-a] pyridine (*);
6- (4- (4-chlorophenoxy) phenyl) tetrazolo [1,5-a] pyridine (*);
6- (4-nitrophenyl) tetrazolo [1,5-a] pyridine (*);
6- (4- (4-fluoro-2-nitrophenoxy) phenyl) tetrazolo [1,5-a] pyridine (*);
N, N-dimethyl-6- (4- (trifluoromethoxy) phenyl) tetrazolo [1,5-a] pyridin-5-amine (*);
6- (4- (4-chlorophenoxy) phenyl) tetrazolo [1,5-b] pyridazine (*);
5-methyl-6- (6-methyl-5- (4- (trifluoromethoxy) phenyl) pyridin-2-yl) tetrazolo [1,5-a] pyridine (*);
6- (4- (4-chlorophenoxy) phenyl) tetrazolo [1,5-a] pyridin-5-amine (*);
6- (2-methoxy-5- (trifluoromethoxy) phenyl) tetrazolo [1,5-a] pyridine (*);
6- [6- (2,2,2-trifluoroethoxy) pyridin-3-yl] tetrazolo [1,5-a] pyridine (*);
5-methyl-6- (4- (trifluoromethoxy) phenyl) tetrazolo [1,5-a] pyridine (*); and
8-methyl-6- (3-methyl-5- (4- (trifluoromethoxy) phenyl) pyridin-2-yl) tetrazolo [1,5-a] pyridine (*).
C. Preparation of compounds of Formula I by changing R<sup>1</sup>, In<sup>1</sup>, and in<sup>2</sup>
Similarly, following the procedure of Reference Example 8A above, but substituting other precursors for 1-iodo-4- (trifluoromethoxy) benzene or other boronic acids for 6-chloro-5-methylpyridin-3-ylboronic acid, other compounds of Formula I can be prepared.
Reference example 9
Preparation of the compound of Formula I where W<sup>1</sup>. IN<sup>2</sup>, and in<sup>3</sup> are CH, X<sup>1</sup> means CR<sup>and</sup>, and X<sup>2</sup> means N
A. Preparation of a compound of Formula I in which R<sup>1</sup> is 4-phenoxyphenyl, Q is a covalent bond, W<sup>1</sup> means N, W<sup>2</sup> and W.<sup>3</sup> are CH, X<sup>1</sup> is isopropyl, and X<sup>2</sup> means N (included only as a reference)
<img file="PL2464645T3_D0135.tif" />
<img file="PL2464645T3_D0136.tif" />
Step 1. Preparation of 6-bromo-3-isopropyl- [1,2,4] triazolo [4,3-a] pyrimidine, a compound of Formula (1).
- EP 2464645
<img file="PL2464645T3_D0137.tif" />
To a rounded bottom flask was added 5-bromo-2-hydrazinopyrimidine (2.65 mmol) in dichloromethane (40 mL). Isobutyraldehyde (2.65 mmol) and 2 drops of acetic acid were added to this solution. The reaction mixture was stirred at rt for 2 h after which iodobenzene diacetate (2.77 mmol) was added. The resulting reaction mixture was stirred at RT for another 2 h. The mixture was evaporated in vacuo and purified by preparative TLC eluting with a mixture of 5% methanol and dichloromethane to give 6-bromo-3-isopropyl- [1,2,4] triazolo [4,3-a] pyrimidine.
MS m / z 330.1 (M<sup>+</sup>).
Step 2. 3-Isopropyl-6- (4-phenoxyphenyl) - [1,2,4] triazolo [4,3-a] pyrimidine.
<img file="PL2464645T3_D0138.tif" />
Preparation of the final product was achieved using the same methods as disclosed in Example 1A, Step 2.
MS m / z 330.1 (M<sup>+</sup>).
B. Preparation of compounds of Formula I by changing R<sup>1</sup> and X<sup>1</sup>
Similarly, following the procedure of Reference Example 9A above, but optionally substituting other boronic acids or pinacolate esters for 4-trifluoromethoxyphenylboronic acid and / or substituting other compounds of Formula (1), obtained commercially or made using other precursors of formula (1) or other anhydrides, other compounds of Formula I can be prepared.
Example 10
Preparation of the compound of Formula I
A. Preparation of a compound of Formula I in which R<sup>1</sup> is 4-trifluoromethoxyphenyl, Q is a covalent bond, W<sup>1</sup>. IN<sup>2</sup> and W.<sup>3</sup> means CH, X<sup>1</sup> is 1,1-difluoro-2-hydroxyethyl, and X<sup>2 </sup>means N
<img file="PL2464645T3_D0139.tif" />
Step 1. Preparation of the difluorohydroxymethyl intermediate.
- EP 2464645
<img file="PL2464645T3_D0140.tif" />
In a sealed flask, hydrazide (3.84g, 20.4 mmol), ethyl 2,2-difluoro-3-hydroxypropanoate (3.15g, 20.4 mmol) and pyridine p-toluenesulfonate (775 mg, 3.06 mmol) were combined and heated to 135 ° C. Note: considerable pressure has been generated from the evolution of EtOH. The reaction was stirred for 6 h and cooled. The resulting solid cake was suspended in EtOAc, homogenized with sonication, and filtered to give the desired 2- (6-bromo- [1,2,4] triazolo [4,3-a] pyridin-3-yl) -2,2- difluoroethanol.
Step 2. Adding the R group<sup>1</sup> .
<img file="PL2464645T3_D0141.tif" />
Formation of the final product was obtained using the same methods as disclosed in Example 1A, Step 2, to obtain the final product, 2,2-difluoro-2- (6- (4- (trifluoromethoxy) phenyl) - [1,2,4] triazolo [4,3-a] pyridin-3-yl) ethanol.
MS m / z 375.2 (M + 1).
B. Optional secondary modification of the alcohol moiety R<sup>and</sup>
<img file="PL2464645T3_D0142.tif" />
DMF (1 mL) was added to a mixture of alcohol (55 mg, 0.153 mmol), NaH (24 mg, 0.60 mmol, 60% dispersion in mineral oil), and 3- (bromomethyl) pyridine hydrobromide (58 mg, 0.23 mmol). The reaction was stirred at rt for several hours and concentrated. The residue was purified by RP-HPLC to give the product, 3- (1,1-difluoro-2- (pyridin-3-ylmethoxy) ethyl) -6- (4- (trifluoromethoxy) phenyl) [1,2,4] triazolo [ 4,3-a] pyridine as a white powder.
451.1 (M + 1).
C. Optional secondary modification of the alcohol moiety R<sup>and</sup>
Level 1
- 97 EP 2464645
<img file="PL2464645T3_D0143.tif" />
To a solution of alcohol (400mg, 1.24 mmol) in CH2Cl2 (60 mL) was added Dess Martin periodate (610 mg, 1.42 mmol), and the reaction was stirred for 1 h. N a2S2O3 (430 mg, 2.8 mmol) in NaHCO3 (water) was added. ) and stirred 1 h. The layers were separated and the aqueous layer was washed with CH 2 Cl 2 (2 x 25 mL). The combined organic layers were dried over MgSO4, filtered and concentrated to give the product 6- (4- (trifluoromethoxy) phenyl) - [1,2,4] triazolo [4,3-a] pyridine-3-carbaldehyde as a white solid .
Stage 2
<img file="PL2464645T3_D0144.tif" />
To a solution of aldehyde (65 mg, 0.21 mmol) in THF (1 mL) at 0 ° C was added methylmagnesium bromide (75 μL, 0.25 mmol, 3.0 M solution in THF). The reaction was stirred for 10 minutes, warmed to rt, and quenched by the addition of water. The mixture was diluted with EtOAc, the layers separated, the organic concentrated and the residue purified by column chromatography (Rf = 0.55, EtOAc / 10% MeOH) to give the product, 1- (6- (4- (trifluoromethoxy) phenyl) - [1,2,4 ] triazolo [4,3-a] pyridin-3-yl) ethanol as a white solid.
324.1 (M + 1).
Alternate Stage 2
<img file="PL2464645T3_D0145.tif" />
TMS-CF was added to the aldehyde solution (62 mg, 0.20 mmol)<sub>3</sub> (57 μL, 0.36mmol) and the reaction stirred for 1 h. 1N HCl (2mL) was added, stirred 1 h and the reaction was diluted with Et<sub>2</sub>About and water. The layers were separated, the organic concentrated, and the residue purified by RP-HPLC to give the product, 2,2,2-trifluoro-1- (6- (4- (trifluoromethoxy) phenyl) - [1,2,4] triazolo [4,3- a] pyridin-3-yl) ethanol as a white powder.
378.1 (M + 1).
Alternate Stage 2
<img file="PL2464645T3_D0146.tif" />
- EP 2464645
To a mixture of aldehyde (70 mg, 0.23 mmol), pyrrolidine (38 μL, 0.46 mmol), and MeOH (1 mL) was added sodium triacetoxyborohydride (72 mg, 0.34 mmol) and the reaction was stirred overnight. The mixture was concentrated, and the residue was purified by RP-HPLC to give the product, 3- (pyrrolidin-1-ylmethyl) 6- (4- (trifluoromethoxy) phenyl) - [1,2,4] triazolo [4,3-a] pyridine (incorporated by reference) as a white powder.
363.1 (M + 1).
D. Optional secondary modification of the alcohol moiety R<sup>and</sup>
Level 1
<img file="PL2464645T3_D0147.tif" />
(6- (4- (trifluoromethoxy) phenyl) - [1,2,4] triazolo [4,3-a] pyridin-3-yl) methanol (50.0 mg, 0.162 mmol) dissolved in DMF (3 mL) in 50 mL flask with a rounded bottom. The solution was treated with NaH (60% in mineral oil, 9.7 mg, 0.243 mmol, 1.5 eq) at rt for 20 min. and 4-fluorobenzyl bromide (61.2 mg, 0.324 mmol, 2.0 equiv) was added to the reaction mixture. The mixture was stirred for 1 h at the same temperature. H2O (30 mL) was added to the reaction mixture and it was extracted with EtOAc (30 mL × 3). The combined organic layers were washed with brine (30 mL) and dried with Na2SO4. The solvent was removed under reduced pressure. The resulting crude mixture was purified by column chromatography (SiO2 = 25 g, EtOAc / hexane = 1: 1 to EtOAc to 5% MeOH / EtOAc, Rf = 0.2 with EtOAc) to give the desired product as a colorless oil.
LCMS (EI: 70 eV) 418 (M ++ 1)
E. Optional secondary modification of the alcohol moiety R<sup>and</sup> to obtain the amino group R<sup>and</sup>
Level 1
<img file="PL2464645T3_D0148.tif" />
For alcohol solution (240 mg, 0.68 mmol) and Et<sub>3</sub>N (120 μL, 0.88 mmol) in CH<sub>2</sub>cl<sub>2</sub> (7 mL) Tf was added<sub>2</sub>O (140 μL, 0.81 mmol), and the reaction was stirred at rt for 30 minutes. The mixture was concentrated, the residue was dissolved in DMF (2 mL), and NaN3 (176 mg, 2.7 mmol) was added. The reaction was stirred for 1 h, concentrated, and the residue purified by column chromatography (Rf = 0.43, 1: 1 Hexanes / EtOAc) to give the product, 3- (2-azido-1,1-difluoroethyl) -6- (4- ( trifluoromethoxy) phenyl) - [1,2,4] triazolo [4,3-a] pyridine as a brown solid.
Stage 2
- EP 2464645
<img file="PL2464645T3_D0149.tif" />
To the material isolated above (172 mg, 0.45 mmol), 10% Pd / C (22 mg, 50 mg / mmol) was added, the flask was filled with N2 and EtOAc (5 mL) was added. The reaction was washed with H2 and stirred for 4 h. The mixture was filtered through celite and the filtrate was concentrated under reduced pressure to give the amine, 2,2-difluoro-2- (6- (4- (trifluoromethoxy) phenyl) - [1,2,4] triazolo [4,3-a] pyridin-3-yl) ethanamine as a brown solid.
359.2 (M + 1).
Optional Step 3 - Modification of the amino R group<sup>and</sup>
<img file="PL2464645T3_D0150.tif" />
To a solution of amine (34 mg, 0.095 mmol) in CH<sub>2</sub>cl<sub>2</sub> Et<sub>3</sub>N (40 μL, 0.28 mmol) and MsCl (18 μL, 0.23 mmol), and the reaction was stirred 30 minutes. The mixture was concentrated, and the residue was purified by RPHPLC to give the product as a white powder.
437.0 (M + 1).
Optional Step 3 - Modification of the amino R group<sup>and</sup>
<img file="PL2464645T3_D0151.tif" />
To a mixture of amine (49 mg, 0.14 mmol), picolinic acid (19 mg, 0.15 mmol), HATU (63 mg, 0.16 mmol), and NMM (18 μL, 0.16 mmol) was added DMF (1 mL) and the reaction was stirred for 1hr . The mixture was concentrated, CH3CN and H2O were added and the solids were collected by filtration to give the amide, N- (2,2-difluoro-2- {6- [4- (trifluoromethoxy) phenyl] [1,2,4] triazolo [4, 3-a] pyridin-3-yl} ethyl) pyridine-2-carboxamide as a white solid. Alternatively, the product can be purified by RP-HPLC.
464.3 (M + 1).
Optional Step 3 - Modification of the amino R group<sup>and</sup> to obtain a urea bond
<img file="PL2464645T3_D0152.tif" />
- 100 EP 2464645
To a solution of the amine (46 mg, 0.15 mmol) in CH<sub>2</sub>cl<sub>2</sub> (1 mL) phenyl isocyanate (18 μL, 0.16 mmol) was added and a precipitate formed immediately. The solids were collected by filtration to obtain urea, 1- (2,2-difluoro-2- {6- [4- (trifluoromethoxy) phenyl] [1,2,4] triazolo [4,3-a] pyridin-3-yl} ethyl) -3-phenylurea as a white solid. Alternatively, the product can be purified by RP-HPLC.
478.0 (M + 1).
F. Preparation of compounds of Formula I by changing R<sup>1</sup> and X<sup>1</sup>
Similarly, according to the procedures of Example 10A-10E above, but using other precursors or secondary reagents, the following other compounds of Formula I were prepared (compounds marked with * are only incorporated by reference):
2- (6- (6-cyclopropylpyridin-3-yl) - [1,2,4] triazolo [4,3-a] pyridin-3-yl) -2,2-difluoroethanol,
317.0 (M + 1);
3- benzyl-6- (4- (trifluoromethoxy) phenyl) - [1,2,4] triazolo [4,3-a] pyridine, 370.2 (M + 1), (*) <sup>1</sup>H NMR (DMSO) δ 8.73 (s, 1H), 7.83-7.87 (m, 3H), 7.71 (dd, J = 1.2, 9.6 Hz, 1H), 7.52 (d, J = 8.0 Hz,
2H), 7.28-7.36 (m, 4H), 7.21-7.25 (m, 1H), 4.64 (s, 2H);
(6- (4- (trifluoromethoxy) phenyl) - [1,2,4] triazolo [4,3-a] pyridin-3-yl) methanol;
3 - [(1-phenylethoxy) methyl] -6- [4- (trifluoromethoxy) phenyl] [1,2,4] triazolo [4,3-a] pyridine <sup>1</sup>H-NMR (acetone) δ 8.54 (s, 1H), 7.71-7.85 (m, 4H), 7.52 (d, 2H), 7.27-7.41 (m, 5H), 5.03 (s, 2H), 4.67 (q,
1H), 2.80 (d, 3H);
MS m / z 414.1 (M + H)
3 - {[difluoro (pyridin-3-yl) methoxy] methyl} -6- [4- (trifluoromethoxy) phenyl] [1,2,4] triazolo [4,3-a] pyridine,
MS m / z 437.0 (M + H)
Ethyl 2- (2,2-difluoro-2- (6- (4- (trifluoromethoxy) phenyl) - [1,2,4] triazolo [4,3-a] pyridin-3-yl) ethoxy) ethyl acetate;
2- (2,2-difluoro-2- {6- [4- (trifluoromethoxy) phenyl] [1,2,4] triazolo [4,3-a] pyridin-3-yl} ethoxy) -N, N-dimethylethanamine,
431.2 (M + 1).
N- (2,2-difluoro-2- {6- [4- (trifluoromethoxy) phenyl] [1,2,4] triazolo [4,3-a] pyridin-3-yl} ethyl) benzamide
463.0 (M + 1).
3- [1- (pyridin-2-ylmethoxy) ethyl] -6- [4- (trifluoromethoxy) phenyl] [1,2,4] triazolo [4,3-a] pyridine,
415.0 (M + 1).
3- (difluoro (pyridin-2-ylmethoxy) methyl) -6- (4- (trifluoromethoxy) phenyl) - [1,2,4] triazolo [4,3-a] pyridine, LCMS (EI: 70 eV) 451 (M ++ 1).
Ethyl 2- (difluoro (6- (4- (trifluoromethoxy) phenyl) - [1,2,4] triazolo [4,3-a] pyridin-3-yl) methoxy) ethyl acetate,
LCMS (EI: 70 eV) 446 (M ++ 1).
2- (difluoro (6- (4- (trifluoromethoxy) phenyl) - [1,2,4] triazolo [4,3-a] pyridin-3-yl) methoxy) acetonitrile
LCMS (EI: 70 eV) 399 (M ++ 1).
6- (4- (trifluoromethoxy) phenyl) -3 - ((4- (trifluoromethyl) benzyloxy) methyl) - [1,2,4] triazolo [4,3-a] pyridine,
101 EP 2464645
LCMS (EI: 70 eV) 468 (M ++ 1).
3 - ((pyridin-2-ylmethoxy) methyl) -6- (4- (trifluoromethoxy) phenyl) - [1,2,4] triazolo [4,3-a] pyridine, LCMS (EI: 70 eV) 401 ( M ++ 1).
3- [1- (pyridin-2-ylmethoxy) ethyl] -6- [4- (trifluoromethoxy) phenyl] [1,2,4] triazolo [4,3-a] pyridine, 415.0 (M + 1).
3 - ({[4- (trifluoromethoxy) benzyl] oxy} methyl) -6- [4- (trifluoromethoxy) phenyl] [1,2,4] triazolo [4,3-a] pyridine,
484 (M<sup>+</sup>+1).
3 - {[(4-chlorobenzyl) oxy] methyl} -6- [4- (trifluoromethoxy) phenyl] [1,2,4] triazolo [4,3-a] pyridine, 434 (M + 1).
D. Preparation of compounds of Formula I by changing R<sup>1</sup> and X<sup>1</sup>
Similarly, according to the procedures of Example 10A-10D above, but using other precursors or secondary reagents, other compounds of Formula I can be prepared:
Example 11
Preparation of the compound of Formula I
<img file="PL2464645T3_D0153.tif" />
A. Preparation of a compound of Formula I
<img file="PL2464645T3_D0154.tif" />
To a solution of the ester prepared as disclosed in Example 10 (50 mg, 0.11 mmol) in THF (1 mL) at 0 ° C was added methylmagnesium bromide (94 μL, 0.28 mmol, 3.0 M solution in THF). The reaction was stirred for 10 minutes, warmed to rt, and quenched by the addition of water. The mixture was diluted with EtOAc, the layers separated, the organic concentrated and the residue purified by RP-HPLC to give the product, V, as a white powder.
MS m / z 432.1.1 (M + 1).
B. Preparation of other compounds of Formula I
Similarly, following the procedures of Example 11A above, but substituting other ester compounds, other compounds of Formula I can be prepared.
- 102 EP 2464645
Example 12
Preparation of the compound of Formula I where W<sup>3</sup> means CR<sup>4</sup>
A. Preparation of a compound of Formula I in which R<sup>4</sup> means hydroxymethyl
<img file="PL2464645T3_D0155.tif" />
To a solution of a commercially available ester (2.1g, 10 mmol) in MeOH (50 mL) at 0 ° C was added NaBH4 (570 mg, 0.15 mmol) in portions over 30 minutes. The reaction was stirred for another 30 minutes and quenched by the addition of water. The reaction was diluted with EtOAc (100 mL), and the organic was washed with NaHCO3 and brine. The organic layer was dried over MgSO4, filtered and concentrated to give the alcohol as a yellow oil.
Stage 2.- Protection of the Hydroxy group
<img file="PL2464645T3_D0156.tif" />
NaH (522 mg, 13 mmol, 60% dispersion in mineral oil) was added to a mixture of the alcohol produced in Step 1 (775 mg, 434 mmol) and benzyl bromide (570 μL, 4.8 mmol) in DMF (8 mL). The reaction was stirred for 2h and diluted with EtOAc (50 mL), washed with brine (2x), organic dried over MgSO 4, filtered and concentrated. The residue was purified by column chromatography (Rf = 0.5, 5: 1 Hexanes / EtOAc) to give the product.
Stage 3. - Hydrazine chain addition
<img file="PL2464645T3_D0157.tif" />
The sealed flask was charged with 2- (benzyloxymethyl) -3,6-dichloropyridine prepared in Step 2 (950 mg, 3.5 mmol), hydrazine hydrate (1 mL) was added, and the reaction was heated to 120 ° C overnight. After
Cooling, the solids were collected by filtration to obtain 2- (benzyloxymethyl) -3-chloro-6-hydrazinylpyridine.
Stage 4. - Core cyclization, Obn
TFAA <sup>cl</sup>7i <sup>N</sup> zNH2 <sup>Shoe</sup>s<sup>ronitr</sup>s<sup>l</sup>
N 135 ° C
<img file="PL2464645T3_D0158.tif" />
Formation of the chlorinated core was achieved using the same methods as disclosed in Example 1A, Step 1.
Stage 5. - Deprotection of the Hydroxy group
<img file="PL2464645T3_D0159.tif" />
To a solution of 5- (benzyloxymethyl) -6-chloro-3- (trifluoromethyl) - [1,2,4] triazolo [4,3-a] pyridine, prepared as described in Step 4 (700 mg, 2.1 mmol), was added acid methanesulfonic (2 mL, 70% in water) and the reaction was heated to reflux overnight. The reaction was concentrated and the residue purified by flash chromatography to give (6-chloro-3- (trifluoromethyl) - [1,2,4] triazolo [4,3-a] pyridin-5-yl) methanol.
Step 6 - Addition of the R group<sup>1</sup>
<img file="PL2464645T3_D0160.tif" />
Formation of the final product was obtained at Example 1A, Step 2.
using the same methods as described in
MS m / z 378.1 (M + 1)
Optional Step 7 - Modification of the hydroxy R group<sup>4</sup>
<img file="PL2464645T3_D0161.tif" />
Formation of the final product, 5- (methoxymethyl) -6- [4- (trifluoromethoxy) phenyl] -3 (trifluoromethyl) [1,2,4] triazolo [4,3-a] pyridine, was obtained according to the methods disclosed in Example
10B.
- 104 EP 2464645
MS m / z 392.2 (M + 1).
B. Preparation of the compound of Formula I by changing R<sup>4</sup>
Similarly, according to the procedures of Example 12A above, but using other precursors or secondary reagents, the following compound of Formula I was prepared: ({6- [4- (trifluoromethoxy) phenyl] -3- (trifluoromethyl) [1,2,4 ] triazolo [4,3-a] pyridin-5-yl} methoxy) acetonitrile
MS m / z 416.3 (M + 1)
C. Preparation of compounds of Formula I by changing R<sup>1</sup>, R<sup>4</sup>, and X<sup>1</sup>
Similarly, following the procedure of Example 12A above, but using other precursors or secondary reagents, other compounds of Formula I may be prepared.
Example 13
Preparation of a compound of Formula I where R<sup>1</sup> means 2- (morpholinomethyl) -3- (trifluoromethoxy) phenyl, W<sup>1</sup>, In<sup>2</sup> and W.<sup>3</sup> are CH, and X<sup>1</sup> is CHCF3, and X<sup>2</sup> means N
<img file="PL2464645T3_D0162.tif" />
A. Preparation of a compound of Formula I in which R<sup>1</sup> means 2- (morpholinomethyl) -3 (trifluoromethoxy) phenyl, W<sup>1</sup>, In<sup>2</sup> and W.<sup>3</sup> are CH, and X<sup>1</sup> mean CIICIA and X<sup>2</sup> means N
<img file="PL2464645T3_D0163.tif" />
3-bromomethyl-4-trifluoromethoxyphenylboronic acid pinacol ester (0.420 mmol) in DMF (3 mL) was added to the round-bottomed flask. To this solution, potassium carbonate (0.840 mmol) and morpholine (0.84 mmol) were added. The suspension was stirred at rt for 4 h, and the reaction mixture
- EP 2464645 was transferred to a microwave tube. To this mixture, tetrakis (triphenylphosphine) palladium (0.021 mmol) and 1 mL water and 6-bromo-3- (trifluoromethyl) - [1,2,4] triazolo [4,3-b] pyridine (0.462 mmol) was added. The resulting reaction mixture was heated in the microwave at 130 C for 10min. The reaction mixture was diluted with ethyl acetate and filtered through celite. The filtrate was washed with water. The organic extract was dried over Na2SO4 and evaporated in vacuo. The crude residue was purified by preparative HPLC to give 4- (2- (trifluoromethoxy) -5- (3- (trifluoromethyl) - [1,2,4] triazolo [4,3-a] pyridin-6-yl) benzyl) morpholine.
MS m / z 447.1 (M<sup>+</sup>).
B. Preparation of the compound of Formula I by changing R<sup>1</sup>, In<sup>1</sup>, and in<sup>2</sup>
Similarly, according to the procedures of Example 13A above, but substituting other precursors for 6-bromo-3- (trifluoromethyl) - [1,2,4] triazolo [4,3-b] pyridine or other boronic acids for the pinacol ester of acid 3 -bromomethyl-4-trifluoromethoxyphenylboronic acid compound, the following compound of Formula I was prepared: 6- {3 - [(4-methylpiperazin-1-yl) methyl] -4- (trifluoromethoxy) phenyl} -3 (trifluoromethyl) [1,2,4 ] triazolo [4,3-a] pyridine,
MS m / z 460.1 (M<sup>+</sup>); and
2 - ({2- (trifluoromethoxy) -5- [3- (trifluoromethyl) [1,2,4] triazolo [4,3-a] pyridin-6-yl] benzyl} amino) ethanol, MS m / z 421.1 (M<sup>+</sup>).
C. Preparation of compounds of Formula I by changing R<sup>1</sup>
Similarly, following the procedure of Example 13A above, but substituting other precursors for 6-bromo-3- (trifluoromethyl) - [1,2,4] triazolo [4,3-b] pyridine or other boronic acids for 3-bromomethyl acid pinacol ester -4-trifluoromethoxyphenylboronic acid, other compounds of Formula I can be prepared.
Example 14
Preparation of a compound of Formula I where R<sup>2</sup> means amino
A. Preparation of a compound of Formula I in which R<sup>1</sup> means 4-triflouromethylphenyl, W<sup>1</sup>, In<sup>2</sup> and W.<sup>3 </sup>are CH, R<sup>2</sup> is NH ?, and X<sup>1</sup> means CHR<sup>and</sup>, R<sup>and</sup> is isopropyl, and X<sup>2</sup> means N
Stage 1 - Reduction of the Nitro group to form Amine
<img file="PL2464645T3_D0164.tif" />
<img file="PL2464645T3_D0165.tif" />
Compound B was prepared by heating A, 6-bromo-3-isopropyl-8-nitro- [1,2,4] triazolo [4,3a] pyridine, prepared as described in Example 9A, Step 1, (0.777 mmol) in acid vinegar (6 mL)
- 2464645 in the presence of powdered zinc (3.89 mmol) at 60 C for 1 h. The reaction mixture was diluted with methanol and filtered through celite. The filtrate was concentrated and the residue was filtered through silica gel first with ethyl acetate and then with a 1: 4 mixture of methanol and dichloromethane. The filtrate was evaporated in vacuo to afford B, 6-bromo-3-isopropyl- [1,2,4] triazolo [4,3-a] pyridin-8-amine.
Stage 2. Addition of the R grouping<sup>1</sup>.
<img file="PL2464645T3_D0166.tif" />
Formation of the final product was achieved using the same methods as disclosed in Example 1A, Step 2, to give the final product, 3-isopropyl-6- (4- (trifluoromethoxy) phenyl) [1,2,4] triazolo [4,3- a] pyridin-8-amine.
MS m / z 337.1 (M<sup>+</sup>).
B. Optional secondary modification of the amino R group<sup>2</sup>
<img file="PL2464645T3_D0167.tif" />
To a thick-walled pressure tube, 3-isopropyl-6- (4- (trifluoromethoxy) phenyl) [1,2,4] triazolo [4,3-a] pyridin-8-amine was added at 9A in toluene. Acetic anhydride (0.1 mL) and triethylamine (0.1 mL) were added to this suspension. The mixture was heated in a 110 C oil bath for 12 h. The reaction mixture was evaporated in vacuo and purified by preparative HPLC to give N- (3isopropyl-6- (4- (trifluoromethoxy) phenyl) - [1,2,4] triazolo [4, 3-a] pyridin-8-yl) acetamide.
MS m / z 379.1 (M<sup>+</sup>).
C. Preparation of compounds of Formula I by changing R<sup>1</sup>, R<sup>2</sup>, X<sup>1</sup>, and X<sup>2</sup>
Similarly, following the procedure of Example 14A and B above, but substituting other nitro precursors for 6-bromo-3-isopropyl-8-nitro- [1,2,4] triazolo [4,3-a] pyridine, other boronic acids for 4- (trifluoromethoxy) phenylboronic acid, or other anhydrides for acetic anhydride, the following compounds of Formula I were prepared
N- {3-methyl-6- [4- (trifluoromethoxy) phenyl] [1,2,4] triazolo [4,3-a] pyridin-8-yl} propanamide,
MS m / z 365 (M<sup>+</sup>);
3-methyl-6- [2-methyl-4- (trifluoromethoxy) phenyl] [1,2,4] triazolo [4,3-a] pyridin-8-amine,
MS m / z 323 (M<sup>+</sup>);
3-methyl-6- [4- (trifluoromethoxy) phenyl] [1,2,4] triazolo [4,3-a] pyridin-8-amine,
- EP 2464645
MS m / z 309 (M<sup>+</sup>);
3-phenyl-6- [4- (trifluoromethoxy) phenyl] [1,2,4] triazolo [4,3-a] pyridin-8-amine.
MS m / z 371.1 (M<sup>+</sup>); and
N- {3-methyl-6- [2-methyl-4- (trifluoromethoxy) phenyl] [1,2,4] triazolo [4,3-a] pyridin-8-yl} acetamide, MS m / z 365 ( M<sup>+</sup>).
D. Preparation of the compound of Formula I by changing R.<sup>1</sup>, R<sup>2</sup>, X<sup>1</sup>, and X<sup>2</sup>
Similarly, following the procedure of Example 14A and B above, but substituting other nitro precursors for 6-bromo-3-isopropyl-8-nitro- [1,2,4] triazolo [4,3-a] pyridine, other boronic acids for acid
4- (trifluoromethoxy) phenylboronic acid, or other anhydrides for acetic anhydride, other compounds of Formula I can be prepared.
Example 15
Preparation of a compound of Formula I where R<sup>1</sup> means 3- (1,3,4-oxadiazol-2-yl) -4 (trifluoromethoxy) phenyl, W<sup>1</sup>, In<sup>2</sup> and W.<sup>3</sup> are CH, and X<sup>1</sup> is CHCF3, and X<sup>2</sup> means N
<img file="PL2464645T3_D0168.tif" />
A. Preparation of a compound of Formula I in which R<sup>1</sup> means (trifluoromethoxy) phenyl, W<sup>1</sup>, In<sup>2</sup> and W.<sup>3</sup> are CH, and X<sup>1</sup> means CHCF
3- (1,3,4-oxadiazol-2-yl) -4<sub>3</sub>, and X<sup>2</sup> means N
<img file="PL2464645T3_D0169.tif" />
Ethyl-5-bromo-2- (trifluoromethoxy) benzoate (0.638 mmol) in ethanol (10 mL) was added to the round-bottomed flask. To this solution, 1 mL of hydrazine monohydrate was added and the resulting mixture was refluxed overnight. The reaction mixture was evaporated in vacuo to afford A. To A was added trimethyl orthoformate in a thick-walled pressure tube. The resulting mixture was heated to 100
C for 18 h. The reaction mixture was concentrated and purified by preparative TLC to give B, which was coupled with 3- (trifluoromethyl) - [1,2,4] triazolo [4,3-a] pyridin-6-ylboronic acid using methods disclosed above to obtain 2- (2- (trifluoromethoxy) -5- (3- (trifluoromethyl) [1,2,4] triazolo [4,3-a] pyridin-6-yl) phenyl) -1,3,4 oxadiazole.
- EP 2464645
MS m / z 416.1 (M<sup>+</sup>).
B. Preparation of the compound of Formula I by changing R<sup>1</sup>, In<sup>1</sup>, and in<sup>2</sup>
Similarly, following the procedures in Example 15A above, but substituting other precursors for ethyl-5-bromo-2- (trifluoromethoxy) benzoate or other boronic acids for 3- (trifluoromethyl) [1,2,4] triazolo [4,3] -a] pyridin-6-ylboronic acid, other compounds of Formula I can be prepared.
Example 16
Preparation of a compound of Formula I where R<sup>1</sup>is 3- (methylcarbamoyl) -4- (trifluoromethoxy) phenyl,
IN<sup>1</sup>, In<sup>2</sup> and W.<sup>3</sup> are CH, and X<sup>1</sup> is CHCF3, and X<sup>2</sup> means N
<img file="PL2464645T3_D0170.tif" />
A. Preparation of a compound of Formula I in which R<sup>1</sup> is 3- (methylcarbamoyl) -4 (trifluoromethoxy) phenyl, W<sup>1</sup>, In<sup>2</sup> and W.<sup>3</sup> is CH, and X<sup>1</sup> is CHCF3, and X<sup>2</sup> means N
<img file="PL2464645T3_D0171.tif" />
To the thick-walled ethyl-5-bromo-2-pressure tube was charged (trifluoromethoxy) benzoate (0.3 mL) and methylamine (1.5 mL). The mixture was heated at 60 C for 2 h.
The reaction mixture was concentrated to give A, which was coupled with 3- (trifluoromethyl) [1,2,4] triazolo [4,3-a] pyridin-6-ylboronic acid using the methods disclosed above to give N-methyl-2- (trifluoromethoxy) -5- [3- (trifluoromethyl) [1,2,4] triazolo [4,3-a] pyridin-6-yl] benzamide.
MS m / z 405.1 (M<sup>+</sup>).
B. Preparation of the compound of Formula I by changing R<sup>1</sup>, In<sup>1</sup>, and in<sup>2</sup>
Similarly, following the procedures in Example 16A above, but substituting other precursors for ethyl-5-bromo-2- (trifluoromethoxy) benzoate or other boronic acids for 3- (trifluoromethyl) [1,2,4] triazolo [4,3] -a] pyridin-6-ylboronic acid, other compounds of Formula I can be prepared.
- EP 2464645
Example 17
Preparation of a compound of Formula I where R<sup>1</sup> is substituted with oxadiazol-5-yl
<img file="PL2464645T3_D0172.tif" />
A. Preparation of a compound of Formula I in which R<sup>1</sup> means 3- (3-methyl-1,2,4-oxadiazol-5-yl) -4 (trifluoromethoxy) phenyl, W<sup>1</sup>, In<sup>2</sup> and W.<sup>3</sup> is CH, and X<sup>1</sup> is CHCF3, and X<sup>2</sup> means N
Step 1 - Formation of the acid precursor
<img file="PL2464645T3_D0173.tif" />
Ethyl-5-bromo-2- (trifluoromethoxy) benzoate (1.59 mmol) and sodium hydroxide (3.99 mmol) in ethanol (12 mL) were added to the round-bottomed flask. The reaction mixture was refluxed for 18 h. The mixture was concentrated and diluted with water and washed with dichloromethane. The aqueous layer was treated with 1 N
HCl to pH 4. The precipitate was filtered and air dried overnight to give A.
Stage 2 - Addition of the ring chain
<img file="PL2464645T3_D0174.tif" />
A (0.484) and 1,1-carbonyldiimidazole (CDI) (0.964 mmol) in DMF (3mL) were added to the round-bottomed flask. The mixture was stirred at rt for 30 min and hydroxyacetoimidamide was added. The resulting mixture was stirred at rt for another 18 h. The reaction mixture was concentrated and purified by preparative TLC to give B.
Step 3 - Cyclizing the Oxadiazole ring and coupling to the compound core
<img file="PL2464645T3_D0175.tif" />
To the round bottom flask was added B (0.322 mmol), and tetrabutylammonium fluoride hydrate (0.645 mmol) in THF (3 mL). The reaction mixture was stirred at rt overnight. The reaction mixture was concentrated and purified by preparative TLC to afford C, which was coupled with the desired acid
- boronic to obtain 6- [3- (3-methyl-1,2,4-oxadiazol-5-yl) -4- (trifluoromethoxy) phenyl] -3 (trifluoromethyl) [1,2,4] triazolo [4,3-a] pyridine.
MS m / z 430.1 (M<sup>+</sup>).
B. Preparation of the compound of Formula I by changing R<sup>1</sup>, In<sup>1</sup>, and in<sup>2</sup>
Similarly, according to the procedures of Example 17A above, but substituting other precursors for ethyl-5-bromo-2- (trifluoromethoxy) benzoate or 1,1-carbonyl diimidazole or other boronic acids for 3- (trifluoromethyl) - [1,2, 4] triazolo [4,3-a] pyridin-6-ylboronic acid, other compounds of Formula I can be prepared.
Example 18
Preparation of a compound of Formula I where R<sup>1</sup> means 4- (trifluoromethoxy) phenyl, W<sup>1</sup>, In<sup>2</sup> and W.<sup>3</sup> are CH, and X<sup>1</sup> is CH-R<sup>and</sup>, R<sup>and</sup> is 2-fluorobenzyloxy) methyl and X<sup>2</sup> means N
<img file="PL2464645T3_D0176.tif" />
A. Preparation of a compound of Formula I
<img file="PL2464645T3_D0177.tif" />
A, (6- (4- (trifluoromethoxy) phenyl) - [1,2,4] triazolo [4,3a] pyridin-3-yl) methanol, prepared as disclosed in Example 10 (0.162 mmol) was added to the round-bottomed flask. ) and 2-fluorobenzyl bromide (0.324 mmol) in DMF and sodium hydride. The reaction mixture was stirred at rt for 1 h. The mixture was treated with 1N HCl. The precipitate, 3 - {[(2-fluorobenzyl) oxy] methyl} -6- [4- (trifluoromethoxy) phenyl] [1,2,4] triazolo [4,3-a] pyridine, filtered and purified by prep HPLC. MS m / z 418.1 (M<sup>+</sup>).
<sup>1</sup>H-NMR (DMSO) 8.694 (s, 1H), 7.764-7.913 (m, 4H), 7.526-7.554 (d, 2H), 7.200-7.411 (m, 2H), 7.1237.173 (m, 2H), 5.169 (s, 2H), 4.665 (s, 2H).
B. Preparation of the compound of Formula I by changing R<sup>and</sup>
Similarly, following the procedures of Example 18A above, but substituting other precursors for 2-fluorobenzyl bromide, the following compounds of Formula I were prepared:
3- (1,1-difluoro-2- (oxirane-2-ylmethoxy) ethyl) -6- (4- (trifluoromethoxy) phenyl) - [1,2,4] triazolo [4,3-a] pyridine;
- EP 2464645
6- [4- (trifluoromethoxy) phenyl] -3 - ({[2- (trifluoromethyl) benzyl] oxy} methyl) [1,2,4] triazolo [4,3-a] pyridine,
MS m / z 468.1 (M<sup>+</sup>), <sup>1</sup>H-NMR (DMSO) 8.771 (s, 1H), 7.513-7.930 (m, 10H), 5.225 (s, 2H), 4.782 (s, 2H);
3 - {[(2,4-difluorobenzyl) oxy] methyl} -6- [4- (trifluoromethoxy) phenyl] [1,2,4] triazolo [4,3-a] pyridine,
MS m / z 436.1 (M<sup>+</sup>), <sup>1</sup>H-NMR (DMSO) 8.681 (s, 1H), 7.763-7.911 (m, 4H), 7.451-7.555 (m, 3H), 7.200-7.311 (t, 1H), 7.0007.173 (t, 1H), 5.158 (s, 2H), 4.630 (s, 2H);
3 - {[(2-fluorobenzyl) oxy] methyl} -6- [4- (trifluoromethoxy) phenyl] [1,2,4] triazolo [4,3-a] pyridine,
MS m / z 469.1 (M<sup>+</sup>), <sup>1</sup>H-NMR (DMSO) 8.741 (s, 1H), 7.803-7.889 (m, 4H), 7.402-7.549 (m, 5H), 5.212 (s, 2H), 4.668 (s, 2H); 3 - {[(2,4-dimethylbenzyl) oxy] methyl} -6- [4- (trifluoromethoxy) phenyl] [1,2,4] triazolo [4,3-a] pyridine,
MS m / z 428.1 (M<sup>+</sup>), <sup>1</sup>H-NMR (DMSO) 8.657 (s, 1H), 7.827-7.883 (m, 4H), 7.519-7.546 (d, 2H), 7.119-7.911 (d, 1H), 6.8567.000 (m, 1H), 5.113 (s, 2H), 4.546 (s, 2H), 2.162-2.208 (m, 6H);
3 - {[(5-methylpyridin-2-yl) methoxy] methyl} -6- [4- (trifluoromethoxy) phenyl] [1,2,4] triazolo [4,3-a] pyridine, MS m / z 415.1 (M<sup>+</sup>);
3 - [(benzyloxy) methyl] -6- [4- (trifluoromethoxy) phenyl] [1,2,4] triazolo [4,3-a] pyridine,
400.1 (M + 1);
3 - [(cyclopropylmethoxy) methyl] -6- [4- (trifluoromethoxy) phenyl] [1,2,4] triazolo [4,3-a] pyridine,
364.1 (M + 1); and
3 - [(2,2,2-trifluoroethoxy) methyl] -6- [4- (trifluoromethoxy) phenyl] [1,2,4] triazolo [4,3-a] pyridine,
392.1 (M + 1).
C. Preparation of compounds of Formula I by changing R<sup>1</sup>
Similarly, following the procedure of Example 18A above, but substituting other precursors for 2-fluorobenzyl bromide or other substituted alcohol cores for (6- (4- (trifluoromethoxy) phenyl) [1,2,4] triazolo [4,3-a ] pyridin-3-yl) methanol, other compounds of Formula I can be prepared.
Example 19
Preparation of a compound of Formula I where R<sup>1</sup> is 4- (trifluoromethoxy) phenyl, X1 is CH-R<sup>and</sup>, R<sup>and</sup> is 1,1-difluoro-2- (oxyran-2-ylmethoxy) ethyl, W<sup>1</sup>, In<sup>2</sup> and W.<sup>3</sup> are CH, and X<sup>2</sup> means N
<img file="PL2464645T3_D0178.tif" />
A. Preparation of a compound of Formula I
- 112 EP 2464645
<img file="PL2464645T3_D0179.tif" />
<img file="PL2464645T3_D0180.tif" />
To a rounded bottom flask was added 3- (1,1-difluoro-2- (oxyran-2-ylmethoxy) ethyl) -6- (4- (trifluoromethoxy) phenyl) - [1,2,4] triazolo [4,3- a] pyridine, prepared as described in Example 15, and 2-chlorophenol in acetone and potassium carbonate (sodium hydride in DMF at RT will also work). The reaction mixture was refluxed overnight. Potassium carbonate was filtered off. The filtrate was concentrated and purified by prep TLC and by prep HPLC to give 1- (2-chlorophenoxy) -3- (2,2-difluoro-2- (6- (4 (trifluoromethoxy) phenyl) - [1,2,4] triazolo [4,3-a] pyridin-3-yl) ethoxy) propan-2-ol.
MS m / z 545.1 (M<sup>+</sup>).
B. Preparation of the compound of Formula I by changing R<sup>and</sup>
Similarly, following the procedures of Example 19A above, but substituting the other hydroxyl for 2-chlorophenol, the following compound of Formula I was prepared:
1- (2,2-difluoro-2- {6- [4- (trifluoromethoxy) phenyl] [1,2,4] triazolo [4,3-a] pyridin-3-yl} ethoxy) -3- (2 , 5dimetylofenoksy) propan-2-ol,
MS m / z 538.1 (M +).
C. Preparation of the compound of Formula I by changing R<sup>1</sup>, In<sup>1</sup>, and in<sup>2</sup>
Similarly, following the procedures of Example 19A above, but substituting other hydroxyl substituted compounds with 2-chlorophenol or other oxyran-2-yl substituted compounds for 3- (1,1-difluoro-2 (oxyran-2-ylmethoxy) ethyl) - 6- (4- (trifluoromethoxy) phenyl) - [1,2,4] triazolo [4,3-a] pyridine, other compounds of Formula I may be prepared.
Example 20
Preparation of the compound of Formula I - Modification of the hydroxy R group<sup>1</sup>
A. Preparation of a compound of Formula I
<img file="PL2464645T3_D0181.tif" />
In a closed flask, a suspension of phenol, 4- (3- (trifluoromethyl) - [1,2,4] triazolo [4,3-a] pyridin-6-yl) phenol, prepared as described in Example 1 (47 mg, 0.17 mmol) , heteroaryl chloride (39 mg, 0.34 mmol), Cs2CO3 (111 mg, 0.34 mmol), and butyronitrile (1 mL) was heated to 140 ° C overnight. The reaction was concentrated and purified by RP-HPLC to give the desired product, 6- (4- (pyridazin-3-yloxy) phenyl) -3- (trifluoromethyl) - [1,2,4] triazolo [4,3-a] pyridine.
- EP 2464645
MS m / z 358.1 (M + 1).
B. Alternative preparation of a compound of Formula I
<img file="PL2464645T3_D0182.tif" />
To the mixture of phenol prepared as described in Example 1 (40 mg, 0.11 mmol), NaH (8 mg, 0.33 mmol, 60% dispersion in mineral oil), and 1-bromo-2-methoxyethane (16 μL, 0.17 mmol) DMF (1 mL). The reaction was stirred at rt for several hours and concentrated. The residue was purified by RP-HPLC to give the product, 6- [2- (2-methoxyethoxy) -4- (trifluoromethoxy) phenyl] -3 (trifluoromethyl) [1,2,4] triazolo [4,3-a] pyridine, as white powder MS m / z 422.4 (M + 1).
C. Alternative preparation of a compound of Formula I
<img file="PL2464645T3_D0183.tif" />
To the mixture of phenol, prepared as described in Example 1, (50 mg, 0.18 mmol), K2CO3 (75 mg, 0.54 mmol), and 3- (chlorodifluoromethyl) pyridine (147 mg, 0.90 mmol) was added DMF (1 mL). The reaction was stirred at 100-140 ° C overnight (for less reactive substrates a higher temperature end is required). The reaction was diluted with EtOAC and water, the layers separated and the organic concentrated. The residue was purified by RP-HPLC to give the product, 6- {4- [difluoro (pyridin-3-yl) methoxy] phenyl} -3- (trifluoromethyl) [1,2,4] triazolo [4,3-a] pyridine as white powder.
MS m / z 407.2 (M + 1)
D. Preparation of the compound of Formula I
<img file="PL2464645T3_D0184.tif" />
In a closed flask, a suspension of phenol, 4- (3- (trifluoromethyl) - [1,2,4] triazolo [4,3-a] pyridin-6-yl) phenol, prepared as described in Example 1 (47 mg, 0.17 mmol) , aryl halide (46 mg, 0.29 mmol), Cs<sub>2</sub>WHAT<sub>3</sub> (132 mg, 0.41 mmol), ethyl 2-oxocyclohexane carboxylate (62 μL, 0.039 mmol), CuBr (2.8 mg, 0.019 mmol) and DMSO (1 mL) was heated to 100 ° C overnight. The reaction was concentrated and purified
- 2464645 by RP-HPLC to obtain 20 mg of the desired product, 6- (4- (pyridin-3-yloxy) phenyl) -3 (trifluoromethyl) - [1,2,4] triazolo [4,3-a] pyridine.
357.1 (M + 1).
D. Preparation of a compound of Formula I by changing R<sup>1</sup>
Similarly, according to the procedures of Example 20A, B, C, or D above, but substituting other halide compounds or hydroxy R compounds<sup>1</sup> , the following compounds of Formula I were prepared (compound marked with * incorporated by reference only):
6- (4- (pyrazin-2-yloxy) phenyl) -3- (trifluoromethyl) - [1,2,4] triazolo [4,3-a] pyridine,
MS m / z 358.1 (M + 1);
{5- (trifluoromethoxy) -2- [3- (trifluoromethyl) [1,2,4] triazolo [4,3-a] pyridin-6-yl] phenoxy} acetonitrile;
MS m / z 403.2 (M + 1);
6- [6- (methylsulfanyl) pyridin-3-yl] -3- (trifluoromethyl) imidazo [1,5-a] pyridine (*),
MS m / z 434.1 (M + 1);
6- [2-ethoxy-4- (trifluoromethoxy) phenyl] -3- (trifluoromethyl) [1,2,4] triazolo [4,3-a] pyridine,
MS m / z 392.3 (M + 1), <sup>1</sup>H NMR (CDCl3) δ 8.47 (s, 1H), 7.95 (d, J = 7.6 Hz, 1H), 7.65 (d, J = 8.0 Hz, 1H), 7.41 (d, J = 8.4 Hz, 1H), 6.97 (d, J = 7.2 Hz, 1H), 6.87 (s, 1H), 4.11 (q, J = 6.8 Hz, 1H), 1.42 (t, J = 6.8 Hz, 3H);
6- {4- [difluoro (phenyl) methoxy] phenyl} -3- (trifluoromethyl) [1,2,4] triazolo [4,3-a] pyridine,
MS m / z 406.2 (M + 1), <sup>1</sup>H NMR (DMSO) 8.74 (s, 1H), 8.16 (dd, J = 1.2, 10.0 Hz, 1H), 8.01 (dd, J = 1.2, 9.6 Hz, 1H), 7.90 (t, J = 4.8 Hz, 1H ), 7.88 (t, J = 4.8 Hz, 1H), 7.79-7.83 (m, 2H), 7.57-7.66 (m, 3H), 7.48 (t, J = 8.4 Hz, 2H); 4- (Difluoro {4- [3- (trifluoromethyl) [1,2,4] triazolo [4,3-a] pyridin-6-yl] phenoxy} methyl) benzonitrile;
MS m / z 431.2 (M + 1), <sup>1</sup>H NMR (DMSO) 8.73 (s, 1H), 8.15 (d, J = 9.6 Hz, 1H), 8.08 (d, J = 8.4 Hz, 2H), 7.89-8.04 (m, 3H), 7.89 (d, J = 8.4 Hz, 2H), 7.49 (d, J = 8.4 Hz, 2H); and
6- [2- (propan-2-yloxy) -4- (trifluoromethoxy) phenyl] -3- (trifluoromethyl) [1,2,4] triazolo [4,3-a] pyridine MS m / z 406.1 (M + 1) <sup>1</sup>H NMR (CDCl3) δ 8.47 (s, 1H), 7.94 (s, 1H), 7.63 (s, 1H), 7.40 (d, J = 8.4 Hz, 1H), 6.95 (d, J = 7.6 Hz, 1H) , 6.87 (s, 1H), 4.64 (sept, J = 6.0 Hz, 1H), 1.35 (d, J = 6.0 Hz, 6H).
F. Preparation of the compound of Formula I by changing R<sup>1</sup>, In<sup>1</sup>, and in<sup>2</sup>
Similarly, according to the procedures of Example 20A, B, C, or D above, but substituting other halide compounds or other hydroxy R compounds<sup>1</sup> , other compounds of Formula I may be prepared.
Example 21
Preparation of a compound of Formula I - Modification of amino R group<sup>1</sup>
- EP 2464645
A. Preparation of a compound of Formula I
<img file="PL2464645T3_D0185.tif" />
To the suspension of aniline prepared in Example 1 (104 mg, 0.37 mmol) in CH<sub>2</sub>cl<sub>2</sub> (2 mL) trifluoroacetic anhydride (58 μL, 0.41 mmol) was added and the reaction carried out immediately. CH2Cl2 (10 mL) was added and the solids were collected by filtration to obtain 122 mg of a solid. A 10.1M BH solution was added to the suspension of collected solids in THF (2 mL)<sub>3</sub>^ dimethyl sulfide (48 μL, 0.48 mmol). The reaction was heated to 90 ° C for 90 minutes, an additional aliquot of borane solution (16 μL, 0.16 mmol) was added and stirred 30 minutes. The reaction was cooled, 1N HCl (1 mL) and MeOH (1 mL) were added and the reaction was heated to 60 ° C for 15 minutes. The reaction was concentrated and the residue was purified by RPHPLC to give the product, N- (2,2,2-trifluoroethyl) -4- (3- (trifluoromethyl) - [1,2,4] triazolo [4.3a] pyridin-6-yl ) aniline as a white powder.
MS m / z 361.1 (M + 1).
<img file="PL2464645T3_D0186.tif" />
cl
<img file="PL2464645T3_D0187.tif" />
To the mixture of aniline prepared in Example 1 (50 mg, 0.18 mmol), 5-chloro-2-iodobenzonitrile (72 mg, 0.27 mmol), Pd2 (dba) 3 (8.2 mg, 0.0090 mmol), 4,5-Bis (diphenylphosphine) - 9.9-dimethylxanthene (16 mg, 0.030 mmol), and KOtBu (28 mg, 0.25 mmol) in a sealed flask was charged with N2, heated to 100 ° C and stirred overnight. The reaction was concentrated and the residue was purified by RP-HPLC to give the product, 5-chloro-2 - ({4- [3- (trifluoromethyl) [1,2,4] triazolo [4,3-a] pyridin-6-yl] phenyl} amino) benzonitrile as a white powder.
MS m / z 414.2 (M + 1).
C. Preparation of the compound of Formula I
<img file="PL2464645T3_D0188.tif" />
Solution of α-trifluoromethyl benzyl alcohol (73 μL, 0.54 mmol) and 2.6 lutidine (100 μL,
0.81 mmol) in cyclohexane (1 mL) was cooled to 0 ° C and trifluoroacetic anhydride (140 μL, 0.78 mmol) was added. The mixture was stirred for 30 minutes, warmed to rt and water (5 mL) and cyclohexane (5 mL) were added.
The layers were separated and the organic layer was washed with brine, dried over MgSO4, filtered and
Concentrated 2464645. To a solution of concentrated material in cyclohexane (1 mL) was added aniline, 4- (3- (trifluoromethyl) [1.2.4] triazolo [4,3-a] pyridin-6-yl) aniline as prepared in Example 1 (90 mg, 0.33 mmol), K2CO3 (90 mg, 0.66 mmol), and DMF (1 mL). The reaction was stirred overnight, concentrated, and the residue was purified by RP-HPLC to give the product, N- (2,2,2-trifluoro-1-phenylethyl) -4- (3- (trifluoromethyl) [1.2.4] triazolo [4 , 3-a] pyridin-6-yl) aniline as a white powder
437.2 (M + 1).
D. Preparation of the compound of Formula I -Alkylation of the amino R group<sup>1</sup>
<img file="PL2464645T3_D0189.tif" />
DMF (0.5 mL) was added to the mixture of aniline produced in Example 1 (20 mg, 0.056 mmol), NaH (7 mg, 0.11 mmol, 60% dispersion in mineral oil), and iodomethane (11 μL, 0.11 mmol). The reaction was stirred at rt for 2 h and concentrated. The residue was purified by column chromatography (Rf = 0.53, 1: 1 Hexanes / EtOAc) to give the product, N-methyl-N-phenyl-4- [3 (trifluoromethyl) [1,2,4] triazolo [4,3-a ] pyridin-6-yl] aniline.
MS m / z 369.2 (M + 1).
<sup>1</sup>H NMR (DMSO) 8.57 (s, 1H), 8.11 (d, J = 9.6 Hz, 1H), 7.98 (dd, J = 1.6, 9.6 Hz, 1H), 7.68 (d, J = 8.8 Hz, 2H), 7.38 (t, J = 7.6 Hz, 2H), 7.18 (d, J = 8.0 Hz, 2H), 7.10 (t, J = 7.6 Hz, 1H), 7.03 (d, J = 8.8 Hz, 2H), 3.33 ( s, 3H).
Alternative alkylation of the amino R group<sup>1</sup>
<img file="PL2464645T3_D0190.tif" />
N- (4- (3- (trifluoromethyl) - [1,2,4] triazolo [4,3-a] pyridin-6-yl) phenyl) methanesulfonamide (10 mg) was dissolved in DMF (1 mL) and heated with potassium carbonate (39 mg) and methyl iodide (40 mg) for 2 h at 85 ° C. The reaction mixture was filtered, concentrated, and purified by chromatography using 2% MeOH in methylene chloride as eluent. N-methyl-N- (4- (3- (trifluoromethyl) [1,2,4] triazolo [4,3-a] pyridin-6-yl) phenyl) methanesulfonamide was obtained as a white solid.
<sup>1</sup>1 H NMR (400 MHz, CDCl 3): δ 8.61 (s, 1H); 8.03 (d, 1H); 7.69 (d, 1H); 7.68 (d, 1H); 7.58 (m, 4H), 3.40 (s, 3H), 2.91 (s, 3H).
MS (ES +, m / z) 371.0 (base peak, M + H<sup>+</sup>); 763.0 (2M + Na<sup>+</sup>).
E. Preparation of a compound of Formula I by changing R<sup>1</sup>
- 117 EP 2464645
Similarly, according to the procedures of Example 21A, B, or C above, but substituting other halide or anhydride compounds or other amino R compounds<sup>1</sup> , the following other compounds of Formula I were prepared:
4-Chloro-N- {4- [3- (trifluoromethyl) [1,2,4] triazolo [4,3-a] pyridin-6-yl] phenyl} aniline,
MS m / z 389.2 (M + 1); and
4-Fluoro-N- {4- [3- (trifluoromethyl) [1,2,4] triazolo [4,3-a] pyridin-6-yl] phenyl} aniline,
MS m / z 373.2 (M + 1).
F. Preparation of the compound of Formula I by changing R<sup>1</sup>, In<sup>1</sup>, and in<sup>2</sup>
Similarly, according to the procedures of Example 21A, B, or C above, but substituting other halide or anhydride compounds or other amino R compounds<sup>1</sup>, other compounds of Formula I may be prepared.
Example 22
Preparation of the compound of Formula I
A. Preparation of a compound of Formula I in which R<sup>1</sup> is 4-trifluoromethoxyphenyl, Q is a covalent bond, W<sup>1</sup>, In<sup>2</sup>, and in<sup>3</sup> are CH, X<sup>1</sup> means CCF<sub>2</sub>Cl, and X<sup>2</sup> means N
Step 1. Preparation of 6-bromo-3- (chloro-difluoro-methyl) - [1,2,4] triazolo [4,3-a] pyridine, a compound of
Pattern (1).
<img file="PL2464645T3_D0191.tif" />
(5-bromo-pyridin-2-yl) - 6-bromo-3- (chloro-difluoromethyl) hydrazo [1,2,4] triazolo [4,3, a] pyridine (5-Bromo-pyridin-2 -yl) -hydrazine (5.0g, 26.5 mmol) in chlorodifluoroacetic anhydride (11 mL) was heated in the microwave with careful pressure monitoring at 160 ° C for 1h. The reaction was cooled to rt and carefully ventilated with a needle. The reaction was slowly added to stirred sat. sodium bicarbonate solution (250 mL), extracted with ethyl acetate and dried before purification by flash chromatography (rf = 0.5 in 1: 1 hexanes / ethyl acetate) to give 6-bromo-3- (chloro-difluoromethyl) - [1,2, 4] triazolo [4,3-a] pyridine as a pale yellow powder.
M + 1 = 282/284.
Step 2. Preparation of 3- (chloro-difluoro-methyl) -6- (4-trifluoromethoxy-phenyl) - [1,2,4] triazolo [4,3a] pyridine, a compound of Formula I.
<img file="PL2464645T3_D0192.tif" />
6-Bromo-3- (chloro-difluoromethyl) [1,2,4] triazolo [4,3-a] pyridine
<img file="PL2464645T3_D0193.tif" />
3- (chloro-difluoro-methyl) -6- (4-trifluoromethoxyphenyl) - [1,2,4] triazolo [4,3-a] pyridine
- EP 2464645
6-Bromo-3- (chloro-difluoro-methyl) - [1,2,4] triazolo [4,3-a] pyridine (2.76g, 9.8 mmol), 4-trifluoromethoxyphenylboronic acid (2.5g, 12.1 mmol), dppfPdCl2 ( 1,1'bis (diphenylphosphine) ferrocene palladium dichloride (350 mg, 0.5 mmol), and potassium carbonate (2.76g, 20 mmol) were suspended in degassed toluene (20 mL), degassed isopropanol (10 mL) and degassed water (10 mL) under nitrogen. The reaction mixture was heated at 70 ° C for 1 h and cooled to rt. The aqueous phase was discarded and the organic phase was concentrated and purified by flash chromatography (rf = 0.5 in 1: 1 hexanes / ethyl acetate) to give 3- (chloro-difluoromethyl) -6- (4-trifluoromethoxy-phenyl) - [1, 2,4] triazolo [4,3-a] pyridine as a pale orange powder.
M + 1 = 364.
Optional Step 3. Preparation of 4 - ((difluoro (6- (4- (trifluoromethoxy) phenyl) - [1,2,4] triazolo [4,3a] pyridin-3-yl) methoxy) methyl) -2-phenyl- 5- (trifluoromethyl) oxazole, a compound of Formula I.
<img file="PL2464645T3_D0194.tif" />
In a 5 mL microwave test tube, 3- (chloro-difluoromethyl) -6- (4-trifluoromethoxy-phenyl) - [1,2,4] triazolo [4,3-a] pyridine (100 mg, 0.275 mmol) is combined under nitrogen (2 -phenyl-5- (trifluoromethyl) oxazol-4-yl) methanol (107 mg, 0.440 mmol), and NaH (39 mg, 0.96 mmol) in DMF (3 mL) and stirred for 10 minutes. The reaction mixture was quenched with 1M HCl and concentrated before purifying the product, 4 - ((difluoro (6- (4- (trifluoromethoxy) phenyl) - [1,2,4] triazolo [4,3-a] pyridin-3-yl) methoxy ) methyl) 2-phenyl-5- (trifluoromethyl) oxazole, by prep-HPLC (HCl).
571.1 (M + 1).
B. Preparation of compounds of Formula I by changing R<sup>1</sup> and R<sup>and</sup>
Similarly, following the procedure of Example 22A above, but substituting other alcohols for (2-phenyl-5- (trifluoromethyl) oxazol-4-yl) methanol or other boronic acids for 4-trifluoromethoxyphenylboronic acid, the following compounds of Formula I were prepared (compounds marked with * included only as reference):
3- [difluoro (methoxy) methyl] -6- [4- (trifluoromethoxy) phenyl] [1,2,4] triazolo [4,3-a] pyridine
360.1 (M + 1).
<sup>1</sup>H NMR (DMSO) δ 8.6 (s, 1H), 8.09 (dd, J = 9.2, 1.2 Hz, 1H), 7.90 (m, 3H), 7.55 (d, J = 8.0 Hz, 2H), 3.88 (s, 3H).
<sup>19</sup>F NMR (DMSO) δ -57.3 (s, 3F), -70.1 (s, 2F).
3- [difluoro (2-methoxyethoxy) methyl] -6- [4- (trifluoromethoxy) phenyl] [1,2,4] triazolo [4,3-a] pyridine
404.1 (M + 1).
<sup>1</sup>H NMR (DMSO) δ 8.69 (s, 1H), 8.10 (dd, J = 9.6, 1.2 Hz, 1H), 7.94 (dd, J = 8.0, 1.6 Hz, 1H), 7.87 (m,
2H), 7.56 (dd, J 8.8, 0.8 Hz, 2H), 4.34 (m, 2H), 3.67 (m, 2H), 3.27 (s, 3H).
- 119 EP 2464645 <sup>19</sup>F NMR (DMSO) δ -57.3 (s, 3F), -67.6 (s, 2F).
3- {difluoro [(3-metyloksetan-3-yl) methoxy] methyl} -6- [4- (trifluoromethoxy) phenyl] [1,2,4] triazolo [4,3-a] pyridine
430.1 (M + 1).
<sup>1</sup>H NMR (DMSO) δ 8.68 (s, 1H), 8.11 (d, J = 8.0 Hz, 1H), 7.95 (d, J = 8.0 Hz, 1H), 7.86 (d, J = 8.0 Hz, 2H), 7.54 (d, J = 8.0 Hz, 2H), 4.53 (m, 2H), 4.35 (m, 4H), 1.27 (s, 3H).
<sup>19</sup>F NMR (DMSO) δ -57.2 (s, 3F), -66.7 (s, 2F).
3- {difluoro [2- (morpholin-4-yl) ethoxy] methyl} -6- [4- (trifluoromethoxy) phenyl] [1,2,4] triazolo [4,3-a] pyridine
459.1 (M + 1).
1H NMR (DMSO) δ 10.45 (br, 1H), 8.74 (s, 1H), 8.12 (d, J = 8.8 Hz, 1H), 7.92 (m, 3H), 7.55 (d, J = 8.0 Hz, 2H) , 4.67 (m, 2H), 3.95 (m, 2H), 3.10-3.80 (m, 8H).
<sup>19</sup>F NMR (DMSO) δ -57.3 (s, 3F), -69.0 (s, 2F).
3- {difluoro [(5-methyl-1,2,4-oxadiazol-3-yl) methoxy] methyl} -6- [4- (trifluoromethoxy) phenyl] [1,2,4] triazolo [4,3-a ] pyridine
442.1 (M + 1).
<sup>1</sup>H NMR (DMSO) δ 8.90 (s, 1H), 8.11 (dd, J = 9.6, 1.6 Hz, 1H), 7.96 (dd, J = 9.6, 1.6 Hz, 1H), 7.91 (dd, J = 6.8, 2.0 Hz, 2H), 7.57 (d, J = 8.4 Hz, 2H), 5.52 (s, 2H), 2.57 (s, 3H).
<sup>19</sup>F NMR (DMSO) δ -57.3 (s, 3F), -68.9 (s, 2F).
3 - [(benzyloxy) (difluoro) methyl] -6- [4- (trifluoromethoxy) phenyl] [1,2,4] triazolo [4,3-a] pyridine
436.1 (M + 1).
<sup>1</sup>H NMR (DMSO) δ 8.51 (s, 1H), 8.09 (dd, J = 9.6, 1.2 Hz, 1H), 7.91 (dd, J = 9.6, 1.2 Hz, 1H), 7.75 (m, 2H), 7.53 ( m, 4H), 7.41 (m, 3H), 5.32 (s, 2H).
<sup>19</sup>F NMR (DMSO) δ -57.3 (s, 3F), -66.8 (s, 2F).
3- [difluoro (pyridin-4-ylmethoxy) methyl] -6- [4- (trifluoromethoxy) phenyl] [1,2,4] triazolo [4,3-a] pyridine
437.1 (M + 1).
<sup>1</sup>H NMR (DMSO) δ 8.63 (m, 3H), 8.11 (m, 1H), 7.93 (dd, J = 9.6, 2.0 Hz, 1H), 7.83 (m, 2H), 7.53 (m, 4H), 5.41 ( s, 2H).
<sup>19</sup>F NMR (DMSO) δ -57.3 (s, 3F), -67.4 (s, 2F).
2- (Difluoro {6- [4- (trifluoromethoxy) phenyl] [1,2,4] triazolo [4,3-a] pyridin-3-yl} methoxy) ethanol
390.1 (M + 1).
<sup>1</sup>H NMR (DMSO) δ 8.83 (s, 1H0, 8.09 (dd, J = 9.6, 2.0 Hz, 1H0, 7.93 (m, 3H), 7.52 (dd, J = 8.8, 1.0 Hz, 2H), 5.14 (m, 1H), 4.24 (m, 2H), 3.75 (m, 2H).
<sup>19</sup>F NMR (DMSO) δ -57.2 (s, 3F), -67.4 (s, 2F).
1- (difluoro {6- [4- (trifluoromethoxy) phenyl] [1,2,4] triazolo [4,3-a] pyridin-3-yl} methoxy) propan-2-ol
404.1 (M + 1).
<sup>1</sup>H NMR (DMSO) δ 8.85 (s, 1H), 8.09 (dd, J = 9.6, 1.2 Hz, 1H), 7.91 (m, 3H), 7.53 (dd, J = 9.2, 1.2 Hz,
2H), 5.14 (d, J = 4.4 Hz, 1H), 4.14 (m, 1H), 4.00 (m, 2H), 1.15 (d, J = 6.0 Hz, 3H).
- 120 EP 2464645 <sup>19</sup>F NMR (DMSO) δ -57.2 (s, 3F), -67.4 (s, 2F).
3- [difluoro (pyridin-3-ylmethoxy) methyl] -6- [4- (trifluoromethoxy) phenyl] [1,2,4] triazolo [4,3-a] pyridine
437.1 (M + 1).
<sup>1</sup>H NMR (DMSO) δ 8.80 (s, 1H), 8.65 (m, 1H), 8.59 (s, 1H), 8.13 (d, J = 8.0 Hz, 1H), 8.09 (d, J = 9.6 Hz, 1H) , 7.93 (m, 1H), 7.81 (m, 2H), 7.59 (m, 1H), 7.54 (d, J = 8.4 Hz, 2H), 5.43 (s, 2H).
<sup>19</sup>F NMR (DMSO) δ -57.3 (s, 3F), -67.3 (s, 2F).
3 - {[(5-cyclopropyl-1,2,4-oxadiazol-3-yl) methoxy] (difluoro) methyl} -6- [4- (trifluoromethoxy) phenyl] [1,2,4] triazolo [4,3- a] pyridine
468.1 (M + 1).
<sup>1</sup>H NMR (DMSO) δ 8.84 (s, 1H), 8.12 (dd, J = 9.6, 1.6 Hz, 1H), 7.95 (dd, J = 9.6, 1.6 Hz, 1H), 7.90 (m, 2H), 7.56 ( d, J = 8.0 Hz, 2H), 5.46 (s, 2H), 2.31 (m, 1H), 1.19 (m, 2H), 1.01 (m, 2H).
<sup>19</sup>F NMR (DMSO) δ -57.3 (s, 3F), -68.8 (s, 2F).
3- (difluoro {[5- (2-methylpropyl) -1,2,4-oxadiazol-3-yl] methoxy} methyl) -6- [4- (trifluoromethoxy) phenyl] [1,2,4] triazolo [4 3-a] pyridine
484.1 (M + 1).
<sup>1</sup>H NMR (DMSO) δ 8.90 (s, 1H), 8.11 (dd, J = 9.6, 1.6 Hz, 1H), 7.96 (dd, J = 9.6, 1.6 Hz, 1H), 7.91 (m, 2H), 7.56 ( d, J = 8.0 Hz, 2H), 5.54 (s, 2H), 2.79 (d, J = 6.8, 2H), 2.01 (sept, J = 6.8 Hz, 1H), 0.84 (d, J = 6.8 Hz, 6H ).
<sup>19</sup>F NMR (DMSO) δ -57.3 (s, 3F), -68.8 (s, 2F).
3- (difluoro {[5- (propan-2-yl) -1,2,4-oxadiazol-3-yl] methoxy} methyl) -6- [4- (trifluoromethoxy) phenyl] [1,2,4] triazole [4,3-a] pyridine
470.1 (M + 1).
<sup>1</sup>H NMR (DMSO) δ 8.86 (s, 1H), 8.22 (dd, J = 9.6, 1.6 Hz, 1H), 7.95 (dd, J = 9.6, 1.6 Hz, 1H), 7.90 (m, 2H), 7.55 ( d, J = 8.0 Hz, 2H), 5.52 (s, 2H), 3.24 (sept, J = 6.8 Hz, 1H), 1.22 (d, J = 6.8 Hz, 6H).
<sup>19</sup>F NMR (DMSO) δ -57.3 (s, 3F), -68.8 (s, 2F).
3- [difluoro (pyridin-2-ylmethoxy) methyl] -6- [4- (trifluoromethoxy) phenyl] [1,2,4] triazolo [4,3-a] pyridine
437.1 (M + 1).
<sup>1</sup>H NMR (DMSO) δ 8.94 (s, 1H), 8.56 (m, 1H), 8.09 (dd, J = 9.6, 1.6 Hz, 1H), 7.88 (m, 4H), 7.60 (m, 3H), 7.42 ( m, 1H), 5.41 (s, 2H).
<sup>19</sup>F NMR (DMSO) δ -57.3 (s, 3F), -67.4 (s, 2F).
4- [(difluoro {6- [4- (trifluoromethoxy) phenyl] [1,2,4] triazolo [4,3-a] pyridin-3-yl} methoxy) methyl] quinoline
487.1 (M + 1).
<sup>1</sup>H NMR (DMSO) δ 8.92 (d, J = 4.8 Hz, 1H), 8.44 (s, 1H), 8.24 (d, J = 7.2 Hz, 1H), 8.07 (d, J = 8.4 Hz, 2H), 7.87 (dd, J = 9.6, 1.6 Hz, 1H), 7.77 (m, 1H), 7.64 (m, 4H), 7.47 (d, J = 8.4 Hz, 2H), 5.88 (s, 2H).
<sup>19</sup>F NMR (DMSO) δ -57.3 (s, 3F), -67.6 (s, 2F).
3 - [(cyclopropylmethoxy) (difluoro) methyl] -6- [4- (trifluoromethoxy) phenyl] [1,2,4] triazolo [4,3-a] pyridine
400.1 (M + 1).
121 EP 2464645 <sup>1</sup>H NMR (DMSO) δ 8.66 (s, 1H), 8.10 (dd, J = 9.6, 1.6 Hz, 1H), 7.94 (dd, J = 9.6, 1.6 Hz, 1H), 7.88 (m, 2H), 7.55 ( d, J = 8.0 Hz, 2H), 4.09 (d, J = 7.6 Hz, 2H), 1.27 (m, 1H), 0.60 (m, 2H), 0.38 (m, 2H).
<sup>19</sup>F NMR (DMSO) δ -57.3 (s, 3F), -66.7 (s, 2F).
3- {difluoro [(1-phenyl-1H-1,2,3-triazol-4-yl) methoxy] methyl} -6- [4- (trifluoromethoxy) phenyl] [1,2,4] triazolo [4,3- a] pyridine
503.1 (M + 1).
<sup>1</sup>H NMR (DMSO) δ 9.03 (s, 1H), 8.66 (s, 1H), 8.08 (dd, J = 9.6, 1.2 Hz, 1H), 7.90 (m, 5H), 7.60 (m, 2H), 7.53 ( m, 1H), 7.41 (d, J = 8.0 Hz, 2H), 5.51 (s, 2H).
<sup>19</sup>F NMR (DMSO) δ -57.3 (s, 3F), -67.7 (s, 2F).
3- [difluoro (pyridazin-3-ylmethoxy) methyl] -6- [4- (trifluoromethoxy) phenyl] [1,2,4] triazolo [4,3-a] pyridine
438.1 (M + 1).
<sup>1</sup>H NMR (DMSO) δ 9.30 (m, 1H), 9.02 (s, 1H), 8.10 (dd, J = 9.6, 1.2 Hz, 1H), 7.95 (m, 4H), 7.81 (m, 1H), 7.55 ( dd, J = 9.2, 0.8 Hz, 2H), 5.65 (s, 2H).
<sup>19</sup>F NMR (DMSO) δ -57.2 (s, 3F), -67.6 (s, 2F).
3- {difluoro [(1-methyl-5-phenyl-1H-pyrazol-3-yl) methoxy] methyl} -6- [4- (trifluoromethoxy) phenyl] [1,2,4] triazolo [4,3-a ] pyridine
516.1 (M + 1).
<sup>1</sup>H NMR (DMSO) δ 8.62 (s, 1H), 8.07 (dd, J = 9.6, 1.2 Hz, 1H), 7.91 (dd, J = 9.6, 1.6 Hz, 1H), 7.80 (m, 2H), 7.48 ( m, 5H), 7.38 (d, J = 8.0 Hz, 2H), 6.58 (s, 1H), 5.25 (s, 2H), 3.74 (s, 3H).
<sup>19</sup>F NMR (DMSO) δ -57.3 (s, 3F), -67.3 (s, 2F).
3 - {[(2,2-difluoro-1,3-benzodioxol-5-yl) methoxy] (difluoro) methyl} -6- [4- (trifluoromethoxy) phenyl] [1,2,4] triazolo [4,3- a] pyridine
516.1 (M + 1).
<sup>1</sup>H NMR (DMSO) δ 8.52 (s, 1H), 8.08 (d, J = 9.2 Hz, 1H), 7.91 (d, J = 9.6 Hz, 1H), 7.78 (m, 2H), 7.66 (s, 1H) , 7.51 (d, J = 8.4 Hz, 2H), 7.45 (d, J = 8.4 Hz, 1H), 7.39 (m, 1H), 5.32 (s, 2H).
<sup>19</sup>F NMR (DMSO) δ -49.7 (s, 2H), -57.3 (s, 3F), -66.9 (s, 2F).
3 - {[(2,5-dimethyl-1,3-oxazol-4-yl) methoxy] (difluoro) methyl} -6- [4- (trifluoromethoxy) phenyl] [1,2,4] triazolo [4,3- a] pyridine
455.1 (M + 1).
<sup>1</sup>H NMR (DMSO) δ 8.64 (s, 1H), 8.08 (dd, J = 9.6, 1.2 Hz, 1H), 7.92 (dd, J = 9.6, 1.6 Hz, 1H), 7.87 (m, 2H), 7.56 ( d, J = 8.0 Hz, 2H), 5.13 (s, 2H), 2.28 (s, 3H), 2.21 (s, 3H).
<sup>19</sup>F NMR (DMSO) δ -57.3 (s, 3F), -67.6 (s, 2F).
3- {difluoro [(5-methyl-2-phenyl-1,3-oxazol-4-yl) methoxy] methyl} -6- [4- (trifluoromethoxy) phenyl] [1,2,4] triazolo [4,3- a] pyridine
517.1 (M + 1).
<sup>1</sup>H NMR (DMSO) δ 8.57 (s, 1H), 8.06 (dd, J = 9.6, 1.2 Hz, 1H), 7.85 (m, 3H), 7.72 (m, 2H), 7.48 (m, 3H),
7.23 (d, J = 8.0 Hz, 2H), 5.26 (s, 2H), 2.43 (s, 3H).
<sup>19</sup>F NMR (DMSO) δ -57.2 (s, 3F), -67.4 (s, 2F).
- EP 2464645
3- {difluoro [1- (pyridin-2-yl) ethoxy] methyl} -6- [4- (trifluoromethoxy) phenyl] [1,2,4] triazolo [4,3-a] pyridine
451.1 (M + 1).
<sup>1</sup>H NMR (DMSO) δ 8.82 (s, 1H), 8.50 (d, J = 4.8 Hz, 1H), 8.07 (d, J = 9.6 Hz, 1H), 7.92 (dd, J = 10.0, 1.6
Hz, 1H), 7.85 (m, 3H), 7.59 (m, 3H), 7.36 (m, 1H), 5.85 (q, J = 6.4 Hz, 1H), 1.68 (d, J = 6.4 Hz, 3H). <sup>19</sup>F NMR (DMSO) δ -57.3 (s, 3F), -63.5 (d, J = 155 Hz, 1F), -68.1 (d, J = 155 Hz, 1F).
3 - {[1- (4-chlorophenyl) ethoxy] (difluoro) methyl} -6- [4- (trifluoromethoxy) phenyl] [1,2,4] triazolo [4,3-a] pyridine
484.1 (M + 1).
<sup>1</sup>H NMR (DMSO) δ 8.19 (s, 1H), 8.06 (dd, J = 9.2, 1.2 Hz, 1H), 7.90 (dd, J = 9.2, 1.2 Hz, 1H), 7.71 (m, 2H), 7.53 ( m, 4H), 7.40 (m, 2H), 5.80 (q, J = 6.8 Hz, 1H), 1.67 (d, J = 6.8 Hz, 3H).
<sup>19</sup>F NMR (DMSO) δ -57.2 (s, 3F), -65.1 (d, J = 155 Hz, 1F), -66.6 (d, J = 155 Hz, 1F). 3- [difluoro (pyrimidin-2-ylmethoxy) methyl] -6- [4- (trifluoromethoxy) phenyl] [1,2,4] triazolo [4,3-a] pyridine
438.1 (M + 1).
<sup>1</sup>H NMR (DMSO) δ 9.43 (s, 1H), 8.83 (d, J = 5.2 Hz, 2), 8.11 (dd, J = 9.2, 1.2 Hz, 1H), 7.96 (dd, J = 9.6, 1.6 Hz, 1H), 7.92 (m, 3H), 7.63 (d, J = 8.0 Hz, 1H0, 7.56 (t, J = 5.2 Hz, 1H), 5.52 (s, 2H).
<sup>19</sup>F NMR (DMSO) δ -57.3 (s, 3F), -67.7 (s, 2F).
3 - {[(5-cyclobutyl-1,2,4-oxadiazol-3-yl) methoxy] (difluoro) methyl} -6- [4- (trifluoromethoxy) phenyl] [1,2,4] triazolo [4,3- a] pyridine
482.1 (M + 1).
<sup>1</sup>H NMR (DMSO) δ 8.87 (s, 1H), 8.11 (dd, J = 9.6, 1.2 Hz, 1H), 7.95 (dd, J = 9.6, 1.6 Hz, 1H), 7.90 (m, 2H), 7.56 ( d, J = 8.0 Hz, 2H), 5.52 (s, 2H), 3.81 (quint, J = 8.0 Hz, 1H), 2.30 (m, 4H), 2.04 (m, 1H), 1.87 (m, 1H).
<sup>19</sup>F NMR (DMSO) δ -57.3 (s, 3F), -68.8 (s, 2F).
3 - [(difluoro {6- [4- (trifluoromethoxy) phenyl] [1,2,4] triazolo [4,3-a] pyridin-3-yl} methoxy) methyl] benzonitrile
461.1 (M + 1).
<sup>1</sup>H NMR (DMSO) δ 8.59 (s, 1H), 8.09 (m, 2H), 7.90 (m, 3H), 7.80 (d, J = 8.8 Hz, 2H), 7.63 (t, J = 8.0 Hz, 1H) , 7.54 (d, J = 8.0 Hz, 2H), 5.38 (s, 2H).
<sup>19</sup>F NMR (DMSO) δ -57.3 (s, 3F), -67.2 (s, 2F).
3 - [(cyclopropylmethoxy) (difluoro) methyl] -6- [6- (trifluoromethyl) pyridin-3-yl] [1,2,4] triazolo [4,3-a] pyridine
385.1 (M + 1).
<sup>1</sup>H NMR (DMSO) δ 9.16 (d, J = 2.4 Hz, 1H), 8.87 (s, 1H), 8.48 (dd, J = 8.0, 2.4 Hz, 1H), 8.17 (dd, J = 9.6, 1.2 Hz, 1H), 8.09 (d, J = 8.4 Hz, 1H), 8.02 (dd, J = 9.6, 1.6 Hz, 1H), 4.10 (d, J = 7.2 Hz, 2H), 1.28 (m, 1H), 0.59 ( m, 2H), 0.40 (m, 2H).
<sup>19</sup>F NMR (DMSO) δ -66.7 (s, 2F), -66.9 (s, 3F).
5 - [(difluoro {6- [4- (trifluoromethoxy) phenyl] [1,2,4] triazolo [4,3-a] pyridin-3-yl} methoxy) methyl] quinoline
487.1 (M + 1).
- 123 EP 2464645 <sup>1</sup>H NMR (DMSO) δ 8.90 (d, J = 4.0 Hz, 1H), 8.68 (d, J = 8.4 Hz, 1H), 8.28 (s, 1H), 8.05 (m, 2H), 7.83 (d, J = 9.6 Hz, 1H), 7.76 (m, 2H), 7.57 (dd, J = 8.4, 4.4 Hz, 1H), 7.48 (m, 4H), 5.83 (s, 2H).
<sup>19</sup>F NMR (DMSO) δ -57.3 (s, 3F), -67.1 (s, 2F).
3- [1- (difluoro {6- [4- (trifluoromethoxy) phenyl] [1,2,4] triazolo [4,3-a] pyridin-3-yl} methoxy) ethyl] quinoline
501.1 (M + 1).
<sup>1</sup>H NMR (DMSO) δ 9.04 (d, J = 2.4 Hz, 1H), 8.48 (d, J = 1.6 Hz, 1H), 8.23 (s, 1H), 8.01 (m, 2H), 7.95 (m, 1H) , 7.80 (m, 2H), 7.62 (m, 3H), 7.34 (dd, J = 9.2, 1.0 Hz, 2H), 6.06 (q, J = 6.8 Hz, 1H), 1.84 (d, J = 6.8 Hz, 3H).
<sup>19</sup>F NMR (DMSO) δ -57.2 (s, 3F), -65.2 (d, J = 157 Hz, 1F), -66.6 (d, J = 157 Hz, 1F).
3 - {[2- (2,6-dimethylphenoxy) ethoxy] (difluoro) methyl} -6- [4- (trifluoromethoxy) phenyl] [1,2,4] triazolo [4,3-a] pyridine
494.1 (M + 1).
<sup>1</sup>H NMR (DMSO) δ 8.82 (s, 1H), 8.11 (d, J = 9.6 Hz, 1H), 7.94 (d, J = 9.6, 1.6 Hz, 1H), 7.77 (d, J = 8.8 Hz, 2H) , 7.23 (d, J = 8.0 Hz, 2H), 6.92 (m, 3H), 4.55 (m, 2H), 4.12 (m, 2H), 2.10 (s, 6H).
<sup>19</sup>F NMR (DMSO) δ -57.3 (s, 3F), -67.7 (s, 2F).
3- {difluoro [(1-phenyl-1H-pyrazol-4-yl) methoxy] methyl} -6- [4- (trifluoromethoxy) phenyl] [1,2,4] triazolo [4,3-a] pyridine
502.1 (M + 1).
<sup>1</sup>H NMR (DMSO) δ 8.74 (s, 1H), 8.51 (s, 1H), 8..06 (d, J = 9.6 Hz, 1H), 7.89 (m, 2H), 7.81 (d, J = 8.4 Hz , 2H), 7.73 (d, J = 8.4 Hz, 2H), 7.50 (m, 2H), 7.34 (m, 3H), 5.31 (s, 2H).
<sup>19</sup>F NMR (DMSO) δ -57.3 (s, 3F), -67.0 (s, 2F).
3- [difluoro ({2- [4- (trifluoromethyl) phenyl] -1,3-oxazol-4-yl} methoxy) methyl] -6- [4- (trifluoromethoxy) phenyl] [1,2,4] triazolo [ 4,3-a] pyridine
571.1 (M + 1).
<sup>1</sup>H NMR (DMSO) δ 8.58 (s, 1H), 8.46 (s, 1H), 8.09 (m, 4H), 7.88 (m, 4H), 7.70 (d, J = 8.0 Hz, 2H), 7.21 (d, J = 8.0 Hz, 2H), 5.33 (s, 2H). <sup>19</sup>F NMR (DMSO) δ -57.5 (s, 3F), 62.3 (s, 3H), -67.5 (s, 2F).
4- [(difluoro {6- [4- (trifluoromethoxy) phenyl] [1,2,4] triazolo [4,3-a] pyridin-3-yl} methoxy) methyl] -2-methylquinoline
501.1 (M + 1).
<sup>1</sup>H NMR (DMSO) δ 8.59 (s, 1H), 8.35 (d, J = 8.0 Hz, 1H), 8.28 (d, J = 8.0 Hz, 1H), 8.07 (d, J = 9.6 Hz, 1H), 7.98 (m, 1H), 7.90 (m, 2H), 7.80 (m, 1H), 7.71 (d, J = 8.0 Hz, 2H), 7.47 (d, J = 8.0 Hz, 2H), 6.03 (s, 2H) , 1.73 (s, 3H).
<sup>19</sup>F NMR (DMSO) δ -57.3 (s, 3F), -67.8 (s, 2F).
6 - [(difluoro {6- [4- (trifluoromethoxy) phenyl] [1,2,4] triazolo [4,3-a] pyridin-3-yl} methoxy) methyl] quinoxaline
488.1 (M + 1).
- 124 EP 2464645 <sup>1</sup>H NMR (DMSO) δ 8.98 (s, 2H), 8.60 (s, 1H), 8.26 (d, J = 1.6 Hz, 1H), 8.15 (d, J = 8.4 Hz, 1H), 8.07 (dd, J = 9.6, 1.2 Hz, 1H), 8.01 (dd, J = 9.6, 1.6 Hz, 1H), 7.90 (dd, 9.6, 1.6 Hz, 1H), 7.76 (m, 2H), 7.45 (d, J = 8.0 Hz, 2H), 5.61 (s, 2H).
<sup>19</sup>F NMR (DMSO) δ -57.3 (s, 3F), -67.0 (s, 2F).
3 - [(but-2-yn-1-yloxy) (difluoro) methyl] -6- [4- (trifluoromethoxy) phenyl] [1,2,4] triazolo [4,3-a] pyridine
398.1 (M + 1).
<sup>1</sup>H NMR (DMSO) δ 8.63 (s, 1H), 8.10 (d, J = 9.6 Hz, 1H), 7.93 (dd, J = 9.6, 1.6 Hz, 1H), 7.88 (m, 2H), 7.56 (d, J = 8.0 Hz, 2H), 4.94 (q, J = 2.4 Hz, 2H), 1.79 (t, J = 2.4 Hz, 3H).
<sup>19</sup>F NMR (DMSO) δ -57.3 (s, 3F), -68.6 (s, 2F).
3 - {[(2,2-difluorocyclopropyl) methoxy] (difluoro) methyl} -6- [4- (trifluoromethoxy) phenyl] [1,2,4] triazolo [4,3-a] pyridine
436.1 (M + 1).
<sup>1</sup>H NMR (DMSO) δ 8.64 (s, 1H), 8.10 (d, J = 9.2 Hz, 1H), 7.94 (d, J = 9.6 Hz, 1H), 7.88 (d, J = 8.8 Hz, 2H), 7.54 (d, J = 8.0 Hz, 2H), 4.43 (m, 1H), 4.23 (m, 1H), 2.31 (m, 1H), 1.77 (m, 1H), 1.62 (m, 1H). δ -57.3 (s, 3F), -68.0 (m, 2F), 128.7 (m, 1F), 142.6 (m, 1F).
3- {difluoro [(3-phenylprop-2-yn-1-yl) oxy] methyl} -6- [4- (trifluoromethoxy) phenyl] [1,2,4] triazolo [4,3-a] pyridine
460.1 (M + 1).
<sup>1</sup>H NMR (DMSO) δ 8.67 (s, 1H), 8.09 (d, J = 8.8 Hz, 1H), 7.91 (dd, J = 9.6, 1.6 Hz, 1H), 7.84 (m, 2H), 7.40 (m, 7H), 5.26 (s, 2H). δ -57.3 (s, 3F), -68.5 (m, 2F).
3- {difluoro [(1-methyl-1H-benzimidazol-2-yl) methoxy] methyl} -6- [4- (trifluoromethoxy) phenyl] [1,2,4] triazolo [4,3-a] pyridine
490.1 (M + 1).
3 - {[(1-benzyl-1H-1,2,3-triazol-4-yl) methoxy] (difluoro) methyl} -6- [4- (trifluoromethoxy) phenyl] [1,2,4] triazolo [4 3-a] pyridine
517.1 (M + 1).
3- {difluoro [(5-phenyl-1,2-oxazol-3-yl) methoxy] methyl} -6- [4- (trifluoromethoxy) phenyl] [1,2,4] triazolo [4,3-a] pyridine
503.1 (M + 1).
<sup>1</sup>H NMR (DMSO) δ 8.78 (s, 1H), 8.01 (d, J = 9.2 Hz, 1H), 7.90 (m, 5H), 7.55 (m, 3H), 7.38 (d, J = 8.4 Hz, 2H) , 7.39 (s, 1H), 5.52 (s, 2H).
<sup>19</sup>F NMR (DMSO) δ -57.3 (s, 3F), -68.1 (s, 2F).
3- {difluoro [(2-phenyl-1,3-oxazol-4-yl) methoxy] methyl} -6- [4- (trifluoromethoxy) phenyl] [1,2,4] triazolo [4,3-a] pyridine
503.1 (M + 1).
3- {difluoro [(5-methyl-2-phenyl-2H-1,2,3-triazol-4-yl) methoxy] methyl} -6- [4- (trifluoromethoxy) phenyl] [1,2,4] triazole [4,3-a] pyridine
517.1 (M + 1).
- 125 EP 2464645
3 - [{[1- (4-chlorophenyl) -5-methyl-1H-pyrazol-3-yl] methoxy} (difluoro) methyl] -6- [4- (trifluoromethoxy) phenyl] [1,2,4] triazole [4,3-a] pyridine
550.1 (M + 1).
3 - [(3,3-difenylopropoksy) (difluoro) methyl] -6- [4- (trifluoromethoxy) phenyl] [1,2,4] triazolo [4,3-a] pyridine
540.1 (M + 1).
3- (difluoro {[3- (pyrimidin-2-yl) benzyl] oxy} methyl) -6- [4- (trifluoromethoxy) phenyl] [1,2,4] triazolo [4,3-a] pyridine
514.1 (M + 1).
3- (difluoro {[3- (pyridin-3-yl) benzyl] oxy} methyl) -6- [4- (trifluoromethoxy) phenyl] [1,2,4] triazolo [4,3-a] pyridine
513.1 (M + 1).
3- {difluoro [(1-methyl-1H-indazol-3-yl) methoxy] methyl} -6- [4- (trifluoromethoxy) phenyl] [1,2,4] triazolo [4,3-a] pyridine
490.1 (M + 1).
<sup>1</sup>H NMR (DMSO) δ 8.45 (s, 1H), 8.05 (d, J = 8.8 Hz, 1H), 7.87 (m, 2H), 7.63 (m, 3H), 7.47 (d, J = 8.4 Hz, 2H) , 7.41 (t, J = 8.8 Hz, 1H), 7.14 (t, J = 8.0 Hz, 1H), 5.65 (s, 2H), 3.96 (s, 3H).
<sup>19</sup>F NMR (DMSO-d6) δ -57.3 (s, 3F), -67.3 (s, 2F).
3- (difluoro {[2- (1H-1,2,4-triazol-1-yl) benzyl] oxy} methyl) -6- [4- (trifluoromethoxy) phenyl] [1,2,4] triazolo [4, 3-a] pyridine
503.1 (M + 1).
3- (difluoro {[2- (2-methyl-1H-imidazol-1-yl) benzyl] oxy} methyl) -6- [4- (trifluoromethoxy) phenyl] [1,2,4] triazolo [4,3- ] pyridine
516.1 (M + 1).
3- (difluoro {[2-phenyl-5- (trifluoromethyl) -1,3-oxazol-4-yl] methoxy} methyl) -6- [4- (trifluoromethoxy) phenyl] [1,2,4] triazolo [4 3-a] pyridine
571.1 (M + 1).
3- (difluoro {[6- (1H-pyrazol-1-yl) pyridin-3-yl] methoxy} methyl) -6- [4- (trifluoromethoxy) phenyl] [1,2,4] triazolo [4,3- ] pyridine
503.1 (M + 1).
6-cyclopropyl-2 - [(difluoro {6- [4- (trifluoromethoxy) phenyl] [1,2,4] triazolo [4,3-a] pyridin-3-yl} methoxy) methyl] -3,4'- bipyridine
554.1 (M + 1).
3 - [{[3- (4-cyclopropyl-1 H-imidazol-1-yl) benzyl] oxy} (difluoro) methyl] -6- [4- (trifluoromethoxy) phenyl] [1,2,4] triazolo [4, 3-a] pyridine
521.1 (M + 1).
3- (difluoro {[2- (piperidin-1-yl) -pyridin-4-yl] methoxy} methyl) -6- [4- (trifluoromethoxy) phenyl] [1,2,4] triazolo [4,3-a] pyridine
520.1 (M + 1).
- 126 EP 2464645
3 - {[(2,2-dimethyl-2,3-dihydro-1-benzofuran-7-yl) methoxy] (difluoro) methyl} -6- [4- (trifluoromethoxy) phenyl] [1,2,4] triazole [4,3-a] pyridine
506.1 (M + 1).
3 - {[2- (2,6-difluorophenyl) ethoxy] (difluoro) methyl} -6- [4- (trifluoromethoxy) phenyl] [1,2,4] triazolo [4,3-a] pyridine
486.1 (M + 1).
3- {difluoro [(5-phenyl-1,2,4-oxadiazol-3-yl) methoxy] methyl} -6- [4- (trifluoromethoxy) phenyl] [1,2,4] triazolo [4,3-a ] pyridine
504.1 (M + 1).
<sup>1</sup>H NMR (DMSO) δ 8.87 (s, 1H), 8.11 (dd, J = 9.6, 1.2 Hz, 1H), 8.04 (m, 2H), 7.94 (dd, J = 9.6, 1.6 Hz, 1H), 7.86 ( m, 2H), 7.72 (m, 1H), 7.60 (m, 2H), 7.41 (d, J = 8.0 Hz, 2H), 5.63 (s, 2H).
<sup>19</sup>F NMR (DMSO) δ -57.2 (s, 3F), -68.6 (s, 2F).
3 - [{[2- (6-cyclopropyl-pyridin-3-yl) benzyl] oxy} (difluoro) methyl] -6- [4- (trifluoromethoxy) phenyl] [1,2,4] triazolo [4,3-a] pyridine
553.1 (M + 1).
3- (difluoro (3- (2-methoxyphenylthio) -2-methylpropoxy) methyl) -6- (4- (trifluoromethoxy) phenyl) [1,2,4] triazolo [4,3-a] pyridine:
LCMS (EI: 70 eV) 540 (M ++ 1)
3- (difluoro (2- (4- (4-methoxyphenyl) piperazin-1-yl) ethoxy) methyl) -6- (4- (trifluoromethoxy) phenyl) [1,2,4] triazolo [4,3-a ] pyridine:
LCMS (EI: 70 eV) 564 (M ++ 1)
3 - (((3-cyclopropyl-1-methyl-1H-pyrazol-5-yl) methoxy) difluoromethyl) -6- (4- (trifluoromethoxy) phenyl) [1,2,4] triazolo [4,3-a ] pyridine:
LCMS (EI: 70 eV) 480 (M ++ 1)
C. Preparation of compounds of Formula I by changing R<sup>1</sup> and X<sup>1</sup>
Similarly, following the procedure of Example 22A above, but optionally substituting other boronic acids or pinacolate esters for 4-trifluoromethoxyphenylboronic acid and / or substituting other alcohols for (2-phenyl-5- (trifluoromethyl) oxazol-4-yl) methanol, make other compounds of Formula
AND.
Example 23
Preparation of the compound of Formula I
A. Preparation of a compound of Formula I in which R<sup>1</sup> is 4-trifluoromethoxyphenyl, Q is a covalent bond, W<sup>1</sup>, In<sup>2</sup>, and in<sup>3</sup> are CH, X<sup>1</sup>is CCF ™ Cl, and X<sup>2</sup> means N
Stage 1. Addition of the R group<sup>and</sup> and ring chain
- 127 EP 2464645
<img file="PL2464645T3_D0195.tif" />
(5-bromo-2-hydrazinylpyridine (1.83 g, 9.73 mmol) and methyl 2,2-difluoro-3-methoxypropanoate (1.00 g, 6.49 mmol) were refluxed in toluene (35 mL) overnight. The reaction mixture was concentrated and purified by chromatography (EtOAc: hexanes = 1: 4) to give N '- (5-bromopyridin-2-yl) 2,2-difluoro-3-methoxypropanhydrazide.
<img file="PL2464645T3_D0196.tif" />
1,4-Dioxane p-toluenesulfonic acid monohydrate, 160<sup>about</sup>C, 80min, microwave
br
FO 'r
N '- (5-bromopyridin-2-yl) -2,2-difluoro-3-methoxypropanehydrazide (0.25 g, 0.81 mmol) and p-toluenesulfonic acid monohydrate (0.12 g, 0.65 mmol) in 1,4-dioxane (3.5 mL) was microwaved at 160 ° C for 80 min. The reaction mixture was diluted with EtOAc and washed sequentially with aqueous NaHCO3 and brine. The organic layer was dried over Na2SO4. Evaporation of the solvent and purification by HPLC gave 6-bromo-3- (1,1-difluoro-2-methoxyethyl) - [1,2,4] triazolo [4,3-a] pyridine.
Optional Step 3. Creating the "Q" Alkenylene linker and adding the R group<sup>1</sup>
<img file="PL2464645T3_D0197.tif" />
To a mixed solution of 6-bromo-3- (1,1-difluoro-2-methoxyethyl) - [1,2,4] triazolo [4,3-a] pyridine (46 mg, 0.16 mmol) in THF (5 mL) a catalytic amount of dichlorobis (triphenylphosphine) palladium (II) (11 mg) and copper (I) iodide (3 mg), and 1-ethynyl-4- (trifluoromethyl) benzene (41 mg, 0.24 mmol) was added. The resulting mixture was flushed with N2 and Et3N (2 mL) was added. The reaction mixture was stirred at 70 ° C overnight and purified by prep-TLC (EtOAc: hexanes = 2: 3) and by HPLC to give 3- (1,1-difluoro-2-methoxyethyl) -6 - ((4- (trifluoromethyl) phenyl) ethynyl) - [1,2,4] triazolo [4,3-a] pyridine.
MS m / z 382.0 (M + H) <sup>1</sup>H-NMR (acetone) δ 8.81 (s, 1H), 7.94 (dd, 1H), 7.83 (dd, 4H), 7.65 (dd, 1H), 4.36 (t, 2H), 3.52 (s, 3H);
B. Preparation of compounds of Formula I by changing R<sup>1</sup> and R<sup>and</sup>
Similarly, following the procedure of Example 23A above, but substituting other precursors for
Methyl 2,2-difluoro-3-methoxypropanoate or other alkynyl compounds R<sup>1</sup> for 1-ethynyl-4- (trifluoromethyl) benzene, the following compounds of Formula I were prepared:
3- (trifluoromethyl) -6 - {[4- (trifluoromethyl) phenyl] ethynyl} [1,2,4] triazolo [4,3-a] pyridine,
- 128 EP 2464645
MS m / z 356.0 (M + H);
- (1,1-difluoro-2-methoxyethyl) -6- [4- (trifluoromethoxy) phenyl] [1,2,4] triazolo [4,3-a] pyridine,
MS m / z 374.0 (M + H);
6- [4- (4-chlorophenoxy) phenyl] -3- (1,1-difluoro-2-methoxyethyl) [1,2,4] triazolo [4,3-a] pyridine
MS m / z 416.0 (M + H)
3- (1,1-difluoro-2-methoxyethyl) -6- [4- (4-fluorophenoxy) phenyl] [1,2,4] triazolo [4,3-a] pyridine
MS m / z 400.0 (M + H)
3- (1,1-difluoro-2-methoxyethyl) -6- [6- (2,2,2-trifluoroethoxy) pyridin-3-yl] [1,2,4] triazolo [4,3-a] pyridine
MS m / z 389.0 (M + H)
3- (1,1-difluoro-2-methoxyethyl) -6- [3-methyl-4- (trifluoromethoxy) phenyl] [1,2,4] triazolo [4,3-a] pyridine
MS m / z 388.0 (M + H
3- (1,1-difluoro-2-methoxyethyl) -6- [2-methyl-4- (trifluoromethoxy) phenyl] [1,2,4] triazolo [4,3-a] pyridine
MS m / z 388.0 (M + H)
3- (1,1-difluoro-2-methoxyethyl) -6- [3-fluoro-4- (trifluoromethoxy) phenyl] [1,2,4] triazolo [4,3-a] pyridine
MS m / z 392.0 (M + H)
3- (1,1-difluoro-2-methoxyethyl) -6- (3,5-difluoro-4-phenoxyphenyl) [1,2,4] triazolo [4,3-a] pyridine
MS m / z 418.0 (M + H)
3- (1,1-difluoro-2-methoxyethyl) -6- (phenylethynyl) [1,2,4] triazolo [4,3-a] pyridine,
MS m / z 314.1 (M + H); and
2.2- difluoro-2- (6 - {[4- (trifluoromethyl) phenyl] ethinyl} [1,2,4] triazolo [4,3-a] pyridin-3-yl) ethanol,
MS m / z 368.0 (M + H).
C. Preparation of compounds of Formula I by changing R<sup>1</sup> and R<sup>and</sup>
Similarly, following the procedure of Example 23A above, but substituting other precursors for
Methyl 2.2- difluoro-3-methoxypropanoate or other alkynyl compounds R<sup>1</sup> for 1-ethynyl-4- (trifluoromethyl) benzene, other compounds of Formula I can be prepared:
Reference example 24
Preparation of the compound of Formula I where X<sup>2</sup> means CR<sup>b</sup> (enabled by reference)
<img file="PL2464645T3_D0198.tif" />
A. Preparation of a compound of Formula I where X<sup>2</sup> means CR<sup>b</sup>
- 129 EP 2464645
Stage 1 - Creation of the halide intermediate
<img file="PL2464645T3_D0199.tif" />
6- (4- (trifluoromethoxy) phenyl) -3- (trifluoromethyl) imidazo [1,5-a] pyridine (1,2001 g, 3,466 mmol) was dissolved in CH2Cl2 (20 mL) in a 250 mL round-bottomed flask. The solution was treated with NBS (925.4 mg, 5.199 mmol, 1.5 equivalent) at 0 ° C for 30 min. and the solvent removed by rotavap to give the crude mixture. The resulting crude mixture was purified by column chromatography (SiO2 = 80 g, EtOAc / hexane = 1: 7 Rf = 0.5) to give 1-bromo-6- (4- (trifluoromethoxy) phenyl) -3- (trifluoromethyl) imidazo [1,5 -a] pyridine as a colorless oil.
Stage 2 - Addition of group R<sup>b</sup>
<img file="PL2464645T3_D0200.tif" />
1-bromo-6- (4- (trifluoromethoxy) phenyl) -3- (trifluoromethyl) imidazo [1,5-a] pyridine (50.0 mg, 0.118 mmol), NaCN (7.0 mg, 0.142 mmol, 1.2 equivalent), CuI (2.2 mg, 0.0118 mmol, 0.1 equiv) and KI (3.9 mg, 0.0236 mmol, 0.2 equiv) were successively placed in a 5 mL Samith tube. A solution of N, N'-dimethylethylenediamine (10.4 mg, 0.118 mmol, 1.0 eq) in toluene (5 mL) was added to the tube. The suspension was heated with a microwave reactor (Biotage, Personal Chemistry) at 130 ° C for 60 min. The suspension was filtered through Celite (3 g) with EtOAc (70 mL). The solvent was removed from the filtrate under reduced pressure to obtain a crude mixture. The crude mixture was purified by preparative TLC (SiO2 = 1 plate, EtOAc / hexane = 1: 7 Rf = 0.1) to give 6- (4 (trifluoromethoxy) phenyl) -3- (trifluoromethyl) imidazo [1,5-a] pyridine- 1-carbonitrile as colorless crystals.
LCMS (EI: 70 eV) 372 (M ++ 1),
H-NMR (300 MHz, CDCls): 7.40 (2H, d, J = 8.4 Hz), 7.57 (1H, d, J = 9.6 Hz), 7.61 (2H, d, J = 8.4 Hz), 7.93 (1H, d, J = 9.6 Hz), 8.35 (1H, s).
Alternate Step 2 - Addition of the R moiety<sup>b</sup> through Ligation
<img file="PL2464645T3_D0201.tif" />
- 130 EP 2464645
1-bromo-6- (4- (trifluoromethoxy) phenyl) -3- (trifluoromethyl) imidazo [1,5-a] pyridine (50.0 mg, 0.118 mmol) was dissolved in ether (2 mL) in a 50 mL round-bottomed flask under nitrogen. The solution was cooled to -78 ° C and treated with t-BuLi (1.7 M pentane solution, 0.15 mL, 0.255 mmol, 2.2 equiv) for 5 min. A solution of MeI (65.8 mg, 0.464 mmol, 4.0 equiv) in ether (1 mL) was added to the mixture. The reaction was heated to rt for 30 min. H2O (30 mL) was added to the mixture and it was extracted with EtOAc (30 mL x 3). The combined organic layers were washed with brine (30 mL) and dried with Na2SO4. The solvent was removed under reduced pressure to obtain a crude mixture. The crude mixture was purified by preparative TLC (SiO2 = 1 plate, ether / hexane = 1: 3 Rf = 0.4) to give 1-methyl-6- (4- (trifluoromethoxy) phenyl) -3- (trifluoromethyl) imidazo [1,5-a ] pyridine (incorporated by reference) as pale yellow crystals.
LCMS (EI: 70 eV) 361 (M ++ 1)
Alternate Step 2 - Addition of the alkoxycarbonyl R moiety<sup>b</sup>
<img file="PL2464645T3_D0202.tif" />
1-bromo-6- (4- (trifluoromethoxy) phenyl) -3- (trifluoromethyl) imidazo [1,5-a] pyridine (50.0 mg, 0.118 mmol), Pd (AcO)<sub>2</sub> (2.6 mg, 0.0118 mmol, 0.1 equiv) and P (o-tol)<sub>3</sub> (14.4 mg, 0.0472 mmol, 0.4 eq.) Was placed in a 50 mL round bottom flask under nitrogen. DMF (1 mL) solution Et was added to the flask<sub>3</sub>N (30.0 mg, 0.295 mmol, 2.5 eq) in DMF (1 mL) and a solution of methyl methyl acrylate (50.8 mg, 0.59 mmol, 5.0 eq.). The mixture was heated at 80 ° C for 19 h and the solvent removed from the reaction mixture to give a crude mixture. The crude mixture was purified by column chromatography (SiO2 = 25 g, EtOAc / hexane = 1: 7 to 1: 3, Rf = 0.1 with EtOAc / hexane = 1: 7) to give 3- (6 (4- (trifluoromethoxy) phenyl) (E) -methyl (E) -methyl (trifluoromethyl) imidazo [1,5-a] pyridin-1-yl) acrylate (incorporated by reference) as pale yellow crystals.
LCMS (EI: 70 eV) 431 (M ++ 1).
Optional Step 3- Saturation of the alkoxycarbonylalkenyl moiety R b
<img file="PL2464645T3_D0203.tif" />
3- (6- (4- (trifluoromethoxy) phenyl) -3- (trifluoromethyl) imidazo [1,5-a] pyridin-1-yl) (E) methyl acrylate (25.6 mg, 0.0595 mmol) and 10% Pd / C (25.6 mg) was placed in a 100 mL round bottom flask under nitrogen. THF (5 mL) was added to the flask. and nitrogen was replaced with hydrogen. The reaction mixture was stirred at
- 131 EP 2464645 rt. After 17 h (57% conv.), The Pd catalyst was removed by filtration using Celite (3 g). The reaction was started using Pd / C (25.6 mg) under hydrogen at 45 ° C. After 4 h (100% conv.), The Pd catalyst was removed in a similar manner. The solvent was removed from the filtrate under reduced pressure to obtain a crude mixture. The crude mixture was purified by column chromatography (SiO2 = 25 g, EtOAc / hexane = 1: 7 to 1: 3, Rf = 0.4 with EtOAc / hexane = 1: 3) to give 3- (6- (4 (trifluoromethoxy) phenyl) -3- (trifluoromethyl) imidazo [1,5-a] pyridin-1-yl) propanoate (incorporated by reference) as colorless crystals.
LCMS (EI: 70 eV) 433 (M ++ 1)
B. Preparation of compounds of Formula I by changing R<sup>b</sup>
Similarly, following the procedure of Reference Example 24A above, but substituting other electrophiles for MeI, the following compound of Formula I was prepared (compounds marked with * are included only as a reference):
6- (4- (trifluoromethoxy) phenyl) -3- (trifluoromethyl) imidazo [1,5-a] pyridin-1-yl) methanol (*): LCMS (EI: 70 eV) 377 (M ++ 1).
C. Preparation of compounds of Formula I by changing R<sup>b</sup>
Similarly, following the procedure in Reference Example 24A, but substituting other electrophiles for
MeI or other R<sup>b</sup> unsubstituted cores for 6- (4- (trifluoromethoxy) phenyl) -3- (trifluoromethyl) imidazo [1,5a] pyridine, other reference compounds of Formula I can be prepared:
Example 25
Preparation of a compound of Formula I by the addition of R<sup>and</sup> to the core
A. Preparation of a compound of Formula I in which R<sup>1</sup> means 4-trifluoromethoxyphenyl, Q is
<img file="PL2464645T3_D0204.tif" />
N
Step 1. Preparation of 3-chloro-6- (4- (trifluoromethoxy) phenyl) - [1,2,4] triazolo [4,3-] pyridine (1).
NCS
cl
DMF
6- (4- (trifluoromethoxy) phenyl) - [1,2,4] triazolo [4,3-a] pyridine (0.6 g) was placed in a 50 mL round-bottomed flask and dissolved in 10 mL DMF. NCS (0.43 g) and reaction mixture were added
Heated to 50 ° C for 1 h, diluted with EtOAc (100 mL), washed 3 times with water, brine, dried over Na 2 SO 4, and concentrated to give an orange solid containing 3-chloro-6- (4 (trifluoromethoxy) phenyl) - [1,2,4] triazolo [4,3-a] pyridine and a trace amount of succinimide (<5 wt%).
<sup>1</sup>1 H NMR (400 MHz, CDCl 3): δ 8.11 (t, 1H); 7.62 (dd, 1H); 7.62 (d, 2H), 7.57 (dd, 1H), 7.38 (d, 2H).
Step 2. Preparation of 3- (pyridin-4-yloxy) -6- (4- (trifluoromethoxy) phenyl) - [1,2,4] triazolo [4,3a] pyridine by SNAr reaction.
<img file="PL2464645T3_D0205.tif" />
In a 15 mL round-bottomed flask 3-chloro-6- (4- (trifluoromethoxy) phenyl) - [1,2,4] triazolo [4.3a] pyridine (100 mg), 4-hydroxypyridine (60 mg), and potassium carbonate (88 mg) was suspended in DMA (3 mL). The reaction mixture was stirred at 150 ° C for 6 h, concentrated, the residue subjected to gradient chromatography (MeOH / dichloromethane) to give 3- (pyridin-4-yloxy) -6- (4- (trifluoromethoxy) phenyl) - [1,2,4 ] triazolo [4,3-a] pyridine as an amber oil (28 mg, 24%).
<sup>1</sup>1 H NMR (400 MHz, CDCl 3): δ 7.99 (s, 1H); 7.88 (d, J = 9.6 Hz, 1H); 7.63 - 7.53 (m, 5H); 7.30 (d, J = 8.0 Hz, 2H); 6.59 (d, J = 7.2 Hz, 2H).
MS (ES +, m / z) 373.0 (base peak, M + H<sup>+</sup>); 767.1 (2M + Na<sup>+</sup>).
Alternate Step 2. Preparation of 3- (pyridin-4-yloxy) -6- (4- (trifluoromethoxy) phenyl) [1,2,4] triazolo [4,3-a] pyridine by Ullmann coupling.
<img file="PL2464645T3_D0206.tif" />
In a 15 mL round-bottomed flask, NaH (60 wt.%, 40 mg) was added to trifluoroethanol (0.072mL) in DMF (3 mL). After 10 minutes, 3-iodo-6- (4- (trifluoromethoxy) phenyl) [1,2,4] triazolo [4,3-a] pyridine, prepared according to the method disclosed in Step 1, (100 mg) was added and CuI (48 mg). The reaction mixture was stirred at 90 ° C for 4 h, concentrated, the residue subjected to gradient chromatography (ethyl acetate / hexanes). The resulting mixture was subjected to hydrogenolysis (cyclohexene / Pd on carbon, 10%, in EtOAc) and again chromatographed using first 3% MeOH in dichloromethane, and then 1: 1 EtOAc / hexanes to give 3- (pyridin-4-yloxy) - 6- (4- (trifluoromethoxy) phenyl) - [1,2,4] triazolo [4,3-a] pyridine as an amber oil (3.4 mg, 3.6%).
<sup>1</sup>1 H NMR (400 MHz, CDCl 3): δ 8.02 (s, 1H); 7.82 (d, 1H); 7.63 - 7.53 (m, 3H); 7.39 (d, 2H).
<sup>19</sup>F NMR (377 MHz, CDCl3): δ -58.39 (s, 1F); -74.48 (t, 1F).
MS (ES +, m / z) 378.0 (base peak, M + H<sup>+</sup>); 777.1 (2M + Na<sup>+</sup>).
1 2
B. Preparation of compounds of Formula I by changing R, X, and X
- 133 EP 2464645
Similarly, following the procedure of Example 25A above for the SNAr or Ullmann reaction above, but optionally substituting other O-, N-, or S-nucleophiles for 4-hydroxypyridine and / or substituting Nbromosuccinimide or N-iodosuccinimide for N-chlorosuccinimide and using the appropriate 3-bromo-6- (4 (trifluoromethoxy) phenyl) - [1,2,4] triazolo [4,3-a] pyridine or 3-iodo-6- (4- (trifluoromethoxy) phenyl) [1,2, 4] triazolo [4,3-a] pyridine, the following compounds of Formula I were prepared:
3- (phenylsulfanyl) -6- [4- (trifluoromethoxy) phenyl] [1,2,4] triazolo [4,3-a] pyridine MS (ESI +) 388.0 (base peak, M + H<sup>+</sup>); 797.1 (2M + Na<sup>+</sup>);
N, N-dimethyl-6- [4- (trifluoromethoxy) phenyl] [1,2,4] triazolo [4,3-a] pyridine-3-amine,
MS (ESI +) 323.0 (base peak, M + H<sup>+</sup>); 667.1 (2M + Na<sup>+</sup>);
3-phenoxy-6- [4- (trifluoromethoxy) phenyl] [1,2,4] triazolo [4,3-a] pyridine,
MS (ESI +) 365.0 (base peak, M + H<sup>+</sup>); 751.1 (2M + Na<sup>+</sup>);
6- [4- (trifluoromethoxy) phenyl] -3- [3- (trifluoromethyl) phenoxy] [1,2,4] triazolo [4,3-a] pyridine,
MS (ESI +) 440.0 (base peak, M + H<sup>+</sup>);
3- (4,4-difluoro-piperidin-1-yl) -6- [4- (trifluoromethoxy) phenyl] [1,2,4] triazolo [4,3-a] pyridine,
MS (ESI +) 399.2 (base peak, M + H<sup>+</sup>); and
3- (2-methylphenoxy) -6- [4- (trifluoromethoxy) phenyl] [1,2,4] triazolo [4,3-a] pyridine,
MS (ESI +) 386.1 (base peak, M + H<sup>+</sup>); 793.1 (2M + Na<sup>+</sup>).
C. Preparation of compounds of Formula I by changing R<sup>1</sup>, X<sup>1</sup>, and X<sup>2</sup> similarly, following the procedure of Example 25A above for the SNAr or Ullmann reaction above, but optionally substituting other O-, N-, or S-nucleophiles for 4-hydroxypyridine and / or substituting Nbromosuccinimide or N-iodosuccinimide for N-chlorosuccinimide and using the appropriate 3-bromo-6- (4 (trifluoromethoxy) phenyl) - [1,2,4] triazolo [4,3-a] pyridine or 3-iodo-6- (4- (trifluoromethoxy) phenyl) [1,2, 4] triazolo [4,3-a] pyridine, other compounds of Formula I may be prepared:
Example 26
Preparation of compounds of Formula I - Modification of the methyl ester group R<sup>1</sup>
A. Preparation of a compound of Formula I
<img file="PL2464645T3_D0207.tif" />
Methyl 4- (3- (trifluoromethyl) - [1,2,4] triazolo [4,3-a] pyridin-6-yl) benzoate (33 mg) was dissolved in THF (1 mL) and cooled to -78 ° C . Methyllithium (1.6 M in ether) was added in one portion. 1 mL of water was quenched to which 2 drops of 1N HCl were added. Extracted with EtOAc and purified by
Chromatography using 1: 1 hexanes / ethyl acetate as eluent. 11 mg of 2- (4- (3 (trifluoromethyl) - [1,2,4] triazolo [4,3-a] pyridin-6-yl) phenyl) propan-2-ol (33%) was isolated.
<sup>1</sup>1 H NMR (400 MHz, CDCl 3): δ 8.32 (s, 1H); 7.99 (d, J = 9.6 Hz, 1H); 7.73 (dd, J = 10.8, 1.5 Hz, 1H); 7.66 (d, J = 8.4 Hz, 2H); 7.55 (d, J = 8.4, 2H); 1.91 (s, 1H); 1.65 (s, 6H).
MS (ES +, m / z) 322.1 (base peak, M + H<sup>+</sup>); 665.1 (2M + Na<sup>+</sup>).
Optional secondary modification of the Hydroxy group
<img file="PL2464645T3_D0208.tif" />
In a 10-ml cone-shaped flask equipped with a 2- (4- (3 (trifluoromethyl) - [1,2,4] triazolo [4,3-a] pyridin-6-yl) phenyl) propan-2- magnetic stir bar ol (28 mg) was dissolved in dry THF (1 mL) and NaH (60% suspension in mineral oil, 20 ec) and MeI (50 ec) were added. The reaction mixture was stirred overnight at rt. Extracted with water and EtOAc, the organic layer was dried over MgSO4, concentrated, and purified by chromatography (3% MeOH in methylene chloride). The desired 6- (4- (2-methoxypropan-2-yl) phenyl) -3- (trifluoromethyl) - [1,2,4] triazolo [4,3-a] pyridine was isolated.
<sup>1</sup>1 H NMR (400 MHz, CDCl 3): δ 8.27 (s, 1H); 7.95 (d, 1H); 7.70 (d, 1H); 7.53 (br s, 4H); 3.09 (s, 3H); 1.54 (s, 6H).
MS (ES +, m / z) 336.1 (base peak, M + H<sup>+</sup>); 358.1 (M + Na<sup>+</sup>); 693.1 (2M + Na<sup>+</sup>).
B. Preparation of the compound of Formula I
<img file="PL2464645T3_D0209.tif" />
Level 1
Methyl 4- (3- (tritluoromethyl) - [1,2,4] triazolo [4,3-a] pyridin-6-yl) benzoate (12 mg) was dissolved in dioxane (1.5 mL). Lithium hydroxide (1 M in water, 0.5 mL) was added in one portion. After 24 h, 1N HCl was quenched. Extract with dichloromethane, dry with MgSO 4, and concentrate. 11 mg of 4- (3- (tritluoromethyl) - [1,2,4] triazolo [4,3-a] pyridin-6-yl) benzoic acid (~ 100%) was isolated.
<img file="PL2464645T3_D0210.tif" />
Stage 2
- 135 EP 2464645
4- (3- (trifluoromethyl) - [1,2,4] triazolo [4,3-a] pyridin-6-yl) benzoic acid (52 mg) was dissolved in DMF (2 mL). 3,3-difluouazazidine hydrochloride (26 mg), diisopropylethylamine (35 L) and HATU (93 mg) were added successively. After 24 h, additional diisopropylethylamine (105 μL) and HATU (279 mg) were added. When the reaction was almost complete, it was quenched with ethyl acetate / water, washed with 0.1N HCl, and concentrated NaHCO3. Purified on a prep-TLC plate using 5% MeOH / dichloromethane. 37 mg (3,3-difluoroazetidin-1-yl) (4- (3- (trifluoromethyl) - [1,2,4] triazolo [4,3-a] pyridin-6-yl) phenyl) methanone (57) was isolated %).
<sup>1</sup>1 H NMR (400 MHz, CDCl 3): δ 8.35 (s, 1H); 8.01 (d, J = 9.2 Hz, 1H); 7.80 (d, J = 8.4 Hz, 2H); 7.71 (dd, J = 9.2, 1.2 Hz, 1H); 7.66 (d, J = 8.4, 2H); 4.57 (t, J = 11.8 Hz).<sup>19</sup>F NMR (377 MHz, CDCl3): δ -63 (s, 3F); 100 (quintet, 2F).
MS (ES +, m / z) 383.2 (base peak, M + H<sup>+</sup>).
C. Preparation of compounds of Formula I by changing R<sup>1</sup>
Similarly, following the above procedure, but optionally substituting 3,3-difluoroazetidine hydrochloride for 4,4-difluoropyrimidine hydrochloride, the following compound of Formula I (4,4-difluoropiperidin-1-yl) (4- (3- (trifluoromethyl) - [ 1,2,4] triazolo [4,3-a] pyridin-6-yl) phenyl) -methanone, <sup>19</sup>F NMR: -63.49 (s, 3F); -98.47 (m, 2F).
D. Preparation of compounds of Formula I by changing R<sup>1</sup>, X<sup>1</sup>, and X<sup>2</sup>
Similarly, following the procedure of Example 26A or B above, but optionally substituting other benzoates for methyl 4- (3- (trifluoromethyl) - [1,2,4] triazolo [4,3-a] pyridin-6-yl) benzoate or compounds with methyllithium, lithium hydroxide, or 4,4-difluoropyrimidine hydrochloride, other compounds of Formula I can be prepared:
Example 27
Preparation of the compound of Formula I - Modification of the ethanone methyl ester group R<sup>1</sup>
A. Preparation of a compound of Formula I
<img file="PL2464645T3_D0211.tif" />
In a 50-ml round-bottom flask equipped with a magnetic stir bar 1- (4- (3 (trifluoromethyl) - [1,2,4] triazolo [4,3-a] pyridin-6-yl) phenyl) ethanone (50 mg ) was dissolved in dry toluene (1 mL), and ethylene glycol (0.1 mL) and camphorsulfonic acid (several crystals) were added. The reaction mixture was stirred overnight at reflux. Extract with concentrated NaHCO3 and EtOAc, the organic layer was dried over MgSO4, concentrated, and purified by chromatography (1: 1
(EP 2464645 hexanes / EtOAc). The desired 6- (4- (2-methyl-1,3-dioxolan-2-yl) phenyl) -3- (trifluoromethyl) [1,2,4] triazolo [4,3-a] pyridine was isolated.
<sup>1</sup>1 H NMR (400 MHz, CDCl 3): δ 8.38 (s, 1H); 8.02 (d, 1H); 7.75 (d, 1H); 7.70 (d, 2H); 7.57 (d, 2H); 4.12 (t, 2H); 3.83 (t, 2H).
MS (ES +, m / z) 350.0 (base peak, M + H<sup>+</sup>); 721.1 (2M + Na<sup>+</sup>).
B. Preparation of the compound of Formula I
<img file="PL2464645T3_D0212.tif" />
In a 50-mL round-bottomed flask equipped with a magnetic stir bar, ethyl cyanomethylphosphonate (73 mg) was stirred NaOMe (0.1 mL, 25 wt% in MeOH) in 4 mL MeOH and stirred for 15 min at rt. To this mixture, 1- (4- (3- (trifluoromethyl) - [1,2,4] triazolo [4,3-a] pyridin-6-yl) phenyl) ethanone (104 mg) was added as a solution in MeOH (1 mL ) and dry THF (3 mL). The reaction mixture was stirred overnight at reflux. Extracted water and dichloromethane, the organic layer was dried over MgSO 4, concentrated, and the mixture was separated by reverse phase chromatography (C (18), ACN / water).
(Z) -3- (4- (3- (trifluoromethyl) - [1,2,4] triazolo [4,3-a] pyridin-6-yl) phenyl) but-2-enenitrile was isolated and found to be 100% pure.
<sup>1</sup>1 H NMR (400 MHz, CDCl 3): δ 8.35 (s, 1H); 8.03 (d, J = 9.6 Hz, 1H); 7.75 (d, J = 8.4 Hz, 1H); 7.64 (s, 4H); 5.72 (s, 1 H); 2.54 (s, 3H).
MS (ES +, m / z) 329.0 (base peak, M + H<sup>+</sup>); 351.0 (M + Na<sup>+</sup>); 679.1 (2M + Na<sup>+</sup>).
(E) -3- (4- (3- (trifluoromethyl) - [1,2,4] triazolo [4,3-a] pyridin-6-yl) phenyl) but-2-enonitrile was isolated as a 5: 1 mixture from (Z) -3- (4- (3- (trifluoromethyl) - [1,2,4] triazolo [4,3-a] pyridin-6-yl) phenyl) but-2-enonitrile.
<sup>1</sup>1 H NMR (400 MHz, CDCl 3): δ 8.35 (s, 1H); 8.03 (d, J = 9.6 Hz, 1H); 7.75 - 7.70 (m, 3H); 7.64 (d, J = 8.8 Hz, 2H); 5.49 (s, 1H); 2.34 (s, 3H).
MS (ES +, m / z) 329.0 (base peak, M + H<sup>+</sup>); 351.0 (M + Na<sup>+</sup>); 679.1 (2M + Na<sup>+</sup>).
C. Preparation of compounds of Formula I by changing R<sup>1</sup>, X<sup>1</sup>, and X<sup>2</sup>
Similarly, according to the procedure of Example 27A or B above, but optionally substituting other ethanones for 1- (4- (3- (trifluoromethyl) - [1,2,4] triazolo [4,3-a] pyridin-6-yl phenyl) ethanone or other compounds for ethylene glycol or ethyl cyanomethylphosphonate, other compounds of Formula I can be prepared:
- 137 EP 2464645
Example 28
Hard gelatin capsules containing the following ingredients are made:
<td>Ingredient</td><td>Quantity (mg / capsule)</td>
<td>Active ingredient</td><td> 30.0</td>
<td>Starch</td><td> 305.0</td>
<td>Magnesium stearate</td><td> 5.0</td>
<td colspan="2">The above ingredients were mixed and filled into hard gelatin capsules.</td>
<td>Example 29</td><td></td>
<td colspan="2">A tablet according to Formula (I) was prepared using the following ingredients:</td>
<td>Ingredient</td><td>Quantity (mg / tablet)</td>
<td>Active ingredient</td><td> 25.0</td>
<td>Microcrystalline cellulose</td><td> 200.0</td>
<td>Colloidal silica</td><td> 10.0</td>
<td>Stearic acid</td><td> 5.0</td>
<td>The ingredients were mixed and pressed to obtain tablets.</td><td></td>
<td>Example 30</td><td></td>
<td colspan="2">An inhalable dry powder formulation was prepared containing the following ingredients:</td>
<td>Ingredients</td><td>Weight%</td>
<td>Active ingredient</td><td> 5</td>
<td>Lactose</td><td> 95</td>
<td colspan="2">The active ingredient was mixed with lactose and the mixture was added to a dry inhalation device</td>
<td>powder.</td><td></td>
<td>Example 31</td><td></td>
<td colspan="2">Tablets, each containing 30 mg of active ingredient, are prepared as follows:</td>
<td>Ingredient</td><td>Quantity (mg / tablet)</td>
<td>Active ingredient</td><td>30.0 mg</td>
<td>Starch</td><td>45.0 mg</td>
<td>Microcrystalline cellulose</td><td>35.0 mg</td>
<td>polyvinylpyrrolidone</td><td></td>
<td>(as a 10% solution in sterile water)</td><td>4.0 mg</td>
<td>Sodium carboxymethyl starch</td><td>4.5 mg</td>
<td>Magnesium stearate</td><td>0.5 mg</td>
<td>Talc</td><td>1.0 mg</td>
<td>Together</td><td>120 mg</td>
The active ingredient, starch and cellulose were passed through a No. 20 US sieve and mixed thoroughly. The polyvinylpyrrolidone solution was mixed with the obtained powders, which were passed through a No. 16 US sieve. The granules thus obtained were dried at 50 ° C to 60 ° C and passed through a No.
- 138 EP 2464645
US sodium carboxymethyl starch, magnesium stearate, and talc, previously passed through a US No. 30 screen, are added to the granules, which, after mixing, are compressed in a tablet press to obtain tablets of 120 mg each.
Example 32
Suppositories, each containing 25 mg of active ingredient are made as follows:
Component Quantity
Active ingredient 25 mg
Glycerides saturated fatty acids up to 2,000 mg
The active ingredient was passed through a 60 US sieve and suspended in saturated fatty acid glycerides previously melted using the minimum necessary heat. The mixture was poured into suppository molds with a nominal size of 2.0 g and allowed to cool.
Example 33
Suspensions, each containing 50 mg of active ingredient per 5.0 mL dose are made as follows:
Component Quantity
<td>Active ingredient</td><td>50.0 mg</td>
<td>Xanthan gum</td><td>4.0 mg</td>
<td>Sodium carboxymethyl cellulose (11%)</td><td></td>
<td>Microcrystalline cellulose (89%)</td><td>50.0 mg</td>
<td>Saccharose</td><td>1.75 g</td>
<td>Sodium benzoate</td><td>10.0 mg</td>
<td>Flavor and color</td><td>qv</td>
<td>Purified water for</td><td>5.0 mL</td>
The active ingredient, sucrose and xanthan gum were mixed, passed through a US No. 10 screen, and mixed with a previously made solution of microcrystalline cellulose and sodium carboxymethyl cellulose in water. Sodium benzoate, flavor, and coloring were diluted with some water and added with stirring. Sufficient water was then added to obtain the desired volume.
Example 34
The subcutaneous formulation may be prepared as follows:
Component Quantity
5.0 mg active ingredient
Corn oil 1.0 mL
Example 35
An injection preparation is prepared having the following composition:
- 139 EP 2464645
<td>Ingredients</td><td>Quantity</td>
<td>Active ingredient</td><td>2.0 mg / ml</td>
<td>Mannitol, USP</td><td>50 mg / ml</td>
<td>Gluconic acid, USP</td><td>qs (pH 5-6)</td>
<td>water (distilled, sterile)</td><td>qs up to 1.0 ml</td>
<td>Gaseous nitrogen, NF</td><td>qs</td>
<td>Example 36</td><td></td>
<td>A topical formulation is prepared having the following composition</td><td></td>
<td>Ingredients</td><td>grams</td>
<td>Active ingredient</td><td> 0.2-10</td>
<td>Span 60</td><td> 2.0</td>
<td>Tween 60</td><td> 2.0</td>
<td>Mineral oil</td><td> 5.0</td>
<td>Petrolatum</td><td> 0.10</td>
<td>methylparaben</td><td> 0.15</td>
<td>propyl paraben</td><td> 0.05</td>
<td>BHA (butylated hydroxyanisole)</td><td> 0.01</td>
<td>Water</td><td>qs up to 100</td>
<td>All of the above ingredients, except water, were combined and</td><td>heated to 60 ° C with stirring.</td>
<td colspan="2">Sufficient water was added at 60 ° C with vigorous stirring to emulsify the ingredients, and</td>
<td>water was then added qs 100 g.</td><td></td>
<td>Example 37</td><td></td>
<td>Sustained release composition</td><td></td>
<td>Ingredient</td><td>Weight range%</td>
<td>Active ingredient</td><td> 50-95</td>
<td>Microcrystalline cellulose (filler)</td><td> 1-35</td>
<td>Methacrylic acid copolymer</td><td> 1-35</td>
<td>Sodium hydroxide</td><td> 0.1-1.0</td>
<td>hydroxypropyl methylcellulose</td><td> 0.5-5.0</td>
<td>Magnesium stearate</td><td> 0.5-5.0</td>
The sustained release formulations of the present invention are prepared as follows: the compound and the pH-dependent binder and any optional excipients are mixed thoroughly (dry mixing). The dry-mixed mixture is granulated in the presence of a strong base aqueous solution, which is injected into the mixed powder. The granulate is dried, sieved, mixed with optional lubricants (such as talc or magnesium stearate), and compressed into tablets. Preferred aqueous solutions of the strong base are solutions of alkali metal hydroxides such as sodium or potassium hydroxide, preferably sodium hydroxide, in water (optionally containing up to 25% water-miscible solvents such as lower alcohols).
- 140 EP 2464645
The resulting tablets can be coated with an optional film-forming agent for identification, taste masking and to improve swallowing. The film-forming agent will typically be present in an amount of from 2% to 4% of the weight of the tablet. Suitable film forming agents are known in the art and include hydroxypropyl methylcellulose, cationic methacrylate copolymers (copolymers of dimethylaminoethyl methacrylate / methyl butyl methacrylate - Eudragit® E - Rohm. Pharma) and the like. These film forming agents can optionally contain dyes, plasticizers, and other additional ingredients.
The compressed tablets preferably have a hardness sufficient to withstand compression of 8 Kp. The size of the tablet will mainly depend on the amount of compound in the tablet. The tablets will contain from 300 to 1100 mg of the free base compound. Preferably, the tablets will contain an amount of the free base of the compound from 400600 mg, 650-850 mg, and 900-1100 mg.
To affect the dissolution rate, the time during which the powder containing compound is wet mixed is controlled. Preferably, the total powder mixing time, i.e. the time during which the powder is exposed to the sodium hydroxide solution, will be from 1 to 10 minutes and preferably from 2 to 5 minutes. After granulation, the particles are removed from the granulator and placed in a fluid bed dryer for drying at about 60 ° C.
Example 38
Activity testing is performed in the Examples below using methods described herein and those known in the art.
Sodium current screening tests:
Tests of late sodium current (Late INa) and peak sodium channel (Peak INa) are performed on an automatic electrophysiological platform, PatchXpress 7000A (MDS Analytical Technologies, Sunnyvale, CA), which uses the whole cell patch clamp technique to measure cell membrane currents up to 16 cells simultaneously. The test uses the HEK293 (human embryonic kidney) cell line heterologously expressing the wild type human cardiac sodium channel, hNav1.5, purchased from Millipore (Billerica, MA). There were no beta subunits co-expressed with Na channel alpha subunit. Cells are maintained according to standard tissue culture procedures and stable expression of the channel is maintained with 400 μg / ml Geneticin in culture medium. Cells isolated for use on PatchXpress are incubated for 5 minutes in Versene 1X and then for 2 minutes in 0.0125% Trypsin-EDTA (both at 37 ° C) to ensure that 80-90% of the cells are single and not part of a cell cluster. Experiments are performed at 24-27 ° C.
For both Late INa and Peak INa tests, the series resistance compensation is set to 50% and the compensation for whole cells is performed automatically. Currents are filtered at low flow at 10 kHz and digitized at 31.25 kHz. Currents through open sodium channels are automatically saved and stored in the DataXpress2 database (MDS Analytical Technologies, Sunnyvale, CA). The analysis is performed using DataXpress2 software and the data is compiled in Excel.
Compound stock solutions are routinely prepared in glass tubes up to 10 mM in dimethyl sulfoxide (DMSO). In some cases, when the compounds are not soluble in DMSO, they are
- made from 100% ethanol. Stock solutions are sonicated as needed. The extracellular solution for screening of Late INa is composed of: 140 mM NaCl, 4 mM KCl, 1.8 mM CaCl2, 0.75 mM MgCl2, and 5 mM HEPES with pH adjusted to 7.4 using NaOH. The extracellular solution for the Peak INa screening consists of: 20 mM NaCl, 120 mM N-methyl-D glucamine, 4 mM KCl, 1.8 mM CaCl<sub>2</sub>, 0.75 mM MgCl<sub>2</sub>, and 5 mM HEPES with the pH set to 7.4 using HCl. The intracellular solution used to perfuse the interior of the cells for both the Late INa and Peak INa assays contains: 120 mM CsF, 20 mM CsCl, 5 mM EGTA, 5 mM HEPES and pH set to 7.4 using CsOH. Compounds are diluted in an extracellular solution to 10 μΜ in glass tubes and transferred to glass wells before being automatically added to the cells. The 0Na cell solution used at the end of each experiment for the Late INa and Peak INa tests to measure the baseline current contains: 140 mM N-methyl-D-glucamine; 4 mM KCl; 1.8 mM CaCl<sub>2</sub>; 0.75 mM MgCl<sub>2</sub>; 5 mM HEPES and pH was set to 7.4 with HCl.
Late IN screening test:
For the Late INa assay, sodium channels are activated every 10 seconds (0.1 Hz) by depolarizing the cell membrane to -20 mV for 250 milliseconds (ms) from the holding potential of -120 mV. In response to the -20 mV voltage stage, typical sodium Nav1.5 currents activate quickly to peak negative current and deactivate almost completely within 3-4 ms.
All compounds are tested to determine their activity in blocking the late sodium current. The late INa current is generated by adding 10 μΜ Tefluthrin (pyrethroid) to the extracellular solution with the recording of Na currents. For some experiments, 50 nM ATX II (marine anemone toxin), another late INa activator, was used to generate the late component. Both activators generate late components that are large enough that the blocking of the late component by the compounds can easily be measured. For screening purposes, late INa is defined as the average current between 225 ms and 250 ms after switching to -20 mV for activation of Na channels. After setting up the whole cell recording configuration, the late INa activators were added to each well 4 times for a period of 16-17 minutes so that the late Na component reaches a stable value. Compounds are then added (typically in 10 μΜ), in the presence of late INa activator, with 3 additions within 7 or 8 minutes. Measurements are typically made at the end of the exposure to the third addition of the compound. Measurements are taken at the end of the exposure to the third addition of the compound and the values normalized to the current level when all Na<sup>+ </sup>is removed from the extracellular solution after two additions of 0Na-ECF. The results are given as a percentage of late IN block
Peak INa screening test:
The compounds were also evaluated for their effect in several other tests, including their effect on Peak INa. After screening for late INa, selected compounds are evaluated for their effect in several other tests, including their effect on peak INa. One goal of this program is to avoid the significant INa peak block. Because the peak INa in our cells can be very large, introducing artifacts in the record, the concentration of Na<sup>+</sup> in the bath it is reduced to 20 mM and an impermeable cation is added for Na compensation<sup>+</sup> which was removed to maintain osmolarity and ionic strength
Solution (see solution details above). All measurements are normalized to the current level when all Na<sup>+</sup> is removed from the extracellular solution after two additions of 0Na-ECF.
In some cases, the effect of the compound on the peak INa was measured using data from the late INa test. But often the peak currents were too high to be possible, requiring a separate test to assess the effect on peak INa. For the original peak INa assay, the channel is activated every 10 seconds by depolarizing the cell membrane to -20 mV for 250 ms from a holding potential of -120 mV. After establishing the recording configuration for whole cells, the recorded currents are allowed to stabilize for 6-7 minutes. The compound is added in 10 μΜ with three additions over a period of 8-9 minutes. The analysis of peak INa generally requires correction per round before determining the% of the peak current block by the test compound.
A new Peak INa screening test has been developed to enable an assessment of the effect of compounds on peak INa at low and high stimulation frequencies. The goal is to identify compounds that are highly selective for late INa block but do not block late INa. A low stimulation frequency of 0.1 Hz is used to determine the effect of a relationship when a channel spends most of its time in a resting (closed) state and provides tonic block (TB) information. A higher pacing frequency (3 Hz) is used to measure a channel block when it spends more time in active and inactive states, and provides a use-dependent block (UDB) measurement. Holding potential -100 mV and 3 Hz stimulation frequency were chosen so that our benchmark relationship would have a small but detectable effect under experimental conditions, allowing direct comparison of new compounds with the benchmark.
For the new INa peak test, Na channels<sup>+</sup> is activated by depolarizing the cell membrane to 0 mV for 20 ms from a holding potential of -100 mV. After establishing the entire cell recording configuration, the channels are stimulated at a low frequency to open (0.1 Hz) for 7 minutes so that the recording can be monitored and the degree of recording stabilization can be assessed. After a stabilization period, the stimulation frequency was increased to 3 Hz for 2 minutes, and returned to 0.1 Hz. Because 3 Hz stimulation causes a small drop in peak current even in the absence of a compound, this internal pattern is used for each cell when no compound is present, to correct the results from 3 Hz stimulation when a compound is present. After 3 Hz stimulation under control conditions, the cell was allowed to recover for 200 seconds before adding the compound. Compound (10 μΜ) is added 3 times at 60 second intervals, with channel stimulation to open at 0.1 Hz to monitor block progress. After the 3rd addition of the compound, a 320 second waiting period was used to equilibrate before the start of the second 3 Hz stimulation period. TB is measured before the second 3 Hz stimulation period. Both TB and UDB are analyzed by enabling round correction for peak INa and UDB is calculated by compensating for the small effect dependent on the use of the stimulation protocol for peak INa in the absence of relationship.
HERG screening test:
Compounds were screened to test their hERG potassium channel blocking activity.
The hERG channel is heterologously expressed in the CHO (Chinese hamster ovary) cell line.
Cells are maintained according to standard tissue culture procedures and stable expression
The channel is maintained with 500 μg / ml G418 in culture medium. Cells were harvested for testing on the PatchXpress automatic patch clamp from Accumax (Innovative Cell Technologies, San Diego, CA) to isolate individual cells.
The following solutions are used for electrophysiological records. The external solution contains: 2 mM CaCl2; 2 mM MgCl2; 4 mM KCl; 150 mM NaCl; 10 mM Glucose; 10 mM HEPES (pH 7.4 with 1M NaOH, osmolarity). The internal solution contains: 140 mM KCl, 10 mM MgCl2, 6 mM EGTA, 5 mM HEPES, 5 mM ATP (pH adjusted to 7.25 with KOH).
The hERG channels are activated when the voltage goes to +20 mV with a holding potential of -80 mV. During the 5 second stage at +20 mV, the channels activate and deactivate significantly, so that the currents are relatively small. After returning to -50 mV from +20 mV, the hERG currents temporarily become much larger when the deactivation is quickly removed and the channel closes. The first stage up to -50 mV for 300 ms is used as the baseline for measuring peak amplitude during the stage up to -50 mV after channel activation. Peak current at -50 mV is measured under control conditions and after compound addition.
All compounds are prepared as 10 mM DMSO solutions in glass tubes. Stock solutions are mixed vigorously by centrifugation and sonication for about 2 minutes at rt. For testing, the compounds are diluted in glass tubes using an intermediate dilution step in pure DMSO and then further diluted to working concentrations in the external solution. Dilutions are prepared no more than 20 minutes before use.
After obtaining the whole cell configuration, the cells are monitored for 90 seconds to assess stability and washed with external solution for 66 seconds. The voltage protocol described above is applied to the cells every 12 seconds and throughout the procedure. Only cells with stable recording parameters and meeting specific health criteria can enter the compound addition procedure.
An external solution containing 0.1% DMSO (medium) is applied to the cells first to establish a control peak current amplitude. After stabilizing the current for 3 to 5 minutes, test compounds 1 μΜ and 10 μΜ were added. each compound concentration is added 4 times and the cells are kept in the test solution until the compound effect is stable or for a maximum of 12 minutes. After adding the test compound, a positive control (1 μΜ Cisapride) was added and must block> 95% current to consider the experiment valid. A wash is made in the internal solution compartment until the current recovery is stable. Data is analyzed using DataXpress, Clampfit (Molecular Devices, Inc., Sunnyvale) and Origin 7 (Originlab Corp.)
Plate test for L-type calcium channel activity
Cell culture: IMR-32 (human neuroblastoma) cells were obtained from The American Type Culture Collection. Cells were maintained in MEM supplemented with 10% fetal bovine serum, 2 mM L-glutamine, 100 IU / ml penicillin, 50 μg / ml streptomycin, 1% sodium pyruvate, 1% sodium bicarbonate and 1% non-essential amino acid. Cells were cultured at 37 ° C in a humidified 5% CO2 / 95% air incubator. The culture medium was changed every two days and the cells were recultivated when they reached 70-80% confluence.
- EP 2464645
Assay: IMR-32 cells were plated on a Microtest 96 well assay plate (BD FALCONTM) at a density of 200,000 cells / well in 200 μΐ culture medium overnight. Culture medium was removed, and replaced by 120 μl of Ca-4 dye (MDS Analytical Technologies, Sunnyvale, CA) in HBSS (1x Hank's balanced salt solution plus 20 mM HEPES, pH 7.4) containing 2 mM probenecid. Cells were incubated for 1 h at 37 ° in an incubator. Test compounds were diluted from 5 μΜ - 50 μΜ in HBSS, and 40 μl was added to the cells before the test. L-type calcium channel activity (Max - Min) was measured after addition of 40 μl 1 μΜ (-) Bay K 8644 plus 50 mM KCl (final concentration) using FlexStation (Molecular Devices) from times after addition of test compounds. The inhibition of L-type calcium channel activity by compounds was then calculated.
The compounds were tested and found to be effective using the described test methods at a concentration of 1 μΜ and 10 μΜ in the Late INa and Peak INa assays, and at 1 μΜ and 10μΜ for hERG and Type L calcium channel tests. Test results showed that the test the compounds showed activity as late sodium current modulators, for example by inhibiting (or reducing) sodium late current.
Compounds were tested using the test methods described. Data were obtained by testing the compounds listed at 10 μΜ and 1 μΜ in the late INa assay, and at 1 μΜ and 10 μΜ for hERG and L-type calcium channel tests. Data are shown in Table 1 below for those compounds that inhibit Late INa by at least 10% at a concentration of 10 μΜ.
- 145 EP 2464645
Table 1: Late IN test results
<td>PóźnyINa_10u M</td><td> 67.5</td><td> 52.9</td><td> 76.8</td><td> 53.5</td><td> 81.3</td><td> 54</td><td> 55.4</td><td> 78.8</td><td> 75.7</td><td> 51.2</td><td> 44.7</td><td> 79.7</td><td> 87.1</td><td> 28.3</td><td> 52.5</td><td> 54.3</td><td> 25.3</td><td> 54.6</td><td> 35.4</td><td> 72.9</td><td> 86.5</td><td> 58.9946</td><td> 74.6757</td>
<td>PóźnyINa_1uM</td><td> 49</td><td></td><td> 09</td><td></td><td> 50.3</td><td></td><td></td><td>HO WHAT</td><td> 29.6</td><td></td><td></td><td> 39.6</td><td> 44.8</td><td></td><td></td><td></td><td></td><td></td><td></td><td> 46.6</td><td> 65.1861</td><td></td><td> 53.5406</td>
<td>Name (compounds marked with * included only as a reference)</td><td>7-Methyl-6- (4- (trifluoromethoxy) phenyl) -3- (trifluoromethyl) - [1,2,4] triazolo [4,3-a] pyridine</td><td>6- (3- (trifluoromethoxy) phenyl) -3- (trifluoromethyl) - [1,2,4] triazolo [4,3-a] pyridine</td><td>3- (trifluoromethyl) -6- [4- (trfluorometylo) phenyl] [1,2,4] triazolo [4,3-a] pyridine</td><td>6- (2,4-dichlorophenyl) -3- (trifluoromethyl) [1,2,4] triazolo [4,3-a] pyridine</td><td>6- [4- (trifluoromethoxy) phenyl] -3- (trifluoromethyl) imidazo [1,5-a] pyridine (*)</td><td>6- [4- (difluoromethoxy) phenyl] -3- (trifluoromethyl) [1,2,4] triazolo [4,3-a] pyridine</td><td>6- (4-phenoxyphenyl) -3- (trifluoromethyl) imidazo [1,5-a] pyridine (*)</td><td>6- [4- (trifluoromethoxy) phenyl] -3- (trifluoromethyl) [1,2,4] triazolo [4,3-b] pyridazine (*)</td><td>6- (3-phenoxyphenyl) -3- (trifluoromethyl) [1,2,4] triazolo [4,3-a] pyridine</td><td>6- [4-chloro-3- (trifluoromethyl) phenyl] -3- (trifluoromethyl) [1,2,4] triazolo [4,3-a] pyridine</td><td>6- (4-phenoxyphenyl) -3- (trifluoromethyl) [1,2,4] triazolo [4,3-b] pyridazine (*)</td><td>3- (difluoromethyl) -6- [4- (trifluoromethoxy) phenyl] [1,2,4] triazolo [4,3-b] pyridazine (*)</td><td>3- (difluoromethyl) -6- (4-phenoxyphenyl) [1,2,4] triazolo [4,3-b] pyridazine (*)</td><td>6- (4-chloro-3-fluorophenyl) -3- (trifluoromethyl) [1,2,4] triazolo [4,3-a] pyridine</td><td>6- [4- (trifluoromethoxy) phenyl] -3- (trifluoromethyl) [1,2,4] triazolo [4,3-a] pyrazine (*)</td><td>6- (4-phenoxyphenyl) -3- (trifluoromethyl) [1,2,4] triazolo [4,3-a] pyrazine (*)</td><td>7-methyl-6- [3- (trifluoromethoxy) phenyl] -3- (trifluoromethyl) [1,2,4] triazolo [4,3-a] pyridine</td><td>3- (difluoromethyl) -6- (4-phenoxyphenyl) [1,2,4] triazolo [4,3-a] pyrazine (*)</td><td>{6- [4- (Trifluoromethoxy) phenyl] [1,2,4] triazolo [4,3-a] pyridin-3-yl} acetic acid</td><td>3- (difluoromethyl) -6- [4- (trifluoromethoxy) phenyl] [1,2,4] triazolo [4,3-a] pyridine</td><td>3-phenyl-6- [4- (trifluoromethoxy) phenyl] [1,2,4] triazolo [4,3-a] pyridine</td><td>6- (4-phenoxyphenyl) [1,2,4] triazolo [4,3-b] pyridazine (*)</td><td>3- (difluoromethyl) -6- [4- (trifluoromethoxy) phenyl] [1,2,4] triazolo [4,3-a] pyrazine (*)</td>
<td>Example No.</td><td>BHN-1.</td><td>BHN-2.</td><td>BHN-3.</td><td>BHN-4.</td><td>BHN-5.</td><td>BHN-6.</td><td>BHN-7.</td><td>BHN-8.</td><td>BHN-9.</td><td>BHN-10.</td><td>Π-ΝΗΉ</td><td>BHN-12.</td><td>BHN-13.</td><td>BHN-14.</td><td>BHN-15.</td><td>BHN-16.</td><td>BHN-17.</td><td>BHN-18.</td><td>BHN-19.</td><td>BHN-20.</td><td>BHN-21.</td><td>BHN-22.</td><td>BHN-23.</td>
- 146 EP 2464645
<td> 89.4833</td><td> 38.9637</td><td> 75.3492</td><td> 84.8865</td><td> 78.3068</td><td> 62.8222</td><td> 77.2627</td><td> 82.5547</td><td> 83.3609</td><td> 75.9223</td><td> 33.3917</td><td> 68.5617</td><td> 64.5106</td><td> 59.7614</td><td> 79.348</td><td> 74.2699</td><td> 38.2354</td><td> 59.1461</td><td> 43.8433</td><td> 25.2135</td><td> 15.0257</td><td> 36.2623</td><td> 53.9313</td><td> 50.7485</td><td> 18.8946</td>
<td> 67.723</td><td></td><td> 64.4143</td><td> 71.9653</td><td> 46.1443</td><td> 20.888</td><td> 24.5771</td><td> 57.5195</td><td> 63.4332</td><td> 59.2146</td><td></td><td></td><td></td><td> 41.7903</td><td> 54.508</td><td> 44.4142</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td>6- (4-tert-butylphenyl) -3- (trifluoromethyl) [1,2,4] triazolo [4,3-a] pyridine</td><td>6- [4- (trifluoromethoxy) phenyl] [1,2,4] triazolo [4,3-b] pyridazine (*)</td><td>6- [2-methyl-4- (trifluoromethoxy) phenyl] -3- (trifluoromethyl) [1,2,4] triazolo [4,3-b] pyridazine (*)</td><td>3- (trifluoromethyl) -6- [4- (trimethylsilyl) phenyl] [1,2,4] triazolo [4,3-a] pyridine</td><td>6- [4- (2,2,2-trifluoroethoxy) phenyl] -3- (trifluoromethyl) imidazo [1,5-a] pyridine (*)</td><td>6- (4-methoxyphenyl) -3- (trifluoromethyl) [1,2,4] triazolo [4,3-a] pyridine</td><td>6- (4-methoxyphenyl) -3- (trifluoromethyl) imidazo [1,5-a] pyridine (*)</td><td>6- (4-phenoxyphenyl) -3- (2,2,2-trifluoroethyl) [1,2,4] triazolo [4,3-b] pyridazine (*)</td><td>6- (4-phenoxyphenyl) -3- (propan-2-yl) [1,2,4] triazolo [4,3-b] pyridazine (*)</td><td>6- [2-methyl-4- (trifluoromethoxy) phenyl] -3- (propan-2-yl) [1,2,4] triazolo [4,3-b] pyridazine (*)</td><td>1-phenyl-6- [4- (trifluoromethoxy) phenyl] -3- (trifluoromethyl) imidazo [1,5-a] pyridine (*)</td><td>3-tert-butyl-6- (4-phenoxyphenyl) [1,2,4] triazolo [4,3-b] pyridazine (*)</td><td>3-tert-butyl-6- [4- (2,2,2-trifluoroethoxy) phenyl] [1,2,4] triazolo [4,3-b] pyridazine (*)</td><td>6- [4- (2,2,2-trifluoroethoxy) phenyl] -3- (trifluoromethyl) [1,2,4] triazolo [4,3-a] pyridine</td><td>3-ethyl-6- (4-phenoxyphenyl) [1,2,4] triazolo [4,3-b] pyridazine (*)</td><td>3-cyclopropyl-6- (4-phenoxyphenyl) [1,2,4] triazolo [4,3-b] pyridazine (*)</td><td>4- [6- (4-phenoxyphenyl) [1,2,4] triazolo [4,3-b] pyridazin-3-yl] benzonitrile (*)</td><td>4- {6- [2-methyl-4- (trifluoromethoxy) phenyl] [1,2,4] triazolo [4,3-b] pyridazin-3-yl} benzonitrile (*)</td><td>4- {6- [4- (trifluoromethoxy) phenyl] [1,2,4] triazolo [4,3-b] pyridazin-3-yl} benzonitrile (*)</td><td>3- (1-methyl-1H-pyrazol-4-yl) -6- (4-phenoxyphenyl) [1,2,4] triazolo [4,3-b] pyridazine (*)</td><td>4- [6- (4-methoxyphenyl) [1,2,4] triazolo [4,3-b] pyridazin-3-yl] benzonitrile (*)</td><td>3- [6- (4-methoxyphenyl) [1,2,4] triazolo [4,3-b] pyridazin-3-yl] benzonitrile (*)</td><td>Methyl 4- [3- (trifluoromethyl) [1,2,4] triazolo [4,3-a] pyridin-6-yl] benzoate</td><td>3- [4- (methylsulfonyl) phenyl] -6- (4-phenoxyphenyl) [1,2,4] triazolo [4,3-b] pyridazine (*)</td><td>2- {4- [3- (trifluoromethyl) [1,2,4] triazolo [4,3-a] pyridin-6-yl] phenyl} propan-2-ol</td>
<td>BHN-24.</td><td>BHN-25.</td><td>BHN-26.</td><td>BHN-27.</td><td>BHN-28.</td><td>BHN-29.</td><td>BHN-30.</td><td>BHN-31.</td><td>BHN-32.</td><td>BHN-33.</td><td>BHN-34.</td><td>BHN-35.</td><td>BHN-36.</td><td>BHN-37.</td><td>BHN-38.</td><td>BHN-39.</td><td>BHN-40.</td><td>BHN-41.</td><td>BHN-42.</td><td>BHN-43.</td><td>BHN-44.</td><td>BHN-45.</td><td>BHN-46.</td><td>BHN-47.</td><td>BHN-48.</td>
- 147 EP 2464645
<td></td><td> 31.0469</td><td> 40.5409</td><td> 44.8746</td><td> 25.1019</td><td></td><td> 90.7299</td><td> 48.512</td><td> 39.4525</td><td> 27.6455</td><td> 39.8471</td><td> 48.5826</td><td> 23.4548</td><td></td><td></td><td> 69.6326</td><td> 85.7214</td><td> 70.6838</td><td> 80.6821</td><td> 21.9692</td><td> 32.102</td><td> 40.385</td><td> 20.5184</td><td> 26.735</td><td> 17.4588</td>
<td></td><td></td><td></td><td></td><td></td><td></td><td> 89.1394</td><td></td><td> 45.8426</td><td></td><td></td><td></td><td></td><td></td><td></td><td> 38.1971</td><td> 55.5803</td><td> 33.1801</td><td> 71.8028</td><td></td><td></td><td></td><td></td><td></td><td></td>
<td>3- {6- [6- (morpholin-4-yl) pyridin-3-yl] [1,2,4] triazolo [4,3-b] pyridazin-3-yl} benzonitrile (*)</td><td>6- (4-phenoxyphenyl) -3- [4- (2H-tetrazol-5-yl) phenyl] [1,2,4] triazolo [4,3-b] pyridazine (*)</td><td>3- [6- (4-fluorophenyl) [1,2,4] triazolo [4,3-b] pyridazin-3-yl] benzonitrile (*)</td><td>3-phenyl-6- [4- (trifluoromethoxy) phenyl] [1,2,4] triazolo [4,3-a] pyridin-8-amine</td><td>4- [3- (trifluoromethyl) [1,2,4] triazolo [4,3-a] pyridin-6-yl] benzonitrile</td><td>6- [2- (1H-tetrazol-5-yl) phenyl] -3- (trifluoromethyl) [1,2,4] triazolo [4,3-a] pyridine</td><td>3,6-bis [4- (trifluoromethoxy) phenyl] [1,2,4] triazolo [4,3-a] pyridine</td><td>3- (propan-2-yl) -6- [4- (trifluoromethoxy) phenyl] [1,2,4] triazolo [4,3-a] pyridine</td><td>6- (biphenyl-4-yl) -3- (trifluoromethyl) [1,2,4] triazolo [4,3-a] pyridine</td><td>(2E) -3- {6- [4- (trifluoromethoxy) phenyl] -3- (trifluoromethyl) imidazo [1,5-a] pyridin-1-yl} prop-2-methylate (*)</td><td>6- (1-methyl-1H-indazol-5-yl) -3- (trifluoromethyl) [1,2,4] triazolo [4,3-a] pyridine</td><td>2- [6- (4-phenoxyphenyl) [1,2,4] triazolo [4,3-b] pyridazin-3-yl] propan-2-ol (*)</td><td>6- [4- (1H-1,2,4-triazol-1-yl) phenyl] -3- (trifluoromethyl) [1,2,4] triazolo [4,3-a] pyridine</td><td>Methyl 6- [4- (trifluoromethoxy) phenyl] [1,2,4] triazolo [4,3-a] pyridine-3-carboxylate</td><td>N-methyl-6- [4- (trifluoromethoxy) phenyl] [1,2,4] triazolo [4,3-a] pirydynao-3-carboxamide</td><td>6- [4- (4-fluorophenoxy) phenyl] -3- (trifluoromethyl) [1,2,4] triazolo [4,3-a] pyridine</td><td>6- [4- (4-chlorophenoxy) phenyl] -3- (trifluoromethyl) [1,2,4] triazolo [4,3-a] pyridine</td><td>2-Methyl-2- {4- [3- (trifluoromethyl) [1,2,4] triazolo [4,3-a] pyridin-6-yl] phenyl} propanenitryl</td><td>6- [3-methyl-4- (trifluoromethoxy) phenyl] -3- (trifluoromethyl) [1,2,4] triazolo [4,3-a] pyridine</td><td>6- [4- (propan-2-ylsulfonyl) phenyl] -3- (trifluoromethyl) [1,2,4] triazolo [4,3-a] pyridine</td><td>3-methyl-6- [4- (trifluoromethoxy) phenyl] [1,2,4] triazolo [4,3-a] pyridin-8-amine</td><td>3-methyl-6- [2-methyl-4- (trifluoromethoxy) phenyl] [1,2,4] triazolo [4,3-a] pyridin-8-amine</td><td>6- [4- (5-methyl-1,3,4-oxadiazol-2-yl) phenyl] -3- (trifluoromethyl) [1,2,4] triazolo [4,3-a] pyridine</td><td>6- [3- (morpholin-4-ylmethyl) -4- (trifluoromethoxy) phenyl] -3- (trifluoromethyl) [1,2,4] triazolo [4,3-a] pyridine</td><td>4- {6- [4- (trifluoromethoxy) phenyl] [1,2,4] triazolo [4,3-a] pyridin-3-yl} benzenesulfonamide</td>
<td>BHN-49.</td><td>BHN-50.</td><td>BHN-51.</td><td>BHN-52.</td><td>BHN-53.</td><td>BHN-54.</td><td>BHN-55.</td><td>BHN-56.</td><td>BHN-57.</td><td>BHN-58.</td><td>BHN-59.</td><td>BHN-60.</td><td>BHN-61.</td><td>BHN-62.</td><td>BHN-63.</td><td>BHN-64.</td><td>BHN-65.</td><td>BHN-66.</td><td>BHN-67.</td><td>BHN-68.</td><td>BHN-69.</td><td>BHN-70.</td><td>BHN-71.</td><td>BHN-72.</td><td>BHN-73.</td>
- EP 2464645
<td> 67.0321</td><td> 30.0736</td><td> 31.8678</td><td> 56.8121</td><td> 49.8074</td><td> 19.2748</td><td> 58.9887</td><td> 30.3438</td><td> 38.8602</td><td> 29.7759</td><td></td><td>00 about cd these about cd</td><td> 86.8539</td><td> 72.2054</td><td> 35.9522</td><td> 20.4645</td><td> 74.8949</td><td> 46.7392</td><td> 76.3047</td><td> 20.9754</td><td> 27.4516</td><td></td><td></td><td></td>
<td> 46.9061</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td> 82.7225</td><td> 38.949</td><td></td><td></td><td> 63.3768</td><td></td><td> 63.5039</td><td></td><td></td><td></td><td> 20.2987</td><td> 73.2015</td>
<td>3- (1,1-difluoro-2-methoxyethyl) -6- [4- (trifluoromethoxy) phenyl] [1,2,4] triazolo [4,3-a] pyridine</td><td>N- (4- {6- [4- (trifluoromethoxy) phenyl] [1,2,4] triazolo [4,3-a] pyridin-3-yl} phenyl) methanesulfonamide</td><td>N- {3-methyl-6- [2-methyl-4- (trifluoromethoxy) phenyl] [1,2,4] triazolo [4,3-a] pyridin-8-yl} acetamide</td><td>6- (4-ethoxyphenyl) -3- (trifluoromethyl) [1,2,4] triazolo [4,3-a] pyridine</td><td>6- (4-tert-Butoxy-phenyl) -3- (trifluoromethyl) [1,2,4] triazolo [4,3-a] pyridine</td><td>4- {6- [4- (trifluoromethoxy) phenyl] [1,2,4] triazolo [4,3-a] pyridin-3-yl} benzamide</td><td>3,3 '- [1,2,4] triazolo [4,3-a] pyridine-3,6-dildibenzoate diethyl</td><td>6- {3 - [(4-methylpiperazin-1-yl) methyl] -4- (trifluoromethoxy) phenyl} -3- (trifluoromethyl) [1,2,4] triazolo [4,3-a] pyridine</td><td>3- (1-methyl-1H-pyrazol-4-yl) -6- [4- (trifluoromethoxy) phenyl] [1,2,4] triazolo [4,3-a] pyridine</td><td>N, N-dimethyl-1- {2- (trifluoromethoxy) -5- [3- (trifluoromethyl) [1,2,4] triazolo [4,3-a] pyridin-6-yl] phenyl} methanamine</td><td>2 - ({2- (trifluoromethoxy) -5- [3- (trifluoromethyl) [1,2,4] triazolo [4,3-a] pyridin-6-yl] -benzyl} -amino) ethanol</td><td>N- {3-methyl-6- [4- (trifluoromethoxy) phenyl] [1,2,4] triazolo [4,3-a] pyridin-8-yl} propanamide</td><td>Ethyl 4- {6- [4- (trifluoromethoxy) phenyl] [1,2,4] triazolo [4,3-a] pyridin-3-yl} benzoate</td><td>Ethyl 3- {6- [4- (trifluoromethoxy) phenyl] [1,2,4] triazolo [4,3-a] pyridin-3-yl} benzoate</td><td>6- (6-cyclopropyl-pyridin-3-yl) -3- (trifluoromethyl) [1,2,4] triazolo [4,3-a] pyridine</td><td>6- (2-cyclopropylpyrimidin-5-yl) -3- (trifluoromethyl) [1,2,4] triazolo [4,3-a] pyridine</td><td>6- (4-cyclopropyl-phenyl) -3- (trifluoromethyl) [1,2,4] triazolo [4,3-a] pyridine</td><td>3- (trifluoromethyl) -6- [6- (trifluoromethyl) pyridin-3-yl] [1,2,4] triazolo [4,3-a] pyridine</td><td>6- [6- (2,2,2-trifluoroethoxy) pyridin-3-yl] -3- (trifluoromethyl) [1,2,4] triazolo [4,3-a] pyridine</td><td>N- (2- {6- [4- (trifluoromethoxy) phenyl] [1,2,4] triazolo [4,3-a] pyridin-3-yl} phenyl) methanesulfonamide</td><td>6- [4- (pyrazin-2-yloxy) phenyl] -3- (trifluoromethyl) [1,2,4] triazolo [4,3-a] pyridine</td><td>N - ({6- [4- (trifluoromethoxy) phenyl] [1,2,4] triazolo [4,3-a] pyridin-3-yl} methyl) methanesulfonamide</td><td>6- (5-cyclopropyl-1,3,4-thiadiazol-2-yl) -3- (trifluoromethyl) [1,2,4] triazolo [4,3-a] pyridine</td><td>6- (4-phenoxyphenyl) tetrazolo [1,5-a] pyridine (*)</td>
<td>BHN-74.</td><td>BHN-75.</td><td>BHN-76.</td><td>BHN-77.</td><td>BHN-78.</td><td>BHN-79.</td><td>BHN-80.</td><td>BHN-81.</td><td>BHN-82.</td><td>BHN-83.</td><td>BHN-84.</td><td>BHN-85.</td><td>BHN-86.</td><td>BHN-87.</td><td>BHN-88.</td><td>BHN-89.</td><td>BHN-90.</td><td>BHN-91.</td><td>BHN-92.</td><td>BHN-93.</td><td>BHN-94.</td><td>BHN-95.</td><td>BHN-96.</td><td>BHN-97.</td>
- 149 EP 2464645
<td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td> 63.0914</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td> 54.0834</td><td> 19.5847</td><td> 27.6277</td><td> 32.3221</td><td> 45.5067</td><td> 40.7323</td><td> 31.6916</td><td> 49.3177</td><td> 38.2035</td><td> 16.5096</td><td> 45.7361</td><td>He ABOUT ABOUT 00 WELL</td><td> 18.2387</td><td> 28.9842</td><td> 32.8537</td><td> 20.132</td><td> 37.3626</td><td>He WELL He 00</td><td> 16.4416</td><td> 66.3166</td><td> 46.2911</td><td> 70.4905</td><td> 20.3841</td><td> 21.9422</td><td> 31.8383</td>
<td>6- [4- (trifluoromethoxy) phenyl] tetrazolo [1,5-a] pyridine</td><td>N-methyl-3- {6- [4- (trifluoromethoxy) phenyl] [1,2,4] triazolo [4,3-a] pyridin-3-yl} benzamide</td><td>6- [4- (pyridin-3-yloxy) phenyl] -3- (trifluoromethyl) [1,2,4] triazolo [4,3-a] pyridine</td><td>6- [6- (methylsulfanyl) pyridin-3-yl] -3- (trifluoromethyl) imidazo [1,5-a] pyridine (*)</td><td>6- [4- (cyclopropyloxy) phenyl] -3- (trifluoromethyl) [1,2,4] triazolo [4,3-a] pyridine</td><td>8-methyl-6- [4- (trifluoromethoxy) phenyl] -3- (trifluoromethyl) [1,2,4] triazolo [4,3-a] pyridine</td><td>7-methoxy-6- [4- (trifluoromethoxy) phenyl] -3- (trifluoromethyl) [1,2,4] triazolo [4,3-a] pyridine</td><td>6- [2-methoxy-4- (trifluoromethyl) phenyl] -3- (trifluoromethyl) [1,2,4] triazolo [4,3-a] pyridine</td><td>6- (naphthalen-2-yl) -3- (trifluoromethyl) [1,2,4] triazolo [4,3-a] pyridine</td><td>3- (trifluoromethyl) -6- (3,4,5-trimethoxyphenyl) [1,2,4] triazolo [4,3-a] pyridine</td><td>8- (trifluoromethoxy) -5- [3- (trifluoromethyl) [1,2,4] triazolo [4,3-a] pyridin-6-yl] quinoline</td><td>6- (3,5-difluoro-4-phenoxyphenyl) -3- (trifluoromethyl) [1,2,4] triazolo [4,3-a] pyridine</td><td>6- [4- (4-fluoro-2-nitrophenoxy) phenyl] -3- (trifluoromethyl) [1,2,4] triazolo [4,3-a] pyridine</td><td>2,2-difluoro-2- [6- (4-phenoxyphenyl) [1,2,4] triazolo [4,3-a] pyridin-3-yl] ethanol</td><td>6- [4- (2-fluorophenoxy) phenyl] -3- (trifluoromethyl) [1,2,4] triazolo [4,3-a] pyridine</td><td>6- [4- (pyridin-4-yloxy) phenyl] -3- (trifluoromethyl) [1,2,4] triazolo [4,3-a] pyridine</td><td>N-phenyl-4- [3- (trifluoromethyl) [1,2,4] triazolo [4,3-a] pyridin-6-yl] aniline</td><td>N- (2,2,2-trifluoroethyl) -4- [3- (trifluoromethyl) [1,2,4] triazolo [4,3-a] pyridin-6-yl] aniline</td><td>N- [5- (trifluoromethoxy) -2- {3- [4- (trifluoromethoxy) phenyl] [1,2,4] triazolo [4,3-a] pyridin-6-yl} phenyl] acetamide</td><td>6- [4- (trifluoromethoxy) phenyl] -3- (trifluoromethyl) imidazo [1,5-a] pyridine-1-carbonitrile (*)</td><td>3,6-bis [4- (trifluoromethoxy) phenyl] [1,2,4] triazolo [4,3-b] pyridazine (*)</td><td>6- [4- (phenylsulfanyl) phenyl] -3- (trifluoromethyl) [1,2,4] triazolo [4,3-a] pyridine</td><td>6- (naphthalen-1-yl) -3- (trifluoromethyl) [1,2,4] triazolo [4,3-a] pyridine</td><td>3- (trifluoromethyl) -6- [6- (trifluoromethyl) pyridazin-3-yl] [1,2,4] triazolo [4,3-a] pyridine</td><td>3- (trifluoromethyl) -6- [2- (trifluoromethyl) pyrimidin-5-yl] [1,2,4] triazolo [4,3-a] pyridine</td>
<td>BHN-98.</td><td>BHN-99.</td><td>ΌΟΐ-ΝΗΉ</td><td>BHN-101.</td><td>BHN-102.</td><td>BHN-103.</td><td>BHN-104.</td><td>BHN-105.</td><td>BHN-106.</td><td>BHN-107.</td><td>BHN-108.</td><td>BHN-109.</td><td>Όΐΐ-ΝΗΉ</td><td>ΐΐΐ-ΝΗΉ</td><td>BHN-112.</td><td>εΐΐ-ΝΗΉ</td><td>BHN-114.</td><td>BHN-115.</td><td>BHN-116.</td><td>BHN-117.</td><td>BHN-118.</td><td>BHN-119.</td><td>BHN-120.</td><td>BHN-121.</td><td>BHN-122.</td>
- 150 EP 2464645
<td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td> 23.357</td><td> 81.9921</td><td> 33.8728</td><td> 26.8698</td><td> 93.196</td><td> 65.6436</td><td>00 about '/ Ί cn 00 "-t</td><td> 21.9314</td><td>kO cn '/ Ί 00</td><td> 29.4015</td><td> 42.4689</td><td> 27.754</td><td> 49.1989</td><td> 44.9887</td><td> 48.1809</td><td> 42.777</td><td> 15.3935</td><td> 53.2223</td><td> 32.4632</td><td> 38.7883</td><td> 81.4091</td><td> 36.3798</td><td> 55.3219</td><td>cn -t nu oO '/ Ί</td><td> 29.0541</td>
<td>4- [3- (trifluoromethyl) [1,2,4] triazolo [4,3-a] pyridin-6-yl] -N- (2,2,2-trifluoro-1-phenylethyl) aniline</td><td>6- [2-bromo-4- (trifluoromethoxy) phenyl] -3- (trifluoromethyl) [1,2,4] triazolo [4,3-a] pyridine</td><td>{6- [4- (trifluoromethoxy) phenyl] -3- (trifluoromethyl) imidazo [1,5-a] pyridin-1-yl} methanol (*)</td><td>3- (difluoromethyl) -8-methoxy-6- [4- (trifluoromethoxy) phenyl] [1,2,4] triazolo [4,3-a] pyridine</td><td>3 - [(benzyloxy) methyl] -6- [4- (trifluoromethoxy) phenyl] [1,2,4] triazolo [4,3-a] pyridine</td><td>3 - [(cyclopropylmethoxy) methyl] -6- [4- (trifluoromethoxy) phenyl] [1,2,4] triazolo [4,3-a] pyridine</td><td>3 - [(2,2,2-trifluoroethoxy) methyl] -6- [4- (trifluoromethoxy) phenyl] [1,2,4] triazolo [4,3-a] pyridine</td><td>{6- [4- (trifluoromethoxy) phenyl] [1,2,4] triazolo [4,3-a] pyridin-3-yl} methanol</td><td>6- [2- (2-methoxy-5-yl) -4- (trifluoromethoxy) phenyl] -3- (trifluoromethyl) [1,2,4] triazolo [4,3-a] pyridine</td><td>6- [2- (pyridin-3-yl) -4- (trifluoromethoxy) phenyl] -3- (trifluoromethyl) [1,2,4] triazolo [4,3-a] pyridine</td><td>1-methyl-6- [4- (trifluoromethoxy) phenyl] -3- (trifluoromethyl) imidazo [1,5-a] pyridine (*)</td><td>2- (trifluoromethoxy) -5- [3- (trifluoromethyl) [1,2,4] triazolo [4,3-a] pyridin-6-yl] aniline</td><td>1- {4- [3- (trifluoromethyl) [1,2,4] triazolo [4,3-a] pyridin-6-yl] phenyl} -cyclopentanecarbonitrile</td><td>3- (1,1-difluoro-2-methoxyethyl) -6- (4-phenoxyphenyl) [1,2,4] triazolo [4,3-a] pyridine</td><td>6- [4- (4-chlorophenoxy) phenyl] -3- (1,1-difluoro-2-methoxyethyl) [1,2,4] triazolo [4,3-a] pyridine</td><td>3- (1,1-difluoro-2-methoxyethyl) -6- [4- (4-fluorophenoxy) phenyl] [1,2,4] triazolo [4,3-a] pyridine</td><td>3- [1,1-difluoro-2- (pyridin-3-ylmethoxy) -ethyl] -6- [4- (trifluoromethoxy) phenyl] [1,2,4] triazolo [4,3-a] pyridine</td><td>3- [difluoro (methoxy) methyl] -6- [4- (trifluoromethoxy) phenyl] [1,2,4] triazolo [4,3-a] pyridine</td><td>3- [difluoro (2-methoxyethoxy) methyl] -6- [4- (trifluoromethoxy) phenyl] [1,2,4] triazolo [4,3-a] pyridine</td><td>3- {difluoro [(3-metyloksetan-3-yl) methoxy] methyl} -6- [4- (trifluoromethoxy) phenyl] [1,2,4] triazolo [4,3-a] pyridine</td><td>3-phenoxy-6- [4- (trifluoromethoxy) phenyl] [1,2,4] triazolo [4,3-a] pyridine</td><td>3- (1,1-difluoro-2-methoxyethyl) -6- [6- (2,2,2-trifluoroethoxy) pyridin-3-yl] [1,2,4] triazolo [4,3-a] pyridine</td><td>6- [2-fluoro-4- (trifluoromethoxy) phenyl] -3- (trifluoromethyl) [1,2,4] triazolo [4,3-a] pyridine</td><td>6- [3-fluoro-4- (trifluoromethoxy) phenyl] -3- (trifluoromethyl) [1,2,4] triazolo [4,3-a] pyridine</td><td>3- {difluoro [(5-methyl-1,2,4-oxadiazol-3-yl) methoxy] methyl} -6- [4- (trifluoromethoxy) phenyl] [1,2,4] triazolo [4,3-</td>
<td>BHN-123.</td><td>BHN-124.</td><td>BHN-125.</td><td>BHN-126.</td><td>BHN-127.</td><td>BHN-128.</td><td>BHN-129.</td><td>BHN-130.</td><td>BHN-131.</td><td>BHN-132.</td><td>BHN-133.</td><td>BHN-134.</td><td>BHN-135.</td><td>BHN-136.</td><td>BHN-137.</td><td>BHN-138.</td><td>BHN-139.</td><td>BHN-140.</td><td>BHN-141.</td><td>BHN-142.</td><td>BHN-143.</td><td>BHN-144.</td><td>BHN-145.</td><td>BHN-146.</td><td>BHN-147.</td>
151 EP 2464645
<td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td></td><td> 71.6539</td><td> 34.0139</td><td> 15.6231</td><td> 43.0922</td><td> 71.7552</td><td> 17.1762</td><td> 19.2153</td><td> 16.193</td><td> 22.3286</td><td>ι / Ί 00</td><td> 32.8836</td><td></td><td> 61.9972</td><td> 49.498</td><td> 29.9168</td><td> 57.2895</td><td> 50.7435</td><td>00 ι / Ί ABOUT 00</td><td> 29.4783</td><td> 45.8073</td><td> 36.0758</td><td> 30.5402</td><td> 66.193</td><td> 49.2574</td>
<td>] pyridine</td><td>3 - [(benzyloxy) (difluoro) methyl] -6- [4- (trifluoromethoxy) phenyl] [1,2,4] triazolo [4,3-a] pyridine</td><td>3- [difluoro (pyridin-4-ylmethoxy) methyl] -6- [4- (trifluoromethoxy) phenyl] [1,2,4] triazolo [4,3-a] pyridine</td><td>2- (2,2-difluoro-2- {6- [4- (trifluoromethoxy) phenyl] [1,2,4] triazolo [4,3-a] pyridin-3-yl} ethoxy) -N, N- dimetyloetanamina</td><td>6- [4- (cyclopropylmethoxy) phenyl] -3- (trifluoromethyl) [1,2,4] triazolo [4,3-a] pyridine</td><td>6- [2-methoxy-4- (trifluoromethoxy) phenyl] -3- (trifluoromethyl) [1,2,4] triazolo [4,3-a] pyridine</td><td>6- [3- (1,3,4-oxadiazol-2-yl) -4- (trifluoromethoxy) phenyl] -3- (trifluoromethyl) [1,2,4] triazolo [4,3-a] pyridine</td><td>1- (4- (3- (trifluoromethyl) - [1,2,4] triazolo [4,3-a] pyridin-6-yl) phenyl) ethanone</td><td>2,2,2-trifluoro-1- {6- [4- (trifluoromethoxy) phenyl] [1,2,4] triazolo [4,3-a] pyridin-3-yl} -ethanol</td><td>(2,2-difluoro-2- {6- [4- (trifluoromethoxy) phenyl] [1,2,4] triazolo [4,3-a] pyridin-3-yl} ethoxy) acetonitrile</td><td>2- (Difluoro {6- [4- (trifluoromethoxy) phenyl] [1,2,4] triazolo [4,3-a] pyridin-3-yl} methoxy) ethanol</td><td>1- (difluoro {6- [4- (trifluoromethoxy) phenyl] [1,2,4] triazolo [4,3-a] pyridin-3-yl} methoxy) propan-2-ol</td><td>3- {6- [2-methyl-4- (trifluoromethoxy) phenyl] [1,2,4] triazolo [4,3-b] pyridazin-3-yl} benzonitrile (*)</td><td>3- (2-chloro-1,1-difluoroethyl) -6- [4- (trifluoromethoxy) phenyl] [1,2,4] triazolo [4,3-a] pyridine</td><td>5- (trifluoromethoxy) -8- [3- (trifluoromethyl) [1,2,4] triazolo [4,3-a] pyridin-6-yl] quinolin a</td><td>6- [4- (2-methyl-1,3-dioxolan-2-yl) phenyl] -3- (trifluoromethyl) [1,2,4] triazolo [4,3-a] pyridine</td><td>6- (phenylethynyl) -3- (trifluoromethyl) [1,2,4] triazolo [4,3-a] pyridine</td><td>6- [3-chloro-4- (trifluoromethoxy) phenyl] -3- (trifluoromethyl) [1,2,4] triazolo [4,3-a] pyridine</td><td>1,1-difluoro-1- {6- [4- (trifluoromethoxy) phenyl] [1,2,4] triazolo [4,3-a] pyridin-3-yl} propan-2-ol</td><td>1-cyclopropyl-2,2-difluoro-2- {6- [4- (trifluoromethoxy) phenyl] [1,2,4] triazolo [4,3-a] pyridin-3-yl} -ethanol</td><td>Ethyl (2,2-difluoro-2- {6- [4- (trifluoromethoxy) phenyl] [1,2,4] triazolo [4,3-a] pyridin-3-yl} ethoxy) ethyl acetate</td><td>N, N-dimethyl-6- [4- (trifluoromethoxy) phenyl] [1,2,4] triazolo [4,3-a] pyridine-3-amine</td><td>(2E) -3- {4- [3- (trifluoromethyl) [1,2,4] triazolo [4,3-a] pyridin-6-yl] phenyl} but-2-enenitrile</td><td>3- (phenylsulfanyl) -6- [4- (trifluoromethoxy) phenyl] [1,2,4] triazolo [4,3-a] pyridine</td><td>3- (cyclopropylethynyl) -6- [4- (trifluoromethoxy) phenyl] [1,2,4] triazolo [4,3-a] pyridine</td>
<td></td><td>BHN-148.</td><td>BHN-149.</td><td>BHN-150.</td><td>BHN-151.</td><td>BHN-152.</td><td>BHN-153.</td><td>BHN-154.</td><td>BHN-155.</td><td>BHN-156.</td><td>BHN-157.</td><td>BHN-158.</td><td>BHN-159.</td><td>BHN-160.</td><td>BHN-161.</td><td>BHN-162.</td><td>BHN-163.</td><td>BHN-164.</td><td>BHN-165.</td><td>BHN-166.</td><td>BHN-167.</td><td>BHN-168.</td><td>BHN-169.</td><td>BHN-170.</td><td>BHN-171.</td>
- 152 EP 2464645
<td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td> 30.6872</td><td> 30.761</td><td> 16.021</td><td> 16.3147</td><td> 15.2148</td><td> 23.6006</td><td>Axis "-t '/ Ί 00</td><td> 49.6909</td><td> 21.0867</td><td>'/ Ί "-t 00</td><td>cn cn "-t Axis 00</td><td> 19.4806</td><td> 29.83</td>
<td>3- [1,1-difluoro-2- (pyridin-2-ylmethoxy) ethyl] -6- [4- (trifluoromethoxy) phenyl] [1,2,4] triazolo [4,3-a] pyridine</td><td>2-methyl-4- {6- [4- (trifluoromethoxy) phenyl] [1,2,4] triazolo [4,3-a] pyridin-3-yl} but-3-yn-2-ol</td><td>N-methyl-2- (trifluoromethoxy) -5- [3- (trifluoromethyl) [1,2,4] triazolo [4,3-a] pyridin-6-yl] benzamide</td><td>N- (2,2-difluoro-2- {6- [4- (trifluoromethoxy) phenyl] [1,2,4] triazolo [4,3-a] pyridin-3-yl} ethyl) methanesulfonamide</td><td>1,1-difluoro-2-methyl-1- {6- [4- (trifluoromethoxy) phenyl] [1,2,4] triazolo [4,3-a] pyridin-3-yl} propan-2-ol</td><td>3- (trifluoromethyl) -6 - {[4- (trifluoromethyl) phenyl] ethynyl} [1,2,4] triazolo [4,3-a] pyridine</td><td>6- [2- (2-methoxyethoxy) -4- (trifluoromethoxy) phenyl] -3- (trifluoromethyl) [1,2,4] triazolo [4,3-a] pyridine</td><td>6- [6- (2,2,2-trifluoroethoxy) pyridin-3-yl] -3- (trifluoromethyl) imidazo [1,5-a] pyridine (*)</td><td>6- [6- (cyclopropyloxy) pyridin-3-yl] -3- (trifluoromethyl) [1,2,4] triazolo [4,3-a] pyridine</td><td>{5- (trifluoromethoxy) -2- [3- (trifluoromethyl) [1,2,4] triazolo [4,3-a] pyridin-6-yl] phenoxy} acetonitrile</td><td>6- [3- (3-methyl-1,2,4-oxadiazol-5-yl) -4- (trifluoromethoxy) phenyl] -3- (trifluoromethyl) [1,2,4] triazolo [4,3-a ] pyridine</td><td>6- (1,3-oxazol-2-yl) -3- (trifluoromethyl) imidazo [1,5-a] pyridine (*)</td><td>N- (2,2-difluoro-2- {6- [4- (trifluoromethoxy) phenyl] [1,2,4] triazolo [4,3-a] pyridin-3-yl} ethyl) pyridine-2-carboxamide</td>
<td>BHN-172.</td><td>BHN-173.</td><td>BHN-174.</td><td>BHN-175.</td><td>BHN-176.</td><td>BHN-177.</td><td>BHN-178.</td><td>BHN-179.</td><td>BHN-180.</td><td>BHN-181.</td><td>BHN-182.</td><td>BHN-183.</td><td>BHN-184.</td>
<td>Late IN 10uM</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td>Late IN 1uM</td><td> 29.11</td><td> 45.1555</td><td> 15.2091</td><td> 41.2582</td><td> 56.8752</td><td> 24.3379</td><td> 19.7625</td><td>ABOUT about cn</td><td> 54.7255</td>
<td>Name (compounds marked with * are included for reference only)</td><td>3-methoxy-6- [4- (trifluoromethoxy) phenyl] [1,2,4] triazolo [4,3-a] pyridine</td><td>3- (2,2,2-trifluoroethoxy) -6- [4- (trifluoromethoxy) phenyl] [1,2,4] triazolo [4,3-a] pyridine</td><td>6- [6- (2,2,2-trifluoroethoxy) pyridazin-3-yl] -3- (trifluoromethyl) [1,2,4] triazolo [4,3-a] pyridine</td><td>3- (1,1-difluoro-2-methoxyethyl) -6- [3-methyl-4- (trifluoromethoxy) phenyl] [1,2,4] triazolo [4,3-a] pyridine</td><td>6- [4- (trifluoromethoxy) -3- (trifluoromethyl) phenyl] -3- (trifluoromethyl) [1,2,4] triazolo [4,3-a] pyridine</td><td>3- {2 - [(3,4-difluorobenzyl) oxy] -1,1-difluoroethyl} -6- [4- (trifluoromethoxy) phenyl] [1,2,4] triazolo [4,3-a] pyridine</td><td>6- (1,3-thiazol-2-yl) -3- (trifluoromethyl) imidazo [1,5-a] pyridine (*)</td><td>3- (1,1-difluoro-2-methoxyethyl) -6- (phenylethynyl) [1,2,4] triazolo [4,3-a] pyridine</td><td>3- {difluoro [(5-methyl-1,2-oxazol-3-yl) methoxy] methyl} -6- [4- (trifluoromethoxy) phenyl] [1,2,4] triazolo [4,3-</td>
<td>Example No.</td><td>BHN-185.</td><td>BHN-186.</td><td>BHN-187.</td><td>BHN-188.</td><td>BHN-189.</td><td>BHN-190.</td><td>BHN-191.</td><td>BHN-192.</td><td>BHN-193.</td>
- EP 2464645
<td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td></td><td> 22.1586</td><td> 47.3307</td><td> 26.84</td><td> 25.3533</td><td> 17.4232</td><td> 20.5936</td><td> 40.8285</td><td> 29.6644</td><td> 74.1576</td><td> 19.2583</td><td> 43.8565</td><td> 25.1679</td><td> 44.7461</td><td> 60.2606</td><td> 70.5329</td><td> 60.9978</td><td>cn RCN cn</td><td> 57.4166</td><td> 59.6452</td><td> 23.9625</td><td>89Ϊ8Ό8</td><td> 36.4338</td>
<td>] pyridine</td><td>6-phenyl-3- (trifluoromethyl) imidazo [1,5-a] pyridine (*)</td><td>1- {4- [3- (trifluoromethyl) [1,2,4] triazolo [4,3-a] pyridin-6-yl] phenyl} cyclopropanecarbonitrile</td><td>2- [3- (trifluoromethyl) imidazo [1,5-a] pyridin-6-yl] -1,3-benzoxazole (*)</td><td>3- (difluoro {6- [4- (trifluoromethoxy) phenyl] [1,2,4] triazolo [4,3-a] pyridin-3-yl} methyl) pentan-3-ol</td><td>2,2-difluoro-2- (6 - {[4- (trifluoromethyl) phenyl] ethynyl} [1,2,4] triazolo [4,3-a] pyridin-3-yl) ethanol</td><td>6- [2,4-bis (trifluoromethyl) phenyl] -3- (trifluoromethyl) [1,2,4] triazolo [4,3-a] pyridine</td><td>3- (1,1-difluoro-2-methoxyethyl) -6- [2-methyl-4- (trifluoromethoxy) phenyl] [1,2,4] triazolo [4,3-a] pyridine</td><td>6- (3,5-difluoro-4-phenoxyphenyl) -3- (propan-2-yl) [1,2,4] triazolo [4,3-b] pyridazine (*)</td><td>5-methyl-6- [4- (trifluoromethoxy) phenyl] -3- (trifluoromethyl) [1,2,4] triazolo [4,3-a] pyridine</td><td>3- (propan-2-yl) -6- [6- (2,2,2-trifluoroethoxy) pyridin-3-yl] [1,2,4] triazolo [4,3-b] pyridazine (*)</td><td>3- [difluoro (pyridin-3-ylmethoxy) methyl] -6- [4- (trifluoromethoxy) phenyl] [1,2,4] triazolo [4,3-a] pyridine</td><td>1- (2,2-difluoro-2- {6- [4- (trifluoromethoxy) phenyl] [1,2,4] triazolo [4,3-a] pyridin-3-yl} ethoxy) -2-methylpropan 2-ol</td><td>3 - {[(5-cyclopropyl-1,2,4-oxadiazol-3-yl) methoxy] (difluoro) methyl} -6- [4- (trifluoromethoxy) phenyl] [1,2,4] triazolo [4,3- a] pyridine</td><td>3- (difluoro {[5- (2-methylpropyl) -1,2,4-oxadiazol-3-yl] methoxy} methyl) -6- [4- (trifluoromethoxy) phenyl] [1,2,4] triazolo [4 3-a] pyridine</td><td>3- (difluoro {[5- (propan-2-yl) -1,2,4-oxadiazol-3-yl] methoxy} methyl) -6- [4- (trifluoromethoxy) phenyl] [1,2,4] triazole [4,3-a] pyridine</td><td>6- [3-fluoro-4- (trifluoromethoxy) phenyl] -3- (trifluoromethyl) [1,2,4] triazolo [4,3-b] pyridazine (*)</td><td>6- (3,5-difluoro-4-phenoxyphenyl) -3- (trifluoromethyl) [1,2,4] triazolo [4,3-b] pyridazine (*)</td><td>3- [difluoro (pyridin-2-ylmethoxy) methyl] -6- [4- (trifluoromethoxy) phenyl] [1,2,4] triazolo [4,3-a] pyridine</td><td>4 - [(difluoro {6- [4- (trifluoromethoxy) phenyl] [1,2,4] triazolo [4,3-a] pyridin-3-yl} methoxy) methyl] quinoline</td><td>2- [3- (trifluoromethyl) imidazo [1,5-a] pyridin-6-yl] -1,3-benzothiazole (*)</td><td>3 - [(cyclopropylmethoxy) (difluoro) methyl] -6- [4- (trifluoromethoxy) phenyl] [1,2,4] triazolo [4,3-a] pyridine</td><td>3- {difluoro [(1-phenyl-1H-1,2,3-triazol-4-yl) methoxy] methyl} -6- [4- (trifluoromethoxy) phenyl] [1,2,4] triazolo [4, 3-</td>
<td></td><td>BHN-194.</td><td>BHN-195.</td><td>BHN-196.</td><td>BHN-197.</td><td>BHN-198.</td><td>BHN-199.</td><td>BHN-200.</td><td>BHN-201.</td><td>BHN-202.</td><td>BHN-203.</td><td>BHN-204.</td><td>BHN-205.</td><td>BHN-206.</td><td>BHN-207.</td><td>BHN-208.</td><td>BHN-209.</td><td>BHN-210.</td><td>BHN-211.</td><td>BHN-212.</td><td>BHN-213.</td><td>BHN-214.</td><td>BHN-215.</td>
- 154 EP 2464645
<td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td></td><td>ο ο WELL cd</td><td> 16.834</td><td> 35.9854</td><td> 36.8658</td><td> 58.508</td><td> 55.0196</td><td> 65.3354</td><td> 54.5146</td><td> 24.1854</td><td> 63.0442</td><td> 59.326</td><td> 79.7579</td><td>CN ABOUT p cc</td><td> 72.1636</td><td> 42.2926</td><td> 62.9341</td><td> 45.3007</td><td> 31.397</td><td> 57.8164</td><td> 41.5423</td><td> 39.9596</td>
<td>] pyridine</td><td>3- [difluoro (pyridazin-3-ylmethoxy) methyl] -6- [4- (trifluoromethoxy) phenyl] [1,2,4] triazolo [4,3-a] pyridine</td><td>3- {difluoro [1- (4-fluorophenyl) ethoxy] methyl} -6- [4- (trifluoromethoxy) phenyl] [1,2,4] triazolo [4,3-a] pyridine</td><td>6- [4- (4-chlorophenoxy) phenyl] tetrazolo [1,5-a] pyridine (*)</td><td>6- [6- (2,2,2-trifluoroethoxy) pyridin-3-yl] tetrazolo [1,5-a] pyridine (*)</td><td>6- [4- (2-methoxy-2-yl) phenyl] -3- (trifluoromethyl) [1,2,4] triazolo [4,3-a] pyridine</td><td>6- [6- (2,2,2-trifluoroethoxy) pyridin-3-yl] -3- (trifluoromethyl) [1,2,4] triazolo [4,3-b] pyridazine (*)</td><td>6- [2-ethoxy-4- (trifluoromethoxy) phenyl] -3- (trifluoromethyl) [1,2,4] triazolo [4,3-a] pyridine</td><td>6- [2- (propan-2-yloxy) -4- (trifluoromethoxy) phenyl] -3- (trifluoromethyl) [1,2,4] triazolo [4,3-a] pyridine</td><td>3- {difluoro [(1-methyl-5-phenyl-1H-pyrazol-3-yl) methoxy] methyl} -6- [4- (trifluoromethoxy) phenyl] [1,2,4] triazolo [4,3- a] pyridine</td><td>3 - {[(2,2-difluoro-1,3-benzodioxol-5-yl) methoxy] (difluoro) methyl} -6- [4- (trifluoromethoxy) phenyl] [1,2,4] triazolo [4,3- a] pyridine</td><td>6- [4- (trifluoromethoxy) phenyl] -3 - ({[4- (trifluoromethyl) benzyl] oxy} methyl) [1,2,4] triazolo [4,3-a] pyridine</td><td>3 - {[(4-fluorobenzyl) oxy] methyl} -6- [4- (trifluoromethoxy) phenyl] [1,2,4] triazolo [4,3-a] pyridine</td><td>3 - {[(2,5-dimethyl-1,3-oxazol-4-yl) methoxy] (difluoro) methyl} -6- [4- (trifluoromethoxy) phenyl] [1,2,4] triazolo [4, 3a] pyridine</td><td>3- {difluoro [(5-methyl-2-phenyl-1,3-oxazol-4-yl) methoxy] methyl} -6- [4- (trifluoromethoxy) phenyl] [1,2,4] triazolo [4, 3a] pyridine</td><td>3- {difluoro [1- (pyridin-2-yl) ethoxy] methyl} -6- [4- (trifluoromethoxy) phenyl] [1,2,4] triazolo [4,3-a] pyridine</td><td>3 - {[1- (4-chlorophenyl) ethoxy] (difluoro) methyl} -6- [4- (trifluoromethoxy) phenyl] [1,2,4] triazolo [4,3-a] pyridine</td><td>3- (1,1-difluoro-2-methoxyethyl) -6- [3-fluoro-4- (trifluoromethoxy) phenyl] [1,2,4] triazolo [4,3-a] pyridine</td><td>3- (1,1-difluoro-2-methoxyethyl) -6- (3,5-difluoro-4-phenoxyphenyl) [1,2,4] triazolo [4,3-a] pyridine</td><td>3- (1,1-difluoro-2-methoxyethyl) -6 - {[4- (trifluoromethyl) phenyl] ethynyl} [1,2,4] triazolo [4,3-a] pyridine</td><td>3- (2 - {[3- (4-chlorophenyl) -1,2-oxazol-5-yl] methoxy} -1,1-difluoroethyl) -6- [4- (trifluoromethoxy) phenyl] [1,2,4 ] triazolo [4,3-a] pyridine</td><td>6- [4- (4-chlorophenoxy) phenyl] -3- (trifluoromethyl) [1,2,4] triazolo [4,3-b] pyridazine (*)</td>
<td></td><td>BHN-216.</td><td>BHN-217.</td><td>BHN-218.</td><td>BHN-219.</td><td>BHN-220.</td><td>BHN-221.</td><td>BHN-222.</td><td>BHN-223.</td><td>BHN-224.</td><td>BHN-225.</td><td>BHN-226.</td><td>BHN-227.</td><td>BHN-228.</td><td>BHN-229.</td><td>BHN-230.</td><td>BHN-231.</td><td>BHN-232.</td><td>BHN-233.</td><td>BHN-234.</td><td>BHN-235.</td><td>BHN-236.</td>
- EP 2464645
<td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td> 44.7068</td><td> 80.6183</td><td> 65.115</td><td> 83.3836</td><td> 82.2111</td><td> 72.2094</td><td> 20.9902</td><td> 17.5037</td><td> 38.7693</td><td> 85.8171</td><td> 74.1378</td><td> 50.2191</td><td> 22.7039</td><td> 79.0732</td><td> 75.7567</td><td> 20.6482</td><td> 39.3884</td><td> 24.5777</td><td> 22.7999</td><td> 62.5676</td><td> 46.2206</td><td> 80.1084</td><td> 71.5761</td><td> 388.4527</td>
<td>3- (difluoromethyl) -6- [6- (2,2,2-trifluoroethoxy) pyridin-3-yl] [1,2,4] triazolo [4,3-b] pyridazine (*)</td><td>3 - {[(2-fluorobenzyl) oxy] methyl} -6- [4- (trifluoromethoxy) phenyl] [1,2,4] triazolo [4,3-a] pyridine</td><td>6- [4- (trifluoromethoxy) phenyl] -3 - ({[2- (trifluoromethyl) benzyl] oxy} methyl) [1,2,4] triazolo [4,3-a] pyridine</td><td>3 - {[(2,4-difluorobenzyl) oxy] methyl} -6- [4- (trifluoromethoxy) phenyl] [1,2,4] triazolo [4,3-a] pyridine</td><td>3 - {[(4-chlorobenzyl) oxy] methyl} -6- [4- (trifluoromethoxy) phenyl] [1,2,4] triazolo [4,3-a] pyridine</td><td>3 - ({[4- (trifluoromethoxy) benzyl] oxy} methyl) -6- [4- (trifluoromethoxy) phenyl] [1,2,4] triazolo [4,3-a] pyridine</td><td>N- (2,2-difluoro-2- {6- [4- (trifluoromethoxy) phenyl] [1,2,4] triazolo [4,3-a] pyridin-3-yl} ethyl) benzamide</td><td>3 - [(pyridin-2-ylmethoxy) methyl] -6- [4- (trifluoromethoxy) phenyl] [1,2,4] triazolo [4,3-a] pyridine</td><td>3- [difluoro (pyrimidin-2-ylmethoxy) methyl] -6- [4- (trifluoromethoxy) phenyl] [1,2,4] triazolo [4,3-a] pyridine</td><td>3 - [(1-phenylethoxy) methyl] -6- [4- (trifluoromethoxy) phenyl] [1,2,4] triazolo [4,3-a] pyridine</td><td>3 - {[1- (2,4-dichlorophenyl) ethoxy] (difluoro) methyl} -6- [4- (trifluoromethoxy) phenyl] [1,2,4] triazolo [4,3-a] pyridine</td><td>1 - [(difluoro {6- [4- (trifluoromethoxy) phenyl] [1,2,4] triazolo [4,3-a] pyridin-3-yl} methoxy) methyl] cyclobutanol</td><td>3- {1- [difluoro (pyridin-3-yl) methoxy] ethyl} -6- [4- (trifluoromethoxy) phenyl] [1,2,4] triazolo [4,3-a] pyridine</td><td>3 - {[(2,4-dichlorobenzyl) oxy] methyl} -6- [4- (trifluoromethoxy) phenyl] [1,2,4] triazolo [4,3-a] pyridine</td><td>3 - {[(2,4-dimethylbenzyl) oxy] methyl} -6- [4- (trifluoromethoxy) phenyl] [1,2,4] triazolo [4,3-a] pyridine</td><td>3 - {[(5-methyl-pyridin-2-yl) methoxy] methyl} -6- [4- (trifluoromethoxy) phenyl] [1,2,4] triazolo [4,3-a] pyridine</td><td>3- (difluoromethyl) -6- [3-fluoro-4- (trifluoromethoxy) phenyl] [1,2,4] triazolo [4,3-b] pyridazine (*)</td><td>4- {4- [3- (trifluoromethyl) [1,2,4] triazolo [4,3-a] pyridin-6-yl] phenyl} tetrahydro-2H-pyran-4-carbonitrile</td><td>3- [1- (pyridin-2-ylmethoxy) -ethyl] -6- [4- (trifluoromethoxy) phenyl] [1,2,4] triazolo [4,3-a] pyridine</td><td>(2S) -2 - [(difluoro {6- [4- (trifluoromethoxy) phenyl] [1,2,4] triazolo [4,3-a] pyridin-3-yl} methoxy) methyl] pyrrolidine-1-carboxylate tert- butyl</td><td>3 - {[difluoro (pyridin-3-yl) methoxy] methyl} -6- [4- (trifluoromethoxy) phenyl] [1,2,4] triazolo [4,3-a] pyridine</td><td>6- [4- (trifluoromethoxy) phenyl] -3- [3- (trifluoromethyl) phenoxy] [1,2,4] triazolo [4,3-a] pyridine</td><td>3 - {[(5-cyclobutyl-1,2,4-oxadiazol-3-yl) methoxy] (difluoro) methyl} -6- [4- (trifluoromethoxy) phenyl] [1,2,4] triazolo [4,3- a] pyridine</td><td>3- (4,4-difluoro-piperidin-1-yl) -6- [4- (trifluoromethoxy) phenyl] [1,2,4] triazolo [4,3-a] pyridine</td>
<td>BHN-237.</td><td>BHN-238.</td><td>BHN-239.</td><td>BHN-240.</td><td>BHN-241.</td><td>BHN-242.</td><td>BHN-243.</td><td>BHN-244.</td><td>BHN-245.</td><td>BHN-246.</td><td>BHN-247.</td><td>BHN-248.</td><td>BHN-249.</td><td>BHN-250.</td><td>BHN-251.</td><td>BHN-252.</td><td>BHN-253.</td><td>BHN-254.</td><td>BHN-255.</td><td>BHN-256.</td><td>BHN-257.</td><td>BHN-258.</td><td>BHN-259.</td><td>BHN-260.</td>
- EP 2464645
<td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td> 56.8413</td><td> 47.7989</td><td> 22.5529</td><td> 54.3394</td><td> 15.3022</td><td> 50.2004</td><td> 26.5068</td><td> 43.151</td><td> 44.6912</td><td> 21.7058</td><td> 19.8602</td><td> 64.8954</td><td>1? ΝΩ ^ 0 00 WELL</td><td> 38.8563</td><td>WHAT He ABOUT ^ 0 00</td><td> 16.248</td><td>'/ Ί 1? ABOUT ABOUT 00</td><td> 54.2033</td><td> 19.1346</td><td> 63.6981</td><td> 53.9362</td><td> 62.7413</td>
<td>3 - [(difluoro {6- [4- (trifluoromethoxy) phenyl] [1,2,4] triazolo [4,3-a] pyridin-3-yl} methoxy) methyl] benzonitrile</td><td>3- (difluoro {3 - [(2-methoxyphenyl) sulfanyl] -2-methyl-propoxy} methyl) -6- [4- (trifluoromethoxy) phenyl] [1,2,4] triazolo [4,3-a] pyridine</td><td>1- (2,2-difluoro-2- {6- [4- (trifluoromethoxy) phenyl] [1,2,4] triazolo [4,3-a] pyridin-3-yl} ethyl) -3-phenyl-urea</td><td>3- (difluoro- {2- [4- (4-methoxyphenyl) piperazin-1-yl] -ethoxy} methyl) -6- [4- (trifluoromethoxy) phenyl] [1,2,4] triazolo [4,3-a] pyridine</td><td>6- [4- (trifluoromethoxy) phenyl] [1,2,4] triazolo [4,3-a] pyridine-3-carboxamide</td><td>3 - {[(3-cyclopropyl-1-methyl-1H-pyrazol-5-yl) methoxy] (difluoro) methyl} -6- [4- (trifluoromethoxy) phenyl] [1,2,4] triazolo [4,3- a] pyridine</td><td>1- (2-chlorophenoxy) -3- (2,2-difluoro-2- {6- [4- (trifluoromethoxy) phenyl] [1,2,4] triazolo [4,3-a] pyridin-3-yl} -ethoxy ) propan-2-ol</td><td>8-methyl-6- [4- (trifluoromethoxy) phenyl] tetrazolo [1,5-a] pyridine (*)</td><td>5-methyl-6- [4- (trifluoromethoxy) phenyl] tetrazolo [1,5-a] pyridine (*)</td><td>6- [4- (4-chlorophenoxy) phenyl] tetrazolo [1,5-b] pyridazine (*)</td><td>6- {4- [difluoro (pyridin-3-yl) methoxy] phenyl} -3- (trifluoromethyl) [1,2,4] triazolo [4,3-a] pyridine</td><td>6- {4- [difluoro (phenyl) methoxy] phenyl} -3- (trifluoromethyl) [1,2,4] triazolo [4,3-a] pyridine</td><td>3- (2-methylphenoxy) -6- [4- (trifluoromethoxy) phenyl] [1,2,4] triazolo [4,3-a] pyridine</td><td>1- (2,2-difluoro-2- {6- [4- (trifluoromethoxy) phenyl] [1,2,4] triazolo [4,3-a] pyridin-3-yl} ethoxy) -3- (2 , 5dimetylofenoksy) propan-2-ol</td><td>3 - [(cyclopropylmethoxy) (difluoro) methyl] -6- [6- (trifluoromethyl) pyridin-3-yl] [1,2,4] triazolo [4,3-a] pyridine</td><td>5-chloro-2 - ({4- [3- (trifluoromethyl) [1,2,4] triazolo [4,3-a] pyridin-6-yl] phenyl} amino) benzonitrile</td><td>5- (methoxymethyl) -6- [4- (trifluoromethoxy) phenyl] -3- (trifluoromethyl) [1,2,4] triazolo [4,3-a] pyridine</td><td>N-methyl-N-phenyl-4- [3- (trifluoromethyl) [1,2,4] triazolo [4,3-a] pyridin-6-yl] -amine</td><td>({6- [4- (trifluoromethoxy) phenyl] -3- (trifluoromethyl) [1,2,4] triazolo [4,3-a] pyridin-5-yl} methoxy) acetonitrile</td><td>4- (Difluoro {4- [3- (trifluoromethyl) 1,2,4] triazolo [4,3-a] pyridin-6-yl] phenoxy} methyl) benzonitrile</td><td>5 - [(difluoro {6- [4- (trifluoromethoxy) phenyl] [1,2,4] triazolo [4,3-a] pyridin-3-yl} methoxy) methyl] quinoline</td><td>3- [1- (difluoro {6- [4- (trifluoromethoxy) phenyl] [1,2,4] triazolo [4,3-a] pyridin-3-yl} methoxy) ethyl] quinoline</td>
<td>BHN-261.</td><td>BHN-262.</td><td>BHN-263.</td><td>BHN-264.</td><td>BHN-265.</td><td>BHN-266.</td><td>BHN-267.</td><td>BHN-268.</td><td>BHN-269.</td><td>BHN-270.</td><td>BHN-271.</td><td>BHN-272.</td><td>BHN-273.</td><td>BHN-274.</td><td>BHN-275.</td><td>BHN-276.</td><td>BHN-277.</td><td>BHN-278.</td><td>BHN-279.</td><td>BHN-280.</td><td>BHN-281.</td><td>BHN-282.</td>
- EP 2464645
<td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td> 27.1761</td><td> 31.3958</td><td> 68.0043</td><td> 56.4045</td><td> 47.119</td><td> 39.2489</td><td> 47.9164</td><td> 34.6127</td><td> 47.0299</td><td> 25.9657</td><td>about HO about 00</td><td> 77.5676</td><td> 87.7093</td><td> 40.1113</td><td> 63.3909</td><td> 70.3125</td><td> 51.1075</td><td> 62.965</td><td> 29.8716</td>
<td>4-Chloro-N- {4- [3- (trifluoromethyl) [1,2,4] triazolo [4,3-a] pyridin-6-yl] phenyl} aniline</td><td>4-Fluoro-N- {4- [3- (trifluoromethyl) [1,2,4] triazolo [4,3-a] pyridin-6-yl] phenyl} aniline</td><td>3 - {[2- (2,6-dimethylphenoxy) ethoxy] (difluoro) methyl} -6- [4- (trifluoromethoxy) phenyl] [1,2,4] triazolo [4,3-a] pyridine</td><td>6- [4- (pentafluoro-lambda-6-sulfulfyl) phenyl] -3- (trifluoromethyl) [1,2,4] triazolo [4,3-a] pyridine</td><td>3- {difluoro [(1-phenyl-1H-pyrazol-4-yl) methoxy] methyl} -6- [4- (trifluoromethoxy) phenyl] [1,2,4] triazolo [4,3-a] pyridine</td><td>3- [difluoro ({2- [4- (trifluoromethyl) phenyl] -1,3-oxazol-4-yl} methoxy) methyl] -6- [4- (trifluoromethoxy) phenyl] [1,2,4] triazolo [ 4,3-a] pyridine</td><td>4 - [(difluoro {6- [4- (trifluoromethoxy) phenyl] [1,2,4] triazolo [4,3-a] pyridin-3-yl} methoxy) methyl] -2-methylquinoline</td><td>4 - [(difluoro {6- [4- (trifluoromethoxy) phenyl] [1,2,4] triazolo [4,3-a] pyridin-3-yl} methoxy) methyl] -2 (trifluoromethyl) quinoline</td><td>6 - [(difluoro {6- [4- (trifluoromethoxy) phenyl] [1,2,4] triazolo [4,3-a] pyridin-3-yl} methoxy) methyl] quinoxaline</td><td>6- (2-chloro-4-nitrophenyl) -3- (trifluoromethyl) [1,2,4] triazolo [4,3-a] pyridine</td><td>3 - [(but-2-yn-1-yloxy) (difluoro) methyl] -6- [4- (trifluoromethoxy) phenyl] [1,2,4] triazolo [4,3-a] pyridine</td><td>3 - {[(2,2-difluorocyclopropyl) methoxy] (difluoro) methyl} -6- [4- (trifluoromethoxy) phenyl] [1,2,4] triazolo [4,3-a] pyridine</td><td>3- {difluoro [(3-phenylprop-2-yn-1-yl) oxy] methyl} -6- [4- (trifluoromethoxy) phenyl] [1,2,4] triazolo [4,3-a] pyridine</td><td>3- {difluoro [(1-methyl-1H-benzimidazol-2-yl) methoxy] methyl} -6- [4- (trifluoromethoxy) phenyl] [1,2,4] triazolo [4,3-a] pyridine</td><td>3 - {[(1-benzyl-1H-1,2,3-triazol-4-yl) methoxy] (difluoro) methyl} -6- [4- (trifluoromethoxy) phenyl] [1,2,4] triazolo [ 4,3-a] pyridine</td><td>3- {difluoro [(5-phenyl-1,2-oxazol-3-yl) methoxy] methyl} -6- [4- (trifluoromethoxy) phenyl] [1,2,4] triazolo [4,3-a] pyridine</td><td>3- {difluoro [(2-phenyl-1,3-oxazol-4-yl) methoxy] methyl} -6- [4- (trifluoromethoxy) phenyl] [1,2,4] triazolo [4,3-a] pyridine</td><td>3- {difluoro [(5-methyl-2-phenyl-2H-1,2,3-triazol-4-yl) methoxy] methyl} -6- [4- (trifluoromethoxy) phenyl] [1,2,4] triazole [4,3-a] pyridine</td><td>3- {difluoro [(1-methyl-1H-pyrazol-3-yl) methoxy] methyl} -6- [4- (trifluoromethoxy) phenyl] [1,2,4] triazolo [4,3-</td>
<td>BHN-283.</td><td>BHN-284.</td><td>BHN-285.</td><td>BHN-286.</td><td>BHN-287.</td><td>BHN-288.</td><td>BHN-289.</td><td>BHN-290.</td><td>BHN-291.</td><td>BHN-292.</td><td>BHN-293.</td><td>BHN-294.</td><td>BHN-295.</td><td>BHN-296.</td><td>BHN-297.</td><td>BHN-298.</td><td>BHN-299.</td><td>BHN-300.</td><td>BHN-301.</td>
- EP 2464645
<td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td></td><td> 52.8348</td><td> 51.0168</td><td>ΟΟ about 00</td><td> 59.565</td><td> 49.7279</td><td> 68.4897</td><td> 71.237</td><td> 25.1867</td><td>69ΪΖ</td><td> 47.274</td><td> 51.3863</td><td> 49.9572</td><td> 24.1634</td><td> 55.8573</td><td> 59.01</td><td> 46.44</td><td>Axis 00</td>
<td>] pyridine</td><td>3 - [{1- (4-chlorophenyl) -5-methyl-1H-pyrazol-3-yl] methoxy} (difluoro) methyl] -6- [4- (trifluoromethoxy) phenyl] [1,2,4] triazolo [ 4,3-a] pyridine</td><td>3 - [(3,3-difenylopropoksy) (difluoro) methyl] -6- [4- (trifluoromethoxy) phenyl] [1,2,4] triazolo [4,3-a] pyridine</td><td>3-phenoxy-6 - {[4- (trifluoromethyl) phenyl] ethynyl} [1,2,4] triazolo [4,3-a] pyridine</td><td>3- (difluoro {[3- (pyrimidin-2-yl) benzyl] oxy} methyl) -6- [4- (trifluoromethoxy) phenyl] [1,2,4] triazolo [4,3-a] pyridine</td><td>3- (difluoro {[3- (pyridin-3-yl) benzyl] oxy} methyl) -6- [4- (trifluoromethoxy) phenyl] [1,2,4] triazolo [4,3-a] pyridine</td><td>3- {difluoro [(1-methyl-1H-indazol-3-yl) methoxy] methyl} -6- [4- (trifluoromethoxy) phenyl] [1,2,4] triazolo [4,3-a] pyridine</td><td>3- [chloro (difluoro) methyl] -6- [4- (trifluoromethoxy) phenyl] [1,2,4] triazolo [4,3-a] pyridine</td><td>3- (1,1-difluoro-2-methoxyethyl) -6 - {[4- (trifluoromethoxy) phenyl] ethynyl} [1,2,4] triazolo [4,3-a] pyridine</td><td>3- (1,1-difluoro-2-methoxyethyl) -6 - [(4-fluorophenyl) ethynyl] [1,2,4] triazolo [4,3-a] pyridine</td><td>3- (difluoro {[2- (1H-1,2,4-triazol-1-yl) benzyl] oxy} methyl) -6- [4- (trifluoromethoxy) phenyl] [1,2,4] triazolo [4 , 3a] pyridine</td><td>3- (difluoro {[2- (2-methyl-1H-imidazol-1-yl) benzyl] oxy} methyl) -6- [4- (trifluoromethoxy) phenyl] [1,2,4] triazolo [4,3- ] pyridine</td><td>3- (difluoro {[2-phenyl-5- (trifluoromethyl) -1,3-oxazol-4-yl] methoxy} methyl) -6- [4- (trifluoromethoxy) phenyl] [1,2,4] triazolo [4 3-a] pyridine</td><td>3- (difluoro {[1-phenyl-3- (trifluoromethyl) -1H-pyrazol-4-yl] methoxy} methyl) -6- [4- (trifluoromethoxy) phenyl] [1,2,4] triazolo [4,3- a] pyridine</td><td>3- (difluoro {[6- (1H-pyrazol-1-yl) pyridin-3-yl] methoxy} methyl) -6- [4- (trifluoromethoxy) phenyl] [1,2,4] triazolo [4,3- ] pyridine</td><td>6-cyclopropyl-2 - [(difluoro {6- [4- (trifluoromethoxy) phenyl] [1,2,4] triazolo [4,3-a] pyridin-3-yl} methoxy) methyl] -3,4 'bipyridine</td><td>3 - [{[3- (4-cyclopropyl-1 H-imidazol-1-yl) benzyl] oxy} (difluoro) methyl] -6- [4- (trifluoromethoxy) phenyl] [1,2,4] triazolo [4, 3-a] pyridine</td><td>3- (difluoro {[5- (4-fluorophenyl) -1,2-oxazol-3-yl] methoxy} methyl) -6- [4- (trifluoromethoxy) phenyl] [1,2,4] triazolo [4, 3a] pyridine</td>
<td></td><td>BHN-302.</td><td>BHN-303.</td><td>BHN-304.</td><td>BHN-305.</td><td>BHN-306.</td><td>BHN-307.</td><td>BHN-308.</td><td>BHN-309.</td><td>Όΐε-ΝΗΉ</td><td>ΐΐε-ΝΗΉ</td><td>BHN-312.</td><td>BHN-313.</td><td>BHN-314.</td><td>BHN-315.</td><td>BHN-316.</td><td>BHN-317.</td><td>BHN-318.</td>
- 159 EP 2464645
<td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td> 38.7</td><td> 57.2</td><td> 38.2</td><td> 83.5</td><td> 61.6</td><td> 40.6</td><td> 87.7</td><td> 67.5</td><td> 52.9</td><td> 76.8</td>
<td>ο ι / Ί Ο CT</td><td> 76.34</td><td> 65.59</td><td> 72.48</td><td>Ο ρ CT</td><td> 46.33</td><td>cn CT 00 kO</td><td> 52.39</td><td> 54.20</td><td> 70.86</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td>3- {difluoro [(5-phenyl-1,2-oxazol-3-yl) methoxy] methyl} -6- [6- (trifluoromethyl) pyridin-3-yl] [1,2,4] triazolo [4, 3a] pyridine</td><td>3- (difluoro {[2- (piperidin-1-yl) -pyridin-4-yl] methoxy} methyl) -6- [4- (trifluoromethoxy) phenyl] [1,2,4] triazolo [4,3-a] pyridine</td><td>3 - {[(2,2-dimethyl-2,3-dihydro-1-benzofuran-7-yl) methoxy] (difluoro) methyl} -6- [4- (trifluoromethoxy) phenyl] [1,2,4] triazole [4,3-a] pyridine</td><td>3 - {[2- (2,6-difluorophenyl) ethoxy] (difluoro) methyl} -6- [4- (trifluoromethoxy) phenyl] [1,2,4] triazolo [4,3-a] pyridine</td><td>3- {difluoro [(5-phenyl-1,2,4-oxadiazol-3-yl) methoxy] methyl} -6- [4- (trifluoromethoxy) phenyl] [1,2,4] triazolo [4,3- a] pyridine</td><td>3- {difluoro [(5-phenyl-1,2-oxazol-3-yl) methoxy] methyl} -6- [6- (2,2,2-trifluoroethoxy) pyridin-3-yl] [1,2,4] triazolo [4,3-a] pyridine</td><td>3 - [{[2- (6-cyclopropyl-pyridin-3-yl) benzyl] oxy} (difluoro) methyl] -6- [4- (trifluoromethoxy) phenyl] [1,2,4] triazolo [4,3-a] pyridine</td><td>3 - [{[5- (2-chlorophenyl) -1,2-oxazol-3-yl] methoxy} (difluoro) methyl] -6- [4- (trifluoromethoxy) phenyl] [1,2,4] triazolo [4 3-a] pyridine</td><td>3- (difluoro {[2- (pyridin-3-yl) benzyl] oxy} methyl) -6- [4- (trifluoromethoxy) phenyl] [1,2,4] triazolo [4,3-a] pyridine</td><td>3- (difluoro {[2- (1H-pyrazol-1-yl) benzyl] oxy} methyl) -6- [4- (trifluoromethoxy) phenyl] [1,2,4] triazolo [4,3-a] pyridine</td><td>6- [4- (trifluoromethoxy) phenyl] [1,2,4] triazolo [4,3-a] pyridine</td><td>3-methyl-6- [4- (trifluoromethoxy) phenyl] [1,2,4] triazolo [4,3-a] pyridine</td><td>N-ethyl-6- [4- (trifluoromethoxy) phenyl] [1,2,4] triazolo [4,3-a] pyridine-3-amine</td><td>6- (4-phenoxyphenyl) -3- (trifluoromethyl) [1,2,4] triazolo [4,3-a] pyridine</td><td>3-methyl-6- (4-phenoxyphenyl) [1,2,4] triazolo [4,3-a] pyridine</td><td>N-ethyl-6- (4-phenoxyphenyl) [1,2,4] triazolo [4,3-a] pyridine-3-amine</td><td>6- [4- (trifluoromethoxy) phenyl] -3- (trifluoromethyl) [1,2,4] triazolo [4,3-a] pyridine</td><td>7-methyl-6- [4- (trifluoromethoxy) phenyl] -3- (trifluoromethyl) [1,2,4] triazolo [4,3-a] pyridine</td><td>6- [3- (trifluoromethoxy) phenyl] -3- (trifluoromethyl) [1,2,4] triazolo [4,3-a] pyridine</td><td>3- (trifluoromethyl) -6- [4- (trifluoromethyl) phenyl] [1,2,4] triazolo [4,3-a] pyridine</td>
<td>BHN-319.</td><td>BHN-320.</td><td>BHN-321.</td><td>BHN-322.</td><td>BHN-323.</td><td>BHN-324.</td><td>BHN-325.</td><td>BHN-326.</td><td>BHN-327.</td><td>BHN-328.</td><td>BHN-329.</td><td>BHN-330.</td><td>BHN-331.</td><td>BHN-332.</td><td>BHN-333.</td><td>BHN-334.</td><td>BHN-335.</td><td>BHN-336.</td><td>BHN-337.</td><td>BHN-338.</td>
- 160 EP 2464645
<td> 53.5</td><td> 54</td><td> 75.7</td><td> 51.2</td><td> 28.3</td><td> 81.3</td><td> 55.4</td><td> 75.1</td><td> 73.6</td><td> 65.7</td><td> 65.1</td><td> 44.5</td><td> 78.8</td><td> 44.7</td><td> 79.7</td><td> 87.1</td><td> 54.3</td>
<td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td>6- (2,4-dichlorophenyl) -3- (trifluoromethyl) [1,2,4] triazolo [4,3-a] pyridine</td><td>6- [4- (difluoromethoxy) phenyl] -3- (trifluoromethyl) [1,2,4] triazolo [4,3-a] pyridine</td><td>6- (3-phenoxyphenyl) -3- (trifluoromethyl) [1,2,4] triazolo [4,3-a] pyridine</td><td>6- [4-chloro-3- (trifluoromethyl) phenyl] -3- (trifluoromethyl) [1,2,4] triazolo [4,3-a] pyridine</td><td>6- (4-chloro-3-fluorophenyl) -3- (trifluoromethyl) [1,2,4] triazolo [4,3-a] pyridine</td><td>6- [4- (trifluoromethoxy) phenyl] -3- (trifluoromethyl) imidazo [1,5-a] pyridine (*)</td><td>6- (4-phenoxyphenyl) -3- (trifluoromethyl) imidazo [1,5-a] pyridine (*)</td><td>6- [4- (trifluoromethoxy) phenyl] [1,2,4] triazolo [1,5-a] pyridine (*)</td><td>6- (3-phenoxyphenyl) [1,2,4] triazolo [1,5-a] pyridine (*)</td><td>2-methyl-6- (3-phenoxyphenyl) [1,2,4] triazolo [1,5-a] pyridine (*)</td><td>8-methyl-6- (4-phenoxyphenyl) [1,2,4] triazolo [1,5-a] pyridine (*)</td><td>5-methyl-6- [4- (trifluoromethyl) phenyl] [1,2,4] triazolo [1,5-a] pyridine (*)</td><td>6- [4- (trifluoromethoxy) phenyl] -3- (trifluoromethyl) [1,2,4] triazolo [4,3-b] pyridazine (*)</td><td>6- (4-phenoxyphenyl) -3- (trifluoromethyl) [1,2,4] triazolo [4,3-b] pyridazine (*)</td><td>3- (difluoromethyl) -6- [4- (trifluoromethoxy) phenyl] [1,2,4] triazolo [4,3-b] pyridazine (*)</td><td>3- (difluoromethyl) -6- (4-phenoxyphenyl) [1,2,4] triazolo [4,3-b] pyridazine (*)</td><td>6- (4-phenoxyphenyl) -3- (trifluoromethyl) [1,2,4] triazolo [4,3-a] pyrazine</td>
<td>BHN-339.</td><td>BHN-340.</td><td>BHN-341.</td><td>BHN-342.</td><td>BHN-343.</td><td>BHN-344.</td><td>BHN-345.</td><td>BHN-346.</td><td>BHN-347.</td><td>BHN-348.</td><td>BHN-349.</td><td>BHN-350.</td><td>BHN-351.</td><td>BHN-352.</td><td>BHN-353.</td><td>BHN-354.</td><td>BHN-355.</td>
161 EP 2464645
The test results shown in the above Table 1 show that the tested compounds showed activity as late sodium current modulators, for example by inhibiting (or reducing) the late sodium current.
In some embodiments, the effects of the invention are specific for late sodium current and show little or no activity on one or more other ion channels. Thus, in some embodiments, a compound having a late sodium current reducing activity will also have little or no activity at peak sodium current. In specific embodiments, a compound having late sodium current reducing activity will also have little or no activity on the hERG potassium channel. In some embodiments, a compound having a late sodium current reducing activity will also have little or no activity on the L-type calcium channel. For example, a given compound may provide 30% (or greater, e.g. greater than 40%, greater than 50%, greater than 60%, greater than 70%, greater than 80%) reduction of the late sodium current in the test described here, and the same compound may show little or no activity for one or more of: peak sodium current, hERG potassium channel, and calcium type L channel. In this regard, a compound having a "small" effect will typically show less than 30% reduction (e.g. less than 20% reduction, less than 15% reduction, less than 10% reduction) of the given activity (e.g., Peak INa, hERG, calcium type L) when measured using the test described herein. In this regard, "no" effect means that any activity measured will differ from the control by less than a standard measurement error. Tests performed to measure activity in this regard should be performed as described above, with the compound at a concentration of 10 μΜ (or with an upper solubility limit if less).
Ca2 + tvp L channel test - ChanTest
Selected compounds were tested for cardiac Ca channel block<sup>2+</sup> type L (hCav1.2, encoded by the human CACNA1C gene and co-expressed with the beta 2 subunit, encoded by the human CACNB2 gene, and alpha2delta1, encoded by the CACNA2D1 gene). Ca channel<sup>2+</sup> is heterologously expressed in the CHO (Chinese hamster ovary) cell line. Cells were maintained according to standard tissue culture procedures and stable channel expression was maintained with the appropriate selection antibiotics in the culture medium. Cells were harvested for testing on automated PatchXpress patch clamp (Model 7000A, Molecular Devices, Sunnyvale, CA) by washing twice with Hank's balanced salt solution, treating cells with trypsin, and resuspending in culture medium (4-6 x10<sup>6</sup> cells (20 mL). The cells in suspension were allowed to recover for 10 minutes in a tissue culture incubator set at 37 ° C in a humidified atmosphere of 95% air, 5% CO2.
The following solutions are used for electrophysiological records. The external solution contains (mM): 137 NaCl, 4 KCl, 1.8 CaCl2, 1 MgCl2, 10 Glucose, 10 HEPES (pH 7.4 with NaOH). The internal solution contains (mM): 130 Cs Aspartan, 5 MgCl2, 5 EGTA, 4 ATP, 0.1 GTP, 10 HEPES, (pH adjusted to 7.2 using N-methyl-D-glucamine).
The medium was applied to naive cells (n> 2, where n = number of cells), for a 5-10 minute exposure time. Each replacement of the solution was made in four copies. At the end
For each experiment, a saturating concentration of nifedipine (10 μΜ) was added for the hCav1.2 current block. The leakage current is digitally subtracted from the record of the total membrane current.
Stock solutions of test compounds were prepared by the addition of dimethyl sulfoxide (DMSO) and stored in freezing. A solution of each test compound in DMSO was sonicated (Model 2510/5510, Branson Ultrasonics, Danbury, CT) at room temperature for at least 20 minutes to facilitate dissolution. Test compound concentrations are prepared fresh daily by diluting the stock solutions to standard extracellular saline (see above). The maximum percentage of DMSO added with a compound is 0.1%. All test compound and control solutions were placed in a glass 96-well plate prior to loading onto PatchXpress.
One or more concentrations (1, 10 μΜ) of each test compound are applied at five (5) minute intervals with disposable polyethylene micropipettes for naive cells (n> 2, where n = cell number / concentration). Each concentration of test compound is added to the cells in quadruplicate. The total exposure time for each test compound concentration is 5 minutes.
Occurrence and stable condition of the hCav1.2 channel block (αΚ7β2 / α2δ ^ was measured using a stimulus voltage formula consisting of a depolarizing test pulse (duration, 200 ms; amplitude, 10 mV) at 10 s intervals from holding potential -80 mV. Current peak is measured during the stage to 10 mV.
Example 39
Screening test Na<sub>v</sub>1.7:
Evidence supports the role of tetrodotoxin sensitive Nav1.7 in the pathogenesis of pain. In this assay, whole-cell patch-clamp techniques were used to determine the effects of compounds of Formula (I) on human Nav1.7 channels (hNav1.7 + e1 subunits) expressed in HEK293 cells. Na cell line<sub>v</sub>1.7 was produced by stably transfecting HEK293 cells with human Na<sub>v</sub>1.7 α subunit and β1 subunit. HEK293 cells stably expressing huNav1.7 were analyzed by patch clamp techniques and were found to have Na currents<sup>+</sup> between -400 and -1800 pA (currents not recorded in non-transfected cells). Current Na<sup>+</sup> in these cells it was blocked by tetrodotoxin (TTX) with an IC50 value of 10-74 nmol / L. Similar results were obtained using membranes sensitive to membrane potential.
Stock solutions of compounds of Formula I ("test compounds") were prepared in DMSO at a concentration of 40 mmol / L just before use. Each test compound was tested in duplicate at 100 μΜ then 1 in 4 serial dilutions to give 8 concentrations for testing. TTX was used as a NaV1.7 current control inhibitor.
The effect of test compounds to reduce current Nav1.7 Na<sup>+</sup> was measured using a fluorescent dye-based membrane potential test kit (# R8123) from Molecular Devices (California, USA). Briefly, cells were plated into black-walled poly-D-lysine pre-coated black and clear bottom 96-well Biocoat plates in 100 Pl culture medium 24 h before assay. On test day, a membrane potential dye was prepared and pre-warmed with the Hepes-HBSS solution to 37 ° C. Down
2464645 each well, 100 μΐ dye added and incubated at 37 ° C for 60 min. Veratridine was added to each well to give a final concentration of 50 μmol / L. Test compound was added to each well at the desired concentration, and fluorescence was recorded. For the data set for each test compound, an IC 50 value was calculated based on the test points obtained.
In specific embodiments, the compound will exhibit high selectivity for the late sodium channel modulator activity compared to activity on one or more other ion channels. The selectivity of a compound can be determined by determining the percentage reduction of the late sodium current due to the compound as measured by the test described above. The percentage reduction in activity of one other ion channel, such as the hERG potassium channel or L-type calcium channel, is determined by the compound as described above. Selectivity was determined by considering the ratio (percent decrease in late sodium current) to (percent decrease in activity of one other ion channel). Performed tests to measure activity in this regard should be performed as described above, with the compound at a concentration of 10 μΜ (or at the upper limit of solubility, if less). In specific embodiments, the selectivity of the compound of the invention will be at least 5: 1, e.g. at least 6: 1, at least 7: 1, at least 8: 1, at least 9: 1, at least 10: 1, at least 12: 1, at least 15: 1, at least 20: 1, or at least at least 25: 1, compared with the percentage reduction in late sodium current relative to the percentage reduction in one of the peak sodium current, the hERG potassium channel current, or the L-type calcium channel.
Example 40
Material and methods
Human cDNA expression<sub>V</sub>1.1
All wild-type (WT) and mutant constructs have been previously tested by our laboratory (Kahlig, 2008; Lossin, 2002; Rhodes, 2004) and cDNA expression was performed as previously described (Kahlig, 2008). Briefly, NaV1.1 expression was obtained by transient transfection using a Qiagen Superfect reagent (5.5 μg DNA was transfected with a 10: 1: 1 plasmid mass ratio of α1: β1: β2). Human β1 and β2 cDNA were cloned into plasmids containing DsRed (DsRedIRES2-hei) or EGFP (EGFP-IRES2-he marker genes)<sub>2</sub>) together with the internal ribosome entry site (IRES). Unless otherwise stated, all reagents were from Sigma-Aldrich (St. Louis, MO, USA).
electrophysiology
Whole-cell voltage-clamp records were used to measure the biophysical properties of WT and mutant NaV1.1 channels as previously described (Kahlig, 2008). Briefly, the pipette solution contained (in mM) 110 CsF, 10 NaF, 20 CsCl, 2 EGTA, 10 HEPES, with pH 7.35 and osmolarity 300 mOsmol / kg. The bath (control) solution contained (in mM): 145 NaCl, 4 KCl, 1.8 CaCl<sub>2</sub>, 1 MgCl<sub>2</sub>, 10 dextrose, 10 HEPES, with pH 7.35 and osmolarity 310 mOsmol / kg. The cells were allowed to stabilize for 10 min after establishing the whole cell configuration before measuring the current. Series resistance
- 90% was compensated 90% to ensure that the set potential is achieved within microseconds with a voltage error <2 mV. Leakage currents were subtracted using the online P / 4 procedure and all currents were low-pass filtered Bessel at 5 kHz and digitized at 50 kHz. For clarity, representative ramp currents are low-pass filtered off-line at 50 Hz.
Specific voltage-clamp protocols assessing activation, rapid deactivation, and channel availability during repeated stimulation are used as shown in the figures. Whole cell conductivity was calculated from peak current amplitude by GNa = INa / (V-ENa) and normalized to maximum conductivity between -80 and +20 mV. The conductivity-voltage curves and the availability of the channel in a stable state were fitted to the Boltzmann function to determine the semi-maximal activation / deactivation voltage (V1 / 2) and slope factor (k). Time-dependent entry into and recovery from deactivation is assessed by matching the peak current recovery with a bi-exponential function, I / Imax = A<sub>f</sub> χ [1-exp (-t / T<sub>f</sub>)] + A.<sub>s</sub> χ [1-exp (-t / T<sub>s</sub>)], where T<sub>f</sub> it<sub>s</sub> mean time constants (fast and slow components, respectively, Af and As represent fast and slow fractional amplitude.
For use-dependent studies, cells are stimulated with a series of depolarizing pulses (-10 mV, 5 ms, 300 pulses, 10 Hz) with a holding potential of -120 mV. Currents are normalized to the peak current recorded in response to the first pulse in each frequency series. For tonic block studies, peak and continuous current are evaluated in response to 200 ms depolarization to -10 mV (0.2 Hz) after digital subtraction of currents recorded in the presence and absence of 0.5 μΜ tetrodotoxin (TTX). The continuous current is calculated during the final 10 ms in the 200 ms stage. Data analysis was performed using Clampfit 9.2 software (Axon Instruments, Union City, CA, USA), Excel 2002 (Microsoft, Seattle, WA, USA), and OriginPro 7.0 (OriginLab, Northampton, MA, USA). The results are presented as mean ± SEM. Unless otherwise specified, statistical comparisons are made using one-way ANOVA and Tukey post-hoc test for WT-NaV1.1.
In vitro pharmacology
A 20mM ranolazine stock solution (Gilead, Foster City, CA) is prepared in 0.1 M HCl. Fresh dilution of a compound of Formula IA or IB in the bath solution is prepared each day of the experiment and the pH is set to 7.35. Direct application of the perfusion solution to the clamped cell is obtained using a Perfusion Pencil system (Automate, Berkeley, CA). Direct perfusion of the cell is driven by gravity at a flow rate of 350 μL / min using a 250 micron tip. This system sequesters the clamped cell in the perfusion stream and allows complete solution exchange within 1 second. The clamped cell is perfused continuously starting after establishing the whole cell configuration. Control currents are measured during perfusion of the control solution.
Solutions containing compounds of the invention are perfused for 3 minutes before recording currents to balance the (tonic) drug block. The peak and constant current tonic block are measured from this stable state. Three consecutive current traces are averaged to obtain the average current for each recording condition (control, ranolazine and TTX). Average current traces are used for offline subtraction and analysis. The block dependent on the use of peak current is measured during pulse number 300 pulse series, (-10 mV, 5 ms, 300 pulses, 10 Hz) from the holding potential -120 mV.
165 EP 2464645
Two subsequent stimuli with a series of pulses are averaged to obtain average current traces for each recording condition, which are then used for offline subtraction and analysis. The block of ramp current is evaluated by voltage ramps up to +20 mV from the holding potential -120 mV at a speed of 20 mV / s stimulated every 30 s. To minimize current shift depending on use, only one trace recorded during the inspection is analyzed, compound according to the invention, or TTX superfusion. TTX was used in the presence of ranolazine. The inhibitory concentration curves were fitted to the Hill equation: I / Imax = 1 / [1 + 10<sup>AND</sup>(Logica<sub>50</sub>-I) * k], where IC<sub>50</sub> is the concentration that causes half inhibition and k is Hill's slope.
In vivo pharmacology
Male Sprague Dawley rats with a jugular vein cannula (250-350g, Charles River Laboratories, Hollister, CA) were used to study brain penetration of a compound of the invention in vivo. The use of animals has been approved by the Institutional Animal Care and Use Committee, Gilead Sciences. Three rats per group were given an intravenous infusion of a compound of the invention in saline at 85.5 μg / kg / min. After 1, 2.5 or 5 h, the animals were sacrificed for plasma and brain sampling, and the concentrations of the compound of the invention were measured by liquid chromatography combined with tandem mass spectrometry (LC-MS / MS). Brain tissue was homogenized in 1% 2N HCl acidified with 5% sodium fluoride (the final homogenate was diluted 3-fold). Plasma and brain homogenate samples (50 μΗ were precipitated with deuterated D3-ranolazine as an internal standard, centrifuged and centrifuged. The supernatant (50 μL) was transferred and diluted with water (450 μΠ before injection (10 μΓ). High performance liquid chromatography was performed using a Shimadzu LC-10AD liquid chromatograph and Luna C18 columns (2), 3 μιη. 20 x 2.0 mm with mobile phase consisting from water containing 0.1% formic acid (solution A) and acetonitrile (solution B) under isocratic conditions (75% solution A, 25% solution B; flow rate 0.300 ml / min). Mass spectrometry analyzes were performed using an API3000 mass spectrometer (Applied Biosystems, Foster City, CA) operating in positive ion mode with MRM 428.1> 98 transition. Brain-plasma ranolazine ratios were calculated for each sample as ng ranolazine / g brain divided by ng ranolazine / ml of plasma.
Results
Using the above methods, it can be demonstrated that the compound of the invention has the ability to inhibit WT-Nav1.1 and the panel of mutant NaV1.1 channels associated with epilepsy and migraine symptoms. GEFS +, SMEI and FHM3 show the ability of compounds of the invention to advantageously block abnormally increased direct current carried through these mutated channels. The ability of the compounds of the invention to cross the blood-brain barrier can also be established using the above methods.
Example 41
Material and methods
- 166 EP 2464645
Human cDNA expression<sub>V</sub>1.2
Wild type cDNA (WT) stably transfected into Chinese hamster ovary (CHO) cells was used to record Na + currents. Unless otherwise specified, all reagents were from
Sigma-Aldrich (St. Louis, MO, USA).
electrophysiology
Voltage-clamp records for whole cells were used to measure the biophysical properties of WT. Briefly, the pipette solution consists of (in mM) 110 CsF, 10 NaF, 20 CsCl, 2 EGTA, 10 HEPES, with pH 7.35 and an osmolarity of 300 mOsmol / kg. The bath solution (control) contains (in mM): 145 NaCl, 4 KCl, 1.8 CaCl2, 1 MgCl2, 10 dextrose, 10 HEPES, with pH 7.35 and osmolarity 310 mOsmol / kg. Cells were allowed to stabilize for 10 min after establishing the whole-cell configuration prior to current measurement. The series resistance was compensated by 90% to ensure that the set potential is obtained within microseconds with a voltage error <2 mV. Leakage currents are subtracted using the online P / 4 procedure and all currents are low-pass Bessel filtered at 5 kHz and digitized at 50 kHz.
For clarity, representative ramp currents are low-pass filtered off-line at 50 Hz. Specific voltage-clamp protocols are used to assess channel activation, rapid deactivation, and availability during repeated stimulation. The results are presented as mean ± SEM, and unless otherwise stated, statistical comparisons are made using unidirectional ANOVA.
The peak current tonic block is measured. Average current traces are used for offline subtraction and analysis. The dependent peak current block is measured during the number of pulses of 300 pulse series (-10 mV, 5 ms, 300 pulses) at frequencies between 10 and 135 Hz from the holding potential of -120 mV. Two subsequent stimulations with a series of pulses are averaged to obtain average current traces for each reading state, which are then used for offline subtraction and analysis.
Specific voltage-clamp protocols are used to assess channel activation, rapid deactivation, and availability during repeated stimulation. The whole cell conductivity is calculated from the peak current amplitude by GNa = INa / (V-ENa) and normalized to a maximum conductivity between -80 and +20 mV. The conductivity-voltage curves and the availability of a stable channel are matched to the Boltzmann function to determine the voltage for semi-maximal activation / deactivation (V1 / 2) and slope factor (k). Time-dependent input and recovery from deactivation is assessed by matching the peak current recovery with the dual exponential function, I / I<sub>max</sub> = A.<sub>f</sub> x [1-exp (-t / T<sub>f</sub>)] + A, x [1-exp (-t / T<sub>s</sub>)], where T<sub>f</sub> and T<sub>s </sub>mean time constants (fast and slow component, respectively), Af and As represent fast and slow fractional amplitude.
For use-dependent studies, cells are stimulated with a series of depolarizing pulses (-10 mV, 5 ms, 300 pulses, 10 Hz) with a holding potential of -120 mV. Currents are normalized to the peak current recorded in response to the first pulse in each frequency series. For tonic block studies, peak and constant current are assessed in response to 200 ms depolarization to -10 mV (0.2 Hz) after digital subtraction of currents recorded in the presence and absence of 0.5 μΜ tetrodotoxin (TTX). The DC current is calculated during the final 10 ms of the 200 ms stage. Data analysis is performed using Clampfit 9.2 software (Axon Instruments, Union City, CA, USA), Excel 2002 (Microsoft, Seattle,
- 167 EP 2464645
WA, USA), and OriginPro 7.0 (OriginLab, Northampton, MA, USA). Results are presented as mean ± SEM. Unless otherwise stated, statistical comparisons are made using one-way ANOVA and Tukey post-hoc test for WT-NaV1.2.
In vitro pharmacology
Stock solutions of 20mM compounds of the invention (Gilead, Foster City, CA) are prepared in 0.1 M HCl. Fresh dilution of the compound of the invention in the bath solution is prepared each day of the experiment and the pH is adjusted to 7.35. Direct application of the perfusion solution to the clamped cell is obtained using a Perfusion Pencil system (Automate, Berkeley, CA). Direct perfusion of the cell is driven by gravity at a flow rate of 350 μL / min using a 250 micron tip. This system sequesters the clamped cell in the perfusion stream and allows complete solution exchange within 1 second. The clamped cell is perfused continuously starting after establishing the whole cell configuration. Control currents are measured during perfusion of the control solution.
Solutions containing ranolazine are perfused for 3 minutes before recording currents to balance the (tonic) drug block. The peak and constant current tonic block are measured from this stable state. Three consecutive current traces are averaged to obtain the average current for each recording condition (control, compounds of the invention and TTX). Average current traces are used for offline subtraction and analysis. The block dependent on the use of peak current is measured during pulse number 300 pulse series, (-10 mV, 5 ms, 300 pulses, 10 Hz) from the holding potential -120 mV. Two consecutive stimuli with a series of pulses are averaged to obtain average current traces for each recording condition, which are then used for offline subtraction and analysis. The block of ramp current is evaluated by voltage ramps up to +20 mV from the holding potential -120 mV at a speed of 20 mV / s stimulated every 30 s. To minimize the use-dependent current shift, only one trace recorded during the control, the compound of the invention, or TTX superfusion is analyzed. TTX was used in the presence of a compound of the invention. The inhibitory concentration curves were fitted to the Hill equation: I / I<sub>max</sub> = 1/[1+10<sup>AND</sup>(Logica<sub>50</sub>-I) * k], where IC<sub>50</sub> is the concentration that causes half inhibition and k is Hill's slope.
Results
Thus, the compounds of the invention have been shown to have the ability to inhibit WT-Nav1.2 by demonstrating the ability of the compounds of the invention to advantageously block an abnormally increased DC current carried through this channel.
Proxy:
> ĄTENTOWY \ ubka-Hmntiitk MA Izabei
LAW FIRM ATTENTION "BELLEPAT"
Izabela Szych niska-Hawranek ul Słowackiego 44, 37-700 Pnrtf.'nvśl tel. (016) 732-37-77 fax: (016) 675-02-87 mobile phone (0608) 503-081 e-mait <a href="mailto:bellepat@op.pl">bellepat@op.pl</a> NIP: 795-207-16-72 REGON: 1803505: 6 at 3192
- 168 EP 2464645
Contents146
56 members in 22 offices
Priority claims11
| Document | Office | Kind | Date |
|---|---|---|---|
| 22886409 | United States of America | P | |
| 36003710 | United States of America | P | |
| 10737724 | European Patent Office (EPO) | A | |
| 2010043264 | United States of America | W | |
| 107377244 | – | – | – |
| 228864P | – | – | – |
| 360037P | – | – | – |
| EP20100737724 | – | – | – |
| US20090228864P | – | – | – |
| US20100360037P | – | – | – |
| WO2010US43264 | – | – | – |
Members56
| Document | Office | Kind | |
|---|---|---|---|
| US2010091898A1 | United States of America | A1 | |
| US2010098198A1 | United States of America | A1 | |
| US2011021521A1 | United States of America | A1 | |
| CA2774715A1 | Canada | A1 | |
| WO2011014462A1 | World Intellectual Property Organization (WIPO) | A1 | |
| UY32805A | Uruguay | A | |
| TW201116528A | Taiwan Province of China | A | |
| US2011129024A1 | United States of America | A1 | |
| AR077598A1 | Argentina | A1 | |
| US2012045008A1 | United States of America | A1 | |
| US2012114053A1 | United States of America | A1 | |
| US2012114069A1 | United States of America | A1 | |
| US2012114080A1 | United States of America | A1 | |
| AU2010276537A1 | Australia | A1 | |
| EP2464645A1 | European Patent Office (EPO) | A1 | |
| CN102725290A | China | A | |
| EA201290121A1 | Eurasian Patent Organization (EAPO) | A1 | |
| US2012287974A1 | United States of America | A1 | |
| US2012300866A1 | United States of America | A1 | |
| US2013022091A1 | United States of America | A1 | |
| NZ598942A | New Zealand | A | |
| US8718208B2 | United States of America | B2 | |
| US2014140423A1 | United States of America | A1 | |
| US8737536B2 | United States of America | B2 | |
| US2014303158A1 | United States of America | A1 | |
| US8952034B2 | United States of America | B2 | |
| AU2010276537B2 | Australia | B2 | |
| US9020050B2 | United States of America | B2 | |
| TWI490217B | Taiwan Province of China | B | |
| US9083573B2 | United States of America | B2 | |
| US9130788B2 | United States of America | B2 | |
| US9130789B2 | United States of America | B2 | |
| US9137054B2 | United States of America | B2 | |
| US9148311B2 | United States of America | B2 | |
| TW201542545A | Taiwan Province of China | A | |
| US9240908B2 | United States of America | B2 | |
| CN102725290B | China | B | |
| US9338033B2 | United States of America | B2 | |
| US9371329B2 | United States of America | B2 | |
| TWI542587B | Taiwan Province of China | B | |
| EA025824B1 | Eurasian Patent Organization (EAPO) | B1 | |
| US9596106B2 | United States of America | B2 | |
| EP2464645B1 | European Patent Office (EPO) | B1 | |
| PT2464645T | Portugal | T | |
| DK2464645T3 | Denmark | T3 | |
| LT2464645T | Lithuania | T | |
| SI2464645T1 | Slovenia | T1 | |
| ES2642586T3 | Spain | T3 | |
| HRP20171454T1 | Croatia | T1 | |
| PL2464645T3This record | Poland | T3 | |
| HRP20171454T8 | Croatia | T8 | |
| ME02847B | Montenegro | B | |
| RS56410B1 | Serbia | B1 | |
| CY1119584T1 | Cyprus | T1 | |
| HUE034911T2 | Hungary | T2 | |
| CA2774715C | Canada | C |
Numbers
- Publication
- 2464645
- Publication, DOCDB
- 2464645
- Publication, EPODOC
- PL2464645T
- Application
- 10737724
- Application, DOCDB
- 10737724
- Application, EPODOC
- PL20100737724T
Titles2
- English
- FUSED HETEROCYCLIC COMPOUNDS AS ION CHANNEL MODULATORS
- Polish
- SKONDENSOWANE HETEROCYKLICZNE ZWIĄZKI JAKO MODULATORY KANAŁÓW JONOWYCH
Classification
- CPC, 8
- C07D487/04
- A61P3/10
- A61P9/00
- A61P9/10
- A61P25/00
- A61P25/08
- A61P29/00
- C07D471/04
- IPC, 6
- C07D471 04
- A61K31 437
- A61K31 4985
- A61K31 5025
- A61K31 519
- A61P9 00